Transcriptional effects of mood stabiliser drugs in a serotonergic cell line by Sinha, Priyanka
i 
 
Transcriptional effects of mood 






A thesis submitted for the degree of 
Doctor of Philosophy 







Attribution of collaborative contributions to work 
in this thesis 
 Chapter 3 
The candidate performed cell culture and prepared total RNA. RNA-
Sequencing was contracted to Novogene (Beijing, China). Dr. John Pearson 
and Dr. Simone Cree guided the candidate through data analysis. The 
candidate established the bioinformatics pipelines, carried out data analysis 
and documented the results.  
 Chapter 4 
The candidate prepared the total RNA and nCounter® assay was contracted 
to New Zealand Genomics Ltd. The candidate carried out the data analysis 
and documented the results.  
 Chapter 5 
The candidate prepared the total RNA and nCounter® assay was contracted 
to New Zealand Genomics Ltd. The candidate carried out the data analysis 
and documented the results.  
 Chapter 6 
The candidate established the bioinformatics pipelines, carried out the data 
analysis and performed the RT-qPCR analysis and documented the results.  
 Chapter 7  
The fixed rat brains used in this Chapter were prepared by Dr. Kit Doudney, 
Tony Harley and Melanie Allington (Gene Structure and Function 
Laboratory, University of Otago Christchurch). The sections for 
iii 
 
immunohistochemistry were prepared by a histology technician. The 
candidate performed the immunohistochemistry experiments, carried out 





Sodium valproate (VPA) and lithium are drugs of different chemical classes that 
are widely prescribed in the treatment of bipolar disorder (BD). Molecular and 
pharmacological studies have revealed some relevant properties and targets, but 
the precise modes of action are not yet understood. In this thesis, the effects of 
lithium and VPA on gene expression in a cell line (RN46A) were examined. This 
cell line is derived from the rat medullary raphe nucleus, and represents a 
relevant cellular model to study the molecular effects of lithium and VPA. 
RNA-Seq analysis of cells treated with 0.5mM lithium for 72 hrs failed to detect 
significant gene expression changes. However, exposure of cells to 0.5mM VPA 
for 72 hrs induced widespread changes in expression of many genes, with more 
than 700 significantly upregulated and ~400 downregulated genes. The 
NanoString platform was used to validate a subset of 23 observed gene 
expression effects, in independent cell culture experiments. High correlation 
(r2=0.75) was observed between RNA-Seq and NanoString for the selected VPA-
regulated genes. Clear validation was observed for ADAM23, LSP1, MAOB, 
MMP13, PAK3, SERPINB2, SNAP91, WNT6 and ZCCHC12. Differential 
alternative splicing was also observed with VPA exposure. Some of the genes 
were both differentially expressed and alternatively spliced.  
VPA is recognized as an inhibitor of chromatin modifying histone deacetylase 
(HDAC) enzymes, and part of its therapeutic action in mood disorders may 
relate to modification of gene expression via this chemical property. To this aim, 
the effects of the non-HDAC inhibitory analogue of VPA, valpromide (VPD), and 
HDAC inhibitors, including trichostatin A (TSA) and CI994, on the selected 
genes was explored. Expression of eight genes was modified by HDAC 
inhibition (HDACi): ZCCHC12 and SHANK3 were upregulated by VPA and 
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CI994 but downregulated by TSA; CDKN1C, MAOB, NGFR and WNT6 were 
upregulated by CI994 only, and MMP13 and VGF were upregulated by TSA 
only. The complex regulatory effects of different HDAC inhibitors or VPD on the 
selected genes suggest VPA can exert its regulatory effects via both HDACi-
dependent and independent properties. 
VPA and lithium are drugs of different chemical classes. Genes displaying 
specific regulation by either or both of these drugs may be relevant to the 
mechanism of action, and co-regulated genes highlighting the common 
pathways are of greatest interest. We failed to detect any significant changes at 
0.5mM lithium so, increased the concentration to 1mM and 2mM. At these 
exposure levels, four genes were co-regulated by VPA and lithium; CDKN1C and 
LSP1 at 1mM and LSP1, SERPINB2 and WNT6 at 2mM. 
We observed extensive gene expression changes in response to VPA with several 
genes and pathways involved in neuronal function or nervous system 
development. Understanding the broader gene regulatory effects of VPA in this 
serotonergic cell model has provided insights into how this drug may work, and 
identified new candidate genes or biochemical pathways that may be of 





My sincerest and heartfelt gratitude to my supervisor Prof. Martin Kennedy, 
who has been instrumental throughout my journey. Not only his guidance and 
support but also the inspiration provided by him from the very beginning of 
this work, brought this thesis to the completion. His confidence in me was a 
great source of motivation which kept me going even when failures are of 
routine. The amount of time and effort he put through in this work added a 
great value to the outcome. Embraced with the exceptional supervision and 
mentoring from him, I consider myself honoured and privileged. 
I would also wish to thank my co-supervisors, Dr. Simone Cree and Associate 
Prof. John Pearson. A special thanks to Simone for helping me with the 
bioinformatic analysis in this thesis. I am indebted to her for being the roadmap 
for becoming a successful scientist, and a devoted and loving mother.  
I am grateful to Allison Miller, whose expertise made experiments a breeze. 
This PhD journey would have been meaningless without the ever fun and 
fabulous GSFL lab members, both present and past: Kim, Aaron, Simran, Cen, 
Sarah, Eng-Wee, Diana, Lucy, Amy and Kit. I am ever so thankful to the 
wonderful staff of Pathology department - Linda, Alice, Bridget and Fran.  
I am also thankful to Dr. Andrew Miller, Dr. Alastair Murray, Matthew 
Pynegar and fellow students, Mak Sarwar and Mohini Puri, for sharing their 
IHC expertise. 
I would like to acknowledge the financial support provided by the Carney 
Centre for Pharmacogenomics.  
vii 
 
A very special thanks to my loving husband, Nishant, who has been the 
driving force behind this thesis. He encouraged me at the weakest moments 
and his continued love and support has helped me get to the conclusion of this 
journey.  
Last, but not the least, my sincerest thanks to my family who has stood by me 
on the PhD journey. My parents and in-laws took care of everything else so I 
could focus on my research. My lovely son, Siddhant has made this journey fun 
with his beautiful smile, and made each and every moment joyous. A very 
special thanks to my siblings, Shweta and Saurabh, for their selfless love and 
care, and making life wonderful. I am really grateful to be surrounded by a 
loving and caring family, and for always offering their unconditional support 




Manuscript in preparation 
1. Sinha P., Cree S., Miller A.L., Pearson J.F., Kennedy M.A. Transcriptional 
analysis of sodium valproate in a serotonergic cell line reveals gene 
regulation through both HDAC inhibition-dependent and independent 
mechanisms.  
 
Abstract from conference presentations 
1. Sinha P., Cree S., Miller A.L., Pearson J.F., Kennedy M.A. Gene expression 
effects of sodium valproate in a serotonergic cell line. Poster presentation 
at: World Congress of Psychiatric Genetics, 11-15th October 2018; 
Glasgow, Scotland. 
 
2. Sinha P., Cree S., Miller A.L., Pearson J.F., Kennedy M.A. Gene expression 
effects of sodium valproate in a serotonergic cell line. Oral presentation 
at: QMB Satellite Bioinformatics, Queenstown Research Week. 30-31 Aug 
2018, Queenstown, New Zealand. 
 
3. Sinha P., Cree S., Miller A.L., Pearson J.F., Kennedy M.A. Gene expression 
effects of sodium valproate in a serotonergic cell line. Oral and poster 
presentation at: Epigenetics User Group Symposium. 27th July, 2018; 
Dunedin, New Zealand. 
 
4. Sinha P., Cree S., Miller A.L., Pearson J.F., Kennedy M.A. Gene expression 
effects of sodium valproate in a serotonergic cell line. Oral presentation 
ix 
 
at: Postgrad symposium, University of Otago, Christchurch. 17-18th July 
2018; Christchurch, New Zealand. 
 
5. Sinha P., Cree S., Miller A.L., Pearson J.F., Kennedy M.A. Identification 
of sodium valproate and lithium co-regulated genes in a serotonergic cell 
line. Oral and poster presentation at: Australasian Genomic Technologies 
Conference (AGTA). 29th Oct-1st Nov, 2017; Hobart, Tasmania, Australia. 
 
6. Sinha P., Cree S., Miller A.L., Pearson J.F., Kennedy M.A. RNA-Seq 
analysis of gene expression changes caused by mood stabilizer drugs in a 
serotonergic cell line. Oral presentation at: Canterbury Omics Symposium 
VI, 8th Nov 2017, Lincoln Universoity, Christchurch, New Zealand.  
 
7. Sinha P., Cree S., Miller A.L., Pearson J.F., Kennedy M.A. RNA-Seq 
analysis of gene expression changes caused by mood stabilizer drugs in a 
serotonergic cell line. Oral presentation at: Canterbury Omics Symposium 
III, 4th Nov 2015, University of Otago, Christchurch, New Zealand.  
 
8. Sinha P., Cree S., Miller A.L., Pearson J.F., Kennedy M.A. RNA-Seq 
analysis of gene expression changes caused by mood stabilizer drugs in a 
serotonergic cell line. Poster presentation at: The Genome and Human 





TABLE OF CONTENTS  
ABSTRACT ................................................................................................................ iv 
ACKNOWLEDGEMENTS ........................................................................................... vi 
PUBLICATIONS ....................................................................................................... viii 
TABLE OF CONTENTS .............................................................................................. x 
LIST OF TABLES .................................................................................................... xvii 
LIST OF FIGURES ................................................................................................... xix 
ABBREVIATIONS .................................................................................................... xxi 
Chapter 1 Introduction ......................................................................................... 1 
1.1 Mood disorders ........................................................................................................ 1 
1.2 Pathophysiology of mood disorders .................................................................... 3 
1.2.1 Monoamine theory ............................................................................................... 3 
1.2.2 Hypothalamus-Pituitary-Adrenal axis dysregulation .................................... 7 
1.2.3 Neuroplasticity hypothesis ............................................................................... 10 
1.2.4 Inflammation theory .......................................................................................... 12 
1.2.5 Mitochondrial dysfunction ............................................................................... 13 
1.2.6 Chronobiological theory .................................................................................... 14 
1.3 Treatment of mood disorders .............................................................................. 16 
1.3.1 Mood stabilizers ................................................................................................. 17 
1.3.2 Antidepressants .................................................................................................. 23 
1.3.3 Antipsychotics .................................................................................................... 24 
1.3.4 Electroconvulsive therapy ................................................................................. 24 
1.3.5 Psychotherapy .................................................................................................... 25 
1.4 Models to study mood disorders ........................................................................ 26 
1.4.1 Cellular models ................................................................................................... 26 
1.4.2 Animal models .................................................................................................... 30 
1.4.3 Postmortem studies............................................................................................ 33 
1.5 Mechanism of action of mood stabilizers ......................................................... 34 
xi 
 
1.5.1 GABAergic and glutamatergic systems .......................................................... 34 
1.5.2 Effects on monoaminergic systems ................................................................. 37 
1.5.3 Effects on ion channels ...................................................................................... 38 
1.5.4 Effects on intracellular signalling pathways .................................................. 39 
1.5.5 Gene expression changes due to lithium and VPA ....................................... 44 
1.5.6 Other research .................................................................................................... 47 
1.6 Histone deacetylase inhibition in treatment of mood disorders .................. 49 
1.7 Research questions ................................................................................................ 52 
Chapter 2 Materials and Methods ..................................................................... 53 
2.1 Materials.................................................................................................................. 53 
2.2 Methods ................................................................................................................... 59 
2.2.1 Cell culture .......................................................................................................... 59 
2.2.2 Drug exposure .................................................................................................... 60 
2.2.3 RNA isolation and QC....................................................................................... 62 
2.2.4 Real-time quantitative polymerase chain reaction (qPCR) .......................... 65 
2.2.5 RNA-Sequencing ................................................................................................ 69 
2.2.6 RNA-Seq analysis tools and software packages ............................................ 75 
2.2.7 Alternative Splicing analysis ............................................................................ 80 
2.2.8 NanoString nCounter® gene expression assay ............................................. 81 
2.2.9 Allen Brain Atlas ................................................................................................ 82 
Chapter 3 Differential gene expression changes in response to lithium and 
sodium valproate in RN46A cells ............................................................................ 84 
3.1 Introduction ............................................................................................................ 84 
3.1.1 RN46A cell line ................................................................................................... 85 
3.1.2 Drug exposure .................................................................................................... 89 
3.1.3 RNA-sequencing ................................................................................................ 90 
3.2 Methods ................................................................................................................... 91 
3.2.1 Cell culture and drug exposure ....................................................................... 92 
3.2.2 RNA quality ........................................................................................................ 92 
xii 
 
3.2.3 Processing of raw reads and quality control .................................................. 95 
3.2.4 Read mapping ..................................................................................................... 96 
3.2.5 Differential gene expression analysis ............................................................ 100 
3.3 Results .................................................................................................................... 101 
3.3.1 RNASeq data exploration ............................................................................... 101 
3.3.2 RNA-Seq analysis of lithium-treated RN46A cells ...................................... 104 
3.3.3 RNA-Seq analysis of VPA-treated RN46A cells .......................................... 104 
3.3.4 Comparative analysis of differential gene expression analysis methods. 118 
3.3.5 Functional enrichment and pathway analysis ............................................. 120 
3.3.6 Serotonergic nature of RN46A ....................................................................... 128 
3.3.7 Overlap of RNA-Seq data with genome-wide association studies ........... 131 
3.4 Discussion ............................................................................................................. 134 
3.4.1 Serotonergic nature of RN46A ....................................................................... 134 
3.4.2 RNA-Seq analysis ............................................................................................. 135 
3.4.3 Differential gene expression changes with lithium ..................................... 136 
3.4.4 Differential gene expression changes with VPA .......................................... 137 
3.4.5 Enrichment and pathway analysis ................................................................. 138 
3.4.6 VPA-regulated genes have been previously implicated in mood disorders
 141 
3.4.7 Comparison with prior RNA-Seq study ....................................................... 148 
3.4.8 Comparison with GWAS studies ................................................................... 149 
3.5 Summary of the chapter ..................................................................................... 150 
Chapter 4 Gene expression of a subset of VPA regulated genes with 
nCounter® assay ................................................................................................... 151 
4.1 Introduction .......................................................................................................... 151 
4.2 Methods ................................................................................................................. 152 
4.2.1 Allen Brain Atlas .............................................................................................. 152 
4.2.2 Genotype-Tissue Expression (GTEx) database ............................................ 152 
4.2.3 Cell culture and NanoString assay ................................................................ 153 
4.2.4 Normalization of nCounter® data ................................................................. 156 
xiii 
 
4.2.5 NanoString data analysis with nSolverTM ..................................................... 157 
4.2.6 NanoString data analysis with NanoStringDiff ........................................... 159 
4.2.7 Comparison of nCounter® and RNA-Seq gene expression ....................... 159 
4.3 Results ................................................................................................................... 159 
4.3.1 Shortlisting of genes ........................................................................................ 159 
4.3.2 nCounter® data analysis results .................................................................... 178 
4.3.3 Comparison of nCounter® and RNA-Seq gene expression ....................... 190 
4.4 Discussion ............................................................................................................. 193 
4.4.1 Most significant genes ..................................................................................... 196 
4.4.2 Other significant genes .................................................................................... 201 
4.4.3 Genes co-regulated by lithium and VPA ...................................................... 211 
4.4.4 No differential expression with lamotrigine ................................................ 212 
4.4.5 Comparison of log2 fold change between datasets ..................................... 213 
4.4.6 Limitations of this model system ................................................................... 213 
4.5 Summary of the chapter ..................................................................................... 214 
Chapter 5 Gene regulation by HDAC inhibitors ............................................. 215 
5.1 Introduction .......................................................................................................... 215 
5.1.1 Valpromide ....................................................................................................... 215 
5.1.2 Trichostatin A ................................................................................................... 216 
5.1.3 CI994 .................................................................................................................. 217 
5.1.4 RGFP966 ............................................................................................................ 217 
5.1.5 PCI34051 ............................................................................................................ 217 
5.1.6 Tubastatin A...................................................................................................... 217 
5.2 Methods ................................................................................................................. 218 
5.2.1 Cell culture and NanoString assay ................................................................ 218 
5.3 Results ................................................................................................................... 222 
5.3.1 Run1: Differential gene expression with VPA, VPD and TSA .................. 222 
5.3.2 Run2: Differential gene expression with VPA, VPD and selective HDAC 
inhibitors ........................................................................................................................ 228 
xiv 
 
5.3.3 Reproducibility of gene expression findings for VPA across all experiments
 238 
5.4 Discussion ............................................................................................................. 240 
5.4.1 Genes regulated through HDAC inhibition by VPA, TSA and CI994 ...... 243 
5.4.2 HDAC6 inhibition has no effect on VPA-regulated genes ......................... 248 
5.4.3 Does HDAC inhibition regulate mood? ........................................................ 249 
5.4.4 Limitations of the study .................................................................................. 249 
5.5 Summary of the chapter ..................................................................................... 251 
Chapter 6 Differential alternative splicing analysis in response to VPA ...... 252 
6.1 Introduction .......................................................................................................... 252 
6.1.1 AS events in psychiatric disorders ................................................................. 254 
6.2 Methods ................................................................................................................. 255 
6.2.1 DEXSeq .............................................................................................................. 256 
6.2.2 JunctionSeq ........................................................................................................ 257 
6.2.3 rMATS ................................................................................................................ 258 
6.2.4 IsoformSwitchAnalyzeR .................................................................................. 259 
6.3 Results .................................................................................................................... 260 
6.3.1 DEXSeq .............................................................................................................. 260 
6.3.2 JunctionSeq ........................................................................................................ 263 
6.3.3 rMATS ................................................................................................................ 267 
6.3.4 IsoformSwitchAnalyzeR .................................................................................. 268 
6.3.5 Summary of differential AS events detected ................................................ 273 
6.3.6 Attempted validation of differential isoform usage in TPM1 .................... 276 
6.4 Discussion ............................................................................................................. 277 
6.4.1 Comparison of the differential splicing tools ............................................... 277 
6.4.2 Genes with best bioinformatic evidence for VPA-induced alternative 
splicing ............................................................................................................................ 278 
6.4.3 Genes both differentially expressed and spliced by VPA .......................... 280 
6.5 Summary of the chapter ..................................................................................... 282 
xv 
 
Chapter 7 Analysis of VPA effects on gene expression in rat brains ........... 283 
7.1 Immunohistochemical detection of protein expression in rat brain ......... 283 
7.1.1 The rationale for choosing the antibodies .................................................... 284 
7.1.2 The rationale for choosing a region of interest ............................................ 287 
7.2 Methods ................................................................................................................. 287 
7.2.1 Treatment of rats .............................................................................................. 287 
7.2.2 Immunohistochemistry ................................................................................... 288 
7.3 Results ................................................................................................................... 290 
7.3.1 MMP13............................................................................................................... 291 
7.3.2 VGF .................................................................................................................... 294 
7.3.3 MAOB ................................................................................................................ 296 
7.3.4 PAK3 .................................................................................................................. 298 
7.4 Discussion ............................................................................................................. 300 
7.5 Summary of the chapter ..................................................................................... 302 
Chapter 8 General discussion ......................................................................... 303 
8.1 Thesis Summary .................................................................................................. 303 
8.1.1 Gene expression effects of VPA ..................................................................... 303 
8.1.2 VPA has a complex gene regulatory pattern ............................................... 305 
8.1.3 VPA affects alternative splicing ..................................................................... 305 
8.1.4 Lithium and VPA co-regulate genes ............................................................. 306 
8.1.5 Matrix metalloproteinases .............................................................................. 307 
8.2 Future work .......................................................................................................... 308 
8.2.1 Other RNA families/species ........................................................................... 308 
8.2.2 Chromatin changes may regulate gene expression ..................................... 308 
8.2.3 Other model systems to examine the effects of VPA .................................. 309 
8.2.4 Screening for potential mood stabilizers ...................................................... 310 
8.3 Final conclusion ................................................................................................... 310 
References ............................................................................................................. 312 
Appendix A: List of software used ....................................................................... 397 
xvi 
 
Appendix B: RNA QC report for RNA-Seq experiment ........................................ 399 
Appendix C: RNA QC and cDNA library QC at Novogene ................................... 401 
Appendix D: RNA-Seq QC report of all 12 samples ............................................. 406 
Appendix E: Code used in thesis .......................................................................... 408 
1. Mapping with STAR aligner ................................................................................. 408 
2. Differential gene expression analysis with Cufflinks2 suite .......................... 410 
3. Differential gene expressiion analysis with DESeq2 ....................................... 412 
4. Transcriptome mapping with Kallisto ................................................................. 415 
5. Differential expression analysis with Sleuth ..................................................... 415 
6. Transcriptome mapping with Salmon ................................................................. 417 
7. Differential expression analysis with Sleuth for Salmon-Wasabi ................. 417 
8. NanoString nCounter® data analysis with NanoStringDiff ........................... 419 
9. Alternative Splicng analysis with rMATS .......................................................... 425 
10. Alternative splicing analysis with IsoformSwitchAnalyzeR ...................... 426 
11. Alternative Splicing analysis with DEXSeq ................................................... 429 
12. Alternative Splicing analysis with JunctionSeq ............................................ 431 
Appendix F: List of DEGs identified with all four methods ................................. 436 






LIST OF TABLES 
 
Table 1.1 Genetic animal models of BD. .................................................................................... 32 
Table 2.1 Reagents and kits used in this thesis. ........................................................................ 53 
Table 2.2 List of buffers used in this thesis. ............................................................................... 58 
Table 2.3 Stock and working concentration of drugs used. ........................................................ 62 
Table 2.4 Primer sequence for TPM1 isoforms. ......................................................................... 67 
Table 2.5 qPCR reaction master mix .......................................................................................... 68 
Table 2.6 RNA-Seq adaptor sequence ....................................................................................... 73 
Table 3.1 Mapping summary of STAR aligner ............................................................................ 97 
Table 3.2 Mapping summary generated by kallisto. ................................................................... 98 
Table 3.3 Mapping summary generated by salmon. .................................................................. 99 
Table 3.4 DEGs detected by each DEA tool in response to VPA. ........................................... 106 
Table 3.5 Top 25 DEGs in response to VPA ............................................................................ 107 
Table 3.6 Number of VPA DEGs used for comparison ............................................................ 118 
Table 3.7 List of the dorsal raphe specific genes expressed in RN46A ................................... 129 
Table 3.8 Twenty-eight VPA-regulated genes overlap with BD GWAS. .................................. 132 
Table 4.1 The effect of treatment of mood stabilizer drugs on reference gene stability in RN46A 
cells. .......................................................................................................................................... 158 
Table 4.2 Selected genes for validation with NanoString assay............................................... 162 
Table 4.3 GTEx expression data and ABA ISH images ........................................................... 169 
Table 4.4 Genes showing significant expression difference after VPA exposure .................... 179 
Table 4.5 Genes showing significant expression difference after VPA exposure .................... 181 
Table 4.6 Genes showing significant expression difference after lithium exposure(Run1), ..... 185 
Table 4.7 Genes showing significant expression difference after lithium exposure (Run2) ..... 186 
Table 4.8 Differential gene expression changes with LTG exposure ....................................... 188 
Table 5.1 Selective HDAC inhibitors and their concentration used in cell culture .................... 221 
Table 5.2 nSolverTM generated log2 fold change and p-values ................................................ 224 
Table 5.3 NanoStringDiff generated log2 fold change and p-values ........................................ 226 
Table 5.4 nSolverTM generated log2 fold change and p-values ................................................ 230 
Table 5.5 NanoStringDiff generated log2 fold change and p-values ........................................ 232 
Table 5.6 nSolverTM generated log2 fold change and p-values ................................................ 234 
Table 5.7 NanoStringDiff generated log2 fold change and p-values ........................................ 236 
Table 5.8 Reproducibility of gene expression findings for VPA across all experiments ........... 238 
Table 6.1 Significant exonic regions and genes affected vary according to padj. .................... 261 
Table 6.2 Differential exon usage between VPA-treated and untreated RN46A cells ............. 262 
Table 6.3 Differential exon usage between VPA-treated and untreated RN46A cells ............. 265 
Table 6.4 Summary of AS events identified with rMATS .......................................................... 267 
xviii 
 
Table 6.5 Summary of genes with significant AS events .......................................................... 274 
Table 7.1 List of the primary antibodies used in IHC experiments. .......................................... 289 




LIST OF FIGURES 
 
Figure 1.1 The HPA axis and glucocorticoid receptor signalling in BD. ....................................... 8 
Figure 1.2 Chemical structure of sodium valproate. ................................................................... 19 
Figure 1.3 Chemical structure of lamotrigine. ............................................................................. 20 
Figure 1.4 Chemical structure of carbamazepine. ...................................................................... 22 
Figure 1.5 Mechanism of action of VPA on glutamate and GABA metabolism. ......................... 35 
Figure 1.6 Signalling pathways involved in the mechanism of action of lithium and VPA. ......... 40 
Figure 2.1 Novogene cDNA library preparation for RNA-Seq. ................................................... 71 
Figure 2.2 A flowchart showing RNA-Seq data analysis ............................................................ 77 
Figure 3.1 Morphology of undifferentiated RN46A cells. ............................................................ 87 
Figure 3.2 Morphology of differentiated RN46A cells. ................................................................ 88 
Figure 3.3 Gel image from TapeStation showing 28S and 18S bands for total RNA ................. 93 
Figure 3.4 Gel image from TapeStation showing 28S and 18S bands for total RNA ................. 94 
Figure 3.5 Gel image from TapeStation showing 28S and 18S bands for total RNA ................. 95 
Figure 3.6 PCA plot for RNASeq raw counts for all twelve samples with the R package prcomp
 .................................................................................................................................................. 102 
Figure 3.7 PCA plot for RNASeq normalized counts for all twelve samples with the DESeq2 R 
package .................................................................................................................................... 103 
Figure 3.8 MA plot between VPA-treated and control samples ................................................ 105 
Figure 3.9 Boxplots showing gene expression differences between VPA-treatment vs untreated 
cells for the top 99 VPA DEGs .................................................................................................. 108 
Figure 3.10 Agreement between the four DEA methods. ......................................................... 119 
Figure 3.11 Heatmap generated with DESeq2 by the iDEP web tool ...................................... 121 
Figure 3.12 Significant GO biological processes associated with VPA up- and down-regulated 
genes ........................................................................................................................................ 123 
Figure 3.13 Significant GO cellular components associated with VPA up- and down-regulated 
genes ........................................................................................................................................ 124 
Figure 3.14 Significant GO molecular function associated with VPA up- and down-regulated 
genes ........................................................................................................................................ 125 
Figure 3.15 Significant KEGG pathways associated with VPA regulated genes at FDR of 0.2
 .................................................................................................................................................. 127 
Figure 4.1 Cell culture design and nCounter® gene expression assay for Run1. ................... 154 
Figure 4.2 Cell culture design and nCounter® gene expression assay for Run2. ................... 156 
Figure 4.3 Location of the dorsal raphe (DR) and medullary raphe magnus (RM) in mouse brain 
(sagittal view). ........................................................................................................................... 167 
Figure 4.4 Location of the dorsal raphe (DR) and medullary raphe magnus (RM) in mouse brain 
(coronal view). ........................................................................................................................... 168 
xx 
 
Figure 4.5 Agreement among nCounter® Run1, Run2 and RNA-Seq gene expression data. 191 
Figure 4.6 Agreement among nCounter® Run1, Run2 and RNA-Seq gene expression data after 
removing low expression genes. ............................................................................................... 192 
Figure 5.1 Cell culture design and nCounter® gene expression assay for Run1. .................... 219 
Figure 5.2 Cell culture design and nCounter® gene expression assay for Run2. .................... 220 
Figure 5.3 Summary of nCounter® Run1 and Run2 gene expression data ............................. 242 
Figure 6.1 Seven types of alternative splicing events. .............................................................. 253 
Figure 6.2 Flowchart showing the steps and tools used in differential alternative splicing analysis.
 .................................................................................................................................................. 256 
Figure 6.3 Mean expression versus log2 fold change plot. ...................................................... 261 
Figure 6.4 Mean expression versus log2 fold change plot. ...................................................... 263 
Figure 6.5 Volcano plot for isoform switching. .......................................................................... 269 
Figure 6.6 Comparison of isoform switching with gene expression changes. .......................... 270 
Figure 6.7 Isoform usage in TPM1. ........................................................................................... 271 
Figure 6.8 Gene expression of TPM1 in VPA exposure and control ........................................ 272 
Figure 6.9 Expression of isoforms of TPM1 .............................................................................. 272 
Figure 6.10. Differential isoform usage of TPM1 isoforms. ....................................................... 273 
Figure 7.1 Photomicrograph from coronal rat brain sections showing negative control at the 
hippocampus. ............................................................................................................................ 291 
Figure 7.2 Photomicrograph from coronal rat brain sections showing MMP13-positive cells at the 
cingulate cortex. ........................................................................................................................ 292 
Figure 7.3 Photomicrograph from coronal rat brain sections showing MMP13-positive cells at the 
cingulate cortex. ........................................................................................................................ 293 
Figure 7.4 Photomicrograph from coronal rat brain sections showing VGF-positive cells at the 
cingulate cortex. ........................................................................................................................ 295 
Figure 7.5 Photomicrograph from coronal rat brain sections showing MAOB-positive cells at the 
cerebral cortex. ......................................................................................................................... 297 
Figure 7.6 Photomicrograph from coronal rat brain sections showing PAK3-positive cells at the 















ABA Allen Brain Atlas 
ACTH Adrenocorticotrophic hormone  
AP-1 Activator Protein 1 
ASD Autism spectrum disorders 
AVP Arginine vasopressin 
BD Bipolar disorder 
BDNF Brain derived neurotrophic factor 
BH4 (6R)-5,6,7,8-Tetrahydrobiopterin 
BLAST Basic local alignment search tool 
bp Base pair 
BSA Bovine serum albumin 
CAGE Cap analysis of gene expression 
cAMP Cyclic adenosine monophosphate 
CBZ Carbamazepine 
cDNA Complementary deoxyribonucleic acid 
CNS Central nervous system 
CREB cAMP response element-binding protein 
CRF corticotrophin-releasing factor 
CRH Corticotrophin-releasing hormone 
CSF Cerebral spinal fluid 
D2/3 Dopamine D2/D3 receptors 
DA Dopamine 
DAT Dopamine transporter 
DEG Differentially expressed genes 
DMEM/F-12 Dulbecco’s modified Eagle medium/ Nutrient mixture  
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
xxii 
 
dNTP Deoxynucleotide triphosphates 
DOPA dihydroxyphenylalanine 
DSM Diagnostic and Statistical Manual of Mental Disorders 
ECT Electroconvulsive therapy 
ENSEMBL European Bioinformatics Institute & Sanger Centre 
ERK Extracellular signal regulated kinase 
EST expressed sequence tags  
G418 Geneticin® 
GABA Gamma (γ)-aminobutyric acid 
GABA=T Gamma (γ)-aminobutyric acid transaminase 
GB Gigabytes 
GIS Gene identification signature  
GO Gene ontology 
GR Glucocorticoid receptors  
GR Glucocorticoid receptor 
GSK-3β  Glycogen synthase kinase-3β 
GTEx Genotype Tissue Expression Project 
GWAS Genome wide association study 
HAT Histone acetyltransferase 
HDAC Histone deacetylase 
HDACi Histone deacetylase inhibition 
HPA Hypothalamus pituitary adrenal axis 
HPA hypothalamus-pituitary-adrenal axis  
hrs Hours 
iDEP Integrated differential expression and pathway analysis  





IMPase Inositol monophosphatase 
ISH In situ hybridisation 
KEGG Kyoto Encyclopedia of Genes and Genomes 
Li Lithium 
LSD Lysergic acid 
LTD long-term depression 




LTP long-term potentiation  
LTP Long-term potentiation 
MAO Monoamine oxidase 
MAOI Monoamine oxidase inhibitor 
MAPK Mitogen-activated protein kinases 
MDD Major Depressive Disorder 
min Minute 
miRNA Micro RNA 
MPSS Massively parallel signature sequencing  
MR Mineralocorticoid receptors  
MR Mineralocorticoid receptor 
mRNA Messenger RNA 
NaB Sodium butyrate 
NCBI  National Centre for Biotechnology Information 
NE Norepinephrine 
NGS Next-generation sequencing 
NGS Next-generation sequencing  
OE Olfactory epithelium  
PI Phosphoinositol 
PI3K Phosphoinositide 3-kinase 
PKA Protein kinase A 
PKB Protein kinase B 
PKC Protein kinase C 
qPCR Real-time quantitative polymerase chain reaction 
RAM Random access memory 
RGD Rat genome database  
RNA Ribonucleic acid 
RNA-Seq RNA-Sequencing 
RT Reverse-transcriptase 
S100B calcium-binding protein B  
SAGE Serial analysis of gene expression  
SCZ Schizophrenia 
SNARE Soluble NSF Attachment Protein Receptor 
SNP Single nucleotide polymorphism 
SNRI Serotonin-norepinephrine reuptake inhibitors 
SPR Sepiapterin reductase 
SSRI Selective serotonin reuptake inhibitors  
STAR Spliced transcripts alignment to a reference  
xxiv 
 
SV-40 Simian virus 40 
T-ag T-antigen 
TBS Tris-buffered saline 
TBST Tris-buffered saline with Triton™ X-100 
TEC-RED trans-spliced exon-coupled RNA end determination 
TNF-α  Tumour necrosis factor α 
TSA Trichostatin A 
UCSC University of California, Santa Cruz 
VPA Valproic acid 
VPD Valpromide 





Chapter 1  
Introduction 
 
1.1 Mood disorders  
Mood disorders are a spectrum of brain disorders characterized by mood lability 
ranging from pure mania to depression. Mania refers to extreme elevation in 
mood. During manic episodes, patients experience euphoria, hyperactivity, high 
reward seeking, hypersexuality, aggression and reduced sleep. Depressive 
episodes are characterized by anhedonia, reduced libido, increased sleep and an 
increased risk of suicide (Nestler et al., 2002). Bipolar disorder (BD) patients 
suffer from comorbidities such as cognitive and metabolic abnormalities, and in 
some cases, hallucinations and psychosis (Craddock & Forty, 2006; Sinha et al., 
2018). 
In the latest edition of the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-5) (American Psychiatric Association, 2013), mood disorders are classified 
separately into bipolar disorders (Angst, 2013) and depressive disorders (Uher 
et al., 2014). Depressive disorders are further classified into 8 types. Major 
depressive disorder (MDD) is the classic form of depression. DSM-5 places 
bipolar disorders between schizophrenia (SCZ) and depressive disorders, as a 
connection between the two based on the symptoms, genetics and family history. 
Bipolar disorders are primarily classified into bipolar I, bipolar II and 
cyclothymic disorder.  
Mood disorders have a substantial socioeconomic burden on the healthcare 
system, patients and their caregivers. Mental disorders are among the top 10 
leading causes of disability which include MDD, BD, SCZ, alcohol and substance 
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abuse, and obsessive compulsive disorder. In 1996, the World Health 
Organization (WHO) estimated MDD to become the second leading cause of 
disability globally by 2020 (Murray & Lopez, 1996) but it became true in 2010, 
ten years earlier than predicted (Ferrari et al., 2013), suggesting mood disorders 
worldwide are on the rise. WHO estimates MDD will become the leading cause 
of disease burden by 2030 (Briley & Lépine, 2011). In New Zealand, the 
prevalence of mood disorders (depression and/or BD) has increased from 10.8% 
in 2006/07 to 16.8% in 2016/17 (Ministry of Health, 2017).  
BD is a heterogeneous condition that affects more than 2% of the population 
globally (Merikangas et al., 2011). It is associated with high morbidity and 
mortality and about 9-13% of patients commit suicide (Medici et al., 2015; Rihmer 
& Kiss, 2002) with higher suicide rates in complex or severe states. The majority 
of patients relapse even with treatment (Geddes et al., 2010; Najafi-Vosough et 
al., 2016). Reduced quality of life is common in BD. Diagnostic and treatment 
improvements are necessary considering the high risk of suicide in BD patients. 
No diagnostic test is available for BD and it is diagnosed based on clinical 
features; family history of mood disorder is a clinical predictor (Phillips & 
Kupfer, 2013).  
Family, twin and adoption genetic studies provide the evidence about the 
genetic contribution to risk. BD is one of the most heritable of the psychiatric 
disorders (Bienvenu et al., 2010). Monozygotic twin concordance rate is 40-70% 
(Craddock & Sklar, 2013) and some twin studies showed higher heritability 
estimates of 89% (McGuffin et al., 2003) and 93% (Kieseppa et al., 2004). Risk of 
disease increased in relatives of bipolar probands with a greater risk for the other 
related psychiatric disorders (Craddock & Sklar, 2013). Several risk loci have 
been identified in candidate gene and genome wide association studies (GWAS), 
and some of these, such as CACNA1C, ANK3, ODZ4, NCAN, have been 
replicated across multiple studies (Ikeda et al., 2018; Wang et al., 2018).  
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1.2 Pathophysiology of mood disorders 
The pathophysiology of mood disorders is poorly understood. Several theories 
have been put forward to explain the disease aetiology. Early theories suggested 
the imbalance of monoamines in depression wherein low levels of 
neurotransmitters results in the disease, and restoration to normal levels would 
treat it. This theory is not proven, in spite of extensive research, however, it led 
to the theories examining other neurotransmitters and their underlying genetic 
components. The research provided insight into the complex underpinning of 
neural circuits, receptor biology, transporters and crosstalk among serotonergic, 
glutamatergic, gamma-aminobutyric acid (GABA) -ergic (GABAergic) and 
dopaminergic systems. No unified hypothesis is available for explaining the 
mood disorders. The different systems discussed below, including the 
monoaminergic neurotransmitters, glutamate, mitochondrial function, 
inflammation and others are interdependent and appear to work together. The 
main contributors to BD pathophysiology include low levels of the neurotrophin 
brain derived neurotrophic factor (BDNF) (Tsai, 2018), decreased neuronal and 
glial density (Harrison et al., 2018), excess glutamate (Jun et al., 2014) and lower 
GABA signalling (Romeo et al., 2018), oxidative stress (Akarsu et al., 2018; 
Valvassori et al., 2018), mitochondrial dysfunction (Kato, 2017) and inflammation 
(Muneer, 2016).  
1.2.1 Monoamine theory 
One of the earliest theories of mood disorder etiology states that dysfunctions in 
monoamines, namely serotonin or 5-hydroxytryptamine (5-HT), dopamine (DA) 
and norepinephrine (NE) are linked to mood disturbances. This theory evolved 
from the study of 5-HT and lysergic acid (LSD) interactions wherein LSD blocked 
peripheral 5-HT receptors (Woolley & Shaw, 1954) and received lots of attention 
(Mulinari, 2012). The original form of the theory suggested low levels of 
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monoamines lead to the mood imbalance and could be restored with external 
administration of monoamines. Several lines of evidence support this theory. 
Reserpine, a monoamine agonist, precipitates depression in hypertensive 
patients (Muller, 1955) reversed by the norepinephrine precursor 
dihydroxyphenylalanine (DOPA) in an animal model of depression (Carlsson et 
al., 1957). Iproniazid, an anti-tuberculosis agent, was shown to improve mood in 
tuberculosis patients with depression (Crane, 1956; Loomer et al., 1957). Later it 
was found to inhibit monoamine oxidase (MAO), a mitochondrial enzyme that 
oxidizes free monoamines in presynaptic cleft (Zeller & Barsky, 1952). However, 
this theory in its original form fails to explain the temporal delay in effects of 
antidepressants. Even though it has not explained the disease, monoamine 
theory has been useful for studying the underlying biology of mood disorders.  
1.2.1.1 Serotonin in mood disorders 
5-HT is an inhibitory monoamine neurotransmitter that regulates mood, 
emotion, sleep, appetite, body temperature and metabolism, and has been 
implicated in multiple psychiatric disorders including mood disorders. It was 
first isolated as “enteramine” by Erspamer from enterochromaffin cells in 1937 
and independently isolated and named as serotonin by Rapport, Page and Green 
in 1948 (Whitaker-Azmitia, 1999). Abnormalities in the serotonergic function 
were implicated in BD as early as the 1950s (Strom-Olsen & Weil-Malherbe, 1958; 
Woolley & Shaw, 1954). Prange et al proposed the permissive hypothesis of 
biogenic amines wherein low levels of 5-HT contributed to mania and 
depression (Prange et al., 1974).  
Dysregulation of the serotonergic neurotransmission in mood disorders led to 
the development of serotonin-selective reuptake inhibitors (SSRIs) that inhibit 
reuptake of 5-HT, one of the most successful antidepressant classes. 
Vulnerability to mania or depression has been attributed to decreased 5-HT 
content, either from less secreted 5-HT or fewer receptors or impaired 
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serotonergic signal transduction (Shiah & Yatham, 2000). Research on animal 
models of mood disorders has shown dysregulations in 5-HT levels, cellular 
machinery for its reuptake/degradation and the activity of the serotonergic 
neurons (Bambico et al., 2009; Bekris et al., 2005; Crawford et al., 2010). Increased 
levels of 5-HT were observed in the frontal cortex and dorsal raphe of rats after 
14 day treatment with antidepressants compared to acute administration (Bel & 
Artigas, 1992). A recent study showed 5-HT was involved in mediating the 
sucrose-dependent amelioration of depression in drosophila (Ries et al., 2017).  
Single nucleotide polymorphisms (SNPs) in the serotonergic receptors 5-HT1A 
(rs6295), 5-HT3A (rs1062613) and 5-HT3B (rs1176744) have been associated with 
BD in European and Japanese populations (Hammer et al., 2012; Niesler, Flohr, 
et al., 2001; Yamada et al., 2006). In vitro studies have shown these variants to 
have functional effects (Hammer et al., 2009; Ji et al., 2008; Kapeller et al., 2008; 
Krzywkowski, Davies, Feinberg-Zadek, et al., 2008; Krzywkowski, Davies, 
Irving, et al., 2008; Meineke et al., 2008; Niesler, Weiss, et al., 2001; Walstab et al., 
2008). For example, SNP 5-HT3B p.Y129S (rs1176744) increases the response to 5-
HT (Krzywkowski, Davies, Feinberg-Zadek, et al., 2008) whereas SNP 5-HT3B 
(H43T) reduces cell surface expression and alters signalling of 5-HT3B receptors 
(Krzywkowski, Davies, Irving, et al., 2008).  
Positron emission tomography imaging in BD patients showed decreased levels 
of the 5-HT1A receptor in the mesiotemporal cortices, anterior cingulate cortex 
and anterior insula (Drevets et al., 2007; Nugent et al., 2013) whereas increased 
levels of the 5-HT1A receptor were reported in the raphe, dorsoprefrontal cortex, 
amygdala and hippocampus (Sullivan et al., 2009). Serotonin transporter binding 
was also affected in BD patients; the binding potential was decreased in the 
anterior cingulate cortex, putamen, thalamus, amygdala, hippocampus and 
midbrain (Oquendo et al., 2007) whereas binding potential was increased in the 
striatum and insula (Cannon et al., 2006). Furthermore, higher binding of pre-
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treatment 5-HT1A receptor was associated with remission in patients with BD 
depression (Lan et al., 2013). Polymorphisms in 5-HT1A receptor were associated 
with increased risk for developing BD (Kishi et al., 2011; Kishi et al., 2013) but this 
did not hold up in GWAS (Ferreira et al., 2008; Sklar et al., 2011).  
The role of 5-HT in depression has received more interest (Kaufman et al., 2016), 
but few studies are available supporting its involvement in mania. Reduced 
central 5-HT function has been reported in mania as evidenced by tryptophan 
depletion, post-mortem and cerebrospinal fluid (CSF) studies (Shiah & Yatham, 
2000). A recent study showed 5-HT depletion in the TPH2 knockout mice led to 
mania-like behaviour which could be corrected with sodium valproate (VPA) 
treatment (Maddaloni et al., 2018). Both lithium and VPA increase central 5-HT 
function in manic patients (Shiah & Yatham, 2000). Short-term lithium treatment 
enhanced 5-HT1A receptor responsiveness whereas long-term treatment 
downregulated 5-HT1A and 5-HT2A receptors (Blier et al., 1987; Goodwin et al., 
1986; Hotta et al., 1986; Odagaki et al., 1990). All this evidence suggests altered 5-
HT activity in BD.  
1.2.1.2 Dopamine theory 
Proposed in the 1970s, dopamine (DA) dysfunction in BD is a key theory and 
links mania and depression with altered levels of DA (Cookson & Silverstone, 
1976). Anti-dopaminergics are well-understood for their action at DA D2/3 
receptors, unlike the mechanism of action of other antidepressants and mood 
stabilizers. Anti-dopaminergics are effective in acute mania treatment. 
Olanzapine and quetiapine are both anti-manic and antidepressant, and prevent 
BD relapse (Arora & Praharaj, 2014; Cipriani et al., 2009; Miura et al., 2014; Suppes 
et al., 2009). The current view is that hyperdopaminergia underlies mania 
whereas hypodopaminergia characterizes depression (Ashok et al., 2017). 
Hyperdopaminergia is associated with higher availability of D2/3 receptors with 
an overactive reward processing network resulting in increased dopaminergic 
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neurotransmission and mania (Ashok et al., 2017; Brust et al., 2015; Del' Guidice 
& Beaulieu, 2015; Masri et al., 2008; Pearlson, 1995). DA has received less 
attention in bipolar depression than mania (Satterthwaite et al., 2015). 
Hypodopaminergia may result from decreased firing of dopaminergic neurons 
and increased striatal DA transporter (DAT) levels, and leads to depression 
(Ashok et al., 2017; Tye et al., 2012). DA and glutamate neurotransmission is 
altered in SPR knockout mice (Choi & Tarazi, 2010), an important gene in the 
tetrahydrobiopterin (BH4) pathway implicated in mood disorders 
(Balasubramanian et al., 2015; McHugh, 2010). 
1.2.2 Hypothalamus-Pituitary-Adrenal axis dysregulation 
The hypothalamus-pituitary-adrenal (HPA) axis (Figure 1.1) theory refers to the 
imbalance in the functioning of the hypothalamus, pituitary and adrenal glands 
and their products affecting each other in turn (Belvederi et al., 2016; Soria et al., 
2018). This neuroendocrine theory states that impaired stress response underlies 
mood disorders. Cortisol is an important component of stress resilience and 
affects the cognitive and affective processes, including circadian coordination 
(Vadnie & McClung, 2017). Sleep-wake cycle abnormalities are central in the BD 
pathophysiology (Alloy et al., 2017; Lee et al., 2013). Cortisol effects are mediated 
through mineralocorticoid receptors (MRs) and glucocorticoid receptors (GRs). 
The function and number of GRs are altered in depressed patients (Shishkina & 
Dygalo, 2017). The HPA axis hyperactivity underlies mood and cognitive 




Figure 1.1 The HPA axis and glucocorticoid receptor signalling in BD. 
Corticotrophin-releasing hormone (CRH) and arginine vasopressin (AVP) are 
released by the hippocampus, which further leads to secretion of 
adrenocorticotrophic hormone (ACTH) from the pituitary and in turn, cortisol 
secretion from the adrenal glands. The cortisol hormone modulates the 
mineralocorticoid receptors (MRs) and glucocorticoid receptors (GRs) and 
regulates several processes in mood disorders. Reprinted with permission from 




Increased cortisol levels were first linked to depression in the 1960s (Gibbons, 
1964) and higher cortisol release was observed during depressive episodes in BD 
patients (Cervantes et al., 2001; Rybakowski & Twardowska, 1999). The HPA axis 
hyperactivity was observed during all phases of BD illness (Belvederi et al., 2016; 
Fries, Vasconcelos-Moreno, Gubert, dos Santos, et al., 2014), and the HPA axis 
activity appears to remain high in remitted patients (Watson et al., 2004). 
Increased levels of corticotrophin-releasing factor (CRF) were also observed in 
the post-mortem MDD brains (Bissette et al., 2003). Early life stress leads to 
increased responsiveness to stress and changes in the HPA system (Heim & 
Nemeroff, 2001) and this has a clear association with mood disorders (Syed & 
Nemeroff, 2017).  
In support of the HPA axis theory, different clinical BD features were associated 
with polymorphisms in glucocorticoid receptor (GR) genes (Ceulemans et al., 
2011; Szczepankiewicz, Leszczynska-Rodziewicz, et al., 2011; Szczepankiewicz, 
Rybakowski, et al., 2011). Abnormal HPA axis activity was seen in unaffected BD 
relatives (Fries, Vasconcelos-Moreno, Gubert, dos Santos, et al., 2014) and BD 
offspring (Ellenbogen et al., 2004; Ellenbogen et al., 2010; Ostiguy et al., 2011). 
FKBP5 has been implicated in BD (Seifuddin et al., 2013). This gene acts as a co-
chaperone for the GR gene and modulates cortisol binding affinity. FKBP5 
mRNA was increased in the post-mortem BD brains (Chen, Wang, et al., 2013) 
and variants in this gene were associated with increased levels of the protein in 
BD patients (Willour et al., 2008). Polymorphisms in FKBP5, acid phosphatase 1 
(ACP1) and glucocorticoid-induced transcript 1 gene (GLCC1) in the stress 
response pathway were associated with degree of response to long-term lithium 
treatment (Szczepankiewicz et al., 2018).  
Stress also affects the antidepressant response. The HPA axis is intricately linked 
to monoaminergic signalling. 5-HT dysfunction was observed in 
hypercortisolaemia patients (Mahar et al., 2014). In a stress model of rats 
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supplemented with exogenous glucocorticoids, the antidepressant fluoxetine 
failed to increase 5-HT levels in the forebrain (Bel & Artigas, 1992). Higher 
cortisol levels in depressed patients resulted in decreased response to 
antidepressants (Fischer et al., 2017). GR sensitivity has been linked to 
antidepressant response (Nestler et al., 2017). GR antagonists could augment the 
SSRI treatment (Johnson et al., 2008) and mifepristone has been shown to 
ameliorate psychotic depression (Block et al., 2018). 
1.2.3 Neuroplasticity hypothesis 
Reduced neuroplasticity in mood disorders is a key theory. Neuroplasticity 
refers to the structural and functional changes in the brain that help adjust to the 
changes in the internal and external environment (Nestler, 2002). Neuroimaging 
and postmortem studies of BD support the neuroplasticity theory (Carlson et al., 
2006; Rocha et al., 2017). The gross brain structure remains preserved during the 
early stages of BD (Lisy et al., 2011) but neurophysiological changes can be 
observed during the course of illness (Lopez-Jaramillo et al., 2010). However, 
early neurodevelopmental changes such as a reduction in the amygdala and 
hippocampal volumes can also be seen (Fornito et al., 2007). This volumetric 
reduction is associated with the length and severity of depression and treatment 
time (Duman, 2014). The morphometric changes have been observed in the 
subgenual prefrontal cortex (Drevets et al., 2008), dorsolateral prefrontal cortex 
and orbitofrontal cortex (Gigante et al., 2010), and hypothalamus and dorsal 
raphe nucleus (Cao et al., 2017; Matthews & Harrison, 2012).  
Altered levels of neurotrophic factors such as BDNF were seen in the serum of 
depressed patients (Ihara et al., 2016; Yu & Chen, 2010). BDNF plays an important 
role in regulating neuroplasticity and resilience. Microglial BDNF regulates 
memory and synaptic plasticity (Rocha et al., 2017). Antidepressants can increase 
neurotrophins, which stimulated neuroplasticity in the prefrontal cortex and the 
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hippocampus (Chen et al., 2001; Post, 2007). Adult hippocampal neurogenesis 
has been linked with depression (Duman et al., 2001) and shown to be required 
for some, but not all, of the behavioural effects of antidepressants (Castrén & 
Hen, 2013; Malberg et al., 2000; Santarelli et al., 2003). This theory helped to 
explain the temporal delay in the therapeutic effects of antidepressants. During 
the lag time, several signalling pathways are activated and long-lasting 
neuroplastic changes occur in the brain. 
Glutamatergic activity is essential for the action of antidepressants, especially 
the “fast-acting” ones like ketamine. Glial cells are the primary mechanism for 
uptake of glutamate. Decreased neuropil and loss of glia has been associated 
with mood disorders (Cobb et al., 2013; Maletic & Raison, 2014; Öngür et al., 2014; 
Soiza-Reilly & Commons, 2014). Similar to antidepressants, the atypical 
antipsychotic clozapine improved neuroplasticity markers, namely adult 
neurogenesis, cell survival and neuronal reorganization in the hippocampus and 
prefrontal cortex (Morais et al., 2017). 
More support for this theory comes from the multiple genetic findings that show 
neuroplasticity-regulating genes were altered in mood disorders. Neuroplastic 
changes in mood disorders are brain-region specific; cAMP response element-
binding protein (CREB) signalling could either decrease or increase depression-
like behaviour in animal models depending on the brain region involved 
(Breuillaud et al., 2012; Gass & Riva, 2007). CREB regulates expression of genes 
that promote neuronal and synaptic plasticity. Protein kinase A (PKA)/CREB 
signalling upregulates BDNF, which regulates neuroplasticity and was involved 
in the action of antidepressants (Tardito, 2006; Xu et al., 2016; Xue et al., 2016; Zou 
et al., 2017). Antidepressants enhance CREB expression through increased 
phosphorylation resulting in increased neurogenesis (Gundersen et al., 2013; 
Rafa–Zabłocka et al., 2017).  
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cAMP–CREB signalling  was deregulated in fibroblasts derived from BD patients 
with a 3-fold increase in cAMP–CREB signalling response in BD patients (Gaspar 
et al., 2014). Exome sequencing of three affected and one unaffected siblings 
identified variants in eight CREB gene targets QUB, JMJD1C, GADD45A, 
GOLGB1, PLSCR5, VRK2, MESDC2 and FGGY linked with BD (Kerner et al., 
2013). A genetic association study showed that two variants in CREB gene have 
been associated with the lithium response (Mamdani et al., 2008). cAMP–CREB 
signalling also regulates the circadian clock which has been shown to be 
disrupted in BD (Soreca, 2014) and mood stabilizers stabilize circadian rhythms 
(section 1.2.6).  
1.2.4 Inflammation theory 
Comorbidity of mood disorders with autoimmune disorders suggests immune-
inflammation response is an important component of the BD pathophysiology 
(Eaton et al., 2010). Mania and depression were associated with a pro-
inflammatory state (Hamdani et al., 2013). Chronic low-grade inflammation was 
seen in BD wherein increased levels of pro-inflammatory cytokines such as IL-4, 
Il-6, IL-10, TNF-α were present, which further increased during mood episodes 
(Barbosa, Machado-Vieira, et al., 2014; Brietzke et al., 2009; Kunz et al., 2011; 
Modabbernia et al., 2013). The immunological disturbance was severe in BD I 
patients (Wang, Lee, et al., 2016). Increased C-reactive protein was associated 
with higher risk of mania (Dickerson et al., 2007) and depression (Dickerson et 
al., 2015). The calcium-binding protein B (S100B) is an inflammatory protein 
released by astrocytes and oligodendrocytes. Both serum and CSF S100B levels 
were increased during episodes of mania and depression (Andreazza et al., 2007; 
da Rosa et al., 2016; Schroeter et al., 2013) with increased gene expression in the 
hippocampus in BD post-mortem samples (Schroeter et al., 2014).  
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Multiple lines of evidence from BD post-mortem studies show the involvement 
of the immune system in its pathophysiology. Transcriptomic study of the dorsal 
striatum in BD patients showed elevated immune-response genes such as 
NLRC5, S100A12, LILRA4 and FCGBP (Pacifico & Davis, 2017). Similarly, 
proteomic studies showed altered levels of immune-regulatory proteins in BD 
patients (Chen et al., 2015; Lee, Joo, et al., 2015; Xu et al., 2012).  
Neuroinflammation is linked to mitochondrial dysfunction; increased 
mitochondrial reactive oxygen species (ROS) production activated NLRP3 
inflammasome and caspase-1 which activated cytokines and altered 
neurotransmission (Kim et al., 2015).  
Pharmacotherapy in BD may also target the immune system. Some 
antidepressants may have immunosuppressive effects; fluoxetine, moclobemide 
and venlafaxine reduced macrophage pro-inflammatory cytokines (Hannestad 
et al., 2011; Leonard, 2001; Nazimek et al., 2016). Lithium changed the expression 
of immune-related genes in peripheral lymphocytes (Anand et al., 2016). 
Furthermore, the cytoprotective effects of both lithium and VPA have been 
linked to their anti-apoptotic effect on T-lymphocytes from BD patients 
(Pietruczuk et al., 2018).  
1.2.5 Mitochondrial dysfunction  
Mitochondrial abnormalities are associated with the pathophysiology of 
psychiatric disorders, including BD, MDD and autism spectrum disorders (ASD) 
(Agam & Toker, 2015). The earliest evidence of mitochondrial dysfunction in BD 
was the observation of increased lactate levels in the brain (Stork & Renshaw, 
2005). The lactate levels were also increased in CSF (Yoshimi et al., 2016) with 
low levels of ATP and phosphocreatine in BD patients (Anglin et al., 2012). 
Studies suggest that abnormalities in mitochondrial energetics between 
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neuronal and glial cells may contribute to the aetiology of BD (Mason, 2005; 
Sigitova et al., 2017). BD post-mortem studies showed altered expression of genes 
encoding mitochondrial enzymes. Some mitochondria-related genes such as 
those encoding components of the electron transport chain (ETC) (Sun et al., 
2006) and PPIF gene encoding cyclophilin D, a component of the mitochondrial 
permeability transition pore (Kubota et al., 2010), were downregulated in the 
postmortem prefrontal cortex of BD patients. Similar gene expression changes 
were seen in the ETC in the hippocampus (Konradi et al., 2004) and prefrontal 
cortex (Andreazza et al., 2010; Iwamoto et al., 2005; Sun et al., 2006). miRNAs that 
target the mitochondrial redox enzymes of the ETC were altered in BD (Kim et 
al., 2018). All these studies suggest a change in mitochondrial function in BD 
(Kim et al., 2017; Stork & Renshaw, 2005). 
A recent study has linked serotonergic and mitochondrial dysfunctions in BD. 
Mitochondrial adenine nucleotide translocator 1 (ANT1) gene implicated in BD 
risk was sequenced in 324 BD patients and two patients with loss-of-function 
mutations in ANT1 were identified (Kato et al., 2018). The authors created 
homozygous Ant1 conditional knockout mice, which showed lowered 
mitochondrial Ca++ retention capacity and enhanced 5-HT turnover. The 
serotonergic neurons of the dorsal raphe showed higher excitability in the 
heterozygous Ant1 knockout mice, which might be linked to abnormal synaptic 
connections and signalling in BD.  
1.2.6 Chronobiological theory  
Sleep and wake abnormalities are associated with mood disorders (Lyall et al., 
2018). Disrupted circadian rhythms such as sleep, appetite, activity and 
hormonal secretion were seen in BD patients (Soreca, 2014) and can act as a 
trigger for manic episodes (Grandin et al., 2006). Manic episodes are associated 
with reduced need for sleep, whereas depression is associated with insomnia or 
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hypersomnia (American Psychiatric Association, 2013). Circadian rhythm 
disruption was also linked to the severity of the illness and treatment resistance 
(Lyall et al., 2018).  
The chronobiological theory involves alterations in melatonin levels and its 
receptors and cortisol levels. Lower melatonin levels were observed in manic, 
depressive and euthymic states in BD patients compared to healthy controls 
(Nurnberger et al., 2000; Seleem et al., 2015). Melatonin interacts with 
serotonergic (Zaki et al., 2017) and dopaminergic systems (Zisapel, 2001). 
Circadian rhythms are connected to monoamine systems. The clock genes 
BMAL1, NPAS2 and PER2 regulated the expression of monoamine oxidase gene 
MAOA in cultured cells (Hampp et al., 2008). Clock genes also regulated GSK-3β 
activity in mice (Besing et al., 2015). Lithium inhibits GSK-3β and can stabilize 
circadian rhythms in humans, animal models and at cellular level (Abe et al., 
2000; Johnsson et al., 1980; Klemfuss & Kripke, 1995; Nagayama, 1996; Vadnie & 
McClung, 2017). 
Candidate gene association studies initially showed association of genes that 
regulate circadian rhythms such as CLOCK, BMAL, NPAS2, CRY1, RORA, 
ARNTL, TIMELESS, PER3 with mood disorders (Mansour et al., 2009; McGrath 
et al., 2009; Nievergelt et al., 2006; Partonen et al., 2007; Shi et al., 2008; Soria et al., 
2010), however, only CLOCK and RORA hold up in GWAS (Ferreira et al., 2008; 
Landgraf et al., 2014; McCarthy, Nievergelt, et al., 2012; Sklar et al., 2011). SNPs 
in ARNTL and TIMELESS were linked to the lithium response in BD patients 
(McCarthy, Nievergelt, et al., 2012; Rybakowski et al., 2014). Both lithium and 
VPA lengthened the circadian rhythm period in fruit flies (Dokucu et al., 2005; 
Hallam et al., 2005). A recent study linked inositol hexphosphate with lithium-
mediated change of circadian rhythms (Wei et al., 2018). VPA normalized the 
lengthened circadian rhythm period in DAT knockdown mice and DAT-
deficient drosophila with elevated DA levels, but failed in circadian-disrupted 
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flies (Landgraf et al., 2016). Similarly, VPA affected the expression of clock genes, 
including CSNK1D and CRY2 in the mouse amygdala (Ogden et al., 2004) and 
PER2 in cultured mouse cells (Johansson et al., 2011).  
The circadian rhythm abnormality in BD can be targeted for therapy. Slow-
release melatonin could be used in treating depression and alleviating sleep 
disorders (Dalton et al., 2000; Laudon & Frydman-Marom, 2014). Agomelatine, a 
melatonin receptor agonist and 5-HT2C receptor antagonist can restore circadian 
rhythms and is used as an atypical antidepressant for treatment of MDD (Taylor 
et al., 2014). Furthermore, bright light therapy has been effective in treating 
bipolar depression (Sit et al., 2018). 
1.3 Treatment of mood disorders 
MDD involves anhedonia and is treated with antidepressants. Monoamine 
oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs) were the first 
generation antidepressants, followed by the second-generation SSRIs and 
serotonin-norepinephrine reuptake inhibitors (SNRIs). Monoamine-modulating 
antidepressants are less effective for bipolar depression than major depression 
and have a risk of inducing mania (Fountoulakis, Kasper, et al., 2012). This 
suggests bipolar depression involves more than monoamine neurotransmission. 
BD is highly recurrent, even with correct diagnosis and treatment (Najafi-
Vosough et al., 2016). Management involves treatment of manic/hypomanic or 
depressive episodes along with maintenance therapy to reduce episodes and 
prevent relapse (National Collaborating Centre for Mental Health (UK), 2018). 
Acute mania is treated with pharmacological therapy (mood stabilizers and 
atypical antipsychotics) (Cipriani et al., 2011), and non-pharmacological 
approaches are used for treatment-resistant and severe mania (Hui Poon et al., 
2015). In cases of severe illness, combination therapy of a mood stabilizer and an 
antipsychotic is used. Bipolar depression is treated with quetiapine, 
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olanzapine/fluoxetine, or lamotrigine (LTG) (Prabhavalkar et al., 2015; van der 
Loos et al., 2011). Off-label or combination therapies like VPA and LTG, lithium 
and LTG are commonly used to reduce the severity of the depressive symptoms 
(Fountoulakis, Kasper, et al., 2012). Once mood episodes are stabilized, effective 
acute phase medication is continued to maintain euthymic phase with 
monitoring. Quetiapine, quetiapine-lithium and quetiapine-VPA is used for 
treatment in the maintenance phase (Cipriani et al., 2013; Cipriani et al., 2009). 
Better drugs are needed for the treatment of both unipolar and bipolar 
depression, preferably targeting a broader range of symptoms (Li, Frye, et al., 
2012; Shim et al., 2017). 
1.3.1 Mood stabilizers 
A mood stabilizer can be used as monotherapy to provide therapeutic and 
prophylactic relief in mania and/or depression for at least a year, without any 
worsening of the symptoms. Even though lithium, VPA, LTG and 
carbamazepine (CBZ) have different chemical structures, all have mood 
stabilizing effects.  
1.3.1.1 Lithium 
Lithium was the first psychiatric drug, discovered by the Australian psychiatrist 
John Cade to be useful for treatment of mania (Cade, 1949) and its mood 
stabilizing effects were described by British psychiatrist Geoffrey Hartigan 
(Hartigan, 1963). It was approved for treatment of BD by U.S. Food Drug 
Administration (FDA) in 1970. Lithium is the first-choice for BD treatment and 
is widely used as a mood stabilizer (Baldessarini & Tondo, 2000; Baldessarini et 
al., 2002). It works well for both acute mania and maintenance therapy (Nivoli et 
al., 2010; Rybakowski, 2011). Along with clozapine, an anti-psychotic, lithium is 
the only drug that has been effective in reducing suicide and relapse rates 
(Geddes et al., 2004; Nivoli et al., 2010; Rybakowski, 2014). A major side-effect of 
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lithium is on kidney function, so patients need to be regularly monitored for 
serum levels of lithium. Long-term use of lithium is associated with reduced 
renal function, hypothyroidism and hypercalcaemia.  
Individual response to lithium varies and it works well in one-third of patients, 
classifying them as excellent lithium responders (Rybakowski et al., 2001). 
Bipolar patients can be categorized into lithium responders, partial responders 
and non-responders. Several studies have shown lithium response is a heritable 
trait with increased response rates in first-degree relatives of responders (Grof et 
al., 1994; Grof et al., 2002). The lithium response has been associated with a 
lifetime history of mixed bipolar episodes (Fountoulakis, Kontis, et al., 2012), 
family history of BD 1 (Grof, 2010; Maj et al., 1985; Mendlewicz et al., 1973), 
episodic pattern of mania-depression and later age of onset of illness 
(Kleindienst et al., 2005). Poor responders tend to comprise of complex forms of 
illness with rapid cycling, mixed state bipolar and alcohol or substance abuse 
(O'Connell et al., 1991). Sometimes initial responders can develop tolerance to 
lithium after long-term treatment (Maj et al., 1989; Post, 2012). Some patients 
discontinue lithium after a good long term response and fail to respond again. 
Lithium resistant depression can be treated with combination therapy using 
antidepressants or anticonvulsants (Lin et al., 2006; Soares-Weiser et al., 2007). 
The mechanism of action of lithium has been described in section 1.5.   
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1.3.1.2 Sodium Valproate 
 
 
Figure 1.2 Chemical structure of sodium valproate. 
 
Sodium valproate (VPA) is an anticonvulsant drug (Figure 1.2). Its 
anticonvulsant properties were discovered when Dr. George Carraz used it as a 
solvent for anti-epileptic drugs (Löscher, 2002; Meunier et al., 1963). It is a 
synthetic analogue of valeric acid, produced by the plant Valerina officinalis 
(Burton, 1882). VPA is widely used for treatment of BD (Goodwin & Jamison, 
2007). It is effective for manic phase, especially in euphoric mania and other 
forms of mania (Grunze et al., 2013) and in lithium non-responders without 
manic relapses (Lambert et al., 1975). It is used in monotherapy or in combination 
with other atypical antipsychotics, mood stabilizers or antidepressants (Cipriani 
et al., 2013). VPA is used in the treatment of other conditions such as SCZ (Suzuki 
et al., 2009), Alzheimer’s disease (Tariot et al., 2011), neuropathic pain (Gill et al., 
2011) and prophylaxis of migraine headaches (Linde et al., 2013). VPA is also 
being trialled in combination therapy in cancers due to its anti-tumour effects 
through the inhibition of class I HDACs (Brodie & Brandes, 2014). A major side-
effect of VPA is its teratogenic effects, so it must not be prescribed to pregnant 
women (Ornoy, 2009; Phiel et al., 2001; Wieck & Jones, 2018). The known 




Lamotrigine (LTG) is an anticonvulsant that is widely used for treatment of 
bipolar depression (Bowden et al., 1999; Calabrese, 1999; Reid et al., 2013) and is 
used for both BD 1 and BD II (Figure 1.3). It is effective in mood stabilization 
maintenance by preventing relapse into depression (Bowden et al., 2003) 
however, it is not effective for mania (Calabrese et al., 2003).  
 
 
Figure 1.3 Chemical structure of lamotrigine.  
 
The precise mechanism of action of LTG is still unclear, but several signalling 
cascades and pathways have been implicated. Several studies show LTG affects 
sodium and calcium channels. LTG blocked voltage-gated sodium channels 
(Ketter et al., 2003; Xie & Hagan, 1998) and reduced neuronal excitability in 
cultured neurons (Cheung et al., 1992). Animal studies show LTG is a Na+ 
channel inhibitor (Lees & Leach, 1993; Stefani et al., 1996; Wang et al., 2001). LTG 
is not a broad-spectrum calcium channel inhibitor (Lees & Leach, 1993) and 
inhibited L-type calcium channels weakly, but inhibited other types of calcium 
channels (N- and P/Q/R- types) in rat cerebellar neurons (Wang et al., 1996; Xie 
& Hagan, 1998). This inhibition of calcium channels can further reduce glutamate 
release (Lee et al., 2008; Waldmeier et al., 1995). 
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Glutamate AMPA and NMDA receptors have been implicated in the mechanism 
of action of LTG (Ketter et al., 2003; Prica et al., 2008). LTG increased the surface 
expression of GluR1/2 AMPA receptors (Du et al., 2007), whereas it inhibited 
currents induced by post-synaptic AMPA receptors (Lee et al., 2008). Chronic 
LTG exposure downregulated arachidonic acid signalling via blocking of 
NMDA receptors (Ramadan et al., 2011; Rapoport, 2014).  
The antidepressant effects of LTG may also involve noradrenergic modulation 
through the activation of α1/2 postsynaptic adrenoceptors (Kaster et al., 2007) 
along with the selective suppression of the currents mediated by α4β2 nicotinic 
acetylcholine receptors in the ventral tegmental DA neurons (Jefferson, 2005). 
LTG may also work through gene expression changes wherein chronic LTG 
administration increased BDNF levels in the hypothalamus and prefrontal cortex 
of rats (Chang et al., 2009; Li, He, et al., 2010; Li et al., 2011). 
1.3.1.4 Carbamazepine 
Carbamazepine (CBZ) is an anticonvulsant drug (Figure 1.4) and is used in the 
treatment of BD (Wang & Ketter, 2005) and borderline personality disorders (de 
la Fuente & Lotstra, 1994; Gardner & Cowdry, 1986; Stoffers et al., 2010). It is also 
effective for neuropathic pain (Wiffen et al., 2014) and trigeminal neuralgia (van 





Figure 1.4 Chemical structure of carbamazepine. 
 
The anti-manic properties of CBZ were first discovered in the early 1970s in 
Japan (Okuma et al., 1973) and later in the USA and Europe (Ballenger & Post, 
1980). It is effective for both acute and maintenance therapy (Chen & Lin, 2012) 
and works well for mixed bipolar states and rapid cycling conditions (Weisler et 
al., 2004; Weisler et al., 2005). It can be used as monotherapy or second line of 
therapy or in combination with lithium or VPA. However, interactions with 
mood stabilizers and antidepressants limit its clinical use. It reduces serum 
concentrations of VPA or LTG by inducing catabolic enzymes such as CYP3A3 
and CYP3A4 (Perucca, 2006). 
The mechanism of action of CBZ is similar to other anticonvulsants VPA and 
LTG. It inhibits voltage-sensitive Na+ and Ca++ channels (Wang & Ketter, 2005). 
It also increases GABA-mediated chloride current (Granger et al., 1995) and 
inhibits glutamate release (Lingamaneni & Jr, 1999; Okada et al., 1998; Waldmeier 
et al., 1995). Its anti-manic effects are linked to an increase in the extracellular 5-
HT and DA levels (Ahmad et al., 2005; Dailey et al., 1997; Lee, 2000). Like VPA, 




Monoamine oxidase inhibitors (MAOIs) developed in the 1950s were one of the 
first drugs discovered to be highly effective for atypical depression (Youdim & 
Bakhle, 2009). These inhibit the mitochondrial enzyme monoamine oxidase, 
which catalyses the oxidative deamination of monoamine neurotransmitters like 
5-HT, DA and nor-epinephrine (NE) (Zeller & Barsky, 1952). Some of the 
commonly prescribed MAOIs are moclobemide and brofaromine. Tricyclic 
antidepressants (TCAs) were first discovered in the 1960s (Klerman & Cole, 
1965) and inhibit 5-HT and NE reuptake and transport, increasing their 
concentrations in the synaptic cleft. Desipramine is a selective NE reuptake 
inhibitor, whereas clomipramine and amitriptyline inhibit 5-HT reuptake 
(Tatsumi et al., 1997).  
Second generation antidepressants, SSRIs such as fluoxetine and serotonin-
norepinephrine reuptake inhibitors have less side-effects, but are no more 
effective than MAOIs and TCAs (Li, Frye, et al., 2012; Liu, Liu, et al., 2017). The 
initial effects of these drugs include increased levels of intra-synaptic 5-HT 
and/or NE (Lucki & O'Leary, 2004). Antidepressant effects are seen after chronic 
administration from several days to weeks, implicating downstream signalling 
cascade and cellular changes such as neuroplasticity for the therapeutic effects 
(Liu, Ge, et al., 2017; Mitchell, 2018; Racagni & Popoli, 2008). 
Ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, has 
shown antidepressant efficacy in bipolar depression and major depression in 
clinical trials; the effect is rapid but transient. It is particularly effective for 
rapidly reducing suicidal ideation (Ballard et al., 2014). High doses of ketamine 
reduced glutamate signalling (Moghaddam et al., 1997) whereas low doses 
resulted in glutamate release (Chowdhury et al., 2012) which was due to 
preferential block of NMDA receptors on subpopulations of GABAergic 
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interneurons (Homayoun & Moghaddam, 2007). This resulted in a cascade of 
disinhibited prefrontal glutamatergic cells, glutamate surge, stimulated AMPA 
receptors and activation of the mTOR pathway (Duman et al., 2012; Li, Lee, et al., 
2010; Maeng, Zarate, et al., 2008). The antidepressant effects of ketamine have 
been attributed to downregulated NMDA receptors and upregulated AMPA 
receptors (Du et al., 2006). Ketamine also inhibited GSK3 to augment signalling 
through AMPA receptors in membrane and synaptosomal extracts from mice 
(Beurel et al., 2016). 
1.3.3 Antipsychotics 
Typical antipsychotics such as chlorpromazine and haloperidol, and atypical 
antipsychotics such as quetiapine, olanzapine, clozapine and risperidone are 
used both in acute mania and maintenance therapy (Bourin, Lambert, et al., 
2005). Atypical antipsychotics are better with fewer side-effects, improved 
cognitive symptoms and reduced risk of suicide (Keks, 2004). Combination 
therapies of atypical antipsychotics with mood stabilizers or antidepressants are 
more effective compared to monotherapy (Buoli et al., 2014). Typical 
antipsychotics block DA D2 receptors (Tohen & Vieta, 2009) and atypical 
antipsychotics may have more targets beyond D2 receptors, including the 5-HT2A 
and 5-HT2C receptors (Meltzer, 1999) or are 5-HT1A receptor partial agonists such 
as asenapine (Ghanbari et al., 2009).  
1.3.4 Electroconvulsive therapy 
Electroconvulsive therapy (ECT) is a short-term treatment to provide immediate 
relief in severe BD, especially for relieving suicidal and psychotic symptoms (Oji 
et al., 2015). ECT is also useful for treatment in pregnant women (Saatcioglu & 
Tomruk, 2008). This therapy has been controversial due to the memory loss and 
attention deficit associated with the treatment (Petrides et al., 2011). ECT affects 
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neuroplasticity by increasing temporal grey matter volume and cortical 
thickness (Sartorius et al., 2016), hippocampal connectivity (Joshi et al., 2016; 
Tendolkar et al., 2013) and stimulates neurogenesis (Madsen et al., 2000; 
Schloesser et al., 2015). 
1.3.5 Psychotherapy 
There are several forms of psychotherapy including cognitive behavioral 
therapy (CBT), mindfulness-based cognitive therapy (MBCT), interpersonal and 
social rhythm therapy (IPSRT), dialectical behavior therapy (DBT), 
psychoeducation (PE) and family therapies such as family-focused therapy (FFT) 
(Leichsenring et al., 2006; Markowitz & Weissman, 2004). Cognitive behavioural 
therapy is one of the most studied and influential psychotherapy. It has been 
effective at reducing the severity of mania, and improving depressive symptoms 
and psychosocial functioning in patients (Mazza et al., 2017). Mindfulness-based 
cognitive therapy has been linked with improving anxiety and depression along 
with mood regulation (Lovas & Schuman-Olivier, 2018). Interpersonal and social 
rhythm therapy has been effective in reducing functional impairment and 
improving social rhythm stability (Goldstein et al., 2018; Inder et al., 2015). Group 
psychoeducation has helped patients remove self-stigma and improve their 
symptoms and quality of life (Çuhadar & Çam, 2014; Etain et al., 2018; Kessing et 
al., 2014; Soo et al., 2018).  
Psychotherapies are increasingly being used in adjunct to pharmacotherapy and 
have helped patients and their families to monitor risk of suicide or relapse 
(Deckersbach et al., 2014). It has been useful in treating depression during 
pregnancy (Muzik et al., 2009). It can be either used as monotherapy or in 
combination with pharmacotherapy which is more effective, and helps prevent 
relapse or recurrence (Cuijpers et al., 2009; Luty et al., 2007; Picardi & Gaetano, 
2014). Patients with complex symptoms and comorbidities have low response 
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rate to psychotherapy (Joyce et al., 2007). Psychotherapy is effective for chronic 
forms of depression.  
1.4 Models to study mood disorders 
The primary goals underlying use of model systems is to find clinical correlates 
and understand pathological features of mood disorders, and to facilitate 
development of novel therapeutics. The structural and functional changes in the 
brain can be visualized through imaging techniques. Pathologic changes are 
often studied in post-mortem brains. Cellular models are essential to study live 
brain cells at cellular and molecular level resolution.  
1.4.1 Cellular models 
1.4.1.1 Peripheral blood mononuclear cells 
Peripheral blood mononuclear cells (PBMCs) have been widely used for 
studying mood disorders. These cells have been used to examine the effect of 
lithium on GSK3β from BD patients compared to controls (Li et al., 2007; 
Munkholm et al., 2018). Proteome analysis of PBMCs and serum from BD 
patients in remission showed 60 proteins with altered in PBMCs cytoskeletal and 
stress-response properties (Herberth et al., 2011). Several studies have used 
PBMCs to study the pathophysiology of BD such as mitochondrial dysfunction 
and apoptosis (Fries, Vasconcelos-Moreno, Gubert, Santos, et al., 2014; Scaini et 
al., 2017), inflammation (Barbosa, Rocha, et al., 2014) and immune function 
associated with psychosis in BD and SCZ (Melbourne et al., 2018).  
Limitations of this model system include the difference in phenotype between 
the PBMCs and neuronal cells and is not the most appropriate model for 
studying brain disorders. In addition, measuring gene expression differences 
with RNASeq could be distorted by the gene expression differences among the 
different cell populations such as T cells vs B cells (Wong et al., 2016).  
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1.4.1.2  Immortalized cell lines 
Immortalized cell lines are easy to use, store and manipulate. Multiple studies 
have used cell lines to study the molecular targets of mood stabilizers and 
antidepressants (Chen et al., 1994; Chen et al., 1996; Chen et al., 2000; Chen, Yuan, 
et al., 1999; Ozaki & Chuang, 2002). Lithium and VPA have been shown to 
increase DNA-binding activity of AP-1 in C6 glioma (Chen et al., 1997; Yuan et 
al., 1998) and SH-SY5Y neuroblastoma cells (Asghari et al., 1998; Daniel et al., 
2005). Lithium and VPA have been shown to inhibit GSK3β in PC-12 and SH-
SY5Y cells, respectively (Chen, Huang, et al., 1999; Stambolic et al., 1996). Cell 
lines are useful in studying gene function, however, interpretation of the results 
needs care.  
Other cell lines available include the human NT2 derived cell line (Yoshioka et 
al., 1997), mouse mesencephalic embryonic cell line A1 mes-c-myc (Colucci-
D'Amato, 1999), HEK293 cells (Johnson et al., 1999) and thyroid C-cell lines 
(Clark et al., 1995). All these cell lines express a component of serotonergic 
signalling rather than being of neuronal origin.  
Rat RN46A is a true serotonergic cell line derived from the medullary raphe and 
endogenously expressing all the serotonergic genes (White et al., 1994). RN46A 
cells can be differentiated into mature neurons and expresses no glial antigens 
(White et al., 1994). This cell line was the primary model used in this thesis and 
will be described in the introduction to chapter 3.  
1.4.1.3 Lymphoblastoid cell lines 
Cell lines with direct reprogramming can be used to study mood disorders 
(Viswanath et al., 2015). Lymphoblastoid cell lines (LCLs) are useful models to 
study the lithium response and have been used to differentiate between lithium 
responders and non-responders based on the electrophysiological recordings of 
neurons derived from patient LCLs (Stern et al., 2017). Lithium reduces 
28 
 
hyperexcitability in only lithium-responder neurons, providing some evidence 
for genetic underpinnings of lithium response. Microarray and RNA-Seq studies 
provide some evidence for gene expression changes in BD patients compared to 
healthy controls and few genes were significantly altered in response to lithium 
treatment (Fries et al., 2017; Kittel-Schneider et al., 2017; Milanesi et al., 2017).  
1.4.1.4 Induced pluripotent stem cells 
Studies using induced pluripotent stem cells (iPSCs) have uncovered important 
neurodevelopmental changes underlying mood disorders such as differential 
expression of genes encoding Ca+2 channels CACNA1E, CACNA1G, CACNB1 and 
CACNG8, and Na+ channel SCN2A and SCN3A (Chen et al., 2014; Madison et al., 
2015). Neuronal morphology, connectivity and synaptic maturation were altered 
in iPSC-derived neurons from BD patients (Soliman et al., 2017; Temme et al., 
2016). Neural patterning genes such as FOXP2 and NKX2-1 were upregulated in 
iPSC-derived neurons from BD patients (Chen et al., 2014). Although useful 
models, patient iPSC-derived neurons can show line-to-line variability, few 
spines, no complex neural circuits and difficulty to differentiate between 
neuronal sub-types (Hoffmann et al., 2018).  
Humanized glial chimera showed SCZ-related symptoms such as excessive 
anxiety and social isolation, and revealed impairment of astrocytic maturation 
and abnormalities in myelination in SCZ patients (Windrem et al., 2017). These 
chimeras can be used to study other psychiatric disorders like BD, ASD, 
Alzheimer’s disease and novel drug development. 
1.4.1.5 Primary neurons 
Primary neurons retain original morphology and can be cultured for 3-4 weeks 
to study chronic effects of mood stabilizers and antidepressants. Chronic, but not 
acute, lithium treatment increased BCL2 levels in rat cortical astrocytic culture, 
but not in neurons-astrocytes mixed cultures (Keshavarz et al., 2013). Thus, 
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mixed cultures of primary neurons with glial cells can be used to study the effect 
of mood stabilizers. Primary cultures of mouse hippocampal neurons have also 
been used to create a neurophysiological assay to study the role of candidate 
genes in neural networks (MacLaren et al., 2011). Although useful models, the 
primary neurons lose the proliferative ability and are difficult to culture for long-
term periods (Giordano & Costa, 2011). 
1.4.1.6  Olfactory epithelium 
The olfactory epithelium (OE) cells, located in the nasal cavity contain stem cells 
and neural progenitor cells that can be further differentiated into neurons and 
glia. These are considered to be closer cellular models for brain disorders than 
blood based cells. Live neuronal cultures grown from OE tissues have been used 
in multiple studies of calcium signalling, apoptosis and cell cycle abnormalities 
in BD (Hahn, Gomez, et al., 2005; McCurdy et al., 2006; Solis-Chagoyan et al., 
2013). OE cells from BD I patients were more sensitive to glutamate-induced 
apoptosis compared to healthy controls (Gao et al., 2017). A study using patient-
derived olfactory neurons showed two genes, GSK-3β and collapsin response 
mediator protein 1 (CRMP1), were associated with the lithium response (McLean 
et al., 2018).  
1.4.1.7 Brain organoids 
Brain organoids and spheroids capture features of the developing brain, and are 
derived from the human pluripotent stem cells. It is a relatively young field. 
These new tools are useful to study the neurodevelopmental changes in mood 
disorders (Di Lullo & Kriegstein, 2017). Insights from postmortem and other 
cellular platforms have revealed significant cellular, molecular and neural 
circuitry changes. Brain organoids can be used to study these changes at a greater 
detail, including synapse formation, vesicle trafficking, synaptic remodelling 
among others (Quadrato et al., 2016). Multiple genetic findings identified over 
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the past decade can be further studied in the patient-derived brain organoids 
and abnormalities in the brain function can be examined.  
1.4.2 Animal models 
A better understanding of BD pathophysiology is essential to improve treatment. 
Animal models are a useful tool to understand the underlying neurobiology. It 
is difficult to establish animal models for BD due to the broad spectrum of 
symptoms and not all the human symptoms can be modelled in animals 
(Valvassori, Varela, et al., 2017). There are four main features of BD: mania, 
depression, possibility of mood swings in euthymic state, and cyclicity (Logan & 
McClung, 2016). Only partial models for each component are available in rodents 
due to the complex features of BD (Chen, Henter, et al., 2011). The animal models 
can mimic behavioural characteristics such as aggression, decision making, risk 
taking, sexual behaviour and locomotor activity (Valvassori, Varela, et al., 2017).  
Depression in rodents can be induced by environmental cues or knocking out 
single genes. Depression models commonly used are despair, reward, anxiety or 
stress based (Deussing, 2006). The gene knockout models of depression are listed 
in Table 1.1, and the depression-like features of these models can be rescued with 
antidepressants (Krishnan & Nestler, 2011).  
Psychostimulants like cocaine or amphetamine can be used to model mania-like 
behaviour in mice, which can be rescued with lithium and VPA (Ågmo et al., 
1997; Aylmer et al., 1987; Jornada et al., 2010). Disruption of circadian rhythms 
can induce mania and ClockΔ19 mutant mice exhibit mania-like behaviour 
(Roybal et al., 2007). Other genetic rodent models of mania are listed in Table 1.1.  
Vulnerability to mood swings can also be modelled using genetic models (Table 
1.1). The cyclical nature of BD is the hardest to model. Most of the available 
animal models either model mania or depression, but a recent HYPER rat model, 
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a natural genetic variant, has been reported to show the cyclical nature of BD 
(Weiss & Boss-Williams, 2017).  
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Table 1.1 Genetic animal models of BD. 
Mania-like behaviour  
Gene Knockout Author 
ClockΔ19 (Roybal et al., 2007) 
GluR6 (Shaltiel et al., 2008) 
ERK1 (Engel et al., 2008) 
DAT (Ralph-Williams et al., 2003) 
GSK- 3β (Prickaerts et al., 2006) 
PACAP (Hattori et al., 2012) 
DBP (Le-Niculescu et al., 2008) 
SHANK3 (Han et al., 2013) 
IMPA1 (Damri et al., 2015) 
BCL2 (Lien et al., 2008) 
Depression-like behaviour  
S100A10 (Egeland et al., 2010) 
VMAT2 (Takahashi et al., 1997) 
NCAM (Aonurm-Helm et al., 2015) 
Vulnerability to mood swings 
GR overexpression (Wei et al., 2004) 
BCL2 heterozygous KO (Einat et al., 2005) 
BAG1 heterozygous KO mice  (Maeng, Hunsberger, et al., 2008) 
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1.4.3 Postmortem studies 
In the 1950s, psychiatric disorders like SCZ and BD were thought to be functional 
psychoses with dysfunctions in neurotransmitter levels and no 
neuropathological changes. Postmortem studies in the 1970s revealed 
morphometric changes in the brain and changed this view to psychiatric 
disorders being brain diseases (Johnstone et al., 1976). Several brain regions, 
including the dorsolateral prefrontal cortex, anterior cingulate cortex, amygdala, 
hippocampus and thalamus showed morphometric changes in BD (Cotter, 2002; 
Law & Harrison, 2003; Rajkowska, 2000; Sakai et al., 2008). The neuropathological 
changes in neurons and glia changed the direction of research from 
monoaminergic analysis to dysfunctions in synaptic and neural plasticity (Kim 
et al., 2017).  
Global scale analysis of postmortem brains with exome or whole genome 
sequencing, RNA expression with microarrays and RNA-Seq, proteomics and 
epigenomics has helped discover new molecules and pathway-related 
alterations. A recent meta-analysis of gene expression studies, including 700 
cortical post-mortem brains from BD, MDD, SCZ, ASD and ADHD revealed 
shared genes and pathways among these psychiatric disorders (Gandal et al., 
2018). Another meta-analysis of post-mortem brains showed increased lactate 
levels and reduced pH in BD and SCZ patients, which has been replicated in the 
animal models (Hagihara et al., 2017). 
Post-mortem studies have been used to study gene regulation in psychiatric 
disorders. Hypoacetylation of histones was observed in BD and SCZ patients in 
the frontal cortex, which could be rescued with HDAC inhibitors (Tang et al., 
2011). Postmortem studies can complement findings from other platforms. 
However, they may be affected by confounding factors such as the delay in tissue 
collection, phase of illness and drug treatments received during the lifetime.   
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1.5 Mechanism of action of mood stabilizers 
Several studies have identified major targets of mood stabilizers that may be 
involved in their therapeutic action, however, no definitive mechanism of action 
has been established. Lithium is supposed to mainly act through GSK-3β 
inhibition, whereas VPA is supposed to affect gene expression through HDAC 
inhibition. The key findings are described below.  
1.5.1 GABAergic and glutamatergic systems 
γ-aminobutyric acid (GABA) is an inhibitory neurotransmitter that modulates 
DA and glutamate neurotransmitters. Originally proposed in the 1980s, the 
GABA hypothesis of depression was derived from the GABAergic action of 
anticonvulsant VPA in the treatment of mania. Modulation of GABAergic 
signalling is well-established in the anticonvulsant action of VPA (Rho & Sankar, 
1999) (Figure 1.5). Inhibition of GABA signalling leads to seizures and 
potentiating the GABA response prevents these seizures. Both the 
anticonvulsant and mood-stabilizing properties of VPA are attributed to 
GABAergic modulation (Löscher, 1993; Löscher, 2002; Löscher & Vetter, 1985; 
Rosenberg, 2007). BD patients have reduced GABAergic neurotransmission and 
reduced expression of GAD1 gene which encodes the GAD67 enzyme (Cherlyn 






Figure 1.5 Mechanism of action of VPA on glutamate and GABA metabolism. This figure shows the pre- and post-synaptic 
processes at the GABAergic synapse in the brain. In the presynaptic neuron, glutamic acid decarboxylase (GAD) synthesises GABA 
from glutamate. GABA is then packaged into synaptic vesicles and released after the presynaptic calcium influx. In the 
postsynaptic neurons, GABA activates the GABA-A receptors, which facilitate the passage of chloride ions. GABA transporters on 
the neuronal and glial membrane remove GABA from the synaptic cleft. GABA-transaminase (GABA-T) degrades GABA into 
succinic semialdehyde (SSA), which is further metabolized into succinic acid in the presynapse and glial cells. VPA inhibits GABA 
catabolism by decreasing the degradation mediated by GABA-T and SSA-DH. VPA enhances the activity of GAD67, key enzyme in 





Both in vitro and ex vivo studies have shown that VPA at therapeutic 
concentrations inhibits succinate semialdehyde dehydrogenase (SSA-DH)  
(Johannessen, 2000), an enzyme responsible for GABA shunt. This GABA shunt 
generates GABA and glutamate. GABA is converted by the GABA transaminase 
(GABA-T) enzyme into succinate semialdehyde (SSA), which is successively 
converted by SSA-DH to succinate. Inhibition of SSA-HD by VPA increases SSA 
levels which inhibits GABA-T activity (Piplani et al., 2016). Inhibition of GABA-
T results in increased GABA levels. VPA has been shown to increase GABA 
levels in rodents (Nagaki et al., 1990). SSA-DH downstream signalling might be 
responsible for the long-term mood stabilizing effects of VPA.  
Animal and human studies have shown that lithium promotes GABAergic 
neurotransmission. Chronic administration of lithium increased GABA levels in 
CSF (Berrettini et al., 1986) and facilitated GABA release at presynaptic terminals 
(Otero Losada & Rubio, 1986). Li, VPA and CBZ upregulated GABA-B receptors 
at the postsynaptic terminal in isolated synaptic membranes from the rat brain 
(Motohashi, 1992; Motohashi et al., 1989).  
Dysfunctional glutamatergic neurotransmission has been implicated in BD. 
Postmortem studies have replicated these findings, showing higher glutamate 
levels in the frontal cortex of BD patients (Hashimoto et al., 2007) associated with 
a hyperglutamatergic state (Gottschalk et al., 2015). Similar hyperglutamatergic 
observations were made in pharmacology (Machado-Vieira et al., 2009) and 
biomarker studies (Gigante et al., 2012; Yüksel & Öngür, 2010). Elevated levels of 
glutamine were present in the anterior cingulate cortex of euthymic patients, 
supporting the glutamatergic dysfunction hypothesis (Soeiro-de-Souza et al., 
2018).  
Lithium and VPA modulate glutamate levels through various mechanisms such 




and glutamate NMDA receptor expression and function (Chiu et al., 2013). 
Lithium (Friedman et al., 2004) and VPA (Soeiro-de-Souza et al., 2015) reduced 
combined levels of glutamate and GABA concentrations. This effect was 
replicated with VPA, but not with lithium in euthymic BD 1 patients in a recent 
study (Soeiro-de-Souza et al., 2018). Factors that may have caused these 
inconsistent results may be the small sample sizes, different bipolar types 
studied and mixed effects from the combination therapy with lithium and VPA.  
Cellular studies have shown that both these mood stabilizers upregulate several 
excitatory amino acid transporters (EAAT) leading to glutamate clearance 
(Aguirre et al., 2008; Dallaspezia et al., 2012; Hassel et al., 2001; Karki et al., 2014). 
Chronic treatment with lithium and VPA decreased intrasynaptic glutamate 
through the inhibition of NMDA receptors-mediated Ca+2 influx (Hashimoto et 
al., 2002; Loscher, 1993; Nonaka et al., 1998). This protected neurons against 
glutamate-induced excitotoxicity. Lithium and VPA also increased vesicular 
glutamate transporter (VGLUT1) expression (Kang et al., 2005; Kim, Kim, et al., 
2007; Moutsimilli et al., 2005); lower levels of VGLUT1 were observed in BD and 
MDD patients (Uezato et al., 2009).  
1.5.2 Effects on monoaminergic systems 
Mood stabilizers affect the serotonergic system. Both VPA and lithium stabilize 
5-HT1A receptor expression in euthymic patients (Sargent et al., 2010) and 
increased central 5-HT function in manic patients (Shiah & Yatham, 2000). VPA 
regulated the monoamine neurotransmitters through activation of MAOA via 
Akt/FoxO1 signalling in the human neuroblastoma BE(2)C cells (Wu & Shih, 
2011) and 5-HT receptor subtypes. It upregulated the 5-HT2A receptor to mediate 
phosphoinositide hydrolysis in the rat C6 glioma cells (Sullivan et al., 2004). 
Short-term lithium treatment enhanced 5-HT1A receptor responsiveness whereas 




brain (Blier et al., 1987; Goodwin et al., 1986; Hotta et al., 1986; Odagaki et al., 
1990). Functional polymorphisms in the serotonin transporter gene (SLC6A4) 
have been linked with lithium prophylactic non-response in BD patients 
(Rybakowski, Suwalska, Czerski, et al., 2005; Serretti et al., 2001; Serretti et al., 
2004; Tharoor et al., 2013). 
Mood stabilizers also affect the dopaminergic system. CBZ and LTG affect levels 
of 5-HT and DA in the rat hippocampus (Ahmad et al., 2005). Lithium affected 
the dopaminergic system through the Akt/GSK signalling pathway (Beaulieu et 
al., 2004). VPA protected dopaminergic neurons through the release of 
neurotrophic factors BDNF and glial cell line-derived neurotrophic factor 
(GDNF) in astrocytes (Chen, Peng, et al., 2006).  
1.5.3 Effects on ion channels 
Modulation of ion-channels is well-established as an effect of mood stabilizers 
(Calderone et al., 2005; Dichter, 1998). Inhibition of voltage-gated Na+ channels 
is the main mechanism of antiepileptic action of VPA (McLean & Macdonald, 
1986b). Other anticonvulsants and mood stabilizers such as LTG (Coulter, 1997; 
Fitton & Goa, 1995) and CBZ (McLean & Macdonald, 1986a) show similar effects 
in neuronal cultures. Phenytoin, an anticonvulsant with similar effect on Na+ 
channels has antimanic properties (McLean & Macdonald, 1983; Mishory, 2000; 
Tonelli et al., 2013). This suggests blockage of Na+ channels underlies the 
therapeutic antimanic effect. However, the effect of VPA on Na+ channels is 
disputed. VPA inhibited neuronal voltage-gated Na+ channels in cell culture 
(McLean & Macdonald, 1986b) but failed to exhibit similar effects in rat 
hippocampal slices (Albus & Williamson, 1998). Chronic VPA treatment can 
upregulate expression of Na+ channels which further activates Ca++ channels 




Lithium can block Na+ channels (Dichter, 1998) which is supposed to be 
independent of GSK-3β inhibition (Yanagita et al., 2007). Ca++ acts as a second 
messenger in the phosphoinositide cycle, targeted by lithium. Lithium affects 
intraneuronal Ca++ activity. It inhibits entry of Ca++ into cells, further inhibiting 
downstream signalling. The effects of lithium are similar to calcium channel 
blockers. Lithium increases voltage-gated K+ currents which lowers Ca+ levels in 
rat CA1 pyramidal neurons (Zhang et al., 2006). In contrast, VPA reduces the 
voltage-gated K+ currents (Van Erp et al., 1990; VanDongen et al., 1986). 
1.5.4 Effects on intracellular signalling pathways 
Mood disorders are not only associated with dysfunctions in neural excitability 
and neurotransmission but also with altered signalling cascades that regulate 
neuroplasticity. Intracellular signalling pathways involved in cell growth, 
survival and metabolism are altered in both BD and MDD. The main signalling 






Figure 1.6 Signalling pathways involved in the mechanism of action of lithium and VPA. This figure shows the various 
intracellular signalling cascades impacted upon by lithium and VPA. Arrows indicate activation and lines with flat ends show 




1.5.4.1 Phosphoinositol pathway 
The inositol monophosphatase 1 (IMPase-1) gene encodes myo-inositol 
phosphatase. Noncompetitive inhibition of IMPase-1 by lithium reduces levels 
of brain inositol and accumulation of phosphoinositides which results in 
reduced downstream signalling (Berridge et al., 1989; Hallcher & Sherman, 1980; 
Sade et al., 2016). Even after 40 years, this hypothesis is still not confirmed or 
refuted. Animal studies showed a decrease in inositol levels after acute exposure 
to therapeutic levels of lithium (Damri et al., 2015; Hallcher & Sherman, 1980) 
and reduced myo-inositol affects neurotransmission (Berridge et al., 1989; Manji 
& Lenox, 1994). Ebelsen, an IMPase inhibitor, has antimanic and antidepressant-
like properties (Singh et al., 2013). The discrepancies across studies may be due 
to the differences in models studied, drug levels, or duration such as acute or 
chronic exposure.  
VPA also appears to inhibit inositol synthesis (O'Donnell et al., 2000; Shaltiel et 
al., 2004; Silverstone & McGrath, 2009; Tokuoka et al., 2008; Vaden et al., 2001). A 
recent study showed Mck1-dependent depletion of inositol by VPA; Mck1 is a 
GSK3 yeast homolog which is required for the activity of the myo-inositol 
phosphate synthase (Yu et al., 2017).  
1.5.4.2 Glycogen synthase kinase-3β/Wnt signalling pathway 
The Wnt signalling pathway is involved in neurodevelopment and regulates the 
structure and function of the adult brain. Wnt proteins are involved in cell fate 
determination, differentiation, growth and migration (Ka et al., 2014). They also 
influence neurogenesis, synaptogenesis and neural plasticity (Ochs et al., 2014). 
Both canonical and non-canonical Wnt pathways have been implicated in BD 
and SCZ (Matigian et al., 2007). Glycogen synthase kinase 3β (GSK-3β) is a 
serine/threonine kinase inhibitor in the Wnt pathway and is also acted upon by 
the PI3K pathway. GSK-3β inhibition activates downstream transcription factors 




(Gould & Manji, 2005; Schloesser et al., 2008). Selective GSK-3β inhibitors have 
been shown to have antimanic and antidepressant-like properties in animal 
models (Chen, Gaisina, et al., 2011; Du et al., 2010). Several studies have shown 
altered levels of inhibitory GSK-3α and GSK-3β in blood and postmortem brain 
of BD patients (Karege et al., 2007; Li, Liu, et al., 2010; Pandey et al., 2015; Polter 
et al., 2010; Ren et al., 2012).  
Lithium and VPA, but not CBZ, inhibit GSK-3β through independent 
mechanisms (Harwood & Agam, 2003). Lithium directly inhibited GSK-3β 
though competition with Mg++ binding (Klein & Melton, 1996; Ryves & 
Harwood, 2001; Stambolic et al., 1996) and could modulate other members of the 
Wnt pathway (Chiu et al., 2013; Daniel et al., 2005; Lazzara & Kim, 2015). Lithium 
also increased platelet levels of phosphorylated GSK3β in depressed BD patients 
(de Sousa et al., 2015). GSK-3β attenuated glutamate excitotoxicity and could 
promote cell survival through anti-apoptotic mechanisms (Daniel et al., 2005; Yu 
et al., 2012). A recent RNA-Seq study showed regulation of proapoptotic genes 
and other apoptosis-related pathways in lithium-responsive neurons from BD 
patients (Breen et al., 2016). Polymorphisms in the GSK-3β gene were associated 
with lithium response (Iwahashi et al., 2014). However, no conclusive evidence 
is available about the effects of VPA on GSK-3β. VPA inhibited GSK-3β and 
modulated Wnt pathway in human neuroblastoma SH-SY5Y cells (Chen, Huang, 
et al., 1999; De Sarno et al., 2002) and decreased levels of phosphorylated GSK-3β 
and attenuated methamphetamine-mediated hyper locomotion activity in 
nucleus accumbens of rats (Hashimoto et al., 2015). In contrast, a study using rat 
primary cultured cortical neurons reported that lithium alone inhibited both 
GSK3-α and -β in direct biochemical assays, and not VPA (Ryves et al., 2005). 
Taken together, these studies suggest VPA may indirectly inhibit GSK-3β (Yu & 
Greenberg, 2016). The mechanism of GSK-3β inhibition by VPA is still not clear, 




(Phiel et al., 2001) which is targeted by other HDAC inhibitors (Bordonaro et al., 
2007). Furthermore, class I HDAC inhibitors have been shown to modulate genes 
in both canonical and non-canonical Wnt pathways (Jang & Jeong, 2018).  
1.5.4.3 Other protein kinase pathways 
Dysregulations in the protein kinase C (PKC) pathway are linked to BD (Hahn 
& Friedman, 1999; Saxena et al., 2017). PKC pathway plays an important role in 
regulation of Ca++ levels in neuronal cells and regulates important BD processes 
such as neuroplasticity, neuronal excitability, apoptosis and mitochondrial 
dysfunction among others. Both lithium and VPA inhibited PKC activity in vitro 
and in vivo (Abrial et al., 2013; Chen et al., 1994; Hahn, Umapathy, et al., 2005; 
Manji & Lenox, 1999; Pandey et al., 2008; Watson et al., 1998), limiting 
translocation of PKC from the cytosol to the cell membrane resulting in reduced 
levels of membrane PKC. The chronic lithium administration has been shown to 
reduce PKC signalling in euthymic patients (Hayashi et al., 2014). Tamoxifen is a 
PKC inhibitor and can alleviate manic symptoms in BD patients (Yildiz et al., 
2016; Yildiz et al., 2008).  
The mitogen-activated protein kinase (MAPK) pathway is involved in the 
neuroprotective effects of lithium and VPA (Einat et al., 2003; Ludtmann et al., 
2011). The ERK/MAPK pathway regulates neurogenesis, neuroplasticity and 
neuronal growth and survival (Miloso et al., 2008; Sweatt, 2004; Thomas & 
Huganir, 2004; Wada & Penninger, 2004). VPA activated the MAPK pathway 
through increased levels of phosphorylated extracellular signal-regulated kinase 
2 (ERK2) (Hao et al., 2004; Yuan et al., 2001). This phosphorylation can be 
modulated through the protein kinase A and GSK pathways (Boeckeler et al., 
2006), PI3K/Janus kinase 2/MEK-1-dependent pathway (Siafaka-Kapadai et al., 




1.5.5 Gene expression changes due to lithium and VPA 
Although the mood stabilizing effects of lithium and VPA are well-established, 
the exact mechanism of therapeutic action remains unclear. Signal transduction 
studies have identified pathways which may underlie the therapeutic action and 
have been described earlier in section 1.5 above. Lithium and VPA though 
dissimilar in structure affect similar pathways such as PI3K/Akt and Wnt. Both 
the drugs affect neurotransmission and synaptic plasticity. Insights into the 
underlying gene expression effects of both lithium and VPA should improve our 
understanding of their mechanism of action. Some of the gene expression effects 
are described below and the epigenetic mechanisms have been described 
separately in section 1.6. 
Initial work to uncover differentially expressed genes (DEGs) focused on 
candidate gene studies. Many studies have focused on neurotrophic factors such 
as BDNF, neurotransmission factors and elements of circadian rhythms. BDNF 
is the most studied gene in BD (Chepenik et al., 2009; Rybakowski, 2008) and 
lithium response (Rybakowski, Suwalska, Skibinska, et al., 2005). This is the most 
abundant neurotrophic factor in the central nervous system and it regulates 
synaptic plasticity, neurogenesis and neuronal survival (Lu, 2003; Yoshii et al., 
2015). Lower serum BDNF levels were observed in BD and MDD patients 
(Fernandes et al., 2015; Li et al., 2018; Wu et al., 2017). Mood stabilizers and 
antidepressants affected BDNF expression (Chang et al., 2009; Chen et al., 2001; 
Frey et al., 2006; Jornada et al., 2010; Nishino et al., 2012; Tseng et al., 2008). 
Lithium and VPA upregulated BDNF and GDNF expression in cellular and 
animal models (Tunca et al., 2014; Varela et al., 2015; Wu et al., 2008).  
BCL2 is another gene extensively studied in relation to the therapeutic effect of 
mood stabilizers. It has apoptotic and neurotrophic properties. The upregulation 




VPA increased BCL2 levels in cultured cells (Creson et al., 2009; Laeng et al., 2004; 
Yuan et al., 2001) and rodent brain regions (Chen, Zeng, et al., 1999; Creson et al., 
2009; Hao et al., 2004). Chronic lithium treatment also increased BCL2 levels in 
cerebellar granule cells (Chen, Zeng, et al., 1999; Chuang, 2004). However, a 
recent systematic review showed lithium-induced upregulation of BCL2 is 
observed only in low-throughput studies, like quantitative PCR (qPCR) but not 
high-throughput studies such as microarrays and RNA-Seq (Odeya et al., 2018). 
A major issue with the qPCR studies is the choice of housekeeping genes used 
for normalization (Bustin & Nolan, 2017; Vandesompele et al., 2002). Mood 
stabilizers have been shown to alter the expression of housekeeping genes 
(Odeya et al., 2018; Powell et al., 2014). The effect of lithium on BCL2 is not 
universal and might differ among varying cell-types, and has been mostly seen 
at higher doses of drugs (Corson et al., 2004; Lai et al., 2006).  
Numerous studies show lithium can inhibit GSK-3β activity in vitro (Chen, 
Huang, et al., 1999; Hall et al., 2002; Ryves & Harwood, 2001; Stambolic et al., 
1996) and in vivo animal studies show the same (Beaulieu et al., 2004; De Sarno et 
al., 2002; Gould et al., 2004). Therefore, it has been hypothesized the inhibitory 
activity of lithium on GSK-3β in humans is responsible for its mood stabilizing 
effects. However, the evidence does not uniformly support this hypothesis 
(Agam & Azab, 2016). Lithium inhibits GSK-3β either through direct competition 
with the Mg++ at the active site or phosphorylation on serine 9; phosphorylated 
Ser9- GSK-3β is used as an indirect marker to measure the inhibited GSK-3β. 
Other markers are β-catenin or phosphorylated tau levels. There appear to be no 
studies that directly measure the GSK3 activity. Due to the differences in 
methods used for measurement of GSK-3β inhibition, some studies show lithium 
inhibited GSK-3β in humans (de Sousa et al., 2015; Li, Liu, et al., 2010) whereas 
others show conflicting results (Li et al., 2007) or failed to detect GSK-3 inhibition 




In contrast to lithium, the inhibitory effect of VPA on GSK-3β is not well-
established in vitro or in vivo. VPA inhibited GSK-3α and -β in human 
neuroblastoma SH-SY5Y cells (Chen, Huang, et al., 1999; De Sarno et al., 2002), 
but other groups did not observe changes in GSK-3β activity in the cultured rat 
neural cells (Ryves et al., 2005) or rat frontal cortex (Kozlovsky et al., 2003). 
Activation of the ERK / MAPK pathway by lithium and VPA regulates 
transcription factors such as CREB, BDNF (Chang et al., 2009; Frey et al., 2006; 
Jornada et al., 2010), BCL2 (Bachmann et al., 2009; Chang et al., 2009; Chen, Zeng, 
et al., 1999) and activator protein-1 (AP-1) (Asghari et al., 1998; Chen et al., 1997; 
Chen, Yuan, et al., 1999; Ozaki & Chuang, 2002).  
Both the drugs increase tyrosine hydroxylase (TH) which is the rate-limiting 
enzyme in the synthesis of NE and DA. Chronic lithium treatment increased TH 
protein in the SH-SY5Y cells and the rat frontal cortex, hippocampus and 
striatum (Chen et al., 1998). VPA increased TH mRNA levels in the rat locus 
coeruleus (Sands, 2000).  
Several microarray studies in the early 2000s were carried out in the cells 
exposed to lithium and VPA (Adams & Schofield, 2001; Bosetti et al., 2005; 
McQuillin et al., 2007; Seelan et al., 2008; Zhang et al., 2012). These identified 
populations of DEGs which differ among studies, presumably due to the 
differences in models, concentration and exposure time (especially acute vs 
chronic exposure), and the microarray platform used. One of the first microarray 
studies treated mice with lithium and VPA for 7 days and observed 20 
upregulated and two downregulated genes in the brain (Adams & Schofield, 
2001). Another microarray study compared VPA DEGs with methamphetamine 
DEGs in several brain regions in rats, which include the prefrontal cortex, 
amygdala, caudate putamen, nucleus accumbens and ventral tegmentum 




putamen and prefrontal cortex and top findings include TAC1, PENK, DARPP-
32, MEF2C, TBR1 and GLUL. A recent microarray study with lithium and VPA 
in drosophila identified overlapping genes and pathways with DEGs related to 
the immune, neuronal and metabolic pathways (Herteleer et al., 2016).  
Microarrays require prior knowledge of genes to be assayed and can be affected 
by non-specific and cross-hybridization issues, and design constraints for 
splicing and unmapped genes (Murphy, 2002). RNA-Seq has advantages over 
microarrays as it facilitates quantification and discovery in the same experiment 
with higher sensitivity. It is clear that lithium and VPA do not target a single 
gene or pathway, therefore a whole transcriptomic approach is required to 
understand the mechanism.  
1.5.6 Other research 
Recent research has focused on the involvement of micro-RNAs (miRNAs) and 
epigenetic changes in the therapeutic action of mood stabilizers. miRNAs are 
short non-coding RNA molecules (21-25 nucleotides in length) that regulate 
post-transcriptional gene expression (Fabian et al., 2010). miRNAs play an 
important role in nervous system development and function affecting several 
processes including cell proliferation, differentiation and apoptosis (Jin et al., 
2013). Altered levels of miRNA have been reported in BD (Azevedo et al., 2016; 
Walker et al., 2015) and miRNAs were implicated in the lithium response as 
evidenced by patient-derived LCLs (Chen et al., 2009). Chronic lithium and VPA 
treatment modulated miRNA levels in rat hippocampus (Zhou et al., 2009). For 
example, miR-34a which targets the gene GRM37 encoding the glutamate 
receptor, has been implicated in the mechanism of action of lithium and VPA in 
several studies (Abdolmaleky et al., 2015; Bavamian et al., 2015; Hunsberger et al., 
2013; Zhou et al., 2009). Another study showed several miRNAs such as miR-34a, 




VPA-mediated neuroprotection from glutamate excitotoxicity (Hunsberger et al., 
2013). 
Epigenetic mechanisms such as DNA methylation and histone modification 
regulate gene expression in a tissue-specific and age-dependent manner. 
Increased DNA methylation leads to suppressed DNA transcription (Besser et 
al., 1990). Histone modifications include methylation (mono-, di- or tri-), 
acetylation, ubiquitination, phosphorylation among others and regulate access 
of transcription factors to the chromatin. For example, histone methylation 
condenses the chromatin (heterochromatin) and suppresses DNA transcription 
whereas histone acetylation relaxes the chromatin (euchromatin) and increases 
gene expression (Paul & Tollefsbol, 2014). Acetylation at H3K9, H3K14 and H4K8 
sites leads to increased transcription (Pokholok et al., 2005; Wang et al., 2009). 
Methylation at H3K27me3 sites results in transcription repression  whereas 
H3K4 methylation, especially H3K4me3 results in transcriptional activation 
(Liang et al., 2004; Santos-Rosa et al., 2002), and H3K9 methylation is associated 
with both repression and activation (Martens et al., 2005; Vakoc et al., 2006). 
Histone modifications also act as signal for other histone modifications by 
recruiting enzymes.  
Epigenetic changes are increasingly being investigated for a potential role in the 
therapeutic mechanism of mood stabilizers. Global hypomethylation was 
observed in lithium responders and relatives compared to controls; increased 
DNA methylation occurred after lithium treatment (Huzayyin et al., 2014). VPA 
altered DNA methylation levels of several genes in cellular models (Asai et al., 
2013; Milutinovic et al., 2007). Lithium, VPA and CBZ have common epigenetic 
targets which suggests epigenetic changes may underlie their therapeutic 
responses (Asai et al., 2013). Differentially methylated regions (DMRs) in BD 





1.6 Histone deacetylase inhibition in treatment of mood disorders 
Epigenetic changes can involve reversible modifications of chromatin histones. 
Histones are small DNA-binding proteins that are crucial for the wrapping of 
DNA into nucleosomes. There are four core histones-H2A, H2B, H3 and H4, 
along with H1, the linker histone. Histone octamers have lysine tails that can be 
modified and are responsible for dynamic regulation of gene transcription. 
Acetylation by histone acetyltransferases (HATs) opens up the chromatin to give 
access to transcription factors (active state) and deacetylation by histone 
deacetylases (HDACs) leads to chromatin compaction (repressive state) and 
gene silencing. Together, these two groups of enzymes control the chromatin 
structure and regulate gene transcription. HDACs also regulate gene expression 
by targeting non-histone proteins. They are classified into four categories based 
on their structure- class I, II, III and IV. Class I contain HDAC 1, 2, 3 and 8 
whereas class II HDACs are further subdivided into IIa (HDAC4, 5, 7 and 9) and 
IIb (HDAC6 and 10). Class IV contains only one isoform HDAC 11. Class III 
HDACs are called sirtuins (SIRT1-7) and use NAD+ as a cofactor in contrast to 
class I, II and IV which contain Zn++ ion at their catalytic centre.  
Chromatin remodelling plays an important role in psychiatric and 
neurodegenerative diseases (Abel & Zukin, 2008; Mirabella et al., 2015; Nestler et 
al., 2016; Sokpor et al., 2017). State and trait-dependent regulation of HDACs was 
observed in both MDD and BD and may be linked to mood disorder 
pathophysiology (Hobara et al., 2010). Altered levels of HDAC2 and -5 mRNA 
were observed in MDD whereas alterations in HDAC4, -6 and -8 were observed 
in BD (Hobara et al., 2010). Other studies using post-mortem brains also show 
altered levels of HDAC1, -2 and -5 in MDD, BD and SCZ patients (Benes et al., 




Inhibition of class I and II HDACs may be involved in the therapeutic action of 
mood stabilizers and antipsychotics (Leng et al., 2008; Leng et al., 2016b). VPA is 
an established class I HDAC inhibitor. VPA resulted in hyperacetylation of H3 
and H4 histones in vitro (Gottlicher et al., 2001; Nightingale et al., 2007; Phiel et 
al., 2001) and in vivo (Gavin et al., 2009). Similarly, VPA increased the levels of 
acetylated H3 histone in BD patients after 4 weeks of treatment (Gavin et al., 
2009). VPA inhibits HDAC activity in vitro by binding to the catalytic centre and 
activates promoters that regulate HDACs and other genes (Machado-Vieira et 
al., 2010).  
Several of the therapeutic effects of VPA have been attributed to its HDACi 
properties. VPA affects GABA levels by increasing mRNA levels of GAD67 and 
acetylated H3 histone attachment at GAD67 promoter, and similar changes were 
produced by TSA (Gavin et al., 2009). VPA has been shown to alter the expression 
of multiple genes through HDAC inhibition (Delcuve et al., 2012). Preclinical 
studies show VPA regulated the expression of fibroblast growth factor (FGF) 
genes (Beenken & Mohammadi, 2009; Kang & Hebert, 2015). VPA upregulated 
FGF1 by increasing H3 histone acetylation at the FGF-1B promoter in 
neuroblastoma cells (Kao et al., 2013). VPA and other HDAC inhibitors increased 
FGF21 expression through HDAC2/3 inhibition in C6 glial and primary glial 
cultures (Leng et al., 2016a). VPA and other class I HDAC inhibitor sodium 
butyrate (NaB), TSA, MS-275 and apicidin, increased H3K4Me2 levels and 
recruited acetyltransferase p300 at the promoter of heat-shock protein-70 in 
neuronal and astrocytic cultures (Marinova et al., 2011).  
The neuroprotective effects of VPA have also been attributed to HDACi. VPA 
increased the levels of neurotrophic factors BDNF and GDNF through increased 
histone acetylation (Lv et al., 2012; Yasuda et al., 2009). It also induced the 
expression of α-synuclein in neurons, which protects against glutamate 




VPA on GSK-3β is reported to be mediated through HDAC inhibition as other 
HDAC inhibitors can increase GSK-3β phosphorylation (De Sarno et al., 2002). 
Disturbances in circadian rhythms have been observed in BD and VPA and TSA, 
but not lithium affected the molecular rhythmicity of PER2::LUC through 
increased acetylation at H3 but not at H4 (Johansson et al., 2011).  
HDAC inhibitors can reverse the hyperactivity observed in animal mania 
models. Lithium, VPA and NaB reversed this hyperactivity (Moretti et al., 2011; 
Stertz et al., 2013). The hyperactivity in amphetamine-induced manic rats was 
associated with increased HDAC levels in the prefrontal cortex and these drugs 
partially reversed HDAC levels (Stertz et al., 2013). Lithium has been reported to 
possess HDACi activity as well (Ookubo et al., 2013) and downregulated 
HDAC1, but not HDAC2, levels in HEK293T, SW480, and HeLa cells (Wu et al., 
2013). In contrast to VPA, HDACi activity with lithium was observed only at 
toxic levels (Kwon & Houpt, 2010). CBZ-induced CYP3A4 expression, which 
increases the risk of drug-drug interactions, required HDAC1 inhibition at the 
gene promoter (Wu et al., 2012). 
Cpd-60, a selective HDAC1/2 inhibitor, showed a mood stabilizer profile in BD 
animal models with gene expression changes in the nucleus accumbens, 
prefrontal cortex and the hippocampus (Schroeder et al., 2013). The upregulated 
genes showed increased histone acetylation with Cpd-60 (Schroeder et al., 2013).  
Histone acetylation has been linked to the action of antipsychotics. The typical 
antipsychotic haloperidol increased acetylation in cellular and animal models (Li 
et al., 2004). HDAC2 was involved at the mGlu2 promoter in response to the 
atypical antipsychotics (Kurita et al., 2012). HDAC inhibitors can even augment 
the antidepressant response of fluoxetine (Schmauss, 2015). Taken together, all 




1.7 Research questions 
BD is a highly heterogeneous mental disorder which is debilitating for those who 
suffer from it. Several theories have been put forward to explain the disease 
pathophysiology. We neither understand the disease mechanisms fully, nor 
understand properly, how the treatments work. Mood stabilizers lithium and 
VPA are the mainstay for treatment in BD, however, we have a relatively poor 
understanding of the mood-stabilizing mechanisms of these drugs. The 
therapeutic effects of these mood stabilizers have been attributed to multiple 
mechanisms which affect several related signalling pathways and networks. 
The primary goal of this thesis was to better understand the transcriptional 
effects of lithium and VPA in the serotonergic cell line RN46A, using the high-
throughput technique of RNA-sequencing.  
1. To look for changes in expression of sets of genes that define drug-specific 
as well as common target pathways for lithium and VPA. 
2. To find the signalling pathways and networks affected by VPA, which are 
relevant to the aetiology of BD. 
3. To corroborate the gene expression data with another gene expression 
platform, NanoString. 
4. To examine the effect of HDAC inhibition on VPA-regulated genes with 
various HDAC inhibitors and the non-HDAC inhibitory analogue VPD.  
5. To examine the alternatively spliced genes in response to VPA from the 
RNA-Seq data.  
6. The final aim was to validate the in vitro gene expression findings with an 
exploratory immunohistochemistry study of protein expression of 





Chapter 2  
Materials and Methods 
 
2.1 Materials 
All the reagents, stock solutions and kits used in this thesis are listed in Table 2.1 
and buffers are listed in Table 2.2. 
 
Table 2.1 Reagents and kits used in this thesis. 




















DMSO (sterile for 
cell culture) 
D2438-50ML Sigma-Aldrich St. Louis, MO, 
USA 












Collagen, Type 1 
solution from rat tail 
C-3867 Sigma-Aldrich St. Louis, MO, 
USA 







Reagent/Kit Catalogue no. Supplier Location 
Fibronectin F1141-1M Sigma-Aldrich St. Louis, MO, 
USA 



































Cellstar® filter cap 



































Reagent/Kit Catalogue no. Supplier Location 






DNA LoBind, 1.5 mL, 
PCR clean, colorless, 
250 tubes  
0030108051 Eppendorf Hamburg, 
Germany 
DNA LoBind, 0.5 mL, 
PCR clean, colorless, 
250 tubes  




MiniPrep (200 Preps) 
R2052 Zymo research Irvine, CA, ISA 



















Reagent/Kit Catalogue no. Supplier Location 
qScript™ Flex cDNA 
Kit  










FBTQTI-3 Fisher Biotec Wembley, WA, 
Australia 








Maob HPA002328 Sigma-Aldrich St. Louis, MO, 
USA 
Mmp13 ab39012 Abcam Milton, UK 
Pak3 ab40808 Abcam Milton, UK 

















Reagent/Kit Catalogue no. Supplier Location 
Cell & Tissue 
Staining 
Kit, 50 Tests 









Lamotrigine L3791-10MG Sigma-Aldrich St. Louis, MO, 
USA 
Lithium chloride 7447-41-8  Sigma-Aldrich St. Louis, MO, 
USA 
Valpromide V3640-10MG Sigma-Aldrich St. Louis, MO, 
USA 
Sodium valproate P4543-25G Sigma-Aldrich St. Louis, MO, 
USA 
























Table 2.2 List of buffers used in this thesis. 
Buffer Recipe 
Phosphate-buffered saline (PBS) 140 mM NaCl, 2.7 mM KCl, 10 mM 
sodium phosphate buffer pH 7.4 
Tris-buffered saline with 0.025% w/v 
Triton™ X-100 (TBST) 
20 mM Tris-HCl, 140 mM NaCl, pH 
7.6 
Sodium citrate with 0.05% Tween® 
20 






2.2.1 Cell culture 
The RN46A cell line was a gift from Dr. Scott Whittemore (Laboratory of 
Molecular Neurobiology, Louisville, Kentucky, USA). This is an immortalized 
serotonergic precursor cell line derived from the medullary raphe nucleus of 
embryonic day 13 rat by infecting with retrovirus Simian virus (SV-40) encoding 
temperature sensitive large tumour antigen (T-ag) (White et al., 1994). When 
grown at a permissive temperature of 33oC, cells have a relatively 
undifferentiated phenotype but are committed to a neuronal lineage and express 
the serotonin transporter (Eaton et al., 1995; White et al., 1994). The doubling time 
is 19h. When grown at the non-permissive temperature of 39oC in an appropriate 
culture medium, the cells cease dividing and differentiate to take on a more 
mature neuronal phenotype.  
The RN46A cells were maintained in Dulbecco's Modified Eagle Medium: 
Nutrient Mixture F-12 (DMEM/F-12) containing glutamine (DMEM/F12 with 
GlutaMAX™-I) and supplemented with 5% fetal bovine serum (FBS) and 250 
µg/ml Geneticin G418. Cells were grown in 25 cm2 (T25) (Cellstar®, Greiner bio-
one, Germany) or 75 cm2 (T75) tissue culture flasks (Nunc™, ThermoFisher 
Scientific, USA) in a 33oC incubator with 5% CO2.  
2.2.1.1 Sub-culturing 
Cells grown in T75 flask to 80-90% confluence were split in 1:5 ratio. Medium 
from T75 flask was discarded, and the cells were treated with 5 ml of TrypLE™ 
Express Stable Trypsin-Like Enzyme (1X) with Phenol Red (ThermoFisher 
Scientific, MA, USA) and incubated at 33oC for 5 min to detach the monolayer 
from a flask. Trypsin was neutralized by adding 10 ml of culture medium to the 
flask and cells were pelleted by centrifugation at 450g for 5 min. Spent medium 




gently resuspended and 2ml of the cell suspension was added to a new T75 flask 
topped up with 30 ml culture medium. Cell counts were taken with either a 
hemocytometer or CountessTM automated cell counter (Invitrogen, Carlsbad, CA, 
USA). 
2.2.1.2 Cryopreservation 
Cells were stored in liquid nitrogen for long term storage. Cells were grown to 
90% confluency in a T75 flask and treated with trypsin and pelleted as described 
above. The cell pellet was resuspended in culture medium with 5% dimethyl 
sulfoxide (DMSO) and 1 ml of cell suspension at ~1.5x106 cells/ml was aliquoted 
in Nunc™ CryoTube® vials (ThermoFisher Scientific, MA, USA), then placed in 
Mr. Frosty™ freezing container (ThermoFisher Scientific, MA, USA) at -80oC. 
Cells were transferred to liquid nitrogen after 24 hours.  
Frozen aliquots were thawed by placing the aliquots in a 37oC water bath for 1-
2 min, then 9 ml of culture medium was added and cells were centrifuged at 450 
g for 5 min. The medium was discarded and the cell pellet was re-suspended in 
10 ml of culture medium and transferred into a T25 flask. The medium was 
changed after 24 hrs and fresh medium was added at intervals of 48 hours until 
cells reached 80-90% confluency. 
2.2.2 Drug exposure 
Stock solutions (Table 2.3) of VPD (69.8mM), TSA (165mM), LTG (3.9mM), CBZ 
(110mM), haloperidol (68mM), CI994 (20mM), RGFP966 (10mM), tubastatin A 
(150mM), PCI-34051 (34mM) were prepared by dissolving the drugs in DMSO 
and then stored at -80oC. Lithium, VPA and NaB were soluble in water and stock 
solutions were prepared in ultrapure Milli-Q® (MQ) water (Millipore, MA, 




were prepared by diluting each stock in differentiation medium. Final DMSO 
concentration in the cell culture medium was around 0.05-1%.  
For exposure experiments, RN46A cells were first grown in an undifferentiated 
state either in CELLSTAR® 6- or 12-well plates (Greiner bio-one) at 33oC with 
5% CO2. Once 80% confluent, differentiation culture medium was added to the 
cells and shifted to 39oC with 5% CO2. Cells were differentiated for 72 hours with 
medium change after 36 hours. The medium was decanted after 72 hours and 
fresh differentiation medium with the respective drug or DMSO was added to 
the cells. The drug-exposed cells were maintained at 39oC for another 72 hours 
and RNA extraction was done as described in the next section. For RNA-Seq 
experiments, control cells were cultured in differentiation medium only, and for 






Table 2.3 Stock and working concentration of drugs used. 





Lithium 0.5M, 1M, 2M 0.5mM, 1mM, 
2mM 
MQ water 
Sodium Valproate 5mM 0.5mM MQ water 
Valpromide 69.8mM 0.5mM DMSO 
Lamotrigine 3.9mM 50µM DMSO 
Trichostatin A 165mM 30nM DMSO 
CI994 20mM 0.5µM DMSO 
RGFP966 10mM 0.08µM DMSO 
PCI-34051 34mM 0.01µM DMSO 
Tubastatin A 150mM 0.015µM DMSO 
 
 
2.2.3 RNA isolation and QC 
2.2.3.1 Trizol® with phenol-chloroform 
RNA was isolated using Trizol® (ThermoFisher Scientific, MA, USA), from cells 
grown in 6-well (3.5cm) plates. The medium was aspirated from the wells and 
the cells were washed once with ice-cold phosphate-buffered saline (PBS). To 




lyse and homogenize cells. Cell lysates from 3 wells were pooled together and 
transferred to a 1.5ml centrifuge tube, and incubated at room temperature (RT) 
for 5min. 300µl of chloroform was added and mixed by vigorously shaking for 
15sec and incubated for 15 min at RT. Samples were then centrifuged at 12,000g 
for 15 min at 4oC. The upper aqueous phase was aspirated by angling the tube at 
450 and transferred to a clean tube. 800µl of isopropanol was added to the 
solution to precipitate the RNA and incubated for 10min at RT. Samples were 
centrifuged at 12,000g for 10min at 4oC. Supernatant was removed and the RNA 
pellet was washed with 1.2ml 75% ethanol. Samples were centrifuged at 7,500g 
for 5min at 4oC. Supernatant was discarded and samples were centrifuged briefly 
at 12,000g for 30sec at 4oC and excess ethanol was removed. The RNA pellet was 
air-dried for 10min and dissolved in RNase-free water and incubated at 55oC for 
10min. RNA was quantified using the NanoDrop™ 8000 Spectrophotometer 
(ThermoFisher Scientific, MA, USA), by measuring the absorbance at 260 nm 
which provides total nucleic acid content, while the absorbance at 280 nm 
determines protein contamination and absorbance at 230 nm detects organic 
compounds. The A260/A280 ratio of ~2 is considered pure. All RNA samples 
with OD260/280 ratio of ~2.0 were chosen for the experiments. OD260/230 determines 
contamination with organic compounds such as phenol and Trizol, and ratios 
below 1.8 are considered to have a significant amount of these contaminants that 
can interfere with downstream applications. To reduce contamination with 
organic compounds and increase purity of extracted RNA, we purified RNA 
using Zymogen Direct-Zol columns. RNA was stored at -70oC until further use.  
2.2.3.2 Trizol® with Direct-zol columns 
The initial RNA preparations proved to be relatively impure, so an alternative 
isolation method was used for later NanoString experiments. We used Zymogen 
direct-zol RNA Miniprep kit. The medium was aspirated from the well of a 12-




well and mixed thoroughly. 400µl of 100% ethanol was added to each well and 
mixed thoroughly. Cell lysates from two wells were pooled together and 700µl 
cell lysate was added to the column with collection tube. Columns were 
centrifuged at 16,000g for 30sec at RT. The flow-through was discarded and the 
column was reloaded with the remaining cell lysate and centrifuged at 16,000g 
for 30sec at RT. The column was transferred into a new collection tube and 400µl 
RNA wash buffer was added, then the tube was centrifuged at 16,000g for 30sec 
at RT. The flow-through was discarded. In a separate tube, 5µl DNase I (6 U/µl) 
and 75µl DNA digestion buffer were mixed by gentle inversion and added to 
each column. Columns were incubated at RT for 15min to digest the DNA. 400µl 
RNA PreWash solution was added to the column and centrifuged at 16,000g for 
30sec at RT. The flow-through was discarded and the RNA PreWash step was 
repeated. 700µl RNA wash buffer was added to the column and centrifuged at 
16,000g for 2min at RT. The column was transferred to a RNase free tube and 
50µl RNase-free water was added and centrifuged at 16,000g for 30sec at RT. 
RNA was quantified using the NanoDrop™ 8000 Spectrophotometer and stored 
at -70oC until further use. All extracted RNA samples had OD260/280 and OD260/230 
ratios of ~2 indicating intact RNA free of contamination of proteins and organic 
compounds.  
2.2.3.3 RNA quality control 
RNA quantification with NanoDrop is not precise so final quality control was 
performed using Agilent 2200 TapeStation system (Agilent Technologies, Santa 
Clara, CA, USA) which measures the RNA integrity using micro-capillary 
electrophoresis. This device generates an RNA Integrity Number (RIN), which 
reflects the RNA quality. RIN is calculated algorithmically by including the 
28S/18S ratio, the region before the peaks, signal areas, and intensities. A RIN 




completely degraded sample. Sample with RIN's greater than 7 is recommended 
for most applications.  
2.2.4 Real-time quantitative polymerase chain reaction (qPCR) 
For qPCR, cDNA was synthesized from total RNA and gene expression profiling 
was done on the LightCycler® 480 System (Roche Applied Science, Mannheim, 
Germany).  
2.2.4.1 cDNA synthesis  
Prior to cDNA synthesis, extracted total RNA was treated with DNase1 
(ThermoFisher Scientific, MA, USA) to remove any contaminating genomic 
DNA. To 1 µg of total RNA, 1 µl 10X DNase I Reaction Buffer and 1 µl DNase I 
was added and the final volume was made up to 10 µl using nuclease-free water 
(ThermoFisher Scientific, MA, USA). The tubes were incubated at RT for 15 min. 
The DNase I was inactivated by adding 1 µl of 25 mM EDTA solution to the 
reaction mixture, and heated at 65oC for 10 min.  
First-strand cDNA synthesis was done using qScript™ Flex cDNA Kit 
(Quantabio, MA, USA) according to manufacturer’s recommendation. Briefly, all 
components were thawed (except enzyme), mixed thoroughly and centrifuged 
before use and kept on ice before use. In a 0.2 ml thin-walled PCR tube, 2 µl of 
random primer and 2 µl of oligodT primer were added to 11 µl of DNase I-
treated RNA mixture. The combination primer strategy was used to remove any 
bias towards RNA template sizes; random primer was suitable for RNA 
templates less than 1 kb whereas oligodT primers worked for RNA templates up 
to 12 kb. The components were mixed by gentle vortexing and centrifuged for 
10s, and incubated at 65oC for 5 min and snap chilled on ice. To the primed RNA 
template mixture, 4 µl of qScript Flex Reaction Mix (5X) and 1 µl of qScript 




adding 4 µl of qScript Flex Reaction Mix (5X) and 1 µl of nuclease-free water to 
one of the primed RNA template. The components were mixed by gentle 
vortexing and centrifuged for 10s to collect the contents. The mixture was 
incubated at 25oC for 10 min to allow random primers to anneal, followed by 
42oC for 45 min. The reaction was terminated at 85oC for 5 min and chilled on ice. 
The prepared cDNA was aliquoted and stored at -20oC till further use.  
2.2.4.2 Relative quantification 
The real-time PCR experiments were set up according to the MIQE (Minimum 
Information for Publication of Quantitative Real-Time PCR experiments) 
guidelines. The primers for qPCR were designed using Geneious software 
(Geneious pro version 9.1.8, Biomatters, Auckland, New Zealand). The primer 
sequences for TPM1 isoforms are listed in Table 2.4. The oligonucleotides were 












qPCR experiments were run on the LightCycler® 480 System (Roche Applied 
Science, Mannheim, Germany). The expression of TPM1 isoforms was 
normalized with the geometric mean of two reference genes, GAPDH and ACTB 
(Balasubramanian et al., 2019).  
All PCR reactions were carried out in triplicates in 10 μl volume (Table 2.5) 
containing 1 μl 10X Platinum Taq reaction buffer (Invitrogen, Carlsbad, CA, 
USA), 1 μl 2 mM dNTPs, 0.8 μl 25 mM MgCl2, 0.05 μl Taq-Ti heat-activated DNA 
polymerase (5U/μl) (Fisher Biotec, WA, Australia), 1 μl of 5μM forward and 
reverse primers, 0.3 μl of SYTO™ 9 green fluorescent dye (ThermoFisher 
Scientific, MA, USA), 2 μl of diluted cDNA and appropriate volume of nuclease-






Table 2.5 qPCR reaction master mix 
Components Volume per reaction 
10X reaction buffer 1 μl 
2mM dNTPs 1 μl 
25mM MgCl2 0.8 μl 
Taq Ti heat activated DNA polymerase (5U/μl) 0.05 μl 
5µM Forward primer 1 μl 
5µM Reverse primer 1 μl 
SYTO™ 9 0.3 μl 
cDNA 2 μl 
Nuclease free water 2.85 μl 
Total 10 μl 
 
 
A RT-negative control was added to check for any residual genomic DNA and a no-
template control was added to assess primer-dimer formation. Reactions were set 
up using the LightCycler® 480 96- or 384-well plates (Roche Applied Science, 
Mannheim, Germany). The qPCR assay was carried out using the following 
conditions; denaturing at 94oC for 2 min, followed by 40 cycles of denaturation 
at 94oC for 20s, 20s at annealing temperature (56oC-60oC), 20s extension at 72oC, 
and finished with cooling at 4oC for 1 min. At the end of each qPCR run, melt-
curve analysis with 5 seconds at 95oC and then 1 min hold at 55oC with 0.2°C 





2.2.5.1 RNA-Seq on the Illumina platform 
For RNA-Sequencing (RNA-Seq), mRNA is first polyA enriched and fragmented 
by hydrolysis. cDNA is generated by reverse transcription and dA tailing. Two 
unique Illumina adaptors are attached to the both ends of each fragment. The 
fragment library, is then added to Illumina’s proprietary 8-lane flow-cell with 
the glass surface coated with oligonucleotides. Fragments become attached to 
oligonucleotides complementary to the adaptors. This is followed by alternate 
cycles of bridge amplification and denaturation, generating clusters of about a 
million copies of the same DNA fragment. All four fluorescently labelled 
nucleotides are added simultaneously, but only one gets incorporated per cycle. 
These clusters are denatured and the reverse strand is washed away. The free 
end of bound fragments is blocked to prevent interference during sequencing. 
Sequencing primers, fluorescently labelled dNTPs and DNA polymerase are 
added for forward strand synthesis and primers bind to the complementary 
sequence on each free end. For paired-end sequencing, the free ends are 
unblocked and sequencing is carried out for reverse strand. Acquired images are 
then analysed, and after base calling and filtering of poor quality reads, output 
is generated in form of fastq format.  
RNA samples were lyophilized and shipped at ambient temperature to 
Novogene (Beijing, China) for sequencing. RNA integrity and purity was re-
checked by Novogene as described in section 2.2.5.3. Four RNA samples (A1, A2, 
A3 and C3) failed quality control (Appendix C, figure 1), so another replicate 
was shipped and these samples passed quality control the second time 
(Appendix C, figure 2). The quantity of total RNA for sample C3 was low, so 




RNA-Seq was carried out at Novogene (Beijing, China) (Figure 2.1). Briefly, 
mRNAs were enriched by selecting polyadenylated molecules and fragmented 
via hydrolysis. The cDNA library was prepared and adaptors were ligated to 
both ends, followed by size selection of fragments ~150-200 bp in length, then 
PCR amplification. The quality of the prepared cDNA library was assessed on 
an Agilent Bioanalyzer. All twelve samples passed this stage (Appendix C, figure 
3). Finally the prepared libraries were sequenced on the Illumina HiSeq™ 2500 
platform (Illumina inc. San Diego, CA, USA). For each sample, 16 million 125 bp 
paired-end reads were generated and QC report was generated for all 12 samples 
(Appendix D, Table 1). Both raw and cleaned fastq files were received on an 
external hard drive. 
Four replicates each for lithium, VPA and control were sequenced, but low 
quality of RNA for one lithium sample resulted in poor mapping quality and 
was removed from downstream analysis (A1). For this sample, only 27% of reads 







Figure 2.1 Novogene cDNA library preparation for RNA-Seq.  
Polyadenylated mRNA molecules were fragmented via hydrolysis. mRNA 
fragments were reverse-transcribed to create the cDNA library and adaptors 
were ligated to both ends followed by size selection of ~150-200 bp in length, 





2.2.5.2 RNA-Seq carried by Novogene 
RNA-Seq was contracted to Novogene (Beijing, China), using RNA samples 
generated as below. Total RNA was isolated from cell cultures using Trizol® 
with phenol-chloroform, and quality control was done using TapeStation. RNA 
samples with 260/280 and 260/230 ratios of ~2 and RIN score greater than 7 were 
lyophilized and shipped to Novogene (Beijing, China) at ambient temperature 
for sequencing. The company prepared the libraries and carried out RNA-Seq 
analysis to a minimum of 16 million reads on Illumina HiSeqTM 2500platform. 
They provided fastq data files to our laboratory on a hard drive. I then carried 
out all bioinformatic analyses. All the work carried out by Novogene is 
summarized in the following section.  
2.2.5.3 RNA quality control 
Total RNA quality control was also carried out by Novogene before proceeding 
to sequencing. Briefly, RNA degradation and contamination were monitored on 
1% agarose gels. RNA purity was checked using the NanoPhotometer® 
spectrophotometer (IMPLEN, CA, USA). RNA concentration was measured 
using Qubit® RNA Assay Kit in Qubit®2.0 Fluorometer (ThermoFisher 
Scientific, MA, USA). RNA integrity was assessed using the RNA Nano 6000 
Assay Kit of the Agilent Bioanalyzer 2100 system (Agilent Technologies, Santa 
Clara, CA, USA). 
2.2.5.4 cDNA Library preparation  
cDNA library preparation was carried out at Novogene. A total amount of 3µg 
RNA per sample was used as input material for cDNA preparation. Sequencing 
libraries were generated using NEBNext®Ultra™ RNA Library Prep Kit for 
Illumina® (NEB, USA) and index codes were added to attribute sequences to 
each sample. Briefly, mRNA was purified from total RNA using poly-T oligo-
attached magnetic beads. Fragmentation was carried out using divalent cations 




(5X). First strand cDNA was synthesized using random hexamer primer and M-
MuLV Reverse Transcriptase (RNaseH). Second strand cDNA synthesis was 
subsequently performed using DNA polymerase I and RNaseH. Remaining 
overhangs were converted into blunt ends via exonuclease/polymerase 
activities. After adenylation of 3’ ends of DNA fragments, NEBNext Adaptor 
with hairpin loop structure were ligated to prepare for hybridization. The library 
fragments were purified with AMPure XP system (Beckman Coulter, Beverly, 
USA) to select cDNA fragments of preferentially 150~200 bp in length. Then 3μl 
USER Enzyme (NEB, USA) was used with size-selected, adaptor-ligated cDNA 
at 37oC for 15 min followed by 5 min at 95oC before PCR. Then PCR was 
performed with Phusion High-Fidelity DNA polymerase, Universal PCR 
primers and Index(X) Primer. PCR products were purified (AMPure XP system) 
and library quality was assessed on the Agilent Bioanalyzer 2100 system.  
NEBNext® UltraTM RNA Library Prep Kit was used for library preparation and 
contains the following adaptors (Table 2.6). 
 
Table 2.6 RNA-Seq adaptor sequence 
RNA adaptor Sequence 




RNA 3' Adaptor1 GATCGGAAGAGCACACGTCTGAACTCCAGTCAC
ATCACGATCTCGTATGCCGTCTTCTGCTTG 





2.2.5.5 Clustering and Sequencing 
The clustering of the index-coded samples was performed on a cBot Cluster 
Generation System using the TruSeq SR Cluster Kit v3-cBot-HS (Illumina). After 
cluster generation, the library preparations were sequenced on an Illumina 
HiSeq 2500 platform and 125bp paired-end reads were generated. 
2.2.5.6 Data filtering 
Sequencing generates millions of short reads. RNA-Seq data were provided by 
Novogene as fastq files containing 125-bp paired end reads, both raw and 
trimmed fastq files. Sequenced raw reads often contain low quality or reads with 
adaptors which affect the analysis quality, so raw reads were filtered by 
Novogene based on the following criteria: 
1. Removed reads containing adaptors. 
2. Removed reads with N greater than 10% (meaning the base information 
was inaccurate).  
3. Removed low-quality reads where quality value of over 50% bases of the 
read is <= 5. 
2.2.5.7 Bioinformatics databases and websites 
The following bioinformatics databases were used in this thesis.  
1. National Centre for Biotechnology Information (NCBI) 
(www.ncbi.nlm.nih.gov/)  
NCBI provides valuable resources for genomic research and analyses and 
include tools like BLAST, GenBank and PubMed.  
2. UCSC Genome Bioinformatics (genome.ucsc.edu/)  
The UCSC genome browser is a useful tool to access different eukaryotic 
genome assemblies.  





ENSEMBL provides annotated eukaryotic genomes. 
4. ENSEMBL BioMart (http://www.ensembl.org/biomart/martview/)  
 BioMart is a data mining tool that helps access various ENSEMBL 
database components.  
5. Rat Genome Database (RGD, www.rgd.mcw.edu/wg)  
RGD contains information about the rat genes and its genomics.   
6. Allen Brain Atlas (www.brain-map.org)  
The Allen brain atlas contains a detailed gene expression and anatomical 
data for adult and developing human and mouse brain and non-human 
primates as well.  
7. Genotype-Tissue Expression (GTEx) (https://www.gtexportal.org) 
GTEx contains gene expression data from 53 different human tissue types 
and also provides isoform expression in different cells and tissues.  
8. GWAS catalog (https://www.ebi.ac.uk/gwas/) 
GWAS catalog is a curated database of all published genome-wide 
association studies.  
2.2.6 RNA-Seq analysis tools and software packages 
There are several methods and tools available for RNA-Seq analysis however, 
there is no consensus on the best pipeline/method (Wei et al., 2017). The most 
popular differential gene expression analysis tools are DESeq2 (Love et al., 2014), 
limma-voom (Ritchie et al., 2015), and edgeR (Robinson et al., 2010) among 
parametric analysis tools. It is recommended to combine different methods to 
increase accuracy (Wei et al., 2017). RNA-Seq analysis tools can also be divided 
into ease of use into two broad categories of complete software packages such as 
Partek® software (Partek Inc., St. Louis, MO, USA) or CLC Genomics 




linux or R-based tools. For mapping, tools can be chosen based on the type of 
sequence to be analyzed and quality of annotation available.  
RNA-Seq analysis tools and software packages used in this thesis are listed 
below. For each software, the version used, date downloaded, source and 
resource requirement is listed in Appendix A.  
2.2.6.1 Local computing environment 
Some of the programs used in this thesis were run on a local Linux server with 
96 GB RAM and a maximum of four cores were used (Appendix A). All R 
packages were run in Rstudio installed on a Win 7, 2.6 GHz laptop with 16 GB 
RAM. nSolver™ was also installed on the same laptop. All the bash scripts and 





Figure 2.2 A flowchart showing RNA-Seq data analysis steps used in this 
thesis. Differential gene expression analysis was performed with DESeq2, 
cufflinks2 suite and sleuth. Li: lithium, QC: quality control, DEG: differentially 
expressed genes, iDEP: integrated differential expression and pathway 
analysis. GSEA: gene set enrichment analysis, KEGG: Kyoto encyclopedia of 





2.2.6.2 STAR aligner 
Spliced transcripts alignment to a reference (STAR) is a free, open-source, ultra-
fast RNA-Seq alignment algorithm which first builds its own reference genome 
index and then produces a suffix array index to increase the alignment speed 
(Dobin et al., 2013). It is a splice-aware aligner that detects both known splice 
sites and de novo canonical and non-canonical splice sites. STAR uses paired-end 
fastq files as input and an annotation file to increase the accuracy of alignment. 
The output contains an aligned sam/bam file, mapped splice junctions and 
summary of alignment. The alignment summary contains the information about 
uniquely mapped reads, multi-mapped reads and unmapped reads. The STAR 
aligner was chosen for its high speed, efficiency and accuracy of alignment. 
2.2.6.3 Kallisto 
Kallisto directly compares the raw sequence reads to the transcript sequences to 
find which transcripts the read is compatible with and then quantifies transcript 
abundance (Bray et al., 2016). The comparison is done using a transcriptome-de 
Bruijn graph (T-DBG) built using k-mers present in the reads. The differential 
expression calling is done using sleuth which uses Wald test. 
2.2.6.4 Salmon 
Salmon aligns reads to the transcriptome and uses an index based on the suffix 
array and a Burrows-Wheeler transformation which is used to find shared 
substrings between the read and set of transcripts (Patro et al., 2017). The 
alignment is converted to sleuth-compatible format using the accompanying tool 
wasabi.  
2.2.6.5 HTSeq-count 
HTSeq-count is a python tool that counts how many aligned reads mapped to 
gene/exon/transcript in the bam file by using the reference annotation GTF/GFF 
file (Anders et al., 2014). The counts generated were used as input for DESeq2 for 





DESeq2 is an R package that performs differential gene expression analysis 
(Love et al., 2014). It uses count data as input and builds a model based on the 
three parameters of normalization, dispersion and group difference. The model 
is then fitted using negative binomial distribution, and calculates maximum 
likelihood estimates of each gene and fits the genes accordingly.  
2.2.6.7 Cufflinks2 suite 
Cufflinks2 is a tool for transcriptome assembly, quantification of transcripts and 
comparison of transcripts between different conditions. Cufflinks suite contains 
three main components: cufflinks, cuffmerge and cuffdiff (Trapnell et al., 2012; 
Trapnell et al., 2010). Cufflinks first assembles all possible transcripts from the 
alignment results, and cuffmerge then merges these assemblies. Differential gene 
expression analysis is done by cuffdiff.  
2.2.6.8 Integrative Genomics Viewer  
Integrative genomic viewer (IGV) (Robinson et al., 2011; Thorvaldsdottir et al., 
2012) is a visualization tool for interactive exploration of large, genomic datasets 
(http://software.broadinstitute.org/software/igv/). IGV was used for browsing 
aligned reads from BAM files and was used to create sashimi plots for 
alternatively spliced isoforms.  
2.2.6.9 Venn diagram  
An online Venn diagram drawing tool was used to create Venn diagrams to 
compare the various differential gene expression lists 
(http://bioinformatics.psb.ugent.be/webtools/Venn/).  
2.2.6.10 iDEP webtool 
The integrated differential expression and pathway analysis (iDEP) 
(http://bioinformatics.sdstate.edu/idep/) v0.80 was used for functional 




resource for read processing, differential expression and pathway analysis. It 
combines different Bioconductor R packages to analyse transcriptomic datasets. 
STAR aligner generated raw counts were loaded to the website and converted 
into gene IDs. The normalized counts were analysed with DESEq2, and pathway 
and enrichment analysis were carried out with KEGG database.  
2.2.7 Alternative Splicing analysis 
Four software packages were used in alternative splicing (AS) analysis of RNA-
Seq data for VPA treatment as listed below. 
2.2.7.1 DEXSeq 
DEXSeq v1.20.2, an R package (Anders et al., 2012) was used to identify AS events 
with VPA treatment. STAR aligned bam files were used for analysis. Two Python 
scripts provided with DEXSeq package, dexseq_prepare_ annotation.py and 
dexseq_count.py were used to prepare the count data in HTSeq format. 
ENSEMBL gtf file was used to prepare annotation. Default analysis was 
performed as suggested in the manual.  
2.2.7.2 JunctionSeq 
JunctionSeq v1.5.4, an R package (Hartley & Mullikin, 2016) was used to identify 
AS events with VPA treatment. It is similar to DEXSeq in detecting differential 
exon usage except it counts each read pair once towards exonic regions and 
splice junctions. It first partitions genes into non-overlapping exonic regions and 
assigns read pairs of these to calculate relative expression of each exon and 
identify splice junctions associated with each. It then uses DESeq2 package with 
specialized generalized linear model (GLM) to test the differential usage of each 
exon and splice junction. JunctionSeq uses gene-level counts instead of the sum 





rMATS v3.2.5 (Shen et al., 2014) was used to analyse AS events with VPA 
treatment. It uses a hierarchical model which estimates exon-inclusion level 
differences among sample groups and uses likelihood-ratio test to calculate the 
p-value for significance of exon-inclusion given by the difference between group 
means.  
2.2.7.4 IsoformSwitchAnalyzeR 
IsoformSwitchAnalyzeR v1.3.1, an R package (Vitting-Seerup & Sandelin, 2017) 
was used to analyse isoform switching events with VPA treatment. STAR 
aligned bam files were used for quantification with the cufflinks2.2.1 suite 
(Trapnell et al., 2012; Trapnell et al., 2010). The quantified isoform expression data 
were used as input for isoformSwitchAnalyzeR. The analysis was carried out as 
suggested in the manual 
(https://bioconductor.org/packages/devel/bioc/vignettes/IsoformSwitchAnalyse
R/inst/doc/IsoformSwitchAnalyseR.html). Briefly, cufflinks isoform data were 
imported into Rstudio session and isoform switches were identified by the R 
package. The nucleic acid and amino acid fasta output was used to add 
annotation of the isoform switches with the coding potential assessment tool 
(CPAT) (Wang et al., 2013), pfam protein (Finn et al., 2014) and signalP (Petersen 
et al., 2011) databases. Plots for visualization of isoform switches and functional 
consequences were generated by the R package. 
2.2.8 NanoString nCounter® gene expression assay 
nCounter® analysis system from NanoString Technologies (Seattle, Washington, 
USA) allows digital detection of up to 800 genes in a single sample. This fairly 
new technique is a highly sensitive alternative to quantitative PCR, and is an 
efficient approach to validation of next-generation sequencing data. It uses 5’ 




the actual number of transcripts, rather than amplified values as used in 
quantitative PCR, thus increasing sensitivity. The nCounter® custom assays are 
available in 48, 96, 192 or 384 sample formats. In this thesis, nCounter GX Custom 
CodeSet for 48 samples was used. Rat genome database (RGD) IDs for 26 genes, 
including two housekeeping genes, was submitted to NanoString and a 
customer CodeSet was designed in consultation with the NanoString CodeSet 
design team at Bio-Strategy (Auckland, New Zealand).  
Because major specialized equipment is needed for the nCounter® mRNA gene 
expression assay, the analysis was contracted to New Zealand Genomics Limited 
(Dunedin, New Zealand). For each sample in the RN46A drug exposure 
experiments 100 ng total RNA was extracted and provided to the contractor for 
this work. RNA samples were mixed with the custom CodeSet containing 
reporter and capture probes along with positive and negative probe controls. 
The tripartite complexes of reporter probe-target gene-capture probe were 
immobilized on nCounter® cartridge and analysed with the digital analyzer 
which performs image acquisition and data processing. The output was raw 
mRNA count for all the genes and the positive and negative probes. 
2.2.9 Allen Brain Atlas 
Allen Brain Atlas (ABA) (http://www.brain-map.org) is a publicly available 
online collection of databases of adult and developing human, mouse and non-
human primate brains (Sunkin et al., 2012). It combines gene expression from in-
situ hybridization (ISH) and connectivity data with neuroanatomical 
information. It contains high resolution images from ISH data of ~20,000 genes 
connected together in the neuroanatomical framework. The online query tool 
allows data mining, visualization and anatomical search of these databases. 




calculation of fold changes and comparison of similar studies and 
neuroanatomical features of the desired brain region.  
ABA can be used to study expression profiles of various regions in the brain and 
compare them. The adult mouse in-situ hybridisation (ISH) database from Allen 
Brain Atlas (ABA) was used to query the gene expression profile of the 
medullary raphe and dorsal raphe. A differential gene expression search was 
performed for the nucleus raphe magnus vs the rest of the brain (denoted as 
“grey” in ABA) and the corresponding genes were downloaded using the API 
query (http://help.brain-map.org/display/mousebrain/API#API-
ExpressionStructures) as suggested on the website. The same differential gene 
expression search was carried out for the dorsal raphe nucleus vs grey and genes 
were downloaded using the API query.  
For each of the 24 shortlisted DEGs, brain expression was separately analysed in 
ABA adult mouse ISH database with the high resolution image viewer. Gene 
search was first carried out with the list of 24 genes and sagittal sections 
corresponding to the medullary and dorsal raphe regions (sections 18-21) along 
with the reference ISH images were downloaded from the database for each 
gene. When not available, coronal images corresponding to the medullary and 






Chapter 3  
Differential gene expression changes in 
response to lithium and sodium valproate 
in RN46A cells 
 
3.1 Introduction 
Lithium and VPA are drugs of very different chemical classes that are widely 
prescribed in the treatment of BD and other conditions. Molecular and 
pharmacological studies have revealed some relevant properties and targets of 
these drugs, but their precise modes of action are not yet understood (Courtney 
& Ford, 2016; Weissmann-Nanopoulos et al., 1985). Previous work in our 
laboratory revealed differential gene expression changes in response to VPA 
exposure both in vivo and in vitro (Balasubramanian et al., 2015; Balasubramanian 
et al., 2019; Deng, 2011). VPA was used as a positive control drug while 
examining the mechanism of action of antidepressants in rats, and it was 
observed to cause a large change in the expression of sepiapterin reductase 
(SPR), a BH4 pathway gene (Deng, 2011). The same effect was later observed in 
the serotonergic cell line RN46A in response to VPA (Balasubramanian, 2015). A 
pilot RNA-Seq study of differential gene expression changes in response to 
lithium and VPA led to the discovery of novel and some shared gene targets 
(Balasubramanian et al., 2019). We hypothesized that genes co-regulated by both 





Dysregulation in the serotonergic system has been implicated in the 
pathophysiology of mood disorders (Shiah & Yatham, 2000). Lithium and VPA 
regulated expression of serotonin receptor 5HT1A (Sargent et al., 2010). Notably, 
the serotonergic 5HT1A receptor is a heteroreceptor responsible for feedback 
auto-inhibition in serotonergic neurons and is highly expressed in neurons in the 
raphe nucleus (Courtney & Ford, 2016; Weissmann-Nanopoulos et al., 1985). The 
serotonergic neurons originate from the median and the dorsal raphe nucleus in 
the brain stem and project to different brain regions and secrete serotonin to 
regulate mood (Hornung, 2003). In this chapter, I investigated differential gene 
expression changes in response to VPA and lithium in the serotonergic RN46A 
cells, using RNA-Seq.  
3.1.1 RN46A cell line 
Mood stabilizers have been shown to affect the serotonergic system (Shiah & 
Yatham, 2000). RN46A represents a relevant model for the neurological effects 
of lithium and VPA. This is an immortalized serotonergic cell line derived from 
the medullary raphe of embryonic day 13 rat following infection with mutant 
retrovirus encoding temperature-sensitive SV40 large T-antigen (White et al., 
1994). It expresses 5-HT1A receptor and serotonin transporter SERT (5-HTT; 
SLC6A4) (Eaton et al., 1995). It has been used in our laboratory to study the 
mechanism of action of antidepressants and mood stabilizers (Balasubramanian, 
2015; Deng, 2011; Glubb, 2008). Several DEGs were identified in RN46A cells 
after exposure to the antidepressant paroxetine (Glubb, 2008). Both lithium and 
VPA resulted in change in expression of the SPR, an important gene in the BH4 
biosynthetic pathway (Balasubramanian, 2015; Deng, 2011).  
Others have used this cell line to study serotonin transporters and receptors 
(Hadjighassem et al., 2011; Moya et al., 2013; O'Reilly et al., 2007; Yammamoto et 




biosynthesis (Chen et al., 2008; Kaneko et al., 2015; Nawa et al., 2017; Remes 
Lenicov et al., 2007). Pro-inflammatory cytokines have been shown to regulate 
the 5-HT uptake and SERT activity via the p38 induced MAPK pathway in 
RN46A cells (Zhu et al., 2006). 5-HT uptake has been shown to be regulated by 
cAMP and intracellular Ca++ levels (Koldzic-Zivanovic et al., 2006). Mutations in 
DEAF1 have been linked to cognitive defects (Vulto-van Silfhout et al., 2014) and 
this gene could regulate functional C(1019)G polymorphisms in 5-HT1A receptor 
(Czesak et al., 2006). 
RN46A cells propagated in an undifferentiated state at 33oC (Figure 3.1) can be 
differentiated at 39oC into neuronal cells with long multipolar processes (Figure 
3.2) (White et al., 1994). Differentiated RN46A cells express all 5-HT receptors 5-
HT1A, 5-HT1B, 5-HT2A and 5-HT2C and the serotonin transporter SERT. We chose 
to use differentiated RN46A cells for a better representation of the serotonergic 





Figure 3.1 Morphology of undifferentiated RN46A cells. This figure shows 
the RN46A cells propagating at 33oC after 24 hrs. The undifferentiated cells 
have a fibroblast-like morphology. Images acquired with a standard light 






Figure 3.2 Morphology of differentiated RN46A cells. This figure shows the 
RN46A cells propagating at 39oC after 5 days. The differentiated cells acquired 
a neuronal morphology with multipolar processes. Images acquired with a 





3.1.2 Drug exposure 
Three factors guided the concentration of lithium and VPA chosen in this study; 
plasma levels measured in patients undergoing treatment (Chiu et al., 2013; 
Fleming & Chetty, 2006; Reddy & Reddy, 2014; Severus et al., 2008), prior levels 
used in published in vitro (Chalecka-Franaszek & Chuang, 1999; Kim & Thayer, 
2009; Lai et al., 2006; Nciri et al., 2014; Shao et al., 2005) and in vivo studies 
(Fukumoto et al., 2001; Hillert et al., 2012; O'Donnell et al., 2000; Otero Losada & 
Rubio, 1986), and prior levels used in studies from our laboratory 
(Balasubramanian, 2015; Deng, 2011; Glubb, 2008). Previous drug-exposure and 
time-course experiments in our laboratory using RN46A cells determined 
concentrations of 0.5mM lithium and 0.5mM VPA with 72 hours exposure as 
optimal for studying gene expression changes (Deng, 2011). Lithium has a 
narrow therapeutic range of 0.5-1.2 mM (Goodwin & Jamison, 1990). Therapeutic 
serum concentrations of VPA range between 0.3-1.0 mM and it inhibits histone 
deacetylases in vitro at concentrations of 0.3mM-0.6mM (Gottlicher et al., 2001; 
Phiel et al., 2001). 
Therapeutic effects of mood stabilizers have been observed after a temporal 
delay of 2 weeks (Manji et al., 1996). Although long-term exposure of the RN46A 
cells might be of considerable interest, the choice for exposure time was limited 
to 72 hours. Undifferentiated RN46A cells acquire a neuronal phenotype when 
exposed to temperatures of 390C and survive only for 8-10 days in culture once 
differentiation is induced (Eaton et al., 1995; White et al., 1994). RN46A cells were 
allowed to first differentiate for 72 hours and then mood stabilizers were added 





The term “transcriptome” refers to the complete set of all classes of RNAs 
expressed at a particular developmental or functional stage of cell or organism. 
Over the past two decades, several techniques have been developed for large-
scale transcriptome analysis, either hybridization-based or cDNA sequencing 
based. The expressed sequence tags (EST) method of sequencing cloned cDNA 
was one of the earliest method of transcript quantification (Adams et al., 1992; 
Adams et al., 1991; Adams et al., 1995). Better quantitative methods were 
subsequently developed that used the short sequencing tags approach (Harbers 
& Carninci, 2005). Serial analysis of gene expression (SAGE) and massively 
parallel signature sequencing (MPSS) both sequence the 3’end (Brenner et al., 
2000; Velculescu et al., 1995) whereas sequencing of 5’ end-specific tags is 
achieved by cap analysis of gene expression (CAGE), trans-spliced exon-coupled 
RNA end determination (TEC-RED) and 5’-SAGE (Hwang et al., 2004; Shiraki et 
al., 2003). Gene identification signature (GIS) sequences ditags from both ends of 
mRNA (Ng et al., 2005). However, compared to microarrays, the above 
mentioned tag-based methods were expensive and of relatively low-throughput.  
Microarrays were one of the first high-throughput transcriptome analysis 
methods (Schena et al., 1995) and have been extensively used to study gene 
expression changes. However, they require prior knowledge of genes to be 
assayed and can be affected by non-specific and cross- hybridization issues, and 
design constraints for splicing and unmapped genes (Murphy, 2002). With the 
advent of next-generation sequencing (NGS) methods, new approaches to RNA 
expression analysis have become possible (Lister et al., 2008; Mortazavi et al., 
2008; Nagalakshmi et al., 2008). RNA-Seq has two magnitudes greater sensitivity 
than microarrays (Chen, 2011; Zhao et al., 2014), and can facilitate quantification 




splicing, novel transcript expression, genetic variation, gene fusion events and 
allele specific expression. Due to the greater sensitivity and unbiased approach 
towards the transcriptome, we chose RNA-Seq to examine gene expression 
effects of lithium and VPA. In this study, we used Illumina HiSeq™ 2500 
sequencing system (Illumina Inc. San Diego, CA, USA) via the sequencing 
provider Novogene (Beijing, China). The sequencing method of Illumina is 
outlined below.  
3.2 Methods 
The experimental design used in this chapter is shown in Figure 2.2. Four 
biological replicates each from lithium, VPA and untreated cells were used for 
total RNA extraction. Prepared cDNA libraries were sequenced on Illumina 
HiSeq™ 2500 (as described above). 125bp paired-end reads were generated 
which were cleaned and mapped to the whole rat genome with STAR aligner 
(Dobin et al., 2013), and to the transcriptome with kallisto (Bray et al., 2016) and 
salmon (Patro et al., 2017). Differential gene expression analysis was performed 
with DESeq2 (Love et al., 2014), cufflinks2 suite (Trapnell et al., 2012; Trapnell et 
al., 2010) and sleuth (Bray et al., 2016). Functional enrichment and pathway 





3.2.1 Cell culture and drug exposure 
Differentiated RN46A cells were treated with 0.5mM lithium and 0.5mM VPA 
for 72 hrs. Untreated cells cultured in parallel were used as control, and total 
RNA was extracted as described in section 2.2.1. The study was carried out as 
four independent experiments, performed on different days. Each of these 
experiments was carried out in duplicate.  
3.2.2 RNA quality 
The quality of total RNA was analysed using an Agilent 2200 TapeStation system 
(Agilent Technologies, Santa Clara, CA, USA). All the samples contained discrete 
28S and 18S ribosomal RNA bands, indicating the good quality of RNA across 
all samples (Figure 3.3, Figure 3.5 and Figure 3.4). This showed we had good 
quality RNA to proceed with cDNA library preparation. For each independent 
experiment, one set of lithium-treated, VPA-treated and control RNA samples 






Figure 3.3 Gel image from TapeStation showing 28S and 18S bands for total 
RNA from experiment 1. The samples are lithium (B1, E1 and H1), VPA (C1 









Figure 3.4 Gel image from TapeStation showing 28S and 18S bands for total RNA from experiments 2, 3 and 4. The samples are 





Figure 3.5 Gel image from TapeStation showing 28S and 18S bands for total 
RNA  from lithium (C1 and F1), VPA (A1, D1 and G1) and control (B1, E1 and 
H1).  The samples in columns C1, D1, E1, F1, G1 and H1 were from experiment 




3.2.3 Processing of raw reads and quality control 
An important step of RNA-Seq analysis is pre-processing of raw sequencing 
reads to remove adaptor sequences, low-quality reads and poor-quality bases. 
Sequencing generates millions of short fragments called “reads” stored in 
“fastq” files. Raw reads contain sequencing errors and the probability of error 
for each read is represented by Phred quality score. Novogene provided both 
raw and cleaned fastq files. Low-quality reads, adaptor sequences and poor-
quality bases were removed from raw reads to generate clean fastq files 




3.2.4 Read mapping  
For the first step in RNA-Seq analysis, the mapping of reads was done to either 
the whole genome or the transcriptome, the latter being faster, but limiting the 
opportunity to discover novel transcripts. The splice-aware whole genome STAR 
aligner (v2.5.1.b) (Dobin et al., 2013) and two transcriptome aligners, kallisto 
(v0.42.4) (Bray et al., 2016) and salmon (v0.6.1) (Patro et al., 2017) were used, in 
order to compare the outputs of different approaches.  
3.2.4.1 Alignment to reference genome 
For alignment of the mRNA reads to a reference genome, each raw read is given 
a potential mapping location either by exact match to the reference or by 
calculating sequence similarity. Short reads can map to multiple locations so it 
becomes crucial to find the best match. The widely used splice-aware STAR 
aligner (v2.5.1.b) was used for mapping reads to the rat genome. Rnor6, the latest 
rat genome assembly (Jul 2014, version 88) and annotation Rnor_6.0.80 GTF file 
were downloaded from ENSEMBL website. The STAR aligner was described in 
section 2.3.3.1. 
3.2.3.2 Mapping quality 
Mapping quality statistics were generated with STAR aligner (Table 3.1). All 
samples contained uniquely mapped reads (STAR aligner v2.5.1.b) in the range 
78-90% except A1 (27%). Multiple mapped reads, which are an indicator of 
alignment quality, ranged between 3-6%, showing good alignment with 125 bp 
paired-end reads. Due to the low quality of extracted RNA and poor alignment 
(only 27% unique mapped reads), sample A1 was removed from the further 
downstream analysis, resulting in only three rather than four biological 





Table 3.1 Mapping summary of STAR aligner 
Sample name Treatment No of reads Unique mapped 
reads % 
A1 Lithium 15,060,617 27.14 
A2 VPA 17,096,645 85.90 
A3 Control 15,167,832 89.84 
B1 Lithium 16,892,244 88.95 
B2 VPA 17,872,590 90.01 
B3 Control 15,856,005 89.36 
C1 Lithium 16,547,378 89.11 
C2 VPA 16,457,809 78.71 
C3 Control 15,909,420 78.76 
D1 Lithium 18,589,272 88.76 
D2 VPA 17,513,575 87.63 
D3 Control 16,625,525 87.65 
 
3.2.4.2 Alignment to transcriptome 
Alignment of reads to a reference transcriptome, or pseudoalignment, was 
performed with kallisto (v0.42.4) and salmon (v0.6.1) as described in sections 
2.3.3.3 and 2.3.3.4 respectively. Kallisto first built an index for quantification from 
the transcriptome fasta file and performed quantification using the index. 
Mapping percentage of my RNA samples ranged between 72-84% with kallisto 
(Table 3.2), except for one lithium-treated sample (A1) which had low RNA 
quality and a mapping percentage of 31.79%, and was subsequently dropped 
from the analysis. Similarly, mapping percentage of my RNA samples ranged 




(A1) which had low RNA quality and a mapping percentage of 31.81%, and was 
subsequently dropped from the analysis. 
Table 3.2 Mapping summary generated by kallisto. 
Sample 
name 
Treatment No of reads 
processed 




A1 Lithium 15,060,617 4,788,485 31.79 
A2 VPA 17,096,645 12,390,291 72.47 
A3 Control 15,167,832 12,815,695 84.49 
B1 Lithium 16,892,244 13,499,572 79.91 
B2 VPA 17,872,590 14,013,249 78.40 
B3 Control 15,856,005 12,363,610 77.97 
C1 Lithium 16,547,378 12,848,559 77.64 
C2 VPA 16,457,809 11,731,765 71.28 
C3 Control 15,909,420 11,476,696 72.13 
D1 Lithium 18,589,272 14,903,444 80.17 
D2 VPA 17,513,575 14,100,629 80.51 






Table 3.3 Mapping summary generated by salmon. 
Sample 
name 
Treatment No of reads 
processed 




A1 Lithium 15,060,617 4,788,585 31.81 
A2 VPA 17,096,645 12,391,342 72.53 
A3 Control 15,167,832 12,816,495 84.68 
B1 Lithium 16,892,244 13,495, 837 79.95 
B2 VPA 17,872,590 14,066,884 78.70 
B3 Control 15,856,005 12,400,511 78.20 
C1 Lithium 16,547,378 12,848,559 77.64 
C2 VPA 16,457,809 11,766,767 71.50 
C3 Control 15,909,420 11,526,693 72.45 
D1 Lithium 18,589,272 14,903,444 80.17 
D2 VPA 17,513,575 14,140,748 80.74 







3.2.5 Differential gene expression analysis 
The second step in RNA-Seq analysis was identification of DEGs. Four pipelines 
were used for DEG analysis (Figure 2.2), DESeq2 (Love et al., 2014), cufflinks2 
suite (Trapnell et al., 2012; Trapnell et al., 2010) and kallisto-sleuth and salmon-
sleuth (Bray et al., 2016). Kallisto-aligned reads were analysed with the 
accompanying R package sleuth, and salmon output was converted into sleuth-
compatible format using wasabi (Patro et al., 2017). 
3.2.5.1 DESeq2 
DESeq2 (v1.18.1), an R package (Love et al., 2014) was used for DEG analysis. 
Count data were generated from STAR-aligned bam files using HTSeq-count 
(Anders et al., 2014). These count files were analysed with DESeq2 R package in 
Rstudio. Default analysis was performed as suggested in the manual and 
described in section 2.1.6.5. 
3.2.5.2 Cufflinks suite 
Cufflinks2 (v2.2.1) (Trapnell et al., 2012; Trapnell et al., 2010) suite was used with 
STAR-aligned bam files. The bam files were merged together with cufflinks2.2.1 
to generate the transcriptome assembly. These transcriptome assemblies were 
merged using cuffmerge, and gene and transcript expression profiles were 
created using cuffquant. The bam files and the merged assembly were used as 
input for cuffdiff to estimate gene and transcript differential expression. The 
output contained differential gene expression and differential splicing. 
3.2.5.3 Sleuth 
Sleuth (v0.28.0), an R package (Pimentel et al., 2017), was used for differential 
gene expression analysis of kallisto and salmon quantified RNA-Seq data. The 




package, parameters were estimated for sleuth full model and reduced model 
and differential analysis was carried out using the likelihood ratio test. 
3.3 Results 
3.3.1 RNASeq data exploration 
Data exploration was done using principal component analysis (PCA) to check 
how much variance was attributed to the treatment effects and for any batch 
effects. PCA was carried out on RNASeq raw counts generated with HTSeq-
count using STAR-aligned bam files with the R package prcomp. A total of 32, 
662 gene counts were generated with HTSeq-count and filtered to remove the 
genes with zero counts in all the samples using the Bioconductor genefilter 
package, and 20,869 genes were used for PCA. The PCA plot for all twelve 
samples (Figure 3.6) showed that one of the lithium-treated sample (A1) 
separated from rest of the two PCA groups. The remaining eleven samples 
clearly separated into two groups; all control (A3, B3, C3, and D3) and lithium-
treated (B1, C1, and D1) samples grouped together suggesting lithium treatment 






Figure 3.6 PCA plot for RNASeq raw counts for all twelve samples with the 
R package prcomp, spanned by their first two components. Lithium-treated 
(A1, B1, C1, and D1), VPA-treated (A2, B2, C2, and D2) and untreated A3, B3, 
C3, and D3) samples from four independent cell culture experiments were 
analysed. No effect of lithium treatment is seen as they clustered together with 
the untreated samples. A batch effect is seen for VPA-treated sample C2 and 
untreated sample C3 from the same batch.  
 
Principal component analysis was repeated on normalised RNASeq counts with 
the DESeq2 R package. R-log transformed count data was used to calculate the 
components and genes with low expression were removed (Figure 3.7). Even 
after modelling for batch effects during normalization, lithium-treated sample 
A1 separated from the rest of the samples. This sample had low quality RNA 
and only had 27% uniquely mapped reads to the rat reference genome therefore, 
it was removed from further downstream analysis. All of the four VPA-treated 






Figure 3.7 PCA plot for RNASeq normalized counts for all twelve samples 
with the DESeq2 R package, spanned by their first two components. Lithium-
treated (A1, B1, C1, and D1), VPA-treated (A2, B2, C2, and D2) and untreated 
A3, B3, C3, and D3) samples from four independent cell culture experiments 
were analysed with batch correction. No effect of lithium treatment is seen as 
they clustered together with the untreated samples. After modelling for batch, 






3.3.2 RNA-Seq analysis of lithium-treated RN46A cells 
No significant gene expression changes were observed in lithium-treated RN46A 
cells (compared to control cells) with any of the differential expression analysis 
(DEA) methods. Principal component analysis showed lithium-treated samples 
and control samples failed to separate based on treatment, and samples from the 
same batch (experimental replicate) grouped together (Figure 3.7).  
3.3.3 RNA-Seq analysis of VPA-treated RN46A cells 
PCA plot for VPA-treated versus control samples showed there is clear 
separation of VPA-treated and control samples by the first component (Figure 
3.7). The first component explained 36% variance, whereas the second 
component explained 26% variance.  
VPA treatment of RN46A cells resulted in extensive gene expression changes as 
evidenced with the MA plot for VPA-treated samples with respect to controls, as 





Figure 3.8 MA plot between VPA-treated and control samples of the gene 
expression counts generated by the DESeq2 R package. Red dots show the 
DEGs as estimated by Fisher’s exact test at 1%.  
 
Significant gene expression changes were observed with VPA-treated RN46A 
cells. The p-values were adjusted for multiple comparison using the Benjamini-
Hochberg method (Benjamini & Hochberg, 1995). At adjusted p-value (padj) < 
0.05 and log2 fold change (LFC) of 1.5, number of DEGs varied among the four 
DEA methods; 145 DEGs were observed with kallisto, 158 with salmon, 224 with 
DESeq2 and 302 with cuffdiff2 (Table 3.4). The top 25 genes identified with 
DESeq2 are listed in Table 3.5 and boxplots for the top 99 genes are shown in 
Figure 3.9. The boxplots were created in R using normalized gene counts 
generated by DESeq2. The DEG list generated by DESeq2 was used for the 





Table 3.4 DEGs detected by each DEA tool in response to VPA. 
DEA tool DEGs (padj <0.05) DEGs (padj <0.05 and LFC >1.5) 
Cuffdiff2 1097 302 
DESeq2 1212 224 
Kallisto-sleuth 948 145 









Base mean VPA1 
log2FoldChange padj1 
IGF2 1.78 ± 0.71 139.77± 17.44 4.15 8.40E-32 
ADGRB2 34.57 ± 11.33 418.11 ± 47.94 3.03 4.38E-28 
AQP1 1813.82 ± 161.36 349.61 ± 34.24 -2.26 7.43E-28 
MMP13 1066.38 ± 144.15 6415.40 ± 855.59 2.39 1.22E-25 
VGF 30.11 ± 17.49 642.32 ± 161.08 3.34 1.07E-24 
ZCCHC12 60.32 ± 6.42 443.85 ± 73.79 2.52 1.24E-22 
IL20RB 190.62 ± 35.73 14.04 ± 5.16 -2.95 3.27E-20 
NGFR 47.83 ± 8.42 327.14 ± 37.71 2.38 1.79E-19 
TSPAN13 72.98 ± 8.75 457.96 ± 87.42 2.33 1.86E-18 
COL3A1 2014.23 ± 727.89 245.37 ± 50.45 -2.53 4.17E-17 
LSP1 186.31 ± 12.93 22.84 ± 8.96 -2.61 4.63E-17 
AGAP2 0.25 ± 0.44 63.11 ± 9.77 3.31 1.34E-16 
SNAP91 13.02 ± 3.28 137.50 ± 10.69 2.63 2.18E-16 
WNT6 30.12 ± 6.36 227.07 ± 38.69 2.38 8.01E-16 
NXPH4 3.74 ± 2.32 79.60 ± 18.76 2.98 8.42E-16 
TMEM130 19.20 ± 5.1 162.75 ± 26.61 2.47 1.55E-14 
ADAM23 19.14 ± 8.71 123.74 ± 24.97 2.55 1.91E-14 
CLGN 30.93 ± 2.57 176.08 ± 24.33 2.20 8.31E-14 
ERBB3 67.54 ± 16.86 289.04 ± 22.42 1.99 3.36E-13 
RGD1563349 5.10 ± 1.49 67.82 ± 5.15 2.73 7.39E-13 
CHRNA5 2.48 ± 1.86 52.68 ± 6.89 2.86 1.30E-12 
ATP1B2 38.83 ± 8.26 199.63 ± 29.11 2.11 1.34E-12 
TMEFF1 1.88 ± 1.46 53.25 ± 5.51 2.87 1.74E-12 
FAM25A 82.84 ± 33.0 5.53 ± 1.74 -2.71 2.06E-12 
PERP 26.70 ± 4.62 150.22 ± 23.25 2.16 3.29E-12 
1Ranked by p-values. Base mean control and base mean VPA refer to the mean of 





Figure 3.9 Boxplots showing gene expression differences between VPA-
treatment vs untreated cells for the top 99 VPA DEGs (sorted by padj values). 
Normalized counts generated by DESeq2 were used to create boxplots using R. 





   
   
   




   
   
   




   
   
   




   
   
   




   
   
   




   
   
   




   
   
   




   
   
   









3.3.4 Comparative analysis of differential gene expression analysis 
methods 
Differential gene expression analysis was carried out with four tools: DESeq2, 
cuffdiff2, kallisto-sleuth and salmon-wasabi. A cut-off of adjusted p-values 
(FDR) < 0.05 was used to determine significant DEGs for all DEA methods. Table 
3.6 shows the VPA DEGs produced by the four DEA methods and Figure 3.10 
shows the agreement between the DEA methods. DESeq2 detected more DEGs 
than other methods. Cuffdiff2 generated DEGs list using its own identification 
codes, unlike ENSEMBL ID used by the other three DEA tools. Therefore, gene 
name was used to compare DEG lists. Not all the DEGs had associated gene 
names so they were removed from further analysis; 1029 DEGs from cuffdiff2, 
868 from kallisto-sleuth, 923 from salmon-wasabi and 1211 DEGs from DESeq2 
were used for comparison. A four-way comparison showed that a total of 474 
DEGs were in common among the four DEA tools, and a two-way comparison 
to clarify relationship between the whole genome and transcriptome DEA tool 
showed that 749 DEGs were in common to DESeq2 and cuffdiff2, and 724 genes 
were in common to salmon and kallisto (Figure 3.10). 
 
Table 3.6 Number of VPA DEGs used for comparison 
DEA tool Total number of DEGs 
detected 
Number of DEGs used 
for comparison 
Cuffdiff2 1098 1029 
DESeq2 1212 1211 
Kallisto-sleuth 948 868 







Figure 3.10 Agreement between the four DEA methods. The first panel shows 
the four-way comparison of the DEA tools. The lower panels indicate the two-
way comparison to clarify relationships between whole-genome DEA methods 




3.3.5 Functional enrichment and pathway analysis 
Integrated differential expression and pathway analysis (iDEP) web-based tool 
(version 0.80) was used for functional enrichment and pathway analysis. This 
analysis could not be carried out for lithium-treated samples because no DEGs were 
identified with lithium-treated RN46A cells.  
Read count data from STAR aligner for four VPA-treated and four untreated 
control samples were uploaded to the website. 32,402 genes were found across 
the six samples. Genes with low expression i.e. counts per million (CPM) less 
than 1 were removed from further analysis. Of the 13,113 genes that passed filter, 
13,108 were converted to Ensembl gene IDs in the iDEP database. The remaining 
5 genes were kept in the data using original IDs. Differential expression analysis 
was carried out with DESeq2 using the original read counts. The count data were 
rlog transformed (Love et al., 2014) using the edgeR tool for further clustering 
analysis and principal component analysis.  
A total of 985 genes was selected at FDR of 0.1 and fold change of 2. This included 
712 up- and 273 down-regulated genes, as shown in Figure 3.11. A clear 







Figure 3.11 Heatmap generated with DESeq2 by the iDEP web tool showing 
upregulated (red colour) and downregulated (green colour) genes in response 
to VPA treatment. The downregulated genes in response to VPA are displayed 
as blue and upregulated genes as yellow on the side panel. This heatmap 
showed a clear distinction between control and VPA samples based on the gene 





3.3.5.1 Gene Ontology (GO) analysis 
Enrichment analysis was carried out on DEG from the VPA exposure 
experiments using GO and available gene sets with the iDEP web tool (Figure 
3.12). GO analyses were carried out at three different levels, for biological 
components (Figure 3.12), cellular components (Figure 3.13), and molecular 
function (Figure 3.14). 
For up-regulated genes, the most significant biological processes include 
nervous system development, neurogenesis, generation of neurons, neuron 
differentiation and neuron projection development. For down-regulated genes, 
the most significant biological processes include response to biotic stimulus, 
response to external stimulus, response to external biotic stimulus and cellular 






Figure 3.12 Significant GO biological processes associated with VPA up- and 
down-regulated genes using the iDEP web tool. The GO terms are displayed in 
a hierarchical fashion, and correlated gene sets closer to the tree share more 
genes. The p-values are displayed next to each GO term. The size of the circle 







For up-regulated genes, the most significant GO cellular components include 
neuron part, neuron projection, synapse part and synapse. For down-regulated 
genes, the most significant GO cellular components include extracellular region, 
extracellular region part and extracellular space.  
 
 
Figure 3.13 Significant GO cellular components associated with VPA up- and 
down-regulated genes using the iDEP web tool. The GO terms are displayed in 
a hierarchical fashion, and correlated gene sets closer to the tree share more 
genes. The p-values are displayed next to each GO term. The size of the circle 






For up-regulated genes, the most significant GO molecular functions include ion 
binding, calcium ion binding, actin binding and cytoskeletal protein binding 
(Figure 3.14). For down-regulated genes, the most significant GO molecular 
functions include heparin binding, glycosaminoglycan binding, sulphur 
compound binding and fibronectin binding (Figure 3.14).  
 
 
Figure 3.14 Significant GO molecular function associated with VPA up- and 
down-regulated genes using the iDEP web tool. The GO terms are displayed in 
a hierarchical fashion, and correlated gene sets closer to the tree share more 
genes. The p-values are displayed next to each GO term. The size of the circle 






3.3.5.2 KEGG Pathway analysis 
Network or pathway analysis helps leverage external annotation of functional 
networks or pathways to highlight biologically relevant signals in a dataset. It 
was carried out after differential gene expression analysis to define the 
biochemical pathways that were most significantly altered by exposure to VPA. 
Pathway analysis was carried out with the GSEA method and KEGG database 
using the iDEP web tool. The most significant up-regulated pathways include 
cell adhesion molecules, morphine addiction, GABAergic synapse and 
serotonergic synapse (Figure 3.15). The most significant down-regulated 
pathways include spliceosome, systemic lupus erythromatosus, cytokine-





Figure 3.15 Significant KEGG pathways associated with VPA regulated 
genes at FDR of 0.2  The GO terms are displayed in a hierarchical fashion, and 
correlated gene sets closer to the tree share more genes. The p-values are 
displayed next to each GO term. The size of the circle represents the 




3.3.6 Serotonergic nature of RN46A 
RN46A is an immortalized serotonergic cell line derived from the rat medullary 
raphe (White et al., 1994). Our RNA-Seq data provided an opportunity to 
investigate the gene expression profile of cultured RNA46A, allowing an 
assessment of similarity between this cell line and known patterns of gene 
expression in the medullary and dorsal raphe nucleus.  
RNA-Seq data from control RN46A cells was compared with the expression 
profile from in situ hybridisation (ISH) data in the Allen Brain Atlas (ABA). ABA 
contains gene expression data from human and mouse brains. A comparison was 
done with mouse ISH data as rat brain data were not available. 24,382 Ensembl 
IDs from my RN46A RNA-Seq data were successfully converted to gene names 
using the Rnor_6.0 database from BioMart Ensembl Genes 92. This gene list was 
filtered to remove genes which had zero counts. A total of 13,551 genes were 
defined as expressed in the RN46A cells after this filtering. 
A differential gene search was carried out in adult mouse brain data for the 
medullary raphe (RM) against the rest of the brain regions on the ABA website 
as described in section 2.2.9. A total of 5, 754 genes with expression ranging from 
high to low, including both coronal and sagittal sections were downloaded. The 
same was repeated for the dorsal raphe (DR) genes as DR also contains the 
serotonergic neurons. A total of 5037 genes from both coronal and sagittal 
sections were downloaded. The RN46A gene list was compared with the 
medullary raphe gene list and 3300 out of 5754 genes were in common. The same 
was repeated in the dorsal raphe gene list, and 2860 genes from RN46A were in 
common out of 5037 DR genes.  
Another gene list was manually curated based on highly expressed genes in ABA 




published serotonergic genes (Templin et al., 2012). RN46A was found to express 
multiple RM, DR and serotonergic genes, notably MAOA, MAOB, HTR2A, 
SLC18A2, SLC6A4, TPH1 and TSHR (Table 3.7). RN46A cells expressed 49 out of 
99 genes from this curated gene list. 
 






  Gene name1 Base 
mean 
RN46A2 
  Gene name1 Base mean 
RN46A2 
ADM 159.33   GABRG3 0.00   KCNH8 0.00 
ARC 139.67   GABRQ 0.00   KCNK1 0.00 
ARL10 110.00   GCH1 678.67   KCNK9 0.00 
BAIAP3 5.33   GCHFR 859.67   KCNQ3 0.00 
BCL2 10.67   GLRA1 0.00   MAOA 453.33 
BDNF 185.33   GLRA2 0.00   MAOB 12.33 
CACNA1A 292.00   GLRB 93.33   MSMO1 1935.67 
CACNA1B 14.00   GNG2 549.33   PCLO 0.67 
CACNA1H 71.00   GRB10 2.33   PHB 1722.33 
CACNA2D1 35.67   GRIA3 177.67   POMGNT2 215.00 
CACNA2D2 145.33   GRIA4 4.33   PTS 67.67 
CBLN4 0.00   GRIK1 78.33   PVALB 0.33 
CDH13 1.67   GRIK2 3.00   QDPR 558.00 
CHRNA6 0.00   GRIK5 1569.33   RGS17 352.00 
CHRNB2 8.33   HTR1A 0.00   SCN2B 0.00 
CLCN3 874.33   HTR1B 0.00   SCN3B 0.00 
CLCN4 46.33   HTR1D 0.33   SCN4B 0.00 
CLCN5 52.00   HTR1F 0.00   SCRG1 0.33 









  Gene name1 Base 
mean 
RN46A2 
  Gene name1 Base mean 
RN46A2 
CNTN1 7.00   HTR2B 1.30   SLC18A1 1.67 
COL25A1 11.67   HTR2C 0.00   SLC18A2 122.00 
CREB1 83.67   HTR3A 0.00   SLC35G2 5.00 
CRH 0.33   HTR3B 0.00   SLC6A4 6.67 
CRHR2 1.00   HTR4 0.00   SNCG 8.33 
DDC 0.00   HTR5A 0.00   SPR 164.33 
DLK1 0.00   HTR5B 2.00   TPH1 8.00 
DNAJC12 81.67   HTR6 0.00   TPH2   0.00 
ECE2 67.00   HTR7 0.00   TPPP3 197.00 
FXYD6 61.00   IRS4 0.00   TSHR 32.33 
GABRA1 28.67   KCNA1 0.00   TTYH3 1178.67 
GABRB1 0.00   KCNA2 0.00   VAT1L 0.00 
GABRB2 7.00   KCNA3 0.00   ZCCHC12 60.33 
GABRG2 0.00   KCNA4 7.67       
1This table is ranked by alphabetical order.  
2Base mean RN46A refer to the mean of counts from four replicates of 





3.3.7 Overlap of RNA-Seq data with genome-wide association studies 
Several genome-wide association studies (GWAS) have been carried out to 
identify genetic variants contributing to the risk of BD and therapeutic lithium 
response in BD (Cross-Disorder Group of the Psychiatric Genomics Consortium 
et al., 2013; Cross-Disorder Group of the Psychiatric Genomics Consortium & 
Smoller, 2013; Hou et al., 2016; Ikeda et al., 2018; Song et al., 2017; Visscher et al., 
2012). We hypothesised that some of the known risk genes for BD identified with 
GWAS might be regulated by VPA. Therefore, I carried out a preliminary 
comparison of VPA-regulated genes with the GWAS hits. In the latest GWAS 
catalogue (http://www.ebi.ac.uk/gwas/), 97 GWAS in BD have been performed 
as of 4 July 2018. The list of associations with BD were downloaded from the 
website. A total of 966 SNPs were present, which contained several unknown 
and intergenic variants. The SNPs were filtered to p-val < 1.0E-6, and a list of 544 
variants which corresponded to unique genes implicated by GWAS was 
compiled. DEGs from the DESeq2 list were compared with the 544 GWAS genes. 
Twenty-six VPA-regulated genes were common in BD GWAS. Some of these 
genes include, ANK3, DPYD, IGF2 and MAP7. This comparison is not meant to 
be statistically significant as comparison of random gene lists would generate 5% 
of genes to be common (27 genes out of 544 genes). The VPA DEGs and GWAS 
hits comparison was done to highlight the biological relevance of the DEGs 






Table 3.8 Twenty-eight VPA-regulated genes overlap with BD GWAS. 
Gene Name References 
Upregulated genes 
ADGRV1  (Lencer et al., 2017) 
ALCAM (Lencer et al., 2017) 
ANK3 (Charney et al., 2017; Chen, Jiang, et al., 2013; Cross-
Disorder Group of the Psychiatric Genomics Consortium, 
2013; Ferreira et al., 2008; Liu et al., 2011; Muhleisen et al., 
2014; Psychiatric GWAS Consortium Bipolar Disorder 
Working Group, 2011) 
COL22A1 (Lencer et al., 2017) 
DOK5 (Liu et al., 2010) 
DPYD (Bergen et al., 2012; Cross-Disorder Group of the 
Psychiatric Genomics Consortium, 2013; Witt et al., 2017) 
ERC2 (Curtis et al., 2011) 
FAM213A (Witt et al., 2017) 
GPM6A (Greenwood et al., 2012) 
IGF2 (Lencer et al., 2017) 
MAP7 (Lencer et al., 2017) 
MARK1 (Kerner et al., 2011) 
MB21D2 (Lencer et al., 2017) 




Gene Name References 
PLAGL1 (Lencer et al., 2017) 
PLCE1 (Alliey-Rodriguez et al., 2011) 
PTPRU (Wang et al., 2010) 
SLC39A8 (Lencer et al., 2017) 
SORCS2 (Fabbri & Serretti, 2016) 
SYT17 (Lydall et al., 2011) 
Downregulated genes 
ARHGEF19 (Lencer et al., 2017) 
IL20RB (Lencer et al., 2017) 
MMP16 (Cross-Disorder Group of the Psychiatric Genomics 
Consortium, 2013) 
NFYC (Fabbri et al., 2015) 
PTPRG (van Hulzen et al., 2017) 






I hypothesized that studying global gene expression changes in response to 
mood stabilizers will identify genes that are specifically altered and find 
signalling pathways that are crucial to their mode of action (Hunsberger et al., 
2009; Machado-Vieira et al., 2011; Manji & Flores, 2017; Martinowich et al., 2009; 
Quiroz et al., 2010). To this aim, I examined gene expression changes by lithium 
and VPA with RNA-Seq in the rat serotonergic cell line RN46A.  
3.4.1 Serotonergic nature of RN46A 
The RNA-Seq data provided the opportunity to analyse the expression profiling 
of RN46A cells. A semi-quantitative approach was used to examine the 
serotonergic nature of the expression profile of RN46A. As RN46A was derived 
from the medullary raphe, I focused on both the serotonergic regions of the 
medullary and dorsal raphe in ABA. Gene expression profiles for these two 
regions from the ABA ISH database were compared with my RN46A RNA-Seq 
normalized counts. RN46A cells had 50% expression profile similarity with 
raphe nuclei which asserts the serotonergic profile. The difference in gene 
expression between RN46A and ABA data might be due to the heterogeneous 
cellular profile of the raphe nuclei which contains multiple neuronal and non-
neuronal cell populations.  
Highly expressed genes from the medullary and dorsal raphe in the ABA ISH 
database and other published serotonergic genes were then used to curate a list 
of 100 “serotonergic genes”. My RNA-Seq expression data from control RN46A 
cells was then compared with this curated serotonergic gene list. RN46A cells 
expressed 49 out of 99 genes, notably the serotonergic genes MAOA, MAOB, 
HTR2A, SLC18A2, SLC6A4, TPH1 and TSHR establishing the serotonergic nature 




RNA-Seq results showed that only TPH1 was expressed in RN46A cells, not 
TPH2. Tryptophan hydroxylase catalyses the rate-limiting step of 5-HT 
biosynthesis and exists as two isoforms coded by two independent genes, TPH1 
and TPH2; TPH1 is expressed in the periphery and the pineal gland whereas 
TPH2 is the major CNS isoform (McKinney et al., 2005). Similar to my 
observation, a recent study reported TPH1 to be primarily expressed primarily 
in RN46A with TPH2 expression at low levels (Nawa et al., 2017). This difference 
in expression in RN46A cells could be due to the expression of TPH1 in the earlier 
stages of neural development (Nakamura & Hasegawa, 2007; Nakamura et al., 
2006). RN46A is derived from the embryonic day 13 rat and differentiated 
RN46A cells in culture without any external effectors, are at an early 
developmental stage (Eaton et al., 1995; White et al., 1994). 
Taken together, the results in this section support the view that RN46A is of a 
serotonergic nature, and that the expression profile derived by RNA-Seq analysis 
quite strongly resembles the pattern of gene expression generated by ISH, for the 
raphe nuclei, in the ABA. These observations support the choice of this cell line 
as a model for exploring the molecular action of mood stabilisers. 
3.4.2 RNA-Seq analysis 
There is no gold-standard RNA-Seq analysis pipeline available. Limited 
commercial RNA-Seq workflows are available, but they are expensive and limit 
choice of new methods. Available free, open-source software programmes 
perform one component of analysis workflow at a time and require a 
combination of multiple tools to create RNA-Seq workflows which demand 
considerable programming skills. At each step of the analysis, several tools exist, 
but the underlying assumptions and methodologies differ, making the choice 
difficult. This variability leads to results differing between methods, especially 




four RNA-Seq pipelines with freely-available and widely-used tools, and 
compared the different RNA-Seq workflows. I reasoned this would provide 
increased confidence in results and save effort during validation. 
Three different mapping aligners were used, one splice-aware whole genome 
aligner STAR and two transcriptome aligners, kallisto and salmon. Percentage 
of mapped reads is a global indicator of the overall sequencing accuracy. The 
mapping results show STAR produced 78-90% uniquely mapped reads for all 
samples showing good alignment. Mapping quality with kallisto and salmon 
were slightly lower compared to the genome mapper partly due to the loss of 
mapping of reads to unannotated transcripts, and presence of more multiple 
mapped reads shared by different isoforms of the same gene.  
Genes with the lowest FDR corrected p-values and highest fold changes between 
the treatments were selected. We adjusted for sequencing bias, technical bias and 
batch effects with normalization. Using three independent replicates gave us 
power for inferential analysis. At each step quality control was done to monitor 
the quality of data. A four-way comparison between the DEA tools revealed a 
total of 474 genes were common, whereas more than 700 genes were common in 
the two categories of whole genome DEA (DESeq2 and cuffidiff2) and 
transcriptome DEA (salmon and kallisto).  
3.4.3 Differential gene expression changes with lithium 
RNA-Seq analysis of differential gene expression changes of lithium-treated 
RN46A cells resulted in no significant gene expression after FDR correction. 
Principal component analysis revealed that lithium-treated samples clustered 
together with the control samples showing the batch effect (Figure 3.6 and Figure 
3.7). In a previous study in our laboratory, RNA-Seq analysis of lithium-treated 




concentration and exposure time, only three genes were significantly altered 
with the same criteria (LFC >1.5 and FDR < 0.05). This could be the biology 
underlying the transport of lithium ions (Li+) into the RN46A cells. As a 
monovalent cation, Li+ competes with Na+ based on charge and Mg++ based on 
the ionic radius/size.  The distribution and transport of Li+ in the cells is due to 
competition with sodium-selective channels and transporters (Jakobsson et al., 
2017). Li+ can also associate with Mg++-ATP (Briggs et al., 2016). The major 
biochemical effects of Li+ are due to its competition with Mg++-selective 
biomolecules. It might be that the biology of RN46A is impacting the 
concentration of lithium required for significant gene expression changes. Thus, 
0.5mM lithium might be low for this cell line, compared to the higher 
concentration of 10mM used in a gene expression study in hiPSCs (Tobe et al., 
2017). Cruceanu et al (2012) observed no change in synapsin 2a mRNA levels at 
0.5mM lithium in SK-N-AS neuronal cell line, but increased expression at 1.0 and 
2.0 mM, suggesting 0.5mM was insufficient to elicit a response (Cruceanu et al., 
2012). Alternatively, it is possible that lithium works through translational rather 
than transcriptional regulation (Tobe et al., 2017). CRMP2 is a direct substrate of 
GSK-3β which is a known target of lithium. Increased phosphorylation of 
CRMP2 is observed with lithium and GSK-3β inhibitors in lithium-responsive 
neurons derived from BD patients (Tobe et al., 2017).  
3.4.4 Differential gene expression changes with VPA 
RNA-Seq analysis of global gene expression changes of VPA-treated RN46A 
cells yielded 224 DEGs with DESeq2 [LFC >1.5 and padj <0.05]. There was 
variation in methodology among DEA tools. Thus, each bioinfomatic tool 
produced different numbers of DEGs (Table 3.4) with DESeq2 producing the 
highest number, and kallisto and salmon producing similar numbers. The first 




expression method while cuffdiff2 considers the sequencing depth, gene length, 
differential isoform expression and variability within and between the 
conditions for normalization. Sleuth employed a similar strategy to cuffdiff2 
except it first normalized by gene length followed by sequencing depth.  
Poisson distributions fit well to technical replicates whereas biological replicates 
generate more variability or over-dispersion, which are fitted better with the 
negative binomial distribution (Anders & Huber, 2010). DESeq2 modelled count 
data using negative binomial distribution while cuffdiff2 used beta negative 
binomial model. DESeq2 by default removed genes with extreme read counts 
and detected outliers stringently. DESeq2 used a GLM Wald test, cuffdiff2 used 
t-test to calculate p-values and sleuth used Wald test.   
STAR/cufflinks2 pipeline had runtime of several hours, whereas the DE-calling 
R packages took minutes to execute. A comparative analysis of several RNA-Seq 
DE calling tools by Labaj (2016) showed tophat2/cufflinks2 pipeline performed 
the worst with lowest sensitivity and specificity of DEG calling and DESeq2 
performed well for identification of top-ranked DEGs (Łabaj & Kreil, 2016). A 
combination of DESeq2 and kallisto therefore appeared to be a reasonably good 
choice.  
3.4.5 Enrichment and pathway analysis 
Gene lists obtained from differential expression experiments were functionally 
analysed to assign biological relevance to the genes and their molecular 
functions and pathways involved. Gene Ontology (GO) is used for annotation of 
transcriptomic data and contains three main categories: biological processes 
(BP), molecular function (MF) and cellular component (CC). Genes are assigned 





Functional annotation and pathway analysis could not be carried out for lithium-
treated samples because no significant genes were identified. 
The most-enriched GO processes for VPA regulated genes indicated the 
relevance to mood regulation of the genes identified in this RNA-Seq study. GO 
analysis highlighted biological processes “generation of neurons” and 
“neurogenesis” as the most-enriched GO processes. Reduced neurogenesis has 
been linked to mood disorders (Hill et al., 2015; Schloesser et al., 2015) and 
therapeutic effect of antidepressants have been partly attributed to increased 
hippocampal neurogenesis (Castrén & Hen, 2013; Malberg et al., 2000; Santarelli 
et al., 2003). Reduced hippocampal volume was observed in MDD and BD 
patients (Fornito et al., 2007) which could be restored with mood stabilizers and 
antidepressants (Hajek et al., 2012; Schloesser et al., 2007; Schloesser et al., 2012).  
VPA has been shown to affect neuron differentiation and nervous system 
development (Hall et al., 2002; Jacob et al., 2014; Jang & Jeong, 2018; Yu et al., 
2009). Other top GO biological processes included neuron differentiation and 
nervous system development among others (Figure 3.12). Similar biological 
processes such as neuron differentiation, projection and development were 
observed as the most-enriched in functional enrichment analyses of DEGs and 
differentially methylated regions in BD post-mortem brain (Xiao et al., 2014).  
GO analysis of VPA downregulated genes highlighted biological processes 
“cellular response to chemical stimulus” and “cellular response to organic 
substance” as the most enriched processes. Similar biological process of “cellular 
response to mechanical stimulus” was observed in gene expression from SCZ 
post-mortem brains (Xiao et al., 2014). 
Gene set analysis characterizes the phenotype under study by identifying over-
represented/enriched categories of genes that share a similar function within the 




wherein genes are analysed in functional groups, networks or pathways. 
Existing methods can use modest but coordinated changes in expression to 
establish a link between the phenotype and a predefined group of functionally 
related genes. Genes with no obvious biological relevance to the phenotype 
under study might have novel function. 
VPA-regulated genes were analysed with the gene set enrichment analysis 
(GSEA) method (Subramanian et al., 2005) using the iDEP web tool. The top up-
regulated pathway was cell adhesion molecules. ECM remodelling and synaptic 
plasticity dysfunction has been implicated in the pathophysiology of BD and 
SCZ (Berretta, 2012; Drago et al., 2014; Lubbers et al., 2014; Pantazopoulos & 
Berretta, 2016). Cell adhesion genes were most differentially regulated in 
response to VPA and matrix metalloproteinases such as MMP13, MMP9 and 
MMP12 were some of the genes highly upregulated by VPA. MMP13 and 
MMP12 were also upregulated by VPA in the prior RNA-Seq study with the 
undifferentiated RN46A cells. This suggests these genes may be involved in 
ECM remodelling and modulating synaptic plasticity. Alternatively, VPA could 
alter the growth of the RN46A cells and affect expression of MMPs. Microscopic 
observation did not indicate altered growth of differentiated RN46A cells after 
VPA exposure however, measurement of cellular growth rate after VPA 
treatment could have confirmed this visual observation.  
Other top up-regulated pathways were involved in GABAergic and serotonergic 
synapse suggesting that VPA up-regulated genes might be relevant to its mood-
stabilizing effect. Our results of GO and KEGG analysis were consistent with 





3.4.6 VPA-regulated genes have been previously implicated in mood 
disorders 
RNA-Seq analysis of VPA-treated RN46A cells yielded 224 DEGs (DESeq2 list) 
and functional annotation and pathway analysis revealed several of these genes 
were involved in pathways implicated in BD and SCZ.  
3.4.6.1 Calcium channel genes 
Three calcium channel genes CACNA1B (LFC of 2.3, padj 1.5e-11), CACNA1D 
(LFC of 1.2, padj 1.4e-2) and CACNA1H (LFC of 1.5, 8.4e-6) were upregulated by 
VPA. Rare variants in CACNA1B were associated with BD patients in a whole 
genome sequencing study (Ament et al., 2015). 
Calcium signalling dysfunction is implicated in the pathophysiology of BD and 
several calcium channel genes have been identified (Chen et al., 2014; Cipriani et 
al., 2016; Kato, 2008; Uemura et al., 2011). CACNA1C has been identified as a BD 
risk gene (Ferreira et al., 2008; Sklar et al., 2008). CACNA1B can bind to β-catenin 
in the GSK-3β pathway (Pedrosa et al., 2010) which has been implicated in BD 
(Matigian et al., 2007; Sani et al., 2012) and affected by both VPA and lithium 
(Gupta et al., 2012; Rosenberg, 2007; Wexler et al., 2008). Genes regulating calcium 
signalling are altered in BD patient-derived iPSCs (Chen et al., 2014). Brain-
selective calcium channel antagonists are the promising therapeutic targets for 
BD treatment (Cipriani et al., 2016).  
3.4.6.2 Matrix metalloproteinases and their inhibitors 
Seven members of the metalloproteinase family were altered by VPA in my 
dataset. ADAM23 (LFC of 2.5, padj 1.9e-14), MMP-9 (LFC of 1.5, padj 1.1e-3), 
MMP-12 (LFC of 1.1, padj 1.6e-2), MMP-13 (LFC of 2.4, padj 1.2e-25) and MMP-
16 were upregulated, and MMP14 (LFC of -0.8, padj 1.6e-2) and the inhibitor 




matrix metalloproteinases (MMPs) and a disintegrin and metalloprotease 
domain (ADAMs) family. MMPs are zinc-dependent endopeptidases involved 
in cleavage of extracellular matrix (ECM) and cell surface receptors to modulate 
synaptic and circuit organization (Singh et al., 2015). MMPs are broadly 
expressed in the brain and regulate inflammation and microglial activation 
(Brkic et al., 2015). These regulate the development of neural network and 
plasticity through ECM remodelling (Fujioka et al., 2012).  
VPA upregulated MMP9 in this RNASeq dataset. Other studies show both VPA 
and lithium can upregulate MMP9 (Darville et al., 2016; Tsai et al., 2010) and 
MMP-2 (Lee, Pirooznia, et al., 2015; Milutinovic et al., 2007). MMP9 is the synaptic 
partner of SHANK3 (Darville et al., 2016) which was also upregulated by VPA in 
this dataset. MMP9 is involved in synaptic plasticity by regulating long-term 
potentiation in the hippocampus and frontal cortex, and learning and memory 
in the amygdala (Gorkiewicz et al., 2015). Serum levels of MMP9 and MMP2 have 
been shown to be altered in MDD (Rybakowski et al., 2013; Shibasaki et al., 2018) 
and BD patients (Rybakowski et al., 2013). Variants in MMP9 are associated with 
BD (Rybakowski et al., 2009) and SCZ (Lepeta et al., 2017) suggesting MMP9 may 
be a common susceptibility gene.  
ADAM23 was upregulated by VPA. It is upregulated by chronic VPA treatment 
in the rat hippocampus (Nanavati et al., 2011). ADAM23 is associated with 
voltage-gated K+ channels (Long, 2005). It has no catalytic function and is highly 
expressed in the brain and brain nuclei (Novak, 2004) and at the cell surface 
(Goldsmith et al., 2004). It interacts with LGI1 and LGI2, epilepsy-related proteins 
(Cowell, 2014). ADAM23 is altered in the post-mortem brain of antipsychotics 
treated BD patients (Chen, Wang, et al., 2013).  
MMP13 had the lowest p-values and was present in all four DEG lists. The 




well (Balasubramanian et al., 2019). MMP13 plays a role in maintaining cellular 
structure along with ADAM23, other MMPs and their inhibitors.  
TIMP1 was downregulated by VPA. VPA increased expression of MMPs and 
decreased expression of TIMP1. MMPs are synthesised in proenzyme forms and 
need TIMPs for activation. The same trend of increased MMPs and decreased 
TIMPs has been seen in several pathological conditions (Lipka & Boratyński, 
2008). TIMP1 was one of the 13 genes altered in the prefrontal cortex of BD 
suicide cases (Kim, Choi, et al., 2007).  
MMPs are increasingly being associated with psychiatric disorders (Chiarani et 
al., 2013; Drago et al., 2017). Neuroinflammation is associated with mood 
disorders (Berk et al., 2011; Goldstein et al., 2009; Haarman et al., 2014; Haase & 
Brown, 2015; Kotzalidis et al., 2015). MMPs and TIMPs are increasingly being 
investigated in mood disorders due to their role in inflammation. 
Polymorphisms in MMP2, MMP7, MMP9 and TIMP2 have been implicated in 
recurrent depression (Bobińska et al., 2016). 
Several studies provide evidence for the ECM remodelling in mood disorders. 
Serotonergic receptor 5-HT7 forms a protein complex with CD44, a substrate for 
MMP9 cleavage in neuronal cells; cleavage of CD44 engages Cdc42 to regulate 
LTP, synaptogenesis and dendritic spines structure (Bijata et al., 2017). 
Stimulation of the 5-HT7 receptor increases MMP9 activity which triggers 
dendritic spine remodelling (Bijata et al., 2017). Synaptic abnormalities are 
associated with mood disorders. ECM molecules play an important role in 
synaptic regulation during development and adulthood and may be involved in 
the synaptic dysregulation, disruption of axonal guidance, neuronal 
differentiation, and axonal signal conduction and the regulation of blood brain 




3.4.6.3 Synaptic genes 
Several synaptic genes were altered by VPA in the RNA-Seq analysis. Synapsin 
genes SYN1 (LFC of 1.2, padj 4.8e-3) and SYN2 (LFC of 2, padj 6e-7) were 
upregulated by VPA. The synapsins are highly expressed neuron-specific 
phosphoproteins which regulate the synaptic vesicle formation. They are 
involved in synaptic function, maintenance and plasticity; Reduction in SYN1A, 
SYN2A and SYN3A gene expression has been observed in BD and SCZ patients 
(Vawter, 2004; Vawter et al., 2002). SYN2 is upregulated in the prefrontal cortex 
of BD post-mortem brains (Cruceanu et al., 2012). Mood stabilizers affect the 
expression of synapsin genes. SYN2 is modulated by lithium treatment in LCLs 
of lithium responders and the neuronal cell line SK-N-AS and is limited to 
neuronal cells, not astrocytic and glial cells (Cruceanu et al., 2012). SYN1 is 
increased by lithium in the striatum whereas both lithium and VPA increased 
SYN2A in the hippocampus and prefrontal cortex, and SYN2B in the 
hippocampus and striatum in rats (Joshi et al., 2018). 
SYNDIG1 (LFC of -1.3, padj 1.4e-4) was downregulated by VPA. It regulates the 
development of excitatory synapses through AMPA receptor (Kalashnikova et 
al., 2010).  
SNAP25 (LFC of 2.2, padj 5.1e-8) and SNAP91 (LFC of 2.4, 2.2e-16) were 
upregulated by VPA. Soluble NSF attachment protein or synaptosomal-
associated protein (SNAP) is synaptic protein involved in neurotransmitter 
release through membrane fusion and exocytosis as SNARE-NSF-SNAP 
complex. These also have non-SNARE roles. SNAP25 plays an essential role in 
the negative regulation of voltage-gated Ca++ channels (Sheng & Leenders, 2009). 
Variants in SNAP25 are implicated in BD and SCZ (Etain et al., 2010; Fatemi et 
al., 2001; Houenou et al., 2017; Scarr et al., 2006; Thompson et al., 1999). Proteomic 
analysis of postmortem brain of BD patients showed altered levels of SNAP25 in 




Brodmann’s area 9 (Pennington et al., 2008). SNAP91 is associated with the 
transport of clathrin-coated vesicle cycle, and has been associated with a splicing 
QTL in SCZ patients (Takata et al., 2017). 
Neurogranin (NRGN) (LFC of 2.6, padj 4.4e-11) was upregulated by VPA. It is a 
postsynaptic calmodulin-binding protein and primarily brain expressed, 
especially in dendrites. It is a PKC substrate and it is involved in synaptic 
plasticity and LTP (Huang et al., 2007). Polymorphisms in NRGN are associated 
with SCZ, BD and MDD in Han-Chinese population (Wen, Chen, Khan, Wang, 
et al., 2016). The NRGN SNP rs12807809 is associated with the severity of 
psychosis in SCZ (Sudesh et al., 2017) and has been identified as a risk variant in 
BD in two cross-phenotype studies (Steinberg et al., 2012; Williams et al., 2010). 
Thus, it is a shared susceptibility gene for BD, MDD and SCZ.  
3.4.6.4 Neuronal genes 
Several genes involved in neuronal functions such as LINGO1 (LFC of 2.4, padj 
3.7e-10), NOTCH3 (LFC of 1.7, padj 1.3e-5), SHANK3 (LFC of 1.8, padj 6.7e-6) 
were upregulated by VPA. LINGO1 gene encodes for a protein which is involved 
in several key neuronal processes such as inhibition of axonal regeneration, 
oligodendrocyte differentiation and axonal myelination (Ansar et al., 2018).  
NOTCH3 is regulated by VPA (Yuan et al., 2009), and mutations in NOTCH3 
cause cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy (CADASIL) which manifests in some BD II patients 
(Wang, Li, et al., 2017). The notch signalling pathway has been shown to be 
altered in BD and SCZ and could be rescued with lithium treatment (Wang, Ren, 
et al., 2015). 
SHANK3 encodes the SH3 and multiple ankyrin repeat domain 3 scaffold 
protein, which regulates the density and plasticity of the excitatory synapse. 




behaviour which can be rescued with VPA treatment (Han et al., 2013; Lee et al., 
2018). Mutations in SHANK3 are associated with ASD (Durand et al., 2007).  
Nerve growth factor receptor (NGFR) (LFC of 2.4, padj 1.8e-19) was upregulated 
by VPA. Neurotrophins are involved in the growth, differentiation and survival 
of neurons, and regulate synaptic neurotransmission and synaptic plasticity. 
Impaired neuroplasticity and altered levels of neurotrophins are implicated in 
BD and other psychiatric disorders. A nominal association of NGFR is seen in BD 
suicide patients (Perlis et al., 2010). Multiple SNPs in NGF and NGFR are linked 
to SCZ and may be involved in the regulation of synaptic plasticity (Zakharyan 
et al., 2014). BDNF augments the neurogenic potential of NGFR (Young et al., 
2007). Missense mutations in the receptor are linked to depression and suicide 
(Kunugi et al., 2004).  
3.4.6.5 Neuregulin 1/Erbb signalling 
ERBB3 (LFC of 2, padj 3.4e-13) and NRG1 (LFC of 1.5, padj 4.8e-6) were 
upregulated by VPA. Neuregulins activate Erbb receptors. Nrg/Erbb signalling 
is important for circuitry generation, peripheral myelination, synaptic plasticity 
and neurotransmission. NRG1-ErbB3 signalling can increase hippocampal 
neurogenesis and produce antidepressant-like effects (Mahar et al., 2011). 
Heterozygous and transgenic overexpressor mouse models of NRG1 exhibit 
behavioural deficits and synaptic dysfunctions (Burne et al., 2010; O'Tuathaigh 
et al., 2010; Papaleo et al., 2016). NRG1 is a known susceptibility gene for SCZ 
(Mostaid et al., 2016) and has also been linked to BD (Georgieva et al., 2008; 
Walker et al., 2010). It is associated with SCZ, BD and MDD in Han Chinese 
population (Wen, Chen, Khan, Song, et al., 2016). VPA can rescue behavioural 
deficits in NRG1-deficient mice (Pei et al., 2014). AKT1 is a downstream kinase of 
Nrg1 signalling pathway and is known to be regulated by both VPA and lithium 
through GSK-3β (Gupta et al., 2012). Chronic treatment with antipsychotics alter 




and hippocampus (Wang et al., 2008). This suggests that upregulation of 
Nrg/Erbb pathway by VPA may contribute to its mood stabilization effects.  
3.4.6.6 CRMP1 
In my dataset, VPA upregulated collapsin-response mediator protein 1 (CRMP1) 
(LFC of 2, padj 9.2e-7). CRMP1 is involved in semaphorin-3A signalling in 
neurodevelopment. It stabilizes cytoskeleton through microtubule assembly and 
affects F-actin polymerization. CRMPs are differentially expressed in neuronal 
cells undergoing neurogenesis and are downstream targets of GSK-3β. It has 
been shown to be associated with BD status and mood symptom severity, and 
lithium downregulated CRMP1 in the olfactory neuroepithelium of BD patients 
(McLean et al., 2018). CRMP1 has been shown to be differentially expressed in 
BD and SCZ patients (Tajinda et al., 2010). A closely related gene, CRMP2 has 
been shown to be downregulated by lithium in iPSCs from BD responders, 
however, VPA treatment had no effect (Tobe et al., 2017). CRMP1 knockout mice 
show hyperactivity and impaired emotional response (Yamashita et al., 2013). 
This suggests that CRMP1 may be involved in mood stabilizing properties of 
VPA. 
3.4.6.7 VGF 
VGF (non-acronymic) (LFC of 3.3, padj 1.1e-24) was upregulated by VPA and 
this gene encodes for nerve growth factor-inducible neurosecretory protein 
which regulates synaptic plasticity. This gene is regulated by antidepressants 
(Thakker-Varia et al., 2007), and has been shown to be essential to the mood 
stabilizing effects of lithium in mouse hippocampus (Thakker-Varia et al., 2007). 
VGF levels are reduced in the hippocampus and Brodmann’s area 9 of the 
postmortem BD brain samples (Thakker-Varia et al., 2010). Additionally, VGF is 
upregulated in neuropathic pain and VPA has been shown to be effective in 
neuropathic pain (Gill et al., 2011). This suggests that VGF may be important for 





Ankyrin-3 (ANK3) (LFC of 0.7, padj2.2e-2) was upregulated by VPA. It encodes 
for the ankyrin G scaffold protein, which localizes and maintains ion channels 
and cell adhesion molecules at the axonal initial segment and nodes of Ranvier 
(Hedstrom et al., 2008). It can regulate myelination (Ching et al., 1999) and 
neurogenesis (Paez-Gonzalez et al., 2011) in adult brains. Reduced anxiety-like 
behaviour is seen in Ank3+/- heterozygous mice which can be rescued with 
chronic lithium treatment (Leussis et al., 2013). ANK3 SNP rs9804190 is associated 
with lower white matter structural integrity (Lippard et al., 2016). These results 
suggest a potential role of ANK3 in mood biology.  
3.4.6.9 Sepiapterin reductase 
Sepiapterin reductase (SPR) was not altered by VPA and lithium in RNA-Seq 
analysis. BH4 is an important cofactor in the biosynthesis of monoamines- 5-HT, 
NE and DA and SPR is the key enzyme in this pathway. It is suggested to be 
linked to mood disorders and antidepressant response (McHugh et al., 2009). 
SPR is upregulated in the prefrontal cortex of BD and SCZ patients (Iwamoto et 
al., 2005). It has been investigated in our laboratory in response to lithium and 
VPA and has been shown to be upregulated by VPA both in vitro and in vivo 
analysed with RT-qPCR (Balasubramanian et al., 2015; Deng, 2011; McHugh et 
al., 2009; McHugh et al., 2008). However, prior RNA-Seq (Balasubramanian, 
2015) and current RNA-Seq analyses failed to detect its differential expression 
and the reason maybe low levels of expression in RN46A cells.  
3.4.7 Comparison with prior RNA-Seq study 
A prior pilot RNA-Seq study was carried out in our laboratory with VPA in 
undifferentiated RN46A cells with the same concentration and exposure time 
(Balasubramanian, 2015). Extensive gene expression changes were observed 




undifferentiated RN46A cells. At LFC >1.5 and padj <0.05, 225 DEGs were 
identified in my study, whereas only 39 DEGs were identified in the prior RNA-
Seq. Comparison of these 224 vs 39 DEGs revealed 14 genes from my RNA-Seq 
analysis overlapped with the prior RNA-Seq analysis. These include MMP13, 
ZCCHC12, SERPINB2, CCR1, MMP12, ARG2, NTS, FLRT3, SERPINE1, SLC40A1, 
MUM1L1. MAOB, LYNX1 and TRIM16. This suggests VPA upregulates these 
genes irrespective of the cell state, and provides added confidence that the 
observed effects are robust and reproducible. 
ECM re-modelling is implicated in BD and SCZ. Cell adhesion genes were most 
differentially regulated in response to VPA in my RNA-Seq data, and matrix 
metalloproteinases were some of the highly upregulated genes by VPA. The 
same trend was seen in earlier RNA-Seq study of VPA-treated undifferentiated 
RN46A cells. This suggests these core genes in RN46A precursor cells change in 
response to VPA, and in vivo such changes (should they occur), may be involved 
in regulating synaptic plasticity.  
3.4.8 Comparison with GWAS studies 
To find if any of the VPA-regulated genes overlapped with BD GWAS hits, SNPs 
with known gene associations were compared with the DESeq2 DEG list. A total 
of 47 VPA-regulated genes overlapped with 544 genes from BD GWAS. ANK3 
was upregulated by VPA and is one of the first genes to be identified in BD 
GWAS (Ferreira et al., 2008; Schulze et al., 2009) and has been replicated in other 
BD GWAS (Ament et al., 2015; Roby, 2017). It is a common approach to find 
overlap between top GWAS hits and known drug target genes. GWAS often 
contain numerous loci with small effect sizes and most of these lie within the 
non-coding regions. This makes it difficult to predict the effect of the SNPs on 
gene expression. Due to the differences in sample sizes, model choices (in vivo vs 




studies. However, some genes appear common among different studies 
suggesting a crucial role for these in disease pathology. Our comparison of VPA-
regulated DEGs to the published GWAS studies revealed several interesting 
genes such as ANK3, DPYD, IGF2 and MAP7 which might be relevant to mood 
biology. Regulation of such genes by VPA therefore seems particularly relevant 
to potential therapeutic actions of this drug. 
3.5 Summary of the chapter 
Mood stabilizers lithium and VPA have been used to treat BD for more than 60 
years, but I do not understand their therapeutic effects. To examine the global 
effect of these drugs on gene expression, we performed RNA-Seq analysis of 
lithium and VPA in the serotonergic cell line RN46A which represents a relevant 
model for the neurologic effects of these drugs. RNA-Seq analysis with four 
different bioinformatics tools yielded no gene expression changes with lithium.  
VPA treatment resulted in extensive gene expression changes. Pathway analysis 
of ~700 upregulated and ~200 downregulated genes revealed nervous system 
development and other key neuronal processes and pathways relevant to mood 
disorders. Some of the significant genes have been implicated in candidate gene 
studies and GWAS in BD, MDD and SCZ. This suggests that the genes regulated 






Chapter 4  
Gene expression of a subset of VPA 
regulated genes with nCounter® assay 
 
In the previous chapter, RNA-Seq analysis of RN46A cells treated with VPA 
(0.5mM) yielded 224 DEGs (DESeq2) and none with lithium (0.5mM). Most of 
the VPA-regulated genes have known biological significance and some of these 
are also linked to BD and SCZ. As described in Chapter 3, pathway analysis 
highlighted important pathways and genes key to those.  
In the current chapter, I present the gene expression analysis of 24 VPA-
regulated genes using the nCounter® assay. These genes were selected for 
validation based on their statistical and biological significance. No gene 
expression changes were observed with lithium in RNA-Seq analysis so the 
concentration was increased and the shortlisted genes were analysed for 
expression changes with increased concentrations of lithium. Lamotrigine, 
another mood stabilizer effective for bipolar depression (Bowden et al., 1999) was 
also studied for its potential effects on expression of the shortlisted genes.  
4.1 Introduction 
There are two main ways to validate RNA-Seq results. The traditional and 
widely used method is real time quantitative reverse transcription PCR (RT-
qPCR) and another new method gaining traction is targeted transcriptomics with 
NanoString platform (Geiss et al., 2008). nCounter® gene expression assay is a 
highly sensitive alternative to RT-qPCR. It is a quantitative approach that 




amplification is required so it works well with low quantities of RNA and has a 
low background signal. The automated platform uses fluorescent probes that 
hybridize directly to the RNA from target genes. The tripartite complexes of 
reporter probe-target gene-capture probe is immobilized to cartridges and 
analysed with the nCounter® platform, a digital Analyzer which performs 
image acquisition and data processing. Expression of a gene is measured directly 
by counting the number of gene-specific barcodes. These barcodes are tabulated 
as raw counts and analysed with NanoString’s custom nSolverTM package or R 
tools such as NanoStringDiff among others.  
In this chapter, I describe the use of the NanoString nCounter® analysis system 
to validate the VPA-regulated genes. nCounter® assays are available in pre-
designed or custom made formats. For this thesis, nCounter® GX Custom 
CodeSet was designed for 26 genes in 48 samples. 
4.2 Methods 
4.2.1 Allen Brain Atlas 
ABA mouse brain atlas (Lein et al., 2007), a genome-wide 3-D gene expression 
atlas of adult mouse brain, and ISH database was used to examine the expression 
profiles of prioritized genes in the dorsal raphe of brainstem and medullary 
raphe of hindbrain as described in the section 2.2.9. Briefly, for each of 24 genes, 
ISH data from sagittal sections corresponding to the medullary and dorsal raphe 
were downloaded. Coronal images were obtained in case sagittal images were 
unavailable. 
4.2.2 Genotype-Tissue Expression (GTEx) database 
Genotype-Tissue Expression (GTEx) database (https://gtexportal.org/) is an 




53 different tissues from 714 donors (Carithers et al., 2015). It also contains 
histological and clinical information about theses tissues. Its goal is to discover 
the effect of genetic variation on tissue-specific gene expression in the context of 
normal tissues and apply the information to study disease-specific genetic 
regulation. It maps correlations between SNPs and RNA-Seq expression levels 
across different tissues and represents them as shared expression quantitative 
trait loci (eQTL). GTEx v6 (phs000424. v6. p1) database was used to evaluate the 
brain expression of prioritized genes using RPKM values from RNA-Seq studies 
which included 13 brain tissues, from 714 donors. Expression images containing 
RPKM values from RNA-Seq experiments were downloaded from the GTEx 
portal (on 19/04/2017 and 27/04/2017). Genes which showed expression in the 
brain regions were included for validation. 
4.2.3 Cell culture and NanoString assay 
Differentiated RN46A cells were exposed to lithium, VPA and LTG for 72 hours 
as described in section 2.2.2. In the original experiment (Chapter 3), lithium 
exposure failed to show any significant DEGs in the RNA-Seq analysis. Other 
studies have used higher concentrations of lithium in cell culture experiments 
(Cruceanu et al., 2012; Tobe et al., 2017). No change in synapsin 2a mRNA levels 
was observed at 0.5mM lithium in SK-N-AS neuronal cell line, however, at 1.0 
and 2.0 mM, synapsin 2a mRNA levels increased (Cruceanu et al., 2012). This 
suggested 0.5mM lithium might be too low for RN46A cells to elicit a response. 
Therefore, lithium concentration was increased from 0.5mM (as used in the 
RNA-Seq experiments) to 1mM in the first nCounter® run (Run1) and 2mM in 
the second nCounter® run (Run2).  
Figure 4.1 and Figure 4.2 show the experimental design of cell culture used in 
this chapter and the corresponding nCounter® assay. A custom CodeSet, 




by NanoString Technologies, Inc. (Seattle, Washington, USA). This CodeSet was 
used for both runs (Run1 and Run2). For Run1, total RNA from four independent 
cell culture experiments was extracted with Zymogen RNA miniprep column as 
described in section 2.2.3.2. This total RNA was sent to New Zealand Genomics 
Limited (Dunedin, New Zealand) for nCounter® mRNA gene expression assay, 
and raw and normalized mRNA counts were returned to us for analysis. 
 
 
Figure 4.1 Cell culture design and nCounter® gene expression assay for 
Run1. Differentiated RN46A cells were exposed to 1mM lithium, 0.5mM VPA, 
0.5mM VPD, 30nM TSA, 50uM LTG and 0.5% DMSO for the control. Four 
replicates cell culture plates were used. 100nM total RNA was mixed with the 
custom CodeSet; reporter and capture probes hybridized to the target and 
optical barcodes were read by the digital analyser. Greyed out circles for VPD 
and TSA were not included in the nSolver™ analysis in this chapter and were 





During the RNA-Seq experiments (Chapter 3) and NanoString analysis Run1, it 
was observed that the cell culture medium was somewhat limited with some 
acidity of the medium apparent by the end of the 72 hr exposure period. 
Therefore, the volume of the medium used was doubled for Run2. In addition, 
Run2 was carried out 10 months after Run1. 
For Run2, total RNA was extracted from three independent experiments as 
described in section 2.2.3.2. Total RNA was sent to New Zealand Genomics 
Limited (Dunedin, New Zealand) for nCounter® mRNA gene expression assay 
with the same CodeSet used in Run1, and raw and normalized mRNA counts 






Figure 4.2 Cell culture design and nCounter® gene expression assay for 
Run2. Differentiated RN46A cells were exposed to 2mM lithium, 0.5mM VPA, 
0.5mM VPD, 30nM TSA, 50uM LTG and 0.5% DMSO for the control. Three 
replicate cell culture plates were used. 100nM total RNA was mixed with the 
custom CodeSet; reporter and capture probes hybridized to the target and 
optical barcodes were read by the digital analyser. Greyed out circles for the 
VPD, TSA, CI994, RGFP966, PC34051 and TubaA were not included in the 
nSolver™ analysis in this chapter and were analysed separately in chapter 5. 
 
 
4.2.4 Normalization of nCounter® data 
For normalization of positive controls and housekeeping genes, use of a 
geometric mean is advised by NanoString. For normalization of negative 
controls, the choices are mean, median and geometric mean. I looked at the effect 
of normalization of negative controls with mean and geometric mean options. 
Normalization with mean can be done with two standard deviation (SD) or three 
SD. Mean with three SD increases the stringency, reduces false positives, but 




across different negative control normalization methods, it was observed that 
the normalization method employed had no effect on differential expression 
result of genes with higher expression (average mRNA counts >1000). However, 
genes with average mRNA counts in the range 100-500 had decreased 
normalized counts with mean + three SD, and low expressed genes such as IGF2, 
SHANK3, and ERBB3 were affected the most. Therefore, mRNA counts were 
normalized with a geometric mean of positive controls, geometric mean of 
negative controls and geometric mean of housekeeping genes.  
4.2.5 NanoString data analysis with nSolverTM 
Raw and normalized mRNA counts for each gene were provided by NZGL 
(Dunedin, New Zealand) in reporter code count (RCC) files which were 
uploaded to the analysis software, nSolverTM v3.0. First quality control of raw 
counts was performed, followed by normalization of counts and differential 
expression analysis with Welch’s t-test. Quality control checks were done with 
nSolverTM for imaging and binding density. All the samples passed the QC check.  
Reporter probes were designed against six positive and eight negative 
hybridisation controls and were pre-mixed in the CodeSet. The positive controls 
normalize platform associated variance and negative controls estimate non-
specific background in the CodeSet. Normalization is essential to control for 
gene expression variation across samples and any batch variations, and is 
required for accurate and reliable interpretation of differential gene expression 
analysis. NanoString uses low RNA quantity so proper normalization against 
internal reference genes can control for differences in mRNA content and sample 
preparation. Two or more housekeeping genes are recommended for 
normalization. Housekeeping genes are selected based on the stability of their 
expression under the condition studied. In a previous study done in our 




measured in response to 1mM lithium and 0.5mM VPA, among other drugs, for 
the cell line RN46A (Table 4.1) (Balasubramanian, 2015). EXOC7, G6PD and 
MAPK6 were chosen as housekeeping genes based on highest stability values 
from this study. During the nCounter® custom CodeSet design process, probes 
showing homology with only the target gene sequences were chosen and any 
probe showing potential homology with another transcript was removed. 
EXOC7 was initially chosen as a housekeeping gene, but removed because it 
showed homology with other EXOC7-like transcripts.  
 
Table 4.1 The effect of treatment of mood stabilizer drugs on reference gene 
stability in RN46A cells. 









1Table adopted from (Balasubramanian, 2015). RN46A cells were exposed to 
0.5mM VPA, 1mM lithium, 50 μM CBZ, 80 μM LTG, 1 mM sodium butyrate, 3 
nM TSA, 0.5 mM VPD and 1 μM 5'aza-dC for 72 h. Gene expression levels of 
the candidate reference genes were tested using the NormFinder software. 
Table shows the stability value generated by the software for the genes tested. 
 
Log2 fold-change and p-values were generated with nSolverTM. For differential 
expression (DE) analysis, a one-tailed heteroscedastic Welch’s t-test was used by 
nSolverTM. Box plots were generated for each sample to compare gene expression 
across treatment conditions. For calculating the false discovery rate, Benjamini-




4.2.6 NanoString data analysis with NanoStringDiff 
NanoStringDiff (v 1.8.1) was used for normalization of raw nCounter® data and 
DE analysis (Wang, Horbinski, et al., 2016). It uses empirical Bayes shrinkage to 
estimate dispersion parameters and model counts as a negative binomial 
distribution, then applies a GLM maximum likelihood ratio test for DE analysis 
and chi-square approximation for calculating p-values. The Benjamini-Hochberg 
method was used for calculating FDR (Benjamini & Hochberg, 1995). First a 
design matrix was created using the nCounter® raw counts and a NanoStringSet 
object was created for normalization. Normalization was done with 
estNormalizationFactors and a two group comparison (VPA vs control) was 
done for DE analysis using the GLM maximum likelihood ratio test. 
4.2.7 Comparison of nCounter® and RNA-Seq gene expression 
To compare the nCounter® gene expression with RNA-Seq, correlation matrix 
was generated using the R package performanceAnalytics. Log2 fold change 
values for each gene from nCounter® expression data were plotted against log2 
fold change obtained with each DEG tool.  
4.3 Results 
4.3.1 Shortlisting of genes 
As described in Chapter 3, four software packages were used for RNA-Seq 
analysis: DESeq2 (Love et al., 2014), kallisto (Bray et al., 2016), cufflinks2 (Trapnell 
et al., 2012; Trapnell et al., 2010) and salmon (Patro et al., 2017). The first step was 
to filter the DEG lists for log2 fold change (log2FC) > 1.5 and low p-values. The 
next selection criterion was that the DEGs should be consistently apparent across 
the four DEG lists. To extract biological meaning from the filtered DEG lists, 




DEG lists. Functional enrichment and pathway analysis of both these DEG lists 
highlighted the important pathways and genes involved. These genes were 
further searched across BD GWAS and candidate gene studies and genes 
implicated in BD/SCZ studies were selected. Expression of filtered DEGs in 
GTEx database and the ABA ISH database was evaluated and brain-expressed 
genes were selected. Genes were also included if they were shown to be 
regulated by VPA in preclinical studies. In a previous RNA-Seq study in our 
laboratory, undifferentiated RN46A cells treated with same VPA concentration 
and exposure time yielded in 39 DEGs (LFC >1.5 and FDR < 0.05) 
(Balasubramanian et al., 2019). DEGs were also selected for validation if they 
matched with this prior RNA-Seq study. This helped prepare a short list of DEGs 
for validation with NanoString assay, the format of which was limited to a 
maximum of 26 genes, including controls. ABA and GTEx expression analysis is 
described in the following sections.  
One exception to the above criteria was that 6/24 (ADGRB2, CACNA1B, CNTN1, 
IGF2, LZTS1 and SHANK3) genes were not present in all four DEG lists but were 
judged to be biologically significant so were shortlisted for validation. SPR was 
added to this list due to this laboratory’s prior interest in the gene, and despite 
the lack of significance for SPR in both prior RNA-Seq (Balasubramanian, 2015) 
and current RNA-Seq analyses, It was included in this nCounter® assay to detect 
its expression at an increased resolution. 
4.3.1.1 Shortlisted genes 
The shortlisted genes selected for validation are listed in Table 4.2. FDR adjusted 
p-value (q-val) and log2 FC from kallisto DEG list is shown here for all genes 
except CACNA1B and IGF2. These two genes were absent in the kallisto DEG list 
so corresponding values are listed from the DESeq2 DEG list. IGF2 had high 
log2FC with the lowest p-values in the DESeq2 DEG list. CACNA1B, a calcium 




LZTS1 and SHANK3 also had biological significance, so these genes were 
included in the final list despite of not being present in all the four DEG lists. 
Brief descriptions of known biological roles of each gene are indicated and 
relevance to BD, as well as reasons for inclusion according to my prioritization 
criteria. This table also indicates whether the gene was detected in a previous 
RNA-Seq study from our laboratory (Balasubramanian et al., 2019).  
ABA and GTEx query was carried out for all 24 genes and corresponding 
expression data for the 18 brain-expressed genes are listed in Table 4.3 as per 
ABA’s citation policy. The expression data for remaining six genes are added as 






Table 4.2 Selected genes for validation with NanoString assay.  














ADAM23 6.5E-14 2.3 Is involved in cell-
cell and cell-matrix 
interaction including 
neurogenesis 
Epilepsy (Koskinen et al., 
2017; Owuor et al., 2009), 
upregulated by VPA (Guest, 
2015) 
1,2,3,4 Y Y Y Y 
ADGRB2 1.3E-29 2.5 Brain-specific 
inhibitor of 
angiogenesis 
SHANK3-related 1,2,3 Y Y Y Y 
CACNA1B 3.0E-14 2.3 Calcium channel 
gene 
BD (Ament et al., 2015; 
Moskvina et al., 2009; 
Pedrosa et al., 2010) ,  
CACNA1C-related 
2,3,4 Y Y Y Y 
CDKN1C 7.2E-03 2.2 Imprinted gene that 
encodes a cell cycle 
inhibitor 
TSA upregulated 
(Blagosklonny, Yang, et al., 
2009) 
1,2,3,4 Y Y N N 
CNTN1 9.7E-03 1.6 Neuronal growth 
cones and axon 
guidance 
VPA upregulated (Guo et al., 
2014)  
BD (Anderson et al., 2018) 
and SCZ (Behan et al., 2008) 
1,2,4 Y Y Y Y 
ERBB3 1.8E-11 1.6 Encodes a member of 
EGFR family 
BD (Le-Niculescu et al., 2009). 
 SCZ susceptibility gene 
(Aston et al., 2005) 
1,2,3,4 Y Y N N 




VPA mediated miR-124 
downregulated (Oikawa et 
al., 2015; Sng & Oikawa, 
2016) 





















IGF2  5.9E-36 4.2 Imprinted gene 
involved in growth 
and development 
Lowest p-value (DESeq2) 
and high log2 fold change 
(Table 3.5) 
2,4 N Y N N 
LINGO1 1.9E-07 2.2 Inhibitor of neurite 
outgrowth 
SCZ (Fernandez-Enright et 
al., 2014) 
1,2,3,4 Y N Y Y 
LSP1  9.0E-15 -2.3 Encodes intracellular 
F-actin binding 
protein 
Depression (Hennings et al., 
2015) 
1,2,3,4 N Y Y Y 
LZTS1 8.1E-10 3.6 Cell cycle regulation, 




 SCZ (Chatziioannou, 2016) 1,2,3 Y Y Y N 
MAOB 1.5E-05 1.8 Metabolism of 
neuroactive and 
vasoactive amines 
Antidepressants (Finberg & 
Rabey, 2016) 
 
1,2,3,4 Y Y N Y 
MMP13  7.9E-26 1.8 Brain-expressed 
protein involved in 
extracellular matrix 
degradation 
Upregulated by VPA in 
RNASeq (Balasubramanian 
et al., 2019)  
1,2,3,4 N N Y Y 























NGFR 6.5E-16 1.8 Regulates clock 
genes, survival/death 
of neural cells 
SCZ (Zakharyan et al., 2014) 
BD (Perlis et al., 2010), 
Lingo-1 related (Meabon et 
al., 2015) 
1,2,3,4 N Y Y N 
NOTCH3  2.5E-03 1.7 Notch signalling, 
neural development 
VPA activates Notch 
pathway (Yuan et al., 2009) 
1,2,3,4 N Y N N 




Mental retardation (Rejeb et 
al., 2008), 
SCZ (Kim et al., 2016) 
1,2,3,4 Y Y Y Y 
SERPINB2  8.7E-08 1.6 Serine protease 
inhibitor with 
cytoprotective 
properties in neurons 
Upregulated by VPA in 
RNASeq (Balasubramanian 
et al., 2019)  
synaptic activity-induced 
neuroprotection (Zhang et al., 
2009) 
SCZ (Drexhage et al., 2010) 
1,2,3,4 N Y N N 
SHANK3 4.7E-02 1.6 Major scaffold 
protein that supports 
connections between 
neurons; formation 
and maturation of 
dendritic spines 
BD (Alexandrov et al., 2017) 
VPA rescued mania-like 
behaviour in SHANK3 
duplication mice (Han et al., 
2013) 
1,2,4 Y Y N N 
SNAP91 4.9E-08 2.2 Transport clathrin-
coated vesicles 
Mood-incongruent psychotic 
features in BD and SCZ 
(Goes et al., 2012) 



















VGF 5.9E-10 3.1 Regulates synaptic 
plasticity 
Decreased in BD post- 
mortem brains (Thakker-
Varia et al., 2010) 
1,2,3,4 Y Y Y Y 
WNT6 2.3E-14 2.0 Wnt signalling 
pathway 
Wnt pathway linked to 
lithium and VPA-treatment 
(Boku et al., 2014; Wexler et 
al., 2008) 
1,2,3,4 Y Y N N 
ZCCHC12 2.3E-20 1.9 Wnt signalling 
pathway 
Upregulated by VPA in 
RNASeq (Balasubramanian 
et al., 2019)  
1,2,3,4 Y Y Y Y 
SPR2     BH4 biosynthetic 
pathway 
Upregulated by VPA in 
RNASeq (Balasubramanian 
et al., 2019)  
- Y Y N Y 
1 DEG lists column wherein 1 refers to kallisto, 2 is DESEq2, 3 is salmon and 4 is cuffdiff2. 
2SPR was found to be upregulated by VPA in prior work in our laboratory but was not observed in our RNA-Seq analysis. 




4.3.1.2  Allen Brain Atlas 
Brain expression of the shortlisted DEGs was analysed in ABA adult mouse ISH 
database. Online query was done as described in section 2.2.9. Sagittal (Figure 4.3) and 
coronal (Figure 4.4) reference images were downloaded from the adult mouse 
reference atlas along with the respective ISH image for each gene. The serotonergic 
cell line RN46A used in this thesis is derived from the medullary raphe (MR) (White 
et al., 1994). The dorsal raphe (DR) nuclei also contain serotonergic neurons so this 
area was selected for expression evaluation as well. Genes with expression in the ABA 
ISH database, either in DR or MR or both, were selected for validation. Reference atlas 
images in Figure 4.3 and Figure 4.4 show the location of DR and MR in sagittal and 
coronal sections respectively. ABA ISH images are presented together with GTEx 
expression images in Table 4.3 to allow comparison and evaluation of these results. 
The coronal section was preferably chosen for each gene and when not available, the 
sagittal section was used. The results are also summarized in which show the 
expression of each gene in the brain. 
4.3.1.3 GTEx 
ABA mouse ISH data overlapped with human GTEx data for all genes except WNT6 
because the corresponding ISH images were not clear. Eighteen out of 24 shortlisted 
genes were expressed in the brain. Six of these ADGRB2, CACNA1B, LINGO1, 
SNAP91, VGF and ZCCHC12 were primarily expressed in the brain. Eleven genes were 
expressed in the medullary raphe including ADAM23, ADGRB2, CNTN1, GNAI1, 
LZTS1, MAOB, MPP3, PAK3, SNAP91, VGF, and ZCCHC12. Some of the genes such 
as ADGRB2, CACNA1B, CNTN1, MAOB, SHANK3 and SNAP91 had higher expression 






Figure 4.3 Location of the dorsal raphe (DR) and medullary raphe magnus (RM) in mouse brain (sagittal view).  The figure 
shows a modified output from a digital atlas with the neuroanatomical structures from ABA mouse atlas, showing the location of 





Figure 4.4 Location of the dorsal raphe (DR) and medullary raphe magnus (RM) in 
mouse brain (coronal view).  The figure shows a modified output from ABA mouse 
brain atlas, showing the location of DR and RM in coronal brain section (arrowed). 
The left panel shows the Nissl-stained brain section scanned at 10X, 0.95µm/pixel 
and the right panel shows the digital atlas with the neuroanatomical structures. 






Table 4.3 GTEx expression data and ABA ISH images for the 18 brain-expressed genes out of 24 shortlisted genes. 

















































































































4.3.2 nCounter® data analysis results  
4.3.2.1 VPA 
Raw counts from the nCounter® analysis system were analysed with nSolverTM 
and NanoStringDiff for both Run1 and Run2. Log2 fold change and p-value for 
each gene are listed in Table 4.4 for Run1 and Table 4.5 for Run2, respectively. 
Eight genes appeared as VPA DEGs in both Run1 and Run2 for both analysis 
methods. These were SNAP91, ADAM23, LSP1, ZCCHC12, PAK3, WNT6, MAOB 
and MMP13 in increasing p-value order. NanoStringDiff listed more genes as 























SNAP91 143.26 ± 9.77 230.51 ± 11.62 0.69 1.0E-04 0.7 1.3E-02 
ADAM23 1.31 ± 0.41 7.14 ± 1.47  2.47 2.0E-04 26.47 7.5E-03 
CDKN1C 46.70 ± 6.01 135.59 ± 6.73 1.55 2.0E-04 1.6 3.7E-07 
VGF 22.73 ± 6.45 111.87 ± 33.3 2.3 6.0E-04 2.44 8.4E-10 
MPP3 27.87  ± 4.23 78.36  ± 17.39 1.47 7.0E-04 1.59 9.7E-06 
LSP1 167.31  ± 5.19 87.86  ± 11.24 -0.94 2.1E-03 -0.96 1.2E-03 
ZCCHC12 33.68  ± 9.89 86.28  ± 7.44 1.41 5.2E-03 1.47 3.1E-05 
PAK3 93.46  ± 19.31 176.60  ± 34.48 0.92 7.3E-03 0.94 3.5E-03 
LINGO1 3.38  ± 1.27 13.86  ± 2.3 2.17 1.1E-02 7.18 5.6E-05 
WNT6 1.91  ± 0.78 5.77  ± 2.17 1.6 2.2E-02 24.83 7.9E-02 
MAOB 15.09  ± 3.55 24.15  ± 2.79 0.72 4.1E-02 0.84 6.1E-02 
MMP13 2652.46  ± 
964.2 
4593.43  ± 
784.9 
0.85 4.4E-02 0.79 1.8E-02 
SERPIN2B 12.37  ± 4.63 22.20  ± 5.18 0.92 6.9E-02 0.94 5.0E-02 
ERBB3 118.14  ± 22.07 157.60  ± 25.59 0.42 8.9E-02 0.43 1.7E-01 




NGFR 7.90  ± 4.97 13.99  ± 2.31 1.16 1.5E-01 0.96 1.1E-01 
SPR 17.95  ± 7.26 27.53  ± 9.01 0.66 1.5E-01 0.67 1.4E-01 
LZTS1 1.91  ± 0.78 1.10  ± 0.15 -0.67 1.7E-01 -23.42 3.2E-01 
ADGRB2 8.93  ± 4.76 12.53  ± 2.23 0.68 2.4E-01 0.49 4.2E-01 
IGF2 2.66  ± 1.88 1.19 ± 0.17 -0.83 2.4E-01 22.17 4.8E-01 
NOTCH3 3.49  ± 2.36 6.22  ± 2.99 1.03 2.9E-01 21.65 1.3E-01 
SHANK3 13.88  ± 7.86 22.50  ± 4.72 1.26 2.9E-01 0.73 1.2E-01 
CNTN1 2.44  ± 0.97 3.46  ±01.9 0.36 6.3E-01 23.43 6.1E-01 
GNAI1 1.07  ± 0.11 1.10  ± 0.15 0.04 7.7E-01 0.33 2.6E-01 
G6PD 2930.74  ± 
78.41 
3007.88  ± 
98.64 
    
MAPK6 2460.07  ± 67.3 2397.87  ± 80.7 
    
1 Base mean control and base mean VPA refer to the mean of normalized counts 
from four replicates each of untreated and VPA-treated samples in Run1. Fold 
difference between the untreated (control) samples and samples treated with 
VPA are shown.  Ranked by nSolver™ p-values.  
2Greyed values indicate the significant genes with p-val <0.05. 




Table 4.5 Genes showing significant expression difference after VPA 
exposure (Run2). 





log2FC pvalue2 log2FC pvalue2 
WNT6 26.70  ± 3.42 149.11 ± 
8.65 
1.97 2.0E-04 2.18 1.7E-10 
LSP1 698.88  ± 49.72 286.21  ± 
21.02 
-1.26 3.0E-04 -1.27 4.0E-07 
SERPIN2B 1349.53  ± 
67.66 
2715.63  ± 
182.07 
1 5.0E-04 1 1.1E-05 
MAOB 67.00  ± 11.19 376.47  ± 
23.73 
2.27 1.5E-03 2.35 1.1E-14 
NGFR 64.65  ± 16.67 381.39  ± 
57.17 
2.33 1.6E-03 2.41 1.2E-11 
ZCCHC12 28.09  ± 11.78 198.19  ± 
31.0 
2.35 7.2E-03 2.45 1.0E-09 
NOTCH3 27.59  ± 9.5 118.30  ± 
24.31 
1.64 7.3E-03 1.83 7.4E-06 
ADGRB2 55.48  ± 12.95 241.17  ±  
12.21 
1.88 7.9E-03 1.98 2.1E-09 
MMP13 3312.56  ± 
384.81 
5281.11  ± 
300.02 
0.68 1.4E-02 0.67 5.7E-03 




ADAM23 37.50  ± 15.26 148.26  ± 
27.84 
1.66 1.6E-02 1.76 1.3E-05 
SNAP91 33.98  ± 11.26 89.24  ± 
16.86 
1.07 1.8E-02 1.2 1.9E-03 
GNAI1 1.33  ± 0.25 18.23  ± 
11.98 
3.63 2.3E-02 29.67 4.7E-07 
CACNA1B 1.33  ± 0.25 29.80  ± 
17.19 
2.25 2.8E-02 3.74 2.0E-05 
CNTN1 346.69  ± 58.78 598.86  ± 
67.27 
0.77 2.8E-02 0.78 8.2E-03 
LZTS1 1.33  ± 0.25 12.61  ± 
6.41 
3.54 3.1E-02 23.92 5.3E-07 
ERBB3 1.33  ± 0.25 15.53  ± 
3.41 
3.09 4.6E-02 27.19 5.3E-07 
SHANK3 1.33  ± 0.25 2.18  ± 1.34 2.11 5.9E-02 27.37 3.5E-02 
SPR 25.28  ± 7.08 47.36  ± 
7.44 
0.59 6.1E-02 0.68 8.7E-02 
LINGO1 1.33 ± 0.25 10.72 ± 
11.07 
2.27 6.6E-02 34.66 1.6E-04 
MPP3 3.32 ± 2.80 23.32 ± 
14.69 
1 1.1E-01 1.63 1.2E-02 
VGF 44.57 ± 33.22 123.27 ± 
47.85 
1.31 1.2E-01 1.28 2.5E-02 




CDKN1C 113.15 ± 19.3 133.84 ± 
25.09 
0.18 5.1E-01 0.22 5.1E-01 




    




    
1 Base mean control and base mean VPA refer to the mean of normalized counts 
from three replicates each of untreated and VPA-treated samples in Run2. Fold 
difference between the untreated (control) samples and samples treated with 
VPA are shown.  Ranked by nSolver™ p-values.  
2Greyed values indicate the significant genes with p-val <0.05. 





Lithium-treatment of RN46A cells resulted in no genes being significantly 
changed in RNA-Seq analysis (chapter 3). However, the concentration of lithium 
was increased to 1mM and 2mM in nCounter® Run1 and Run2, respectively, as 
the previous concentration of 0.5mM lithium used in the RNA-Seq experiment 
was judged to be quite low for RN46A cells. At 1mM lithium in Run 1, expression 
of two genes (CDKN1C and LSP1) was significantly changed (Table 4.6); and in 
Run 2, 2mM lithium resulted in three significantly altered genes (LSP1, 
SERPINB2 and WNT6) (Table 4.7). Only LSP1 was significant in both runs. When 
analysed with NanoStringDiff, three genes (CDKN1C, LSP1 and SERPIN2B) 
were altered in Run1 (Table 4.6) and six genes (LSP1, SERPIN2B, WNT6, MAOB, 


















CDKN1C 46.70 ± 6.01 75.97 ± 10.25 0.7 3.70E-03 0.71 5.47E-05 
LSP1 167.31  ± 5.19 204.42 ± 19.01 0.28 2.90E-02 0.28 3.23E-03 
SERPIN2B 12.37  ± 4.63 6.72 ±0.76 -0.77 1.00E-01 -1.85 8.78E-03 
NGFR 7.90  ± 4.97 2.71 ±2.04 -1.55 1.10E-01 -29.15 1.54E-03 
MPP3 27.87  ± 4.23 33.71 ±4.61 0.28 1.50E-01 0.29 2.39E-01 
ZCCHC12 33.68  ± 9.89 23.55 ±11.45 -0.6 2.00E-01 -0.56 1.24E-01 
CNTN1 2.44  ± 0.97 5.09 ±2.7 0.95 2.10E-01 21.75 4.36E-01 




-0.49 2.60E-01 -0.49 1.15E-01 
LZTS1 1.91  ± 0.78 1.26 ±0.28 -0.5 2.90E-01 -16.82 3.36E-01 
VGF 22.73 ± 6.45 31.06 ±10.95 0.43 3.10E-01 0.41 2.27E-01 
GNAI1 1.07  ± 0.11 1.26 ±0.28 0.21 3.30E-01 0.33 2.52E-01 
ERBB3 118.14  ± 
22.07 
100.53 ±17.14 -0.23 3.40E-01 -0.23 2.16E-01 
ADAM23 1.31 ± 0.41 3.42 ±3.58 0.77 3.90E-01 -80.18 4.26E-01 
ADGRB2 8.93  ± 4.76 6.23 ± 3.53 -0.58 4.50E-01 -1.8 6.28E-02 
MAOB 15.09  ± 3.55 17.81 ±4.66 0.24 4.60E-01 0.19 6.28E-01 
NOTCH3 3.49  ± 2.36 2.35 ±2.18 -0.6 5.40E-01 -
182.44 
5.05E-01 
WNT6 1.91  ± 0.78 1.51±0.43 -0.26 5.80E-01 -16.82 4.78E-01 
IGF2 2.66  ± 1.88 1.92 ±1.43 -0.43 5.90E-01 15.6 4.75E-01 
PAK3 93.46  ± 19.31 98.75 ±7.69 0.1 5.90E-01 0.08 6.20E-01 
CACNA1B 14.00  ± 8.04 12.55 ±2.67 0.2 8.00E-01 -0.63 1.86E-01 
SHANK3 13.88  ± 7.86 12.16 ±5.14 0.25 8.20E-01 -0.66 1.95E-01 
SNAP91 143.26 ± 9.77 142.10 ±14.13 -0.02 8.80E-01 -0.02 8.73E-01 
LINGO1 3.38  ± 1.27 3.34 ±1.62 -0.08 9.10E-01 14 8.37E-01 
SPR 17.95  ± 7.26 16.39 ±1.92 -0.03 9.20E-01 -0.27 4.84E-01 




    




    
1 Base mean control and base mean lithium refer to the mean of normalized counts 
from four replicates each of untreated and lithium-treated samples in Run1. Ranked by 
nSolver™ p-values. 2Greyed values indicate the significant genes with p-val <0.05. 
































































MMP13 3312.56  ± 
384.81 



































































G6PD 1831.49 ± 63.59 1812.03 ±44.42         
MAPK6 2398.69 ± 85.08 2422.94±60.44         
1 Base mean control and base mean lithium refer to the mean of normalized counts 
from three replicates each of untreated and lithium-treated samples in Run2. Ranked 
by nSolver™ p-values. 2Greyed values indicate the significant genes with p-val <0.05. 






For the LTG exposed cells, log2 fold change and p-value for each gene is listed 
in Table 4.8. None of the genes were significant in response to LTG.  
 








log2FC pvalue log2FC pvalue 
LZTS1 1.33  ± 0.25 1.09  ± 0.15 -0.68 1.60E-01 -16.82 3.20E-01 




0.15 1.70E-01 0.14 2.30E-01 
IGF2 1.33 ± 0.25 1.09 ±0.15 -0.95 1.90E-01 -19.87 4.20E-01 
ADGRB2 55.48  ± 
12.95 
5.01 ±3.7 -1.01 2.50E-01 -1.57 1.30E-01 
ADAM23 37.50  ± 
15.26 
2.26 ±1.15 0.64 2.70E-01 -15.98 4.50E-01 
MAOB 67.00  ± 
11.19 
11.79 ±2.83 -0.36 3.00E-01 -0.53 2.00E-01 




0.08 3.20E-01 0.08 4.70E-01 
SERPIN2B 1349.53  ± 
67.66 
9.58 ±3.11 -0.32 4.80E-01 -0.66 1.60E-01 
SHANK3 1.33  ± 0.25 15.38 ±2.74 0.73 5.10E-01 -0.01 9.80E-01 
CACNA1B 1.33  ± 0.25 15.76 ±5.1 0.48 5.60E-01 0.03 9.50E-01 
LINGO1 1.33 ± 0.25 2.68 ±1.33 -0.38 5.70E-01 1.92 7.80E-01 
CNTN1 346.69  ± 
58.78 
5.52 ±4.94 0.57 5.90E-01 22.38 4.10E-01 
ZCCHC12 28.09  ± 
11.78 
30.38 ±6.77 -0.13 6.70E-01 -0.09 7.10E-01 




0.1 7.10E-01 0.12 6.00E-01 
MPP3 3.32 ± 2.80 29.39 ±4.9 0.07 7.20E-01 0.02 9.20E-01 
NOTCH3 27.59  ± 9.5 4.04 ±5.26 -0.43 7.30E-01 -174.73 6.20E-01 
CDKN1C 113.15 ± 
19.3 
47.93 ±5.35 0.04 7.80E-01 0.04 8.30E-01 
NGFR 64.65  ± 
16.67 
5.81 ±2.35 -0.21 7.80E-01 -1.47 1.60E-01 
GNAI1 1.33  ± 0.25 1.09 ±0.15 0.03 8.40E-01 0.83 2.50E-01 
ERBB3 1.33  ± 0.25 113.74 
±10.15 








-0.07 8.70E-01 -0.04 9.10E-01 
SPR 25.28  ± 
7.08 
18.0 ±4.9 0.06 8.90E-01 -0.09 8.30E-01 
WNT6 26.70  ± 
3.42 
2.25 ±1.62 0.04 9.50E-01 -159.3 5.00E-01 
VGF 44.57 ± 
33.22 
22.40 ±4.88 0.01 9.70E-01 -0.09 7.50E-01 




    




    
1 Base mean control and base mean LTG  refer to the mean of normalized 
counts from four replicates each of untreated and LTG-treated samples in 
Run1. Fold difference between the untreated (control) samples and samples 
treated with LTG are shown.  Ranked by nSolver™ p-values.  







4.3.3 Comparison of nCounter® and RNA-Seq gene expression 
RNA-Seq differential gene expression analysis was done with four approaches - 
cufflinks, DESeq2, kallisto and salmon. Log2 fold change values for each gene 
from nCounter® expression data were plotted against log2 fold change obtained 
with each DEG tool (Figure 4.5 and Figure 4.6). All genes showed similar 
direction of up- or down-regulation between RNA-Seq and NanoString 
nCounter® platforms, however, the log2FC values were generally lower for 
nCounter® data. Figure 4.5 shows the correlation for all 24 shortlisted genes, 
whereas in Figure 4.6 genes with low expression (mRNA counts < 30) were 
removed, which improved the correlation between RNA-Seq and nCounter® 
platforms. 
Kallisto, Cufflinks, Salmon and DESeq 2 all correlated with each other (all pairs 
with r > 0.92, sand p <0.001). NS_run2 correlated with all other methods to a 
lesser extent (r>0.59 p <0.01). NS run1 did not significantly correlate with any 
other method (r<0.4, p>0.05). Correlation improved for Run1 when genes with 
low counts were removed. However, correlation between DESeq2 and cufflinks 






Figure 4.5 Agreement among nCounter® Run1, Run2 and RNA-Seq gene 
expression data. Correlation coefficients calculated with all 24 genes. 







Figure 4.6 Agreement among nCounter® Run1, Run2 and RNA-Seq gene 
expression data after removing low expression genes. Correlation coefficients 






4.4  Discussion 
Twenty-three genes identified as differentially expressed in RNA-Seq analysis of 
VPA-treated RN46A cells were shortlisted for validation with the NanoString 
nCounter® assay. SPR, a gene of interest from previous studies in our laboratory 
was added to this list, meaning a total of twenty-four genes were included in the 
nCounter® assay. Several candidate gene studies and GWAS revealed that genes 
from my RNA-Seq study were linked to BD as shown in Table 4.2. Eighteen out 
of 24 shortlisted genes were clearly expressed in the brain, as shown by ABA and 
GTEx analysis in section 1.3.1. Five out of these 18 genes, ADGRB2, CACNA1B, 
LINGO1, SNAP91 and VGF were predominantly expressed in the brain.  
Cross-platform validation of RNA-Seq results can be done with RT-qPCR, 
nCounter® or OpenArray™. Compared to the widely used RT-qPCR, 
nCounter® assay has increased sensitivity and better correlation with RNA-Seq 
results due to reduced sample handling (Bentley-Hewitt et al., 2016; Prokopec et 
al., 2012). OpenArray™ has similar dynamic range and sensitivity to nCounter® 
(Prokopec et al., 2012). nCounter® assay, but not OpenArray™, was available to 
us through my university, so we chose to use this platform.  
Housekeeping genes are required controls to normalize variations across 
samples and different experimental conditions. A housekeeping gene should be 
constantly transcribed and have similar expression between samples and under 
different experimental conditions with small variations (Vandesompele et al., 
2002). Mood stabilizers can differentially affect the expression of housekeeping 
genes (Powell et al., 2014). In a previous study done in our laboratory, the 
stability of expression of eight housekeeping genes was measured in response to 
1mM lithium and 0.5mM VPA, among other drugs, in the RN46A cell line 
(Balasubramanian et al., 2019). G6PD and MAPK6 were chosen as housekeeping 




Two software packages nSolverTM v3.0 and NanoStringDiff were used for 
normalization and differential expression (DE) analysis. Alternative approaches 
to nCounter® data analysis include normalization with R packages like 
NanoStringNorm (Waggott et al., 2012) and DE analysis of normalized counts by 
DESeq2 (Love et al., 2014), edgeR (Robinson et al., 2010) or limma (Ritchie et al., 
2015). Normalization approach suggested by NanoString works well, as shown 
by Prokopec et al (Prokopec et al., 2012). In nSolverTM, mRNA counts were 
normalized with a geometric mean of positive and negative controls along with 
housekeeping genes. Empirical Bayes shrinkage was used in NanoStringDiff to 
estimate dispersion and generate size scaling factors for normalization. None of 
the housekeeping genes were identified as DE by both the tools showing proper 
normalization and stability of the chosen housekeeping genes for this cell line 
and the drugs used.  
Welch’s t-test was used in nSolverTM for DE analysis, whereas NanoStringDiff 
used GLM likelihood ratio test. NanoStringDiff generated unusually high log2 
fold change for low count genes and removing these low counts did not affect 
fold change and p-values of other genes. Log2FC with nSolverTM for low count 
genes were comparable to RNA-Seq, which showed nSolverTM was well-suited 
to handle the dynamic expression range of nCounter® assay. More genes were 
identified as differentially expressed with NanoStringDiff compared to 
nSolverTM.  
There are three main methods to calculate FDR- Bonferroni, Benjamini-Hochberg 
and Benjamini-Yekuteli. NanoString advises using a less conservative method 
which allows gene significance levels to be either positively or negatively 
correlated as stated in the nCounter® advanced analysis user guide. nSolverTM 
used Benjamini-Yekuteli method to compute FDR whereas NanoStringDiff used 
Benjamini and Hochberg procedure. The Benjamini-Yekuteli method accounts 




adjusted p-value falls between the more conservative tests like the Bonferroni 
correction and more permissive uncorrected p-values (Benjamini & Yekutieli, 
2001). The default approach suggested by NanoString for data analysis works 
well (Prokopec et al., 2012). 
Validation of the RNA-Seq data was done in two separate nCounter® runs and 
the volume of cell culture medium used in each well was doubled for Run2 to 
reduce the medium acidity observed in earlier RNA-Seq and nCounter® Run1 
for RN46A cells. Higher nCounter® mRNA counts were observed in Run2, 
increasing the statistical significance of some genes and this could be likely due 
to the increased medium volume.  
Twenty-four genes were selected for validation. Twelve genes were found to be 
altered by VPA in Run1 and 17 genes in Run2 as identified with both analysis 
methods.  
Although not all genes replicated with VPA, this was partly due to the low 
expression of some genes and failure to reach statistical significance. There were 
differences between the two runs, but the direction of change was the same for 
all significant genes between runs. Fold-changes were also similar between both 
runs, however, counts were higher for some genes in Run2 so the corresponding 
fold changes were higher as well. Thus, cross-platform validation with different 
batches of mRNA validated the RNA-Seq results.  
VPA results were reproducible across runs with slight variation due to the 
software used for analysis. We consider the genes observed in both runs, with 
both analysis software, to be reproducible and of high confidence. Eight genes 
were significant in both runs as identified with both nSolverTM and 
NanoStringDiff. Of these, LSP1, MMP13, PAK3, SNAP91 and ZCCHC12 had high 
counts in both runs, whereas ADAM23, MAOB and WNT6 had low counts in 




Some genes were only found to be differentially expressed (DE) in one of the 
nCounter® runs, not both. CDKN1C, MPP3 and VGF were significant in Run1 
whereas ADGRB2, CNTN1, NGFR, SERPINB2, and ERBB3 were significant only 
in Run2. IGF2, SHANK3 and SPR were not significant in either run. The eight 
genes that were significant in both runs are discussed in the next section.  
4.4.1 Most significant genes 
4.4.1.1 ZCCHC12 
ZCCHC12 encodes a zinc finger domain protein, which is a downstream effector 
of bone morphogenetic protein (BMP) signalling. It acts as a transcriptional 
coactivator. It was upregulated by VPA in RNA-Seq (log2FC of 1.9) and both 
nCounter® runs (log2 FC of 1.41 Run1, log2 FC of 2.5 Run2). This gene was 
expressed predominantly in both human and mouse brain (Table 4.3). ZCCHC12 
is implicated in non-syndromic X-linked mental retardation and papillary 
thyroid cancer (Li, Chen, et al., 2012; Wang, Zheng, et al., 2017). It has been shown 
to be linked to SCZ using a convergent functional genomics approach (Ayalew 
et al., 2012), and is a transcriptional co-activator of AP-1 and CREB (Li et al., 2009). 
It was upregulated by VPA in a prior RNA-Seq analysis using RN46A, from this 
laboratory (Balasubramanian et al., 2019). There is considerable overlap in gene 
expression between BD and SCZ (Gandal et al., 2018; International Consortium 
on Lithium Genetics et al., 2018). The link with SCZ and mental retardation 
makes this gene a good candidate for involvement in mood regulation.  
4.4.1.2 MAOB  
MAOB encodes for an enzyme located in the outer mitochondrial membrane 
which oxidatively deaminates the biogenic monoamines-5-HT, NE and DA. It 
was upregulated by VPA in both RNA-Seq (log2FC of 1.8) and both nCounter® 
runs (log2FC of 0.72 Run1, log2FC of 2.3 Run2). It was expressed in both the 




(Table 4.3). MAOB is involved in the therapeutic action of several 
antidepressants (Finberg & Rabey, 2016), and chronic treatment with 
antipsychotics, risperidone and olanzapine increased MAOB mRNA levels in rat 
frontal cortex (Chen & Chen, 2007). It was upregulated by VPA in prior RNA-
Seq analysis with the same concentration and exposure time in RN46A cells 
(Balasubramanian et al., 2019). This provides high confidence in MAOB as a 
likely VPA target and its established role in the treatment of BD suggest this is a 
strong candidate for involvement in mood regulation.  
4.4.1.3 ADAM23 
ADAM23 encodes a member of membrane-anchored metalloproteinase family, 
which regulate cell-cell and cell matrix interactions. This gene promotes cell 
survival and neuronal differentiation (Markus-Koch et al., 2017). It was 
upregulated by VPA in RNA-Seq (log2FC of 2.3) and both nCounter® runs 
(log2FC of 2.5 Run1, log2FC of 1.6 Run2). ADAM23 was upregulated by 0.5mM 
VPA in normal epithelial cell line MCF10a, the same concentration used in this 
thesis and was also altered in individual gastric cancer patients treated with VPA 
(Guest, 2015). 
ADAM23 has been shown to be a common risk gene for idiopathic epilepsy in 
dogs (Koskinen et al., 2017). In mice, this gene was required for LG11-mediated 
neurite outgrowth and dendritic arborisation to correct neuronal morphology 
related to epilepsy (Owuor et al., 2009). Thus, ADAM23 may be linked to the 
anticonvulsant effects of VPA. A few studies show the involvement of ADAM23 
in BD and SCZ (Chen, Wang, et al., 2013; Mamdani et al., 2013). It was 
differentially expressed in post-mortem brains from BD patients treated with 
antipsychotics (Chen, Wang, et al., 2013). The limited evidence in BD and SCZ 





MMP13 gene encodes for matrix metalloproteinase enzyme that cleaves the 
extracellular matrix and regulates cell-cell communication. It was upregulated 
by VPA in RNA-Seq (log2FC of 1.8) and both nCounter® runs (log2FC of 0.85 
Run1, log2FC of 0.68 Run2). MMP13 has been implicated in multiple cancers 
(Kumamoto et al., 2009; Rybakowski, 2009) and may be involved in anti-tumour 
effects of VPA.  
Originally thought to be involved in tissue remodelling, metalloproteinases have 
multiple functions and may play an important role in the central nervous system. 
These are widely expressed in the brain and regulate several processes such as 
inflammation, microglial activation and dopaminergic apoptosis (Singh et al., 
2015). These enzymes are highly expressed in neurodegenerative disorders such 
as Parkinson’s disease and Alzheimer’s disease (Singh et al., 2015).  
MMP13 may play a role in maintaining cellular structure along with ADAM23, 
four other MMPs and their inhibitor TIMP1 which were all upregulated in 
response to VPA in this study (section 3.3.6.2). It was upregulated by VPA in the 
prior RNA-Seq analysis and had the lowest p-value in that study 
(Balasubramanian et al., 2019).  
Serotonin increases MMP13 expression in muscles through activation of 
ERK1/MAPK pathways by PLC and PKC signalling. It may also regulate MMP13 
expression in the brain through a similar mechanism. MMP13 promoter contains 
AP-1 binding sites and VPA may upregulate its expression by increasing AP-1 
DNA binding activity. Thus, MMP13 may be involved in tissue remodelling in 
the brain and regulation of neuronal and synaptic plasticity. Although not much 
is known about the role of MMP13 in mood disorders, this gene may have a 




4.4.1.5 PAK3  
PAK3 encodes p21-activated kinase 3, a member of serine/threonine kinase 
family, which is downstream effectors of Rac/Cdc42 Rho GTPases. It was 
upregulated by VPA in RNA-Seq (log2FC of 2.1) and both nCounter® runs 
(log2FC of 0.9 Run1, log2FC of 1.1 Run2). It was predominantly expressed in the 
brain, especially the dorsal raphe (Table 4.3). Multiple studies show PAK3 is 
involved in neurological and psychiatric disorders (Fuchsova et al., 2016; Kim et 
al., 2016; Meng, 2005; Morrow et al., 2008; Muthusamy et al., 2017; Peippo et al., 
2007; Rejeb et al., 2008). Deleterious mutations in PAK3 causes nonsyndromic X-
linked intellectual disability (Allen et al., 1998). PAK3 regulates synaptic 
plasticity and has been implicated in synaptic deficits in SCZ (Kim et al., 2016) 
and was upregulated in the dorsolateral prefrontal cortex in SCZ patients (Datta 
et al., 2015).  
Animal studies show PAK3 knockout result in abnormalities in long-term 
synaptic plasticity and reduced expression of CREB, which regulates synaptic 
plasticity and cognition (Meng, 2005). Pak inhibitors are shown to restore 
synaptic deterioration in vitro (Hayashi-Takagi et al., 2014). Together these 
studies indicate that PAK3 regulates synaptic plasticity, which is dysfunctional 
in BD (Du et al., 2004; Eastwood & Harrison, 2010; Pantazopoulos & Berretta, 
2016; Zarate et al., 2006) making it a good candidate gene to study in relation to 
mood regulation.  
4.4.1.6 SNAP91 
SNAP91 encodes for the clathrin coat assembly protein AP180 enriched in the 
presynaptic terminal and is expressed in neurons (Yao et al., 2002). It was 
upregulated by VPA in RNA-Seq (log2FC of 2.2) and both nCounter® runs 




mediated endocytosis and regulates synaptic vesicle transport and axon 
remodelling (Granseth et al., 2006; Morgan et al., 1999).  
SNAP91 is linked to mood in BD and SCZ. AP180 was significantly 
downregulated in anhedonic mice in response to stress (Henningsen et al., 2012). 
Polymorphisms in 6q14.2 within the PRSS35/SNAP91 gene complex were linked 
to mood-incongruent psychotic features in BD and SCZ (Goes et al., 2012). 
SNAP91 interacts with DISC1, a potential risk factor for SCZ (Teng et al., 2018). 
Thus, SNAP91 is linked to BD and SCZ and may be a good candidate gene to 
further study in relation to mood regulation.  
4.4.1.7 WNT6  
WNT6 encodes a member of the WNT family glycoproteins, which are involved 
in growth, differentiation, migration and cell fate determination (Ka et al., 2014). 
These glycoproteins influence neurogenesis, synaptogenesis and neural 
plasticity (Ochs et al., 2014). WNT6 was upregulated by VPA in RNA-Seq (log2FC 
of 2) and both nCounter® runs (log2FC of 1.6 Run1, log2FC of 2 Run2).  
Wnt pathway genes are implicated in BD (Gould & Manji, 2002) and are known 
targets of lithium and VPA (Boku et al., 2014; Wexler et al., 2008). Wnt proteins 
are upstream regulators of GSK-3β which is directly inhibited by lithium (Klein 
& Melton, 1996; Ryves & Harwood, 2001; Stambolic et al., 1996). VPA activates 
the Wnt/β-catenin pathway in autistic rat models (Qin et al., 2016) and in neural 
stem cells for neuronal differentiation (Wang, Liu, et al., 2015).   
There is plenty of evidence for involvement of Wnt proteins in BD pathogenesis 
(Gould & Manji, 2002; Muneer, 2017; Okerlund & Cheyette, 2011; Sani et al., 2012) 
however, not much is known about the role of WNT6. It uses the non-canonical 
pathway in neural crest induction (Schmidt et al., 2007) and both canonical and 
non-canonical Wnt signalling pathways are implicated in BD (Matigian et al., 




WNT6 needs to be further examined to explore any possible role in mood 
regulation.  
4.4.1.8 LSP1 
LSP1 encodes an intracellular F-actin and calcium binding protein which is 
primarily expressed in lymphocytes, neutrophils, macrophages and 
endothelium, and is involved in cellular transmigration (Jongstra-Bilen & 
Jongstra, 2006). It was downregulated by VPA in RNA-Seq (log2FC of -2.3) and 
both nCounter® runs (log2FC of -.94 Run1, log2FC of -1.3 Run2). It has been 
shown to be located on 11p15.5, a region linked to BD (Serretti & Mandelli, 2008) 
but was not further verified in GWAS. LSP1 was downregulated in depressed 
patients after 5 weeks of treatment with antidepressants (Hennings et al., 2015).  
A recent study identified increased macrophages in the frontal cortex of SCZ 
patients (Cai et al., 2018). It has been increasingly shown that inflammation is 
involved in BD pathogenesis; both mania and depression are associated with a 
pro-inflammatory state (Hamdani et al., 2013). Thus, LSP1 may play a role in 
inflammation in SCZ and BD and is downregulated by VPA to reduce 
inflammation. The limited evidence for the role of LSP1 in BD suggest it is a poor 
candidate for mood regulation.  
4.4.2 Other significant genes 
Fifteen of the 24 shortlisted genes were significant only in either Run1 or Run2 
and are presented in this section, although they are of the lower confidence than 
the genes described above. 
4.4.2.1 ADGRB2 
ADGRB2 (previously BAI2) was upregulated by VPA in RNA-Seq (log2FC of 2.3) 
and only nCounter® Run2 (log2FC of 1.9). It was upregulated by VPA in normal 




family of adhesion-GPCRs regulate synapse development and plasticity 
(Duman, Tu, et al., 2016). Knockout mice for this gene showed antidepressant-
like behaviour in stress tests and increased hippocampal cell proliferation 
(Okajima et al., 2011). Less evidence was available for the role of this gene in 
therapeutic effect of VPA, but with interesting antidepressant function, this gene 
should be explored further.  
4.4.2.2 CACNA1B 
CACNA1B was upregulated by VPA in RNA-Seq (log2FC of 2.3) and only 
nCounter® Run2 (log2FC of 2.3). VPA showed upregulation of two other 
calcium channel genes, CACNA1D and CACNA1H in RNA-Seq analysis. SNPs 
in CACNA1B, an L-type calcium channel gene, have been consistently shown to 
be linked with BD across multiple studies (Ament et al., 2015; Moskvina et al., 
2009; Pedrosa et al., 2010). Calcium channel genes are well-studied and SNPs 
in/near another calcium channel gene, CACNA1C have been linked to risk of BD 
and replicated in multiple GWAS studies (Ament et al., 2015; Cross-Disorder 
Group of the Psychiatric Genomics Consortium, 2013; Ferreira et al., 2008; 
Harrison et al., 2017; Lett et al., 2011; Psychiatric GWAS Consortium Bipolar 
Disorder Working Group, 2011).  
L-type calcium channel antagonists have been used in the treatment of BD for 
over 30 years (Cipriani et al., 2016). Several studies show lithium can affect 
calcium signalling and expression of calcium channel genes; neurons derived 
from lithium responders showed altered calcium signalling and expression of 
calcium channel genes than non-responders (Chen et al., 2014; Hahn, Gomez, et 
al., 2005; McCarthy et al., 2016; Mertens et al., 2015). These studies suggest that 
calcium channel genes are central in BD risk and treatment. Although less 
evidence was available for the effect of VPA on CACNA1B from RNA-Seq and 
only one nCounter® run, CACNA1B is a good candidate gene and should be 





CDKN1C is a maternally imprinted gene that encodes a cell cycle inhibitor 
upregulated by VPA in RNA-Seq (log2FC of 2.2) and only nCounter® Run1 
(log2FC of 1.6). Chromatin-modifying drugs such as 5’-aza and TSA de-
repressed the imprinting and upregulated CDKN1C in mice (Van de Pette et al., 
2017). This finding suggests that VPA may also upregulate this gene through 
chromatin modification. This gene has been shown to be involved in 
proliferation and differentiation of midbrain DA neurons and neurogenesis in 
developing brain (Tury et al., 2011; Ye et al., 2008). A transgenic mouse model 
with a twofold increased expression of CDKN1C mimicking loss-of-imprinting, 
showed altered regulation of other brain genes, especially DA-related genes and 
altered behaviour (McNamara et al., 2017). This study suggests that even 
relatively modest levels of gene expression changes may be important in VPA 
action. Abnormalities in sleep-wake cycle is central in BD pathophysiology and 
CDKN1C might may play an important role in mood regulation. This gene has 
interesting properties and should be explored further.  
4.4.2.4 CNTN1 
CNTN1 encodes for a neural adhesion molecule which plays an important role 
in the nerve cone growth and axon guidance (Falk et al., 2002). This gene was 
upregulated by VPA in RNA-Seq (log2FC of 1.6) and only nCounter® Run2 
(log2FC of 0.8). Similarly, VPA upregulated CNTN1 in MECP2 knockout mice, a 
model of Rett syndrome (Guo et al., 2014) and VPA has been used to control 
seizures in Rett syndrome patients (Krajnc et al., 2011).  
Other genes that interact with CNTN1 were also upregulated by VPA in my 
RNA-Seq analysis. CNTN1 interacts with other cell adhesion molecules such as 
L1CAM (Olive et al., 1995) which was upregulated by VPA. CNTN1 acts as a 




implicated in BD and SCZ (Hoseth et al., 2018a) and NOTCH3 was upregulated 
by VPA in RNA-Seq and nCounter® Run2.  
Several studies have implicated CNTN1 in BD, MDD and SCZ. Structural 
abnormalities have been observed in the corpus callosum in BD patients (Han et 
al., 2018; Prunas et al., 2018) and variants in CNTN1 have been shown to affect 
the axon density in corpus callosum in healthy adults (Anderson et al., 2018). 
Animal studies show similar properties; CNTN1 knockout mice showed 
abnormal axon and dendritic projections in cerebellar interneurons (Berglund et 
al., 1999) whereas overexpressing mice showed increased hippocampal size 
associated with increase hippocampal neurogenesis (Puzzo et al., 2013). This 
gene was upregulated in the prefrontal cortex of MDD post-mortem patients 
(Malki et al., 2015). SNPs in CNTN1 were also associated with SCZ risk (Corvin, 
2014). CNTN1 is highly expressed in serotonergic neurons (Spencer & Deneris, 
2017) and all the above evidence suggests that CNTN1 may be relevant to mood 
disorders and is therefore worthy of further study in relation to therapeutic 
effects of VPA.  
4.4.2.5 ERBB3 
ERBB3 was upregulated by VPA in RNA-Seq (log2FC of 1.6) and only 
nCounter® Run 2 (log2FC of 3). It interacts with PI-3/Akt pathway which is 
implicated in mood disorders (Beaulieu, 2012). Variants in Neuregulin-ErB 
pathway are associated with BD, MDD and SCZ (Kao et al., 2010; Law et al., 2007; 
Paterson et al., 2017). This gene was downregulated in the middle temporal gyrus 
of schizophrenic patients (Aston et al., 2004) and temporal cortex of depressed 
patients (Aston et al., 2005). Mood disorders are one of the risk factors for suicide 
(Isometsä, 2014) and reduced hippocampal ERBB3 expression with low numbers 
of ERBB3-expressing neurons in the anterior dentate gyrus were observed in 




ERBB3 was identified as a candidate blood biomarker in depressed BD patients 
with convergent functional genomics (CFG) (Le-Niculescu et al., 2009) and has 
been shown to be decreased in leukocytes of MDD patients (Milanesi et al., 2012). 
Chronic antipsychotic treatment increased ERBB3 and other ERBB receptors in 
the rat hippocampus and prefrontal cortex (Wang et al., 2008). All the evidence 
suggests ERBB3 has an interesting function related to mood regulation and it is 
also a good candidate gene worthy of further study.  
4.4.2.6 GNAI1 
GNAI1 encodes the alpha subunit of G-protein, which are downstream 
transducers of G-protein coupled receptors in various signalling pathways. This 
gene is primarily expressed in the brain and inhibits adenylate cyclase and 
downstream pathways. It was upregulated by VPA in RNA-Seq (log2FC of 2.1) 
and only nCounter® Run 2 (log2FC of 3.6) but with low counts. In contrast, other 
studies show VPA could decrease GNAI1 protein levels by inducing miR-124 
with no change in mRNA levels in both mouse cortical tissues and primary 
neuronal cultures (Oikawa et al., 2015; Sng & Oikawa, 2016). This repression of 
GNAI1 has been suggested to increase cAMP concentration and BDNF 
expression (Oikawa et al., 2015).  
Le-Niculescu et al (2009) linked GNAI1 to BD with the convergent functional 
genomics approach using three GWAS and other human post-mortem and blood 
expression studies (Le-Niculescu et al., 2009). G-protein linked signalling 
pathways are central in BD and MDD pathophysiology (Tomita et al., 2013). G 
protein-coupled signal transduction system-related proteins, including Gnai1, 
Gnai2, Sept4, Ran, Sept5, and Stxbp1 were also found to be significantly altered 
after antipsychotic medication exposure in rats (Ji et al., 2009). Although all the 
above studies suggest GNAI1 has an interesting role in mood disorders, my 




4.4.2.7 LINGO1  
LINGO1 encodes for leucine-rich repeat protein, which is primarily expressed in 
the brain and negatively regulates neuron differentiation and growth, axon 
guidance and regeneration. It was upregulated by VPA in RNA-Seq (log2FC of 
2.2) and only nCounter® Run 1 (log2FC of 2.2) with low counts. Increased 
expression of Lingo1 and related proteins Myt1, TROY, WNK1 was observed in 
the hippocampus and dorsolateral prefrontal cortex in SCZ post-mortem 
samples (Fernandez-Enright et al., 2014). This study also showed the altered 
signalling of Lingo1 pathway may be linked to synaptic plasticity. LINGO1 
negatively regulates oligodendrocyte development (Mi et al., 2005) and its loss 
in humans causes intellectual disability (Ansar et al., 2018). Despite this strong 
evidence for LINGO1 involvement in SCZ, low expression levels of this gene in 
my model system do not allow us to make meaningful conclusions.  
4.4.2.8 LZTS1 
LZTS1 encodes for a transcriptional regulator which is involved in regulation of 
cell growth. It was upregulated by VPA in RNA-Seq (log2FC of 3.6) and only 
nCounter® Run 2 (log2FC of 3.5). VPA upregulated miR-331 and miR-885-3p to 
alleviate the neurological deficits in cerebral ischemia mouse model and rat 
cortical neuronal cultures (Hunsberger et al., 2012). LZTS1 is targeted by both 
miR-331 and miR-885-3p and may regulate cellular movement and neurite 
morphogenesis. Thus, VPA may upregulate this gene through miRNA induction 
as seen earlier with GNAI1 (Oikawa et al., 2015).  
LZTS1 is a postsynaptic density protein, mainly expressed in the hippocampus, 
striatum, olfactory bulb and frontal cortex (Konno, 2002). This gene is involved 
in the regulation of axonal growth and neuronal circuit assembly (Kropp & 
Wilson, 2012). Knockout mouse showed working and cognitive memory deficits 




development (Mayanagi et al., 2015). This study showed LZTS1 modulated Rap2 
activity at postsynaptic sites for glutamatergic synapse maturation.  
Some studies have linked this gene to MDD and SCZ as well. rs1106634 in 8p21.3 
region was associated with downregulation of LZTS1 in MDD patients (Shyn et 
al., 2011) but this did not hold up in large GWAS (Okbay et al., 2016; Wray et al., 
2018). LZTS1 was downregulated in microarray gene expression of the anterior 
prefrontal cortex from SCZ post-mortem samples (Chatziioannou, 2016). 
Although LZTS1 has interesting neuronal functions, less evidence was available 
from my analysis to support a role for this gene in mood regulation.  
4.4.2.9 MPP3 
MPP3 is a member of a family of membrane-associated proteins called MAGUKs 
(membrane-associated guanylate kinase homologs) which interact with the 
cytoskeleton and play important roles in signal transduction. MPP3 was 
upregulated by VPA in RNA-Seq (log2FC of 1.7) and only nCounter® Run 2 
(log2FC of 2.3). MPP3 prevented desensitization of the 5-HT2C receptor Ca+2 
response and the interaction of 5-HT2C receptors with MPP3 increased the 
membrane stability of the receptor (Gavarini et al., 2006). This gene was 
upregulated in lymphocytes of SCZ patients (Vawter, 2004). Even though this 
gene affected the serotonergic system, not enough evidence was available for the 
role of this gene in mood regulation.  
4.4.2.10 NGFR 
NGFR encodes the receptor for the nerve growth factor (NGF) gene, which is 
essential in neuronal apoptosis signalling and regulating synaptic plasticity. It 
was upregulated by VPA in RNA-Seq (log2FC of 1.8) and only nCounter® Run 
2 (log2FC of 2.3). Several studies have linked mutations in NGFR to increased 
risk of MDD and SCZ. Multiple SNPs in NGF and NGFR were linked to SCZ and 




Missense mutations in the receptor is linked to depression and suicide (Kunugi 
et al., 2004). Increased levels of NGFR were observed in MDD patients and 
suicide completers (Dwivedi et al., 2009; Zhou et al., 2013). Ser205Leu functional 
variation in NGFR was linked with increased risk of MDD (Fujii et al., 2011).  
A nominal association of NGFR was seen in BD suicide patients (Perlis et al., 
2010). The neurotrophic factor BDNF augmented the neurogenic potential of 
NGFR in the stem cells of the rat subventricular zone (Young et al., 2007). BDNF 
was involved in the therapeutic action of antidepressants and mood stabilizers 
(Chang et al., 2009; Chen et al., 2001; Frey et al., 2006; Jornada et al., 2010; Nishino 
et al., 2012; Tseng et al., 2008) and both lithium and VPA upregulated BDNF levels 
(Tunca et al., 2014; Varela et al., 2015; Wu et al., 2008). All the above studies 
suggest NGFR has an important function in regulating synaptic plasticity and 
dysfunctions in synaptic plasticity have been implicated in BD (de Sousa et al., 
2014; Duman, Aghajanian, et al., 2016; Machado-Vieira, 2018). This makes this 
gene a good candidate for further study in relation to the therapeutic effects of 
VPA.  
4.4.2.11 NOTCH3 
NOTCH3 encodes a receptor involved in neurodevelopment and adult brain 
homeostasis. It was upregulated by VPA in both RNA-Seq (log2FC of 1.7) and 
nCounter® Run 2 (log2FC of 1.6). Mood disturbances were observed in cerebral 
autosomal dominant arteriopathy with subcortical infarcts and 
leucoencephalopathy (CADASIL) syndrome, which involves mutations in 
NOTCH3, and has been linked to bipolar depression and improved upon VPA 
treatment (Wang, Li, et al., 2017). VPA activated Notch3/c-FLIP pathway in 
cultured vascular smooth muscle cells, linked with CADASIL syndrome (Yuan 
et al., 2009). The notch signalling pathway has been shown to be altered in BD 
and SCZ and could be rescued with lithium treatment (Wang, Ren, et al., 2015). 




activation and vascular inflammation (Quillard & Charreau, 2013; Shang et al., 
2016); neuroinflammation has been increasingly recognised to play a role in BD 
pathophysiology (Wang, Lee, et al., 2016). This gene has interesting functions, 
making it a good candidate for further examination.  
4.4.2.12 SERPINB2 
SERPINB2 encodes for serine protease inhibitor which is essential for the 
processing and activation of plasminogen activators and other proteins, and is 
upregulated during immune responses. This gene is involved in cell 
proliferation, differentiation and growth (Dickinson et al., 1995; Medcalf & 
Stasinopoulos, 2005). This gene was upregulated by VPA in RNA-Seq (log2FC of 
1.6) and only nCounter® Run2 (log2FC of 1). It was found to be upregulated by 
VPA in a prior RNA-Seq analysis in our laboratory in the RN46A cell line 
(Balasubramanian et al., 2019). This gene was upregulated in monocytes from 
SCZ patients associated with inflammatory response (Drexhage et al., 2010). One 
study revealed the neuroprotective properties of this gene to promote the 
survival of hippocampal neurons, which might regulate synaptic plasticity 
(Zhang et al., 2009). This gene has been extensively studied in cancer metastasis 
and influences cancer growth (Croucher et al., 2008). Although this gene had no 
obvious role in BD, it might be important in the therapeutic action of VPA in 
metastasis and cancer growth (Aztopal et al., 2018; Brodie & Brandes, 2014).  
4.4.2.13 SHANK3 
SHANK3 encodes for a major scaffold protein in the postsynaptic density that 
supports connections between neurons and helps in the formation and 
maturation of dendritic spines (Arons et al., 2016). It was upregulated by VPA in 
RNA-Seq (log2FC of 1.6) but had low expression in nCounter® and was only 
significant in Run2 with NanoStringDiff analysis. Multiple mutations in 
SHANK3 have been linked to ASD (Durand et al., 2007), SCZ and intellectual 




Reduced levels of SHANK3 were observed in post-mortem brain samples from 
ASD, BD and SCZ patients (Alexandrov et al., 2017). Mice with SHANK3 
duplication display mania-like hyperactivity and seizures, which were rescued 
by VPA, but not lithium (Han et al., 2013). However, no association was observed 
between ten SHANK3 variants and BDI/II subtypes in Han-Chinese population 
using peripheral blood samples (Zhang et al., 2016). Although this seemed an 
excellent candidate gene with interesting functions, unfortunately nCounter® 
validation did not fully support the initial RNA-Seq findings. 
4.4.2.14 VGF 
VGF encodes for nerve growth factor-inducible neurosecretory protein, which 
regulates synaptic plasticity, neurogenesis and nerve growth (Alder et al., 2003; 
Sato et al., 2012; Thakker-Varia et al., 2014). It was upregulated by VPA in RNA-
Seq (log2FC of 3.1) and nCounter® Run1 (log2FC of 2.3). This gene was 
expressed predominantly in both the human and mouse brains, especially the 
medullary raphe (Table 4.3). VGF has been shown to increase neurogenesis in 
hippocampus (Thakker-Varia et al., 2014; Yang et al., 2016) and has 
neuroprotective effects in cultured neurons (Mezey et al., 2014; Severini et al., 
2008). Both VGF knockout and overexpressing mice showed hyperactivity, 
depression-like behaviour and memory dysfunction (Hunsberger et al., 2007; 
Mizoguchi et al., 2017; Thakker-Varia et al., 2010). These hypomorphic and 
hypermorphic features have also been observed with other neurotrophic factors 
such as NRG1 and BDNF (Mizoguchi et al., 2017). 
VGF has been linked to the action of antidepressants, mood stabilizers and 
antipsychotics (Jiang, Chen, et al., 2017; Mizoguchi et al., 2018; Thakker-Varia et 
al., 2007) and reduced VGF levels were observed in BD postmortem brains 
(Thakker-Varia et al., 2010). In both depressed humans and stressed mice, VGF 
levels were altered; levels were reduced in the dorsal hippocampus and 




VGF has been shown to be robustly regulated by the neurotrophic factor BDNF, 
which underlies rapid antidepressant response by ketamine (Jiang et al., 2018; 
Lin et al., 2015). VGF could also mediate its actions through the PI3K/Akt/mTOR 
signalling pathway (Lu et al., 2014), implicated in BD pathophysiology and 
treatment (Hermida et al., 2017; Kitagishi et al., 2012; Zhang et al., 2017). The 
direct involvement of this gene in antidepressant-like behaviour makes it a 
strong candidate in relation to study mood disorder treatment.  
4.4.2.15 SPR 
Because of this laboratory’s prior interest in the sepiapterin reductase gene 
(SPR), and despite the lack of significance for SPR in both prior RNA-Seq 
(Balasubramanian, 2015) and current RNA-Seq analyses, we included this gene 
in nCounter® custom CodeSet panel. The earlier failure to detect differential 
expression of SPR was attributed to low expression in RN46A cells. It was 
included in this nCounter® assay to detect its expression at an increased 
resolution. Our analysis showed SPR was expressed in RN46A cells at low levels, 
but was not significantly altered by VPA, lithium or LTG. This corroborated the 
RNA-Seq analyses.  
The previous studies in our laboratory used RT-qPCR to show SPR upregulation 
by VPA and lithium in RN46A cells. However, both RNA-Seq and more sensitive 
nCounter® assay revealed that neither VPA nor lithium changed SPR 
expression. These results highlight the reproducibility issues seen with RT-qPCR 
studies (Bustin & Huggett, 2017).  
4.4.3 Genes co-regulated by lithium and VPA 
Four genes in this study that were significantly regulated by VPA were also co-
regulated by lithium (Table 4.6 and Table 4.7). The magnitude of change was less 




(VPA log2FC of 1.97, lithium log2FC of -1.32) were upregulated by VPA but 
downregulated by lithium. LSP1 was downregulated by both drugs (VPA 
log2FC of 1.26, lithium log2FC of 0.53). SERPINB2 was upregulated by both 
drugs (VPA log2FC of 1.0, lithium log2FC of 0.87).  
We hypothesized that genes co-regulated by lithium and VPA, two structurally 
dissimilar mood stabilizers, are potentially relevant to mood stabilizing effects 
and may highlight important pathways in the mechanism of action for these 
drugs. Several genes and pathways overlap between lithium and VPA and these 
could potentially highlight shared mechanisms of action (Balasubramanian et al., 
2019; Gupta et al., 2012; Gurvich & Klein, 2002; Lee, Pirooznia, et al., 2015; 
Valvassori, Dal-Pont, et al., 2017). The co-regulated genes identified, establish 
that these two quite different drugs are capable of impacting on similar 
biochemical pathways. These four co-regulated genes might be linked to 
therapeutic properties of both drugs and warrant further examination to explore 
their role in mood regulation. In my study, validation for lithium was done on a 
small number of DEGs derived from VPA-exposure and a more comprehensive 
analysis of the gene expression effects of higher concentrations of lithium would 
be warranted.  
4.4.4 No differential expression with lamotrigine 
LTG did not change expression of any of the shortlisted genes. Although the 
mechanism of action of LTG is unclear, it inhibits calcium currents and affects 
N-type Ca+2 channels (Stefani et al., 1996; Wang et al., 1996) but did not change 
expression of the L-type calcium channel gene CACNA1B (LFC=0.48, p-val=0.56) 
in this study. This drug also inhibits 5-HT uptake both in vivo and in vitro, 
resulting in elevated extracellular 5-HT (Southam et al., 1998). 5-HT1A receptors 
are involved in the antidepressant action of LTG (Bourin, Masse, et al., 2005; 




sensitive Na+ channel blockade (Codagnone et al., 2007). The lack of the gene 
expression effects observed after exposure to LTG in this study suggests there 
may be little overlap with mechanisms of action of VPA, or that perhaps RN46A 
is insensitive to potential gene expression effects induced by LTG.   
4.4.5 Comparison of log2 fold change between datasets 
RNA-Seq log2 fold change correlated well (Pearson correlation coefficient 
R2=0.8) with log2 fold change from nCounter® assay when low expressed genes 
were removed from nCounter® data. All genes were regulated in the same 
direction and comparable fold change except for low expressed genes. For in 
vitro studies, removing low expression genes improves the correlation between 
the two platforms (Zhou et al., 2015). nCounter® Data analysis guidelines 
provided by NanoString worked well for differential gene expression analysis. 
nSolver™ handles the dynamic expression range of genes from high to low 
values. Normalization of genes with a geometric mean of positive and negative 
controls along with housekeeping genes work well across the dynamic range of 
gene expression. 
4.4.6 Limitations of this model system 
RNA-Seq results were validated with the nCounter® gene expression assay. 
However, serotonergic RN46A cells used in this thesis are a very simplistic 
model to identify gene expression changes. In order to understand if gene 
expression effects observed in this model are relevant to mood disorders or the 
action of mood stabilizer drugs, we would need to validate the results in a more 
complex system such as rodents and eventually humans. It is also important to 
examine whether the observed mRNA regulation by VPA and lithium translate 




direction, by investigating potential protein expression changes in the brain 
tissues of rodents exposed to VPA.  
4.5 Summary of the chapter 
 A subset of 24 DEGs identified by RNA-Seq after VPA exposure of RN46A 
cells were selected as validation set.  
 Twelve of these genes validated with NanoString nCounter® assay in 
independent cell culture experiments. 
 Gene expression between the nCounter® and RNA-Seq platforms had the 
same direction of up- or down-regulation however, the magnitude of 
expression was variable. 
 Increasing the concentration of lithium in cell culture validation 
experiments resulted in the discovery of four genes that showed 
differential expression. 
 These four genes appeared to be co-regulated by lithium and VPA and 
these may be relevant to mood regulation or the therapeutic action of 
these drugs. 
 The mood stabilizer LTG had no obvious effects on expression of the 




Chapter 5  
Gene regulation by HDAC inhibitors 
 
5.1 Introduction 
In the previous chapter, I showed that VPA regulated many genes. It is well-
recognized that VPA has a range of pharmacological properties, including 
HDAC inhibition (HDACi) (Section 1.7). HDAC inhibitors cause chromatin 
changes which regulate gene expression. In this chapter, I examined how the 
HDACi activity of VPA regulated expression of the validated genes. I 
hypothesize that the observed gene expression changes triggered by VPA are 
due to its HDAC inhibition properties. Histone deacetylases (HDACs) can be 
classified into four classes based on their structure: class I, II (a, b), III and IV. 
VPA inhibits HDAC 1, 2, 3 and 8 of class I (Gottlicher et al., 2001; Phiel et al., 
2001). In order to test the above hypothesis, the effects of several different 
HDACi on expression of the genes identified in Chapter 5 were evaluated, using 
the same cell culture model system. These experiments were designed to 
demonstrate whether compounds with HDAC properties like VPA could 
mediate similar gene expression changes, and whether the gene expression 
changes were specific to certain classes of HDACi. The compounds used in these 
experiments are detailed below. 
5.1.1 Valpromide 
Valpromide (VPD), an amide derivative of valproic acid was synthesized by 
Carraz in 1962 for anticonvulsant properties. VPD is marketed as Depamide® by 
Sanofi-Aventis and is prescribed as monotherapy or conjunctive therapy for 




in epileptic patients (Lambert et al., 1971; Lambert et al., 1975; Lambert et al., 
1966). The VPD has antimanic properties and has been shown to be effective for 
the maintenance phase of BD (Emrich et al., 1980; Lambert, 1984; Lambert & 
Venaud, 1992; Lambert & Venaud, 1987; Pużyński & Kłosiewicz, 1984). VPD is a 
VPA prodrug; in humans, it is biotransformed by hydrolysis into VPA on first-
pass through the liver (Bialer, 1991). This drug has shown greater efficacy for 
seizure control than the parent compound VPA (Tasso et al., 2004). Animal 
studies have shown VPD to be more potent as well as non-teratogenic (Bialer, 
1991; Radatz et al., 1998). Moreover, VPD lacks the HDACi properties of VPA 
(Eyal et al., 2005; Gurvich et al., 2004; Phiel et al., 2001). It was included in this 
study to help identify which genes are regulated by VPA, through non-HDACi 
mechanisms of action.  
5.1.2 Trichostatin A 
Trichostatin A (TSA) is an HDAC inhibitor of class I and II. It was the first natural 
hydroxamate identified as HDACi (Yoshida et al., 1990) and causes histone 
hyperacetylation and chromatin remodelling (Langley et al., 2005). Multiple 
studies show TSA influences processes that are implicated in BD. For instance, 
TSA can protect dopaminergic neurons by increasing GDNF and BDNF 
expression in astrocytes (Wu et al., 2008), a key target for mood stabilizers 
(Grande et al., 2010; Mai et al., 2002). It increased BDNF expression in the 
amygdala, which is associated with anxiety-like behaviours (You et al., 2014). It 
also augmented the antidepressant activity of fluoxetine in mice (Schmauss, 
2015). Cognitive impairment is associated with BD (Calafiore et al., 2018; 
Munkholm et al., 2018; Rybakowski, 2016) and TSA rescued long-term memory 
impairment in animal models (Korzus et al., 2004). Dysfunctions in HPA axis 
have been associated with BD (section 1.2.2), and TSA can influence stress 




(Weaver et al., 2004). It was included in this study to examine which of the VPA-
regulated genes are responsive to a class I/IIa HDAC inhibition.  
5.1.3 CI994 
CI994 or tacedinaline is a benzamide originally developed as an anticonvulsant 
(Lelieveld et al., 1985). It can target class I HDACs and mostly HDAC 1 and 3 
isoforms (Loprevite et al., 2005). It has anti-tumour properties (el-Beltagi et al., 
1993; LoRusso et al., 1996) and can induce apoptosis, G1 cell cycle arrest and 
inhibit proliferation (Zhou et al., 2018). CI994 has been reported to inhibit 
HDAC1 at IC50 of 0.9 µM, HDAC2 at 0.9µM, HDAC 3 at 1.2µM and HDAC8 at 
>20mM (Moradei et al., 2007) and was used as an HDAC1 inhibitor in this study.  
5.1.4 RGFP966 
RGFP966 is a carboxamide which inhibits HDAC3 (class I). It has selectivity for 
HDAC3 (IC50 of 0.08µM) over HDAC1 and HDAC2 and does not inhibit other 
HDACs up to 15µM (Malvaez et al., 2013). It was selected as an HDAC3 inhibitor 
in this study.  
5.1.5 PCI34051 
PCI34051 was selected as an HDAC8 inhibitor (class I) in this study. It has high 
selectivity for HDAC8 (HDAC8 IC50 = 10 nM) over other HDAC s 1, 2, 3, 6, and 
10, and influences calcium signalling through PLCγ1 activation and calcium-
induced apoptosis (Balasubramanian et al., 2008).  
5.1.6 Tubastatin A 
Tubastatin A is a hydroxamate which inhibits HDAC6 (class IIb). It protected 




chosen in this study for better selectivity than the parent compound tubacin, also 
a HDAC6 inhibitor (Butler et al., 2010).  
5.2 Methods 
5.2.1 Cell culture and NanoString assay 
Differentiated RN46A cells were exposed to VPA, VPD, TSA and selective 
HDAC 1, 3, 8 and 6 inhibitors for 72 hours as described in section 2.2.2. The study 
was done in two separate nCounter® assays (Figure 5.1 and Figure 5.2). In this 
chapter, we focus only on VPA-, VPD-, TSA-treated and untreated cells from the 
first run (Run1). Except the water-soluble drugs VPA and lithium, rest of the 
drugs were first dissolved in DMSO to prepare the stock (Table 2.3) and were 
diluted with cell culture medium to achieve the required concentration for the 
drug exposure experiments. A custom CodeSet for 26 genes was prepared by 
NanoString Technologies, Inc. (Seattle, Washington, USA) for nCounter® 
experiment, containing a mixture of capture and reporter probes for all genes. 
This CodeSet was used for both runs. In Run1, differentiated RN46A cells were 
exposed to 0.5mM VPA, 0.5mM VPD and 30nM TSA (as well as Li and LTG). 
The Li and LTG results were discussed in the previous chapter and we focus on 
the remaining compounds from Run1 in this chapter, along with Run2 
(described below). Total RNA was extracted from drug-exposed and untreated 
cells after 72 hours with Zymogen RNA miniprep column as described in section 
2.2.3.2. Total RNA from four independent cell culture experiments was sent to 
New Zealand Genomics Limited (Dunedin, New Zealand) for nCounter® 
mRNA gene expression assay, and raw and normalized mRNA counts were 





Figure 5.1 Cell culture design and nCounter® gene expression assay for 
Run1.  Differentiated RN46A cells were exposed to 0.5mM VPA, 0.5mM VPD 
and 30nM TSA along with 0.5% DMSO cell control. 100nM total RNA was 
mixed with the custom CodeSet; reporter and capture probes hybridized to the 
target and optical barcodes were read by the digital analyser. Greyed out 
circles indicate Li and LTG exposures, which were analysed previously in 
chapter 4. 
 
In the second run (Run2), differentiated RN46A cells were exposed to 0.5mM 
VPA, 0.5mM VPD, 0.57µM CI994, 0.08µM RGFP966, 0.01µM PCI34051 and 
0.015µM tubastatin A (as well as 2mM Li). The concentration used for the 
additional compounds was guided by the IC50 stated by the manufacturer (Table 
5.1). As stated in the previous chapter, the cell culture medium volume was 
doubled in Run2 to avoid the acidic medium issue observed in earlier RNA-Seq 
and nCounter® Run1 cell culture experiments. Total RNA was extracted from 
drug-exposed and untreated cells after 72 hours with Zymogen RNA miniprep 




culture experiments was sent to New Zealand Genomics Limited (Dunedin, New 
Zealand) for nCounter® mRNA gene expression assay and raw and normalized 
mRNA counts were returned for analysis. 
 
Figure 5.2 Cell culture design and nCounter® gene expression assay for 
Run2.  Differentiated RN46A cells were exposed to 0.5mM VPA, 0.5mM VPD, 
0.57µM CI994, 0.08µM RGFP966, 0.01µM PCI34051 and 0.015µM tubastatin A 
(tubaA) along with 0.5% DMSO cell control. 100nM total RNA was mixed with 
the custom CodeSet; reporter and capture probes hybridized to the target and 
optical barcodes were read by the digital analyser. Greyed out circle indicate Li 
exposure, which was analysed in chapter 4.  
 
Raw and normalized nCounter® mRNA count data were analysed with 
nSolverTM and NanoStringDiff. Data analysis methods with nSolverTM and 
















CI994 HDAC1 0.57 Class 1 HDAC inhibitor with 
IC50 of 0.9, 0.9, 1.2, and >20 μM 
for human HDAC 1, 2, 3, and 8 
(Moradei et al., 2007). 
RGFP966 HDAC3 0.08 Exhibits no effect on other 
HDAC (up to 15 μM) (Malvaez 
et al., 2013). 
PCI34051 HDAC8 0.01 Exhibits >200-fold selectivity 
over other HDAC 
(Balasubramanian et al., 2008). 
Tubastatin A HDAC6 0.015 No other HDAC (Butler et al., 
2010). 
1For each of the HDAC inhibitors listed here, their IC50 concentration as 
mentioned on the supplier website [AbMole Bioscience (Houston, TX, USA)] 
was used for cell culture experiments. Any other HDAC targets reported has 







The gene expression results of nSolver™ and NanoStringDiff for Run1 (VPA, 
VPD and TSA exposure) are presented first, followed by the gene expression 
results of nSolver™ and NanoStringDiff for Run2 (VPA, VPD and selective 
HDAC inhibitors).  
5.3.1 Run1: Differential gene expression with VPA, VPD and TSA  
Log2FC and p-value for the 24 genes after exposure of RN46A cells to VPA, VPD 
and TSA treatment are shown in Table 5.2 for nSolverTM and Table 5.3 for 
NanoStringDiff algorithms. Genes with Log2FC > 0.5 and p-value <0.05 were 
considered to be differentially expressed (DEG). One notable thing was the 
exceptionally high log2 fold change observed with NanoStringDiff for genes 
with low mRNA counts (Table 5.3). For example, VPD treatment did not affect 
LINGO1 expression; nSolver™ analysis showed 0.65 LFC whereas 
NanoStringDiff showed 182.95 LFC which was inaccurate. NanoStringDiff could 
not compute correct log2 fold change for low mRNA counts therefore, for 
NanoStringDiff analysis genes with inaccurate log2 fold change even with p-val 
< 0.05 were not considered significant.  
Twelve genes were differentially altered in response to VPA as identified with 
both nSolverTM and NanoStringDiff; seven of these were upregulated which 
include CDKN1C, LSP1, MMP13, MPP3, PAK3, SNAP91, VGF and ZCCHC12, 
and LSP1 was downregulated. MAOB and WNT6 were identified as upregulated 
only with nSolverTM, and NGFR and SERPINB2 were identified as upregulated 
only with NanoStringDiff. The remaining 12 genes, although originally selected 
on the basis of either differential expression in RNA-Seq analysis or, because of 





CDKN1C and WNT6 were upregulated, and MMP13 and SERPINB2 were 
downregulated by VPD as identified with both nSolverTM (Table 5.2) and 
NanoStringDiff (Table 5.3). Differential gene expression changes observed with 
VPD were not always in the same direction as VPA. Both VPA and VPD 
upregulated CDKN1C and WNT6. However, VPA upregulated MMP13 and 
SERPINB2 whereas both genes were downregulated by VPD.  
MMP13 and VGF were upregulated whereas ZCCHC12 was downregulated in 
response to TSA as identified with both nSolverTM (Table 5.2) and NanoStringDiff 
(Table 5.3). NOTCH3 was upregulated and SHANK3 was downregulated by TSA 
as identified with NanoStringDiff only and not with nSolver ™. As observed 
earlier with VPD, direction of change for all the affected genes was not the same 
between TSA and VPA exposure. VPA upregulated ZCCHC12 and SHANK3 
















VPA VPD TSA 
Log2FC pvalue2 Log2FC pvalue2 Log2FC pvalue2 
SNAP91 143.26 ± 9.77 230.51 ± 11.62 173.60±9.02 107.60±23.93 0.69 1.20E-04 0.28 9.60E-03 -0.45 1.20E-01 
CDKN1C 46.70 ± 6.01 135.59 ± 6.73 81.56 ±8.05 58.12 ±11.13 1.55 1.50E-04 0.81 9.80E-04 0.3 1.70E-01 
ADAM23 1.31 ± 0.41 7.14 ± 1.47 3.70 ±2.47 3.99 ±2.0 2.47 2.20E-04 1.12 2.00E-01 1.38 9.90E-02 
VGF 22.73 ± 6.45 111.87 ± 33.3 27.11 ±9.58 51.84 ±9.04 2.3 5.80E-04 0.23 5.70E-01 1.23 9.30E-03 
MPP3 27.87  ± 4.23 78.36  ± 17.39 31.83 ±4.07 34.35 ±7.89 1.47 7.30E-04 0.2 2.70E-01 0.28 2.60E-01 
LSP1 167.31  ± 5.19 87.86  ± 11.24 148.89 ±29.32 122.31 ±16.57 -0.94 2.10E-03 -0.2 3.30E-01 -0.47 2.80E-02 
ZCCHC12 33.68  ± 9.89 86.28  ± 7.44 31.37 ±10.99 12.97 ±5.54 1.41 5.20E-03 -0.14 7.20E-01 -1.47 2.10E-02 
PAK3 93.46  ± 19.31 176.60  ± 34.48 86.31±13.46 88.06 ±12..9 0.92 7.30E-03 -0.1 6.50E-01 -0.07 7.40E-01 
LINGO1 3.38  ± 1.27 13.86  ± 2.3 5.22 ±2.15 3.08 ±2.25 2.17 1.10E-02 0.65 3.00E-01 -0.44 6.10E-01 
WNT6 1.91  ± 0.78 5.77  ± 2.17 8.31±3.99 2.52 ±1.52 1.6 2.20E-02 2.05 1.70E-02 0.21 7.70E-01 
MAOB 15.09  ± 3.55 24.15  ± 2.79 18.77 ±3.74 20.41 ±4.99 0.72 4.10E-02 0.33 2.90E-01 0.44 2.00E-01 
MMP13 2652.46  ± 964.2 4593.43  ± 784.9 1118.03 ±367.87 4534.64 ±721.70 0.85 4.40E-02 -1.24 1.80E-02 0.84 4.70E-02 
SERPINB2 12.37  ± 4.63 22.20  ± 5.18 3.74 ±2.4 18.67 ±4.93 0.92 6.90E-02 -2 4.50E-02 0.66 1.60E-01 
ERBB3 118.14  ± 22.07 157.60  ± 25.59 110.57 ±20.89 111.06 ±8.82 0.42 8.90E-02 -0.09 6.90E-01 -0.07 7.20E-01 
CACNA1B 14.00  ± 8.04 28.71  ± 2.44 24.17 ±5.48 11.71 ±4.77 1.43 1.40E-01 1.15 2.00E-01 0.04 9.60E-01 
NGFR 7.90  ± 4.97 13.99  ± 2.31 6.68 ±2.86 6.46 ±4.98 1.16 1.50E-01 -0.04 9.60E-01 -0.27 7.50E-01 
SPR 17.95  ± 7.26 27.53  ± 9.01 22.30 ±7.98 23.66 ±12.7 0.66 1.50E-01 0.34 4.40E-01 0.26 6.70E-01 
LZTS1 1.91  ± 0.78 1.10  ± 0.15 1.30 ±0.25 1.76 ±1.24 -0.67 1.70E-01 -0.44 3.40E-01 -0.26 6.80E-01 
ADGRB2 8.93  ± 4.76 12.53  ± 2.23 11.13 ±1.98 12.26 ±4.99 0.68 2.40E-01 0.51 3.60E-01 0.52 4.30E-01 
IGF2 2.66  ± 1.88 1.19 ± 0.17 1.64 ±0.75 7.27 ±6.29 -0.83 2.40E-01 -0.49 5.00E-01 0.82 5.40E-01 
NOTCH3 3.49  ± 2.36 6.22  ± 2.99 6.65 ±3.55 11.52 ±8.09 1.03 2.90E-01 1.14 2.40E-01 1.46 2.80E-01 















VPA VPD TSA 
Log2FC pvalue2 Log2FC pvalue2 Log2FC pvalue2 
CNTN1 2.44  ± 0.97 3.46  ±01.9 4.49 ±3.31 3.05 ±1.31 0.36 6.30E-01 0.49 6.00E-01 0.29 6.60E-01 
GNAI1 1.07  ± 0.11 1.10  ± 0.15 1.29 ±0.26 1.06 ±0.06 0.04 7.70E-01 0.26 2.30E-01 0 9.80E-01 
G6PD 2930.74  ± 78.41 3007.88  ± 98.64 2974.08 ±49.53 2624.79 ±65.62       
MAPK6 2460.07  ± 67.3 2397.87  ± 80.7 2423.12 ±40.36 2746.48 ±67.03       
1Base mean control, base mean VPA, base mean VPD and base mean TSA refer to the mean of normalized counts from four replicates each of 
untreated, VPA-treated, VPD-treated and TSA-treated samples in Run1, respectively. Fold difference between the untreated vs VPA-treated, 
untreated vs VPD-treated and untreated vs TSA-treated are shown. Ranked by VPA p-values.  






















VPA VPD TSA 
Log2FC pvalue2 Log2FC pvalue2 Log2FC pvalue2 
VGF 22.73 ± 6.45 111.87 ± 33.3 27.11 ±9.58 51.84 ±9.04 2.44 8.40E-10 0.1 7.60E-01 1.22 1.40E-06 
CDKN1C 46.70 ± 6.01 135.59 ± 6.73 81.56 ±8.05 58.12 ±11.13 1.6 3.70E-07 0.8 3.50E-05 0.29 1.80E-01 
MPP3 27.87  ± 4.23 78.36  ± 17.39 31.83 ±4.07 34.35 ±7.89 1.59 9.70E-06 0.05 8.60E-01 0.22 3.90E-01 
ZCCHC12 33.68  ± 9.89 86.28  ± 7.44 31.37 ±10.99 12.97 ±5.54 1.47 3.10E-05 -0.22 4.70E-01 -1.71 7.10E-07 
LINGO1 3.38  ± 1.27 13.86  ± 2.3 5.22 ±2.15 3.08 ±2.25 7.18 5.60E-05 182.95 9.10E-01 -20.36 6.40E-01 
LSP1 167.31  ± 5.19 87.86  ± 11.24 148.89 ±29.32 122.31 ±16.57 -0.96 1.20E-03 -0.2 2.20E-01 -0.47 3.10E-03 
PAK3 93.46  ± 19.31 176.60  ± 34.48 86.31±13.46 88.06 ±12..9 0.94 3.50E-03 -0.15 4.50E-01 -0.1 6.00E-01 
ADAM23 1.31 ± 0.41 7.14 ± 1.47 3.70 ±2.47 3.99 ±2.0 26.47 7.50E-03 0.91 4.90E-01 55.41 5.50E-01 
SNAP91 143.26 ± 9.77 230.51 ± 11.62 173.60±9.02 107.60±23.93 0.7 1.30E-02 0.26 5.00E-02 -0.45 1.40E-02 
CACNA1B 14.00  ± 8.04 28.71  ± 2.44 24.17 ±5.48 11.71 ±4.77 1.06 1.80E-02 0.68 6.30E-02 -0.81 7.70E-02 
MMP13 2652.46  ± 964.2 4593.43  ± 784.9 1118.03 ±367.87 4534.64 ±721.70 0.79 1.80E-02 -1.25 1.20E-05 0.77 2.70E-04 
SERPINB2 12.37  ± 4.63 22.20  ± 5.18 3.74 ±2.4 18.67 ±4.93 0.94 5.00E-02 -23.83 5.10E-05 0.48 2.30E-01 
MAOB 15.09  ± 3.55 24.15  ± 2.79 18.77 ±3.74 20.41 ±4.99 0.84 6.10E-02 0.25 5.40E-01 0.43 2.50E-01 
WNT6 1.91  ± 0.78 5.77  ± 2.17 8.31±3.99 2.52 ±1.52 24.83 7.90E-02 26.73 3.80E-02 -16.82 4.90E-01 
NGFR 7.90  ± 4.97 13.99  ± 2.31 6.68 ±2.86 6.46 ±4.98 0.96 1.10E-01 -0.96 2.90E-01 -1.44 1.30E-01 
SHANK3 13.88  ± 7.86 22.50  ± 4.72 21.07 ±0.87 8.75 ±2.73 0.73 1.20E-01 0.44 2.60E-01 -1.18 2.00E-02 
NOTCH3 3.49  ± 2.36 6.22  ± 2.99 6.65 ±3.55 11.52 ±8.09 21.65 1.30E-01 18.26 5.30E-01 22.4 1.00E-02 
SPR 17.95  ± 7.26 27.53  ± 9.01 22.30 ±7.98 23.66 ±12.7 0.67 1.40E-01 0.16 6.70E-01 0.29 4.20E-01 



















VPA VPD TSA 
Log2FC pvalue2 Log2FC pvalue2 Log2FC pvalue2 
GNAI1 1.07  ± 0.11 1.10  ± 0.15 1.29 ±0.26 1.06 ±0.06 0.33 2.60E-01 3.7 2.50E-01 0.33 2.60E-01 
LZTS1 1.91  ± 0.78 1.10  ± 0.15 1.30 ±0.25 1.76 ±1.24 -23.42 3.20E-01 -0.33 3.60E-01 -16.82 3.60E-01 
ADGRB2 8.93  ± 4.76 12.53  ± 2.23 11.13 ±1.98 12.26 ±4.99 0.49 4.20E-01 0.07 9.10E-01 0.16 7.70E-01 
IGF2 2.66  ± 1.88 1.19 ± 0.17 1.64 ±0.75 7.27 ±6.29 22.17 4.80E-01 2.48 4.40E-01 26.85 6.30E-01 
CNTN1 2.44  ± 0.97 3.46  ±01.9 4.49 ±3.31 3.05 ±1.31 23.43 6.10E-01 -15.98 6.00E-01 17.52 6.00E-01 
G6PD 2930.74  ± 78.41 3007.88  ± 98.64 2974.08 ±49.53 2624.79 ±65.62 
      
MAPK6 2460.07  ± 67.3 2397.87  ± 80.7 2423.12 ±40.36 2746.48 ±67.03 
      
1Base mean control, base mean VPA, base mean VPD and base mean TSA refer to the mean of normalized counts from four replicates each of 
untreated, VPA-treated, VPD-treated and TSA-treated samples in Run1, respectively. Fold difference between the untreated vs VPA-treated, 
untreated vs VPD-treated and untreated vs TSA-treated are shown. Ranked by VPA p-values.  




5.3.2 Run2: Differential gene expression with VPA, VPD and selective HDAC 
inhibitors  
As shown in the previous section, VPA-regulated genes MMP13, VGF and ZCCHC12 
showed differential expression when exposed to TSA thus implying HDAC inhibition 
might be important in regulation of these genes. VPA is a major class I HDACi so in 
this second NanoString run selective HDAC 1, 3 and 8 inhibitors were used. The 
nCounter® assay was designed with 24 genes and we had to use the same CodeSet in 
Run2 therefore, we examined the effect of specific HDAC inhibitors on expression of 
the same 24 gene panel.  
The HDAC6 gene was shown to be upregulated by VPA, in RN46A cells, in a prior 
qPCR study from our laboratory (Deng, 2011) therefore, I also examined the effect of 
HDAC6 inhibition on VPA-regulated genes.  
Log2FC and p-value for 24 genes after exposure of RN46A cells to VPA, VPD and 
CI994 treatments are shown in Table 5.4 for nSolverTM and Table 5.5 for 
NanoStringDiff. Log2FC and p-value for 24 genes after exposure of RN46A cells to 
RGFP966, PCI34051 and tubastatin A treatments are shown in Table 5.6 for nSolver™ 
and Table 5.7 for NanoStringDiff. Genes with Log2FC > 0.5 and p-value <0.05 were 
considered to be DEG. Fourteen genes showed differential expression after exposure 
to VPA as identified with both nSolverTM and NanoStringDiff. These were WNT6, 
LSP1, SERPINB2, MAOB, NGFR, ZCCHC12, NOTCH3, ADGRB2, MMP13, PAK3, 
ADAM23, SNAP91, CACNA1B and CNTN1. In addition, MPP3 and VGF were 
identified as DEG with NanoStringDiff only. 
After exposure to the VPD, only LSP1 was a DEG as identified with both nSolverTM 
(Table 5.4) and NanoStringDiff (Table 5.5). However, WNT6, NOTCH3, ADAM23, 





After exposure to CI994, only MAOB was a DEG as identified with both nSolverTM 
(Table 5.4) and NanoStringDiff (Table 5.5). However, SHANK3 was identified as a 
DEG with nSolverTM only, and CDKN1C, NGFR, WNT6 and ZCCHC12 were identified 
as DEG with NanoStringDiff only. 
No DEG were identified for PCI34051 and tubastatin A exposure using either or both 
analysis tools. However, for RGFP966 exposure, SNAP91 was identified as 













Base mean VPD1 
 
Base mean CI9941 
nSolver™ 
VPA VPD CI994 
Log2FC pvalue2 Log2FC pvalue2 Log2FC pvalue2 
WNT6 26.70  ± 3.42 149.11 ± 8.65 55.41 ±17.14 46.90 ±11.48 1.97 1.70E-04 0.76 5.60E-02 0.53 1.40E-01 
LSP1 698.88  ± 49.72 286.21  ± 21.02 229.45 ±28.71 589.43 ±23.48 -1.26 2.80E-04 -1.55 9.40E-04 -0.24 5.70E-02 
SERPINB2 1349.53  ± 67.66 2715.63  ± 182.07 1305.58 ±363.04 1761.81 ±384.84 1 4.70E-04 -0.1 7.60E-01 0.34 2.90E-01 
MAOB 67.00  ± 11.19 376.47  ± 23.73 64.88 ±8.91 138.75 ±23.76 2.27 1.50E-03 -0.01 9.70E-01 0.9 1.40E-02 
NGFR 64.65  ± 16.67 381.39  ± 57.17 98.63 ±33.46 111.72 ±7.21 2.33 1.60E-03 0.51 2.20E-01 0.69 7.40E-02 
ZCCHC12 28.09  ± 11.78 198.19  ± 31.0 30.43 ±7.65 59.88 ±12.09 2.35 7.20E-03 0.18 6.40E-01 0.84 1.00E-01 
NOTCH3 27.59  ± 9.5 118.30  ± 24.31 51.77 ±28.42 36.14 ±5.10 1.64 7.30E-03 0.58 3.50E-01 0.28 3.70E-01 
ADGRB2 55.48  ± 12.95 241.17  ±  12.21 72.21 ±28.52 71.14 ±9.8 1.88 7.90E-03 0.28 5.30E-01 0.3 2.60E-01 
MMP13 3312.56  ± 384.81 5281.11  ± 300.02 2207.43 ±609.44 4243.11 ±368.70 0.68 1.40E-02 -0.62 1.30E-01 0.36 7.10E-02 
PAK3 29.12  ± 3.11 82.33 ± 7.39 44.48 ±10.71 44.83 ±3.5 1.09 1.50E-02 0.45 1.20E-01 0.43 1.50E-02 
ADAM23 37.50  ± 15.26 148.26  ± 27.84 74.90 ±32.48 40.83 ±11.76 1.66 1.60E-02 0.79 1.50E-01 0.12 7.60E-01 
SNAP91 33.98  ± 11.26 89.24  ± 16.86 66.56 ±30.94 23.70 ±7.71 1.07 1.80E-02 0.67 2.60E-01 -0.36 2.80E-01 
GNAI1 1.33  ± 0.25 18.23  ± 11.98 1.16 ±0.17 1.00 ± 0.0 3.63 2.30E-02 1.9 1.10E-01 0.47 7.00E-01 
CACNA1B 1.33  ± 0.25 29.80  ± 17.19 24.37 ±21.44 1.00 ± 0.0 2.25 2.80E-02 1.78 1.80E-01 -1.41 2.50E-01 












Base mean VPD1 
 
Base mean CI9941 
nSolver™ 
VPA VPD CI994 
Log2FC pvalue2 Log2FC pvalue2 Log2FC pvalue2 
LZTS1 1.33  ± 0.25 12.61  ± 6.41 9.35 ±11.76 1.00 ± 0.0 3.54 3.10E-02 1.83 3.60E-01 -0.23 8.50E-01 
ERBB3 1.33  ± 0.25 15.53  ± 3.41 1.53 ±0.44 1.00 ± 0.0 3.09 4.60E-02 1 4.00E-01 1.85 1.10E-01 
SHANK3 1.33  ± 0.25 2.18  ± 1.34 2.30 ±1.78 1.00 ± 0.0 2.11 5.90E-02 1.29 3.90E-01 1.7 1.80E-03 
SPR 25.28  ± 7.08 47.36  ± 7.44 56.39 ±47.97 22.23 ±5.68 0.59 6.10E-02 0.5 5.90E-01 -0.16 6.50E-01 
LINGO1 1.33 ± 0.25 10.72 ± 11.07 25.79 ±25.73 1.00 ± 0.0 2.27 6.60E-02 2.65 1.00E-01 -1.09 3.50E-01 
MPP3 3.32 ± 2.80 23.32 ± 14.69 37.30 ±37.83 3.53 ±3.58 1 1.10E-01 1.26 2.60E-01 -0.33 4.50E-01 
VGF 44.57 ± 33.22 123.27 ± 47.85 86.71 ±29.54 69.35 ±11.62 1.31 1.20E-01 0.93 2.30E-01 0.69 3.20E-01 
IGF2 1.33 ± 0.25 5.91 ± 3.42 11.35 ±11.49 1.00 ± 0.0 2.62 1.70E-01 2.96 2.20E-01 0.58 6.10E-01 
CDKN1C 113.15 ± 19.3 133.84 ± 25.09 162.22 ±36.3 61.78 ±23.42 0.18 5.10E-01 0.47 1.40E-01 -0.81 1.20E-01 
G6PD 1831.49 ± 63.59 1811.36 ± 36.98 2102.39 ±103.74 1611.69 ±69.43       
MAPK6 2398.69 ± 85.08 2423.39 ± 50.05 2092.30 ±106.51 2727.41 ±114.56       
1Base mean control, base mean VPA, base mean VPD and base mean CI994 refer to the mean of normalized counts from three replicates each of 
untreated, VPA-treated, VPD-treated and CI994-treated samples in Run2, respectively. Fold difference between the untreated vs VPA-treated, 
untreated vs VPD-treated and untreated vs CI994-treated are shown. Ranked by VPA p-values.  







Table 5.5 NanoStringDiff generated log2 fold change and p-values for VPA, VPD and CI994-treated RN46A cells in Run2. 
 Base mean Base mean   NanoStringDiff 
Gene 
Name 
Control1 VPA1 Base mean VPD1 
Base mean 
CI9941 
VPA VPD CI994 
     Log2FC pvalue2 Log2FC pvalue2 Log2FC pvalue2 
MAOB 67.00  ± 11.19 376.47  ± 23.73 64.88 ±8.91 138.75 ±23.76 2.35 1.10E-14 -0.04 9.20E-01 0.97 1.80E-04 
NGFR 64.65  ± 16.67 381.39  ± 57.17 98.63 ±33.46 111.72 ±7.21 2.41 1.20E-11 0.54 1.10E-01 0.7 6.60E-03 
WNT6 26.70  ± 3.42 149.11 ± 8.65 55.41 ±17.14 46.90 ±11.48 2.18 1.70E-10 0.88 1.90E-02 0.68 3.30E-02 
ZCCHC12 28.09  ± 11.78 198.19  ± 31.0 30.43 ±7.65 59.88 ±12.09 2.45 1.00E-09 0.05 9.00E-01 0.85 6.60E-03 
ADGRB2 55.48  ± 12.95 241.17  ±  12.21 72.21 ±28.52 71.14 ±9.8 1.98 2.10E-09 0.35 3.20E-01 0.34 2.10E-01 
LSP1 698.88  ± 49.72 286.21  ± 21.02 229.45 ±28.71 589.43 ±23.48 -1.27 4.00E-07 -1.57 5.60E-07 -0.24 1.90E-01 
GNAI1 1.33  ± 0.25 18.23  ± 11.98 1.16 ±0.17 1.00 ± 0.0 29.67 4.70E-07 24.19 4.20E-01 182.48 6.30E-01 
LZTS1 1.33  ± 0.25 12.61  ± 6.41 9.35 ±11.76 1.00 ± 0.0 23.92 5.20E-07 26.21 5.00E-04 -159.23 5.00E-01 
ERBB3 1.33  ± 0.25 15.53  ± 3.41 1.53 ±0.44 1.00 ± 0.0 27.19 5.30E-07 24.73 3.90E-01 26.51 1.00E-02 
NOTCH3 27.59  ± 9.5 118.30  ± 24.31 51.77 ±28.42 36.14 ±5.10 1.83 7.40E-06 0.77 4.20E-02 0.35 2.80E-01 
SERPINB2 1349.53  ± 67.66 





1 1.10E-05 -0.05 8.80E-01 0.38 9.70E-02 
ADAM23 37.50  ± 15.26 148.26  ± 27.84 74.90 ±32.48 40.83 ±11.76 1.76 1.30E-05 0.85 1.80E-02 0.09 7.70E-01 
CACNA1B 1.33  ± 0.25 29.80  ± 17.19 24.37 ±21.44 1.00 ± 0.0 3.74 2.00E-05 3.39 2.00E-06 -25.01 2.10E-01 
LINGO1 1.33 ± 0.25 10.72 ± 11.07 25.79 ±25.73 1.00 ± 0.0 34.66 1.60E-04 25.94 2.90E-09 -179.2 6.10E-01 
IGF2 1.33 ± 0.25 5.91 ± 3.42 11.35 ±11.49 1.00 ± 0.0 29.59 2.70E-04 30.49 8.50E-07 -64.37 4.90E-01 





 Base mean Base mean   NanoStringDiff 
Gene 
Name 
Control1 VPA1 Base mean VPD1 
Base mean 
CI9941 
VPA VPD CI994 
     Log2FC pvalue2 Log2FC pvalue2 Log2FC pvalue2 
SNAP91 33.98  ± 11.26 89.24  ± 16.86 66.56 ±30.94 23.70 ±7.71 1.2 1.90E-03 0.83 2.30E-02 -0.4 2.30E-01 
MMP13 3312.56  ± 384.81 





0.67 5.70E-03 -0.58 5.50E-02 0.36 6.90E-02 
CNTN1 346.69  ± 58.78 598.86  ± 67.27 351.12 ±93.5 468.11 ±81.9 0.78 8.20E-03 0.02 9.40E-01 0.43 7.20E-02 
MPP3 3.32 ± 2.80 23.32 ± 14.69 37.30 ±37.83 3.53 ±3.58 1.63 1.20E-02 2.18 1.20E-05 -0.29 6.60E-01 
VGF 44.57 ± 33.22 123.27 ± 47.85 86.71 ±29.54 69.35 ±11.62 1.28 2.50E-02 0.77 2.70E-02 0.48 1.90E-01 
SHANK3 1.33  ± 0.25 2.18  ± 1.34 2.30 ±1.78 1.00 ± 0.0 27.37 3.50E-02 20.6 6.20E-01 141.35 6.40E-01 
SPR 25.28  ± 7.08 47.36  ± 7.44 56.39 ±47.97 22.23 ±5.68 0.68 8.70E-02 0.92 1.60E-02 -0.18 6.00E-01 
CDKN1C 113.15 ± 19.3 133.84 ± 25.09 162.22 ±36.3 61.78 ±23.42 0.22 5.10E-01 0.5 1.30E-01 -0.77 9.00E-03 
 G6PD 1831.49 ± 63.59 1811.36 ± 36.98 2102.39 ±103.74 1611.69 ±69.43             
 MAPK6 2398.69 ± 85.08 2423.39 ± 50.05 2092.30 ±106.51 
2727.41 
±114.56 
            
1Base mean control, base mean VPA, base mean VPD and base mean CI994 refer to the mean of normalized counts from three replicates each of 
untreated, VPA-treated, VPD-treated and CI994-treated samples in Run2, respectively. Fold difference between the untreated vs VPA-treated, 
untreated vs VPD-treated and untreated vs CI994-treated are shown. Ranked by VPA p-values.  






















PCI34051 RGFP966 Tubastatin A 
Log2FC pvalue Log2FC pvalue Log2FC pvalue 
ADAM23 37.50  ± 
15.26 
40.83 ±11.76 36.04 ±4.71 29.15 ±2.68 -0.03 9.20E-01 -0.34 3.90E-01 -0.18 6.20E-01 
ADGRB2 55.48  ± 
12.95 
71.14 ±9.8 39.87 ±2.16 46.78 ±7.29 -0.38 1.90E-01 -0.37 2.30E-01 -0.17 5.30E-01 
CACNA1B 1.33  ± 0.25 1.00 ± 0.0 2.98 ±2.03 3.85 ±3.95 0.65 3.40E-01 -0.07 9.30E-01 0.61 4.70E-01 







-0.06 7.80E-01 -0.14 6.90E-01 0.17 6.00E-01 







-0.1 6.70E-01 0.02 9.40E-01 -0.03 8.90E-01 
ERBB3 1.33  ± 0.25 1.00 ± 0.0 1.01 ± 0.01 1.04 ± 0.05 0.72 4.20E-01 0.78 3.90E-01 -0.94 3.90E-01 
GNAI1 1.33  ± 0.25 1.00 ± 0.0 1.01 ± 0.01 1.04 ± 0.05 0.85 3.80E-01 -0.45 6.30E-01 0.7 5.90E-01 
IGF2 1.33 ± 0.25 1.00 ± 0.0 1.01 ± 0.01 1.04 ± 0.05 0.38 6.60E-01 1.09 3.20E-01 1.52 2.80E-01 
LINGO1 1.33 ± 0.25 1.00 ± 0.0 1.01 ± 0.01 1.04 ± 0.05 -0.26 7.90E-01 0.31 7.70E-01 0.38 8.00E-01 








-0.02 8.90E-01 -0.07 4.90E-01 -0.05 6.80E-01 
LZTS1 1.33  ± 0.25 1.00 ± 0.0 1.01 ± 0.01 1.04 ± 0.05 0.13 9.30E-01 -0.49 6.10E-01 1.12 4.30E-01 




83.41 ±7.06 67.20 ±2.37 0.25 2.40E-01 0.16 4.20E-01 0.03 8.70E-01 








-0.03 8.80E-01 -0.05 7.90E-01 -0.07 7.20E-01 



















PCI34051 RGFP966 Tubastatin A 
Log2FC pvalue Log2FC pvalue Log2FC pvalue 
NGFR 64.65  ± 
16.67 
111.72 ±7.21 65.11 ±9.24 63.42 ±6.12 -0.01 9.80E-01 -0.03 9.10E-01 0.01 9.60E-01 
NOTCH3 27.59  ± 9.5 36.14 ±5.1 28.04 ±4.12 27.38 ±8.57 -0.01 9.80E-01 0.06 8.40E-01 0.01 9.90E-01 
PAK3 29.12  ± 
3.11 
44.83 ±3.5 34.22 ±7.76 27.93 ±2.94 0.09 7.20E-01 0.08 7.70E-01 -0.03 8.50E-01 








0.1 2.90E-01 0.09 5.10E-01 0.04 7.60E-01 
SHANK3 1.33  ± 0.25 1.00 ± 0.0 1.01 ± 0.01 1.04 ± 0.05 1.07 2.50E-01 0.86 3.80E-01 0.16 8.70E-01 
SNAP91 33.98  ± 
11.26 
23.7 ±7.71 20.2 ±2.62 33.97 ±9.95 -0.53 1.10E-01 -0.3 3.00E-01 0.01 9.80E-01 
SPR 25.28  ± 
7.08 
22.23 ±5.68 30.5 ±18.92 34.38 ±23.25 -0.06 9.30E-01 0.07 8.30E-01 0.05 9.50E-01 
VGF 44.57 ± 
33.22 
69.35 ±11.62 43.7 ±24.56 40.28 ±18.02 -0.01 9.90E-01 0.12 8.50E-01 0.02 9.80E-01 
WNT6 26.70  ± 
3.42 
46.9 ±11.48 34.61 ±5.21 25.79 ±10.97 0.2 2.70E-01 0.17 3.00E-01 -0.09 8.30E-01 
ZCCHC12 28.09  ± 
11.78 
59.88 ±12.09 31.57 ±7.75 27.6 ±3.49 0.11 7.80E-01 0.33 4.10E-01 0.06 8.60E-01 








      








      
1Base mean control, base mean RGFP966, base mean PCI34051 and base mean TubaA refer to the mean of normalized counts from three 
replicates each of untreated, RGFP966-treated, PCI34051-treated and TubaA-treated samples in Run2, respectively. Fold difference between the 
untreated vs RGFP966-treated, untreated vs PCI34051-treated and untreated vs TubaA-treated are shown.  





Table 5.7 NanoStringDiff generated log2 fold change and p-values for PCI34051, RGFP966 and tubastatin A-treated RN46A 

















RGFP966 PCI34051 Tubastatin A 
Log2F
C 
pvalue2 Log2FC pvalue2 Log2FC pvalue2 
ADAM23 37.50  ± 15.26 40.83 ±11.76 36.04 ±4.71 29.15 ±2.68 -0.42 1.10E-01 -0.09 7.10E-01 -0.28 2.60E-01 
ADGRB2 55.48  ± 12.95 71.14 ±9.8 39.87 ±2.16 46.78 ±7.29 -0.37 1.30E-01 -0.4 9.00E-02 -0.17 4.40E-01 
CACNA1B 1.33  ± 0.25 1.00 ± 0.0 2.98 ±2.03 3.85 ±3.95 0.4 7.60E-01 1.4 1.60E-01 1.37 1.90E-01 
CDKN1C 113.15 ± 19.3 61.78 ±23.42 108.99 ±14.93 131.33 ±35.25 -0.09 7.10E-01 -0.05 8.10E-01 0.21 3.30E-01 
CNTN1 346.69  ± 
58.78 
468.11 ±81.9 321.45 ±41.38 336.56 ±51.07 0.02 9.00E-01 -0.11 5.40E-01 -0.04 8.30E-01 
ERBB3 1.33  ± 0.25 1.00 ± 0.0 1.01 ± 0.01 1.04 ± 0.05 22.97 5.20E-01 19.19 7.40E-01 -1.65 5.20E-01 
GNAI1 1.33  ± 0.25 1.00 ± 0.0 1.01 ± 0.01 1.04 ± 0.05 2.37 5.10E-01 158.96 6.30E-01 14.39 6.40E-01 
IGF2 1.33 ± 0.25 1.00 ± 0.0 1.01 ± 0.01 1.04 ± 0.05 -15.26 5.30E-01 0.33 4.80E-01 -14.87 5.40E-01 
LINGO1 1.33 ± 0.25 1.00 ± 0.0 1.01 ± 0.01 1.04 ± 0.05 23.47 4.40E-01 -156.8 7.20E-01 19.2 4.30E-01 
LSP1 698.88  ± 
49.72 
589.43 ±23.48 692.38 ±51.26 674.84 ±59.23 -0.07 5.60E-01 -0.02 9.10E-01 -0.05 6.80E-01 
LZTS1 1.33  ± 0.25 1.00 ± 0.0 1.01 ± 0.01 1.04 ± 0.05 -16.82 4.40E-01 -14.89 5.90E-01 4.77 6.20E-01 
MAOB 67.00  ± 11.19 138.75 ±23.76 83.41 ±7.06 67.20 ±2.37 0.19 3.10E-01 0.27 1.70E-01 0.01 9.60E-01 
MMP13 3312.56  ± 
384.81 
4243.11 ±368.7 3263.86 ±575.0 3162.33 
±461.37  
-0.05 7.50E-01 -0.02 8.90E-01 -0.07 6.40E-01 
MPP3 3.32 ± 2.80 3.53 ±3.58 5.80 ±6.77 4.74 ±3.48 -1.05 1.50E-01 0.32 5.50E-01 0.16 7.80E-01 
NGFR 64.65  ± 16.67 111.72 ±7.21 65.11 ±9.24 63.42 ±6.12 -0.04 8.40E-01 -0.03 9.10E-01 -0.04 8.50E-01 
NOTCH3 27.59  ± 9.5 36.14 ±5.1 28.04 ±4.12 27.38 ±8.57 0.14 6.20E-01 0.03 9.20E-01 0.07 8.00E-01 





















RGFP966 PCI34051 Tubastatin A 
Log2F
C 
pvalue2 Log2FC pvalue2 Log2FC pvalue2 
SERPINB2 1349.53  ± 
67.66 
1761.81 ±384.84 1443.4 ±784.99 1391.45 ±1.47 0.1 4.10E-01 0.09 4.30E-01 0.04 7.20E-01 
SHANK3 1.33  ± 0.25 1.00 ± 0.0 1.01 ± 0.01 1.04 ± 0.05 -1.89 6.00E-01 2.1 5.80E-01 -0.33 4.90E-01 
SNAP91 33.98  ± 11.26 23.7 ±7.71 20.2 ±2.62 33.97 ±9.95 -0.29 2.70E-01 -0.6 3.20E-02 0.01 9.60E-01 
SPR 25.28  ± 7.08 22.23 ±5.68 30.5 ±18.92 34.38 ±23.25 0.13 6.40E-01 0.17 6.00E-01 0.36 3.00E-01 
VGF 44.57 ± 33.22 69.35 ±11.62 43.7 ±24.56 40.28 ±18.02 -0.04 9.30E-01 -0.1 7.80E-01 -0.16 6.60E-01 
WNT6 26.70  ± 3.42 46.9 ±11.48 34.61 ±5.21 25.79 ±10.97 0.26 3.20E-01 0.29 2.70E-01 0.02 9.50E-01 
ZCCHC12 28.09  ± 11.78 59.88 ±12.09 31.57 ±7.75 27.6 ±3.49 0.28 2.70E-01 0 1.00E+00 -0.12 6.50E-01 
 G6PD 1831.49 ± 
63.59 
1611.69 ±69.43 1820.51 ±105.79 1830.16 
±72.83 
            
 MAPK6 2398.69 ± 
85.08 
2727.41 ±114.56 2418.69 ±146.33 2401.21 
±93.49 
            
1Base mean control, base mean RGFP966, base mean PCI34051 and base mean TubaA refer to the mean of normalized counts from three 
replicates each of untreated, RGFP966-treated, PCI34051-treated and TubaA-treated samples in Run2, respectively. Fold difference between the 
untreated vs RGFP966-treated, untreated vs PCI34051-treated and untreated vs TubaA-treated are shown.  




5.3.3 Reproducibility of gene expression findings for VPA across all 
experiments 
To summarize the gene expression findings from this Chapter, as well as the original 
RNA-Seq analysis, all data are collated in Table 5.8. 




RNA-Seq analysis nCounter® analysis 








ADAM23         
ADGRB2    - - -   
CACNA1B -    -    
CDKN1C       - - 
CNTN1   --  - -   
ERBB3     - -   
GNAI1     - -   
IGF2 -  -  - - - - 
LINGO1       -  
LSP1         
LZTS1    - - -   




MMP13         
MPP3       -  
NGFR     - -   
NOTCH3     - -   
PAK3         
SERPINB2     -    
SHANK3     - - -  
SNPA91         
SPR - - - - - - - - 
VGF       -  
WNT6      -   






Histone deacetylases (HDACs) play an important role in mood regulation. They 
regulate synaptic plasticity and facilitate long term potentiation (Authement et 
al., 2016; Ganai et al., 2016; Kim et al., 2012; Perry et al., 2017). HDAC dysfunctions 
have been reported in the pathophysiology of BD (Hobara et al., 2010; Network 
and Pathway Analysis Subgroup of Psychiatric Genomics Consortium, 2015). 
VPA is a known inhibitor of class I HDACs (Gottlicher et al., 2001; Phiel et al., 
2001) and to a lesser extent inhibits class IIa HDACs (Gurvich et al., 2004). RNA-
Seq analysis (Chapter 3) yielded evidence of gene expression changes in 
response to VPA treatment and so a subset of these genes were validated with 
the nCounter® gene expression assay (Chapter 4). To investigate the role of 
HDAC inhibition in regulation of gene expression, these 24 shortlisted genes 
were examined in this Chapter, using the same probe-set and nCounter® 
platform, after exposure of RN46A cells to the pan-HDAC inhibitor TSA, 
selective HDAC inhibitors CI994, RGFP966, PCI34051, tubastatin A and VPD, the 
non-HDAC inhibitory analog of VPA. The nCounter® gene expression assay 
was carried out for VPA, VPD, TSA and selective HDAC inhibitors along with 
untreated RN46A cells. Data analysis was performed with two analysis tools; 
nSolverTM which uses Welch’s t-test for DE analysis and NanoStringDiff which 
uses the GLM model for DE analysis. Comparative analysis of gene expression 
changes with VPA, VPD, TSA and CI994 exposures with both nSolver™ and 
NanoStringDiff are presented in Figure 5.3. Genes with low expression were not 
included in this figure. 
Not all gene expression changes reported in Chapter 4 were replicated with VPA, 
although there was good correlation. There were differences between Run1 and 
Run2, but overall there was very good reproducibility between runs, with all the 
changes in the same direction, although the magnitude of change was higher in 




medium issue observed in RNA-Seq and Run1 cell culture which possibly 
resulted in higher counts and higher observed magnitude of expression change.  
Overall, gene expression changes due to VPA were highly reproducible across 
runs, with variation due to the software used for analysis (Figure 5.3). We 
considered genes observed in both runs, with either or both analyses, to be 
reproducible and of high confidence: These were LSP1, MAOB, MMP13, MPP3, 
PAK3, SNAP91, SERPINB2, VGF, WNT6 and ZCCHC12. A second group of genes 
appeared less robust, and of lower confidence: ADAM23, ADGRB2, CACNA1B, 
CDKN1C, CNTN1, NGFR and NOTCH3. Other genes which were identified as 
DEG only with NanoStringDiff included MPP3, SERPINB2 and VGF. 
For VPD exposure, more differences were seen between Run1 and Run2 as well 
as nSolver™ and NanoStringDiff. LSP1 was the only DEG identified in both runs 
with both analysis tools. Other high confidence genes were CDKN1C, MMP13 
and WNT6. These genes were regarded as low confidence, less robust genes: 
ADAM23, CACNA1B, MPP3, NOTCH3, SNAP91 and VGF. Comparing DEG 
between VPA and VPD exposures, MMP13 and SERPINB2 were downregulated 





Figure 5.3 Summary of nCounter® Run1 and Run2 gene expression data for 
17 DEGs for VPA, VPD, TSA and CI994. Green and red arrows indicate up- 
and downregulation respectively, and DEG as identified with both nSolver™ 
and NanoStringDiff. Blue arrow indicates upregulated DEGs as identified only 
with NanoStringDiff. The size of the arrows is proportional to the log2 fold 
change. 
 
For HDAC inhibitors, changes were only observed with TSA and CI994. TSA 
upregulated MMP13 and VGF, and downregulated ZCCHC12. CI994 
upregulated MAOB, NGFR, WNT6 and ZCCHC12. Notably, the direction of 
change differed between these two drugs for ZCCHC12; VPA and CI994 
upregulated ZCCHC12 whereas TSA downregulated it.  
The results from Chapter 4 and Chapter 5 revealed important insights into the 
mechanism of action of VPA. Comparing gene expression with VPA, other 
HDACs and non-HDACi analogue of VPA shows that the pattern of DEGs 




regulated DEGs are only partly shared with another HDAC inhibitor or VPD. 
VPA has multiple mechanisms of action, with both its weak HDACi and other 
properties being important.  
No change in gene expression was observed with HDAC3 (RGFP966) and 
HDAC8 inhibitors (PCI34051), which suggested that the HDAC3 and HDAC8 
inhibitory activity of VPA was not relevant to the gene expression effects 
observed in this RN46A assay system. In these experiments, VPA was used at a 
concentration of 0.5mM. VPA is known to inhibit HDAC3 at an IC50 of 1mM 
(Gurvich et al., 2004), and HDAC1 with IC50 of 0.4mM, concentrations which are 
within the therapeutic range in humans (Phiel et al., 2001). VPA inhibited 
HDAC2 at an IC50 which has been variously established as 0.54 ± .22 mM 
(Gottlicher et al., 2001) or 0.8mM (Gurvich et al., 2004). These results, and the 
lower reported IC50 for HDAC1 inhibition by VPA, suggested inhibition of 
HDAC1 was most relevant to gene regulation in RN46A cells. 
5.4.1 Genes regulated through HDAC inhibition by VPA, TSA and CI994 
Eight genes were regulated by HDACi activity as evidenced by both nCounter® 
runs (Table 5.2, Table 5.3, Table 5.4 and Table 5.5). ZCCHC12 was upregulated 
by VPA and CI994 but downregulated by TSA. Similarly, SHANK3 was 
upregulated by CI994 but downregulated by TSA. CDKN1C, MAOB, NGFR and 
WNT6 were upregulated by CI994 only. MMP13 and VGF were upregulated by 
TSA only. These eight genes are further discussed in terms of regulation by 
HDAC inhibitors.  
5.4.1.1 ZCCHC12 is HDAC1 inhibited 
ZCCHC12, previously known as SIZN1, encodes a zinc finger domain protein, 
which is a downstream effector of bone morphogenetic protein (BMP) signalling 




signalling (Li et al., 2009). It was upregulated by VPA and CI994 but 
downregulated by TSA. Other studies show its upregulation by class I/II HDAC 
inhibitors TSA and vorinostat, and HDAC6 inhibitor panobinostat (LaBonte et 
al., 2009; Song et al., 2014; Swiss et al., 2011). The regulation of ZCCHC12 may be 
through HDAC1 inhibition since ZCCHC12 is a transcriptional co-activator of 
CREB and AP-1 (Li et al., 2009) and HDAC1 deacetylates CREB and reduces 
transcription (Canettieri et al., 2003). This gene may also be mediating the effects 
of VPA on AP-1. VPA increases the AP-1 DNA binding activity and expression 
of AP-1 regulated genes (Asghari et al., 1998; Chen et al., 1997; Chen, Yuan, et al., 
1999).  
ZCCHC12 is expressed in human and mouse brain (Table 4.3) and variants in 
this gene have been associated with X-linked mental retardation (Cho, Bhat, et 
al., 2008), which suggests it has an important role in the brain. However, not 
much is known about its role in BD. Given that ZCCHC12 is a transcriptional 
coactivator of CREB, which regulates synaptic plasticity (Meng, 2005) and is 
linked to depression (Blendy, 2006; Gass & Riva, 2007), this gene is a strong 
candidate for involvement in mood regulation, and worthy of closer examination 
in this regard. 
5.4.1.2 MAOB is HDAC1 inhibited 
MAOB encodes for an enzyme present in the outer mitochondrial membrane 
which catalyses oxidative deamination of bioactive amines. It was upregulated 
by VPA and CI994 but not by TSA suggesting HDAC1 regulation. MAOB 
expression is downregulated in the nucleus accumbens and prefrontal cortex 
through cocaine-induced HDAC activity using the chromatin-remodelling sig-
1R/Emerin/BAF/HDAC complex, and both sig-1R and emerin can interact with 
HDAC1 (Tsai et al., 2015). This complex recruitment is facilitated through Sp3 
transcription factor which binds to GC boxes on MAOB core promoter (Wong et 




Won et al., 2002). Use of MAOB inhibitors to treat depression (Finberg & Rabey, 
2016) makes this gene a strong candidate for further examination in the biology 
of mood regulation.  
5.4.1.3 MMP13 is regulated by both HDAC inhibition and non-HDAC inhibition 
MMP13 encodes for a matrix metalloproteinase involved in extracellular matrix 
cleavage and regulation of cell-cell communication. It was upregulated by VPA, 
VPD, TSA and CI994 showing both HDAC-dependent and independent 
regulation. HDAC inhibitors regulate MMPs in multiple cells and can reduce 
MMP13 expression in chondrocytes to reduce inflammation (Young et al., 2005). 
Class I HDACs VPA, TSA and MS-275 regulate MMP13 expression in 
chondrocytes (Culley et al., 2013). ING2-HDAC1-mSin3A corepressor complex 
has been shown to regulate its expression in colon cancer (Kumamoto et al., 
2009). Taken together, these results suggest MMP13 is regulated through HDAC 
inhibition and it may therefore be a good candidate gene to study in relation to 
the therapeutic action of VPA. Dysfunctions in neurodevelopment and neural 
plasticity in mood disorders may involve MMPs through ECM remodelling 
(Lubbers et al., 2014) and it would be interesting to further investigate a potential 
role of this MMP in mood regulation.  
5.4.1.4 VGF 
VGF encodes a nerve growth factor-inducible neurosecretory protein, which 
regulates neurite growth, synaptic plasticity and neurogenesis (Alder et al., 2003; 
Thakker-Varia et al., 2014; Thakker-Varia et al., 2007). It was upregulated by VPA 
and TSA, but not VPD suggesting HDAC inhibition is involved in its regulation. 
VGF was increased in response to the HDACi vorinostat and panobinostat in 
colon cancer cells (LaBonte et al., 2009), and was upregulated in HDAC1/2 double 
knockout cells (Jamaladdin et al., 2014). HDAC2 is associated with the VGF 
promoter region and s-nitrosylation causes HDAC2 dissociation from the 




inhibitors suggests that VGF is regulated through HDAC2 inhibition. VGF was 
decreased in post-mortem brain in BD patients and involved in the mood 
stabilizing action of lithium (Thakker-Varia et al., 2010). All these results suggest 
VGF is a strong candidate gene with potential roles in mood disorders, and 
perhaps in the therapeutic action of VPA.  
5.4.1.5 SHANK3 
SHANK3 encodes a member of the postsynaptic master scaffolds, which connect 
neurotransmitters, ion channels and other proteins with the actin cytoskeleton 
and G-protein coupled pathways. These are involved in synapse formation, 
dendritic spine maturation and maintenance (Arons et al., 2016). SHANK3 had 
low expression and was upregulated by VPA in Run2 as identified with 
NanoStringDiff only. It was upregulated by CI994 (nSolver™) and 
downregulated by TSA (NanoStringDiff). SHANK3 upregulation has been 
shown to be HDAC dependent in SA001-derived neurons where VPA and TSA 
increased the mRNA levels (Darville et al., 2016). The neurological functions and 
prior findings of HDAC involvement in SHANK3 regulation make this an 
intriguing candidate gene for a role in the treatment of mood disorders. 
Unfortunately, the NanoString validation and HDACi results reported here were 
not consistent enough to add strong support for such a role. 
5.4.1.6 NGFR 
NGFR encodes for the neurotrophin receptor which involves ligand binding and 
signalling in the brain. It regulates neuronal differentiation and survival, and 
axonal elongation (Dechant & Barde, 2002). It was upregulated by VPA and 
CI994 but downregulated by TSA. TSA induced its expression in hepatoma cells 
(Chiba et al., 2004). Taken together, these results suggest that HDAC inhibitors 
regulate expression of this gene. As discussed in Chapter 4, both NGF and NGFR 
have been implicated in the biology of BD, MDD and SCZ (Dwivedi et al., 2009; 




may regulate synaptic plasticity, which is essential in BD pathophysiology (de 
Sousa et al., 2014; Duman, Aghajanian, et al., 2016; Machado-Vieira, 2018). Even 
though the HDACi results are inconsistent, this gene has interesting neuronal 
functions and may be relevant to the therapeutic properties of VPA. 
5.4.1.7 CDKN1C 
CDKN1C or p57 encodes a tumour suppressor protein which inhibits G1 cyclin/ 
cyclin-dependent kinases and negatively regulates cell proliferation (Pateras et 
al., 2009). An imprinted gene on chromosome 11 along with IGF2 and H19, 
CDKN1C is expressed from the maternal allele and loss of imprinting has been 
linked with Beckwith-Wiedermann syndrome (Algar et al., 2000; Lam et al., 1999). 
It was upregulated by VPA and VPD as identified with both analysis tools in 
Run1, and was downregulated by CI994 as identified with NanoStringDiff only. 
Several studies have shown that HDAC inhibitors upregulate CDKN1C 
(Blagosklonny, Algar, et al., 2009; Cucciolla et al., 2007), and it is a target of 
HDAC1 and HDAC2 (Zupkovitz et al., 2006). Inhibition of class I or class II 
HDACs led to increased CDKN1C levels (Seo et al., 2008) and SP1 transcription 
factor directly interacted with CDKN1C promoter (Cucciolla et al., 2007). 
Chromatin-modifying drugs such as 5’-aza and TSA de-repress the imprinting 
and upregulated CDKN1C in mice which was associated with the early-life 
adversity (Van de Pette et al., 2017). Taken together, these results suggest that 
VPA regulates CDKN1C through HDAC1 inhibition, but that a non-HDACi 
effect may also be occurring (given the VPD result). CDKN1C needs further 
examination as it has interesting functions and may have novel functions 
relevant to the therapeutic actions of VPA.  
5.4.1.8 WNT6 
WNT6 encodes a member of the WNT family, which is secreted signalling 
protein involved in growth, differentiation, migration, cell fate determination, 




WNT6 was upregulated by VPA, VPD and CI994. This is in contrast to the 
expectation that genes would be regulated either through HDACi or VPD but 
not both. HDAC inhibitors modulate the Wnt signalling pathway (Gotze et al., 
2014; Jang & Jeong, 2018). CI-994 upregulated Wnt signalling through TCF4 
induction in human neural progenitor cells (Hennig et al., 2017). Although Wnt 
proteins are known to be regulated by HDAC inhibitors (Ye et al., 2009), not 
much is known about WNT6 regulation. HDAC1 together with Nemo-like kinase 
(NLK) could negatively regulate Wnt signalling (Masoumi et al., 2017). 
Dysregulated Wnt signalling has been implicated in mood disorders (Sani et al., 
2012) and altered mRNA and protein expression of Wnt pathway members have 
been observed in BD and SCZ (Hoseth et al., 2018b) however, nothing is known 
about the role of WNT6 in this regard. Several members of the Wnt signalling 
pathway were differentially expressed in response to VPA in our RNA-Seq 
analysis, such as WNT3, WNT10A and WNT11 among others. WNT6 is a good 
candidate gene with interesting functions and needs to be further examined in 
relation to the mood stabilizing effects of VPA. 
5.4.2 HDAC6 inhibition has no effect on VPA-regulated genes 
The HDAC6 inhibitor tubastatin A was included in my study to examine the 
effect of HDAC6 inhibition on VPA-regulated genes. Our analysis showed 
tubastatin A treatment did not affect any of the VPA-regulated genes. HDAC6 
deacetylates α-tubulin (Hubbert et al., 2002) and hsp-90 (de Zoeten et al., 2011) 
and has shown to be neuroprotective (Perry et al., 2017). HDAC6 mRNA levels 
were decreased in both BD and MDD (Hobara et al., 2010) and HDAC6 inhibitors 
show an antidepressant phenotype in mouse (Jochems et al., 2013). In a prior 
study done in our laboratory, HDAC6 expression was measured by qPCR in 
response to VPA over several time points in RN46A cells (Deng, 2011). In that 




expression peaked at 12 hours and reduced over 72 hours. In contrast, my RNA-
Seq analysis showed HDAC6 were poorly expressed in RN46A cells and VPA 
treatment for 72 hrs did not affect the expression of HDAC6. Other studies show 
VPA inhibited HDAC6 at >20mM in vitro (Phiel et al., 2001). Taken together, these 
results suggest HDAC6 does not play a role in the expression of this subset of 
VPA-regulated genes in my experimental system. 
5.4.3 Does HDAC inhibition regulate mood? 
It is commonly speculated that VPA regulates mood through its non-histone 
targets and HDACi is responsible for its antitumor properties (Gould et al., 2002; 
Lagace et al., 2004). VPA has a complex pharmacology making it difficult to 
establish the genes that regulate mood. Other HDAC inhibitors have been shown 
to have antimanic effects (Arent et al., 2011; Machado-Vieira et al., 2010). VPA, 
SAHA and MS-275 can normalize mania-like behaviour in CLOCKΔ19 mouse 
model (Roybal et al., 2007). Increased HDAC activity in the prefrontal cortex is 
seen in mania rodent models which can be partially reversed with lithium, VPA 
and NaB (Stertz et al., 2013). VPA DEGs from my study, both HDAC inhibited 
and non-HDAC regulated, have neuronal functions and are implicated in mood 
disorders. This suggests that genes altered by VPA are important to mood 
biology, irrespective of their mechanism of regulation.  
5.4.4 Limitations of the study 
In this study, selective HDAC inhibitors 1, 3, 8 and 6 were used. No selective 
HDAC2 inhibitor was commercially available at the time of this study so none 
was included. Other studies used HDAC2 siRNA for studying the effects of 
HDAC2 on gene expression and showed VPA inhibited HDAC2 which resulted 
in similar gene expression changes (Hrzenjak et al., 2006; Kramer et al., 2003; 




affect the expression of genes for HDAC 1, 2, 3, 5, 10 and 11 however, HDAC7 
expression was downregulated. My RNASeq analysis showed that HDAC6 and 
HDAC9 were expressed at very low levels, whereas HDAC4 and HDAC8 
expression was not detected in untreated RN46A cells. The nCounter® analysis 
was an indirect test of HDAC inhibition and direct measurement of each HDAC 
activity and inhibition would give a better idea of HDAC activity and percentage 
inhibited. This could be done with colorimetric or fluorometric assays such as 
the Epigenase™ HDAC Activity/Inhibition Direct Assay Kit (EpiGentek, NY, 
USA).  
The selective HDAC1 inhibitor CI994 used in this study inhibits HDAC2 at a 
higher concentration of 0.9 µM (Moradei et al., 2007). Although it was used at 
0.05µM in my experiments, and should have inhibited only HDAC1, I did not 
test for specific inhibition of only HDAC1 at this concentration. IC50 can vary with 
different targets and measurement of IC50 of HDACi would have confirmed that 
the selected concentration was appropriate for inhibition of the HDAC isoforms. 
HDAC inhibitors have been shown to behave differently in cell lines compared 
to in vitro experiments. Even with similar selectivity and potency, the HDAC6 
inhibitors tubacin and tubastatin A were found to regulate different genes (Ota 
et al., 2017).  
One main limitation of this work is that we have not directly shown VPA 
regulated gene expression through HDAC inhibition. Examination of the 
patterns of histone marks such as H3K9, H3K14, and H3K4me3 at specific 
promoters for the genes identified in this study, before and after exposure to 
VPA, would be a useful next step in further understanding the mechanisms of 




5.5 Summary of the chapter 
In this chapter, we explored whether other HDAC inhibitors have similar effects 
to VPA and showed pan-HDAC inhibitor TSA and HDAC1 inhibitor CI994 
affected expression of some of the VPA-regulated genes. Some of the genes 
selected in the nCounter® panel were regulated by only VPA and VPD 
suggesting VPA has other HDAC independent gene targets as well. It will be 
interesting to see how these non-histone targets are regulated. Some of the VPA-
regulated genes were HDAC1 inhibited, but not HDAC3 or -8 showing that 
HDAC1 is the major target of VPA in my experimental model system. HDAC2 
has been reported to be altered by VPA so some of the genes could be possibly 
regulated through HDAC2 inhibition and this needs to be further explored. 
CI994 can inhibit both HDAC1 and HDAC2 but at different concentrations; we 
used a concentration that inhibited HDAC1 only. Examining gene regulation by 
CI994 at different concentrations, preferably concentrations which inhibit both 
HDAC1/2, might reveal similar gene expression profiles to VPA, and raise the 
possibility that this drug too may have mood stabilizing properties. The complex 
gene regulatory pattern of VPA has suggested multiple mechanisms of action 




Chapter 6  
Differential alternative splicing analysis in 
response to VPA  
 
In Chapter 3, the RNA-Seq analysis yielded 224 DEGs (DESeq2) in response to 
VPA. In this chapter, I looked at the impact of VPA exposure on alternative 
splicing (AS) in RN46A cells. A significant proportion of the coding genome (50-
80%) in mammals undergoes AS (Lander et al., 2001; Modrek et al., 2001) thus, 
AS consideration is crucial to RNA-Seq data analysis. HDAC inhibitors have 
been shown to influence AS in cells (Hnilicová et al., 2011; Zhang et al., 2012) and 
VPA could influence AS due to its HDAC inhibition properties. 
6.1 Introduction 
AS is the rearrangement of exons in a transcript sequence to generate multiple 
isoforms. When a gene is transcribed, pre-mRNA is produced which contains 
exons, introns, 5' and 3' UTRs. Introns are spliced out to generate mature mRNA. 
During the splicing, some exons can be removed to produce different isoforms 
of the same gene. These isoforms may encode unique proteins which can have 
specific functions. There are five major types of AS events (Figure 6.1) which 
include exon skipping, intron retention, mutually exclusive exons, and the use 
of different 5' and 3' splice sites. Other AS events can include different first or 





Figure 6.1 Seven types of alternative splicing events. Dark blue boxes 
represent constitutively spliced exons. Red, light-blue and green boxes show 
alternatively spliced exons. Image adapted with permission from (Park et al., 
2018).  
 
AS can be differentially regulated across tissues during development and 
disease, referred as differential alternative splicing. In disease, AS may lead to 
truncated proteins with loss of function (Jyotsana & Heuser, 2017). AS plays an 
important role in disease biology and has been implicated in mental disorders 
(Domschke et al., 2009; Glatt et al., 2011; Shamir et al., 2007; Watanuki et al., 2008).  
RNA-Seq can identify AS events, both known and novel, in a genome-wide 
fashion. It can recognize transcripts and splice variants of each gene with an 
objective view of the transcriptome. RNA-Seq has greater sensitivity and higher 
dynamic range than the older approach of microarrays, and allows detection of 
novel splicing events (Zhao et al., 2014). However, microarrays with probes 




compared to RNA-Seq (Nazarov et al., 2017; Romero et al., 2018). To identify low-
abundance isoforms and splice junctions with RNA-Seq, deep sequencing is 
required (Li et al., 2014). 
6.1.1 AS events in psychiatric disorders 
Differential splicing events linked to the disease have been identified for 
Mendelian disorders, but are difficult to identify for complex traits. Several risk 
genes and variants have been identified for psychiatric disorders BD, MDD and 
SCZ, and shared variants for these as well. About 40-90% of variation in complex 
traits are associated with non-coding regions and 50% of these are involved in 
AS regulation (Williams et al., 2012). ANK3, a gene widely replicated in BD 
GWAS studies, has a single-nucleotide variant (SNV) rs414282526 located in 
splice site of a 54-nucleotide exon, and its minor allele results in loss-of-function 
and exclusion of this exon from ANK3 transcript, which is thought to be 
protective for BD and SCZ (Hughes et al., 2016). Twelve differentially spliced 
transcripts have been identified in the dorsolateral prefrontal cortex of BD 
patients, with one of them being serine/arginine-rich splicing factor 5 (SRSF5) 
(Akula et al., 2014). 
Variants in Neuregulin-ErB pathway are associated with BD, MDD and SCZ. The 
T allele of rs10748842 and G allele of rs6584400 in the neuregulin 3 (NRG3) have 
been associated with BD and SCZ respectively (Kao et al., 2010; Paterson et al., 
2017). Alternative splicing of NRG3 leads to expression of 15 transcripts 
classified further into four classes I-IV based on exon homology (Kao et al., 2010). 
Isoform-specific changes in NRG3 expression have been observed in BD, MDD 
and SCZ. Expression of the NRG3 transcript, class I was elevated both in BD, 
MDD and SCZ, whereas the brain-specific isoforms II increased in BD and 
isoform III increased in MDD (Paterson et al., 2017). Similarly, NRG1 variant 




(Paterson et al., 2014) and behavioural abnormalities were observed in transgenic 
mice expressing NRG1-IV (Papaleo et al., 2016). NRG1 receptor ERBB4 includes 
variants in exon 16 and 26 generating major and minor variants, and the shift 
from major-to-minor variant results in lower ERBB4 signalling. This major-to-
minor splicing shift has been observed in the dorsolateral prefrontal cortex of 
SCZ patients (Joshi et al., 2014; Law et al., 2007) and a recent study showed the 
magnitude of major-to-minor shift increases from MDD to BD to SCZ patients 
(Chung et al., 2018). Taken together, these studies suggest alternative splicing 
may play an important role in the complex biology of neuropsychiatric 
disorders.  
6.2 Methods 
We used the RNA-Seq data generated earlier (Chapter 3) to examine effects of 
VPA on alternative splicing. Briefly, differentiated RN46A cells were exposed to 
0.5mM VPA for 72 hrs in four independent experiments and total RNA extracted 
was used for RNA-Seq as described in section 2.2.5. To analyse RNA-Seq data 
for identification of differential AS events, I made pipelines with different 
downloaded software (Figure 6.2), each of which is described in the following 
subsections. RNA-Seq read mapping and alignment was done as described in 
section 3.2.3. Briefly, reads were mapped using splice-aware STAR aligner 
(Dobin et al., 2013) and aligned to the rat reference genome assembly Rnor6. Bam 
files were then used by each AS tool to identify the differential AS events in 
response to VPA exposure. Cufflinks2 (Trapnell et al., 2012; Trapnell et al., 2010) 
quantified isoform data was used as input for isoformSwitchAnalyzeR (Vitting-
Seerup & Sandelin, 2017). The schematic representation of the different steps and 





Figure 6.2 Flowchart showing the steps and tools used in differential 
alternative splicing analysis. STAR-aligned bam files were used by all three 
exon-centric tools, DEXSeq, junctionSeq and rMATS to predict different AS 
events. The fourth tool, isoformSwitchAnalyzeR used cuffllinks2/cuffdiff2 
quantified isoform counts. 
 
6.2.1 DEXSeq 
DEXSeq v1.20.2, an R package (Anders et al., 2012) was used to identify 
differential AS events with VPA exposure. STAR aligned bam files were used for 
analysis. Two Python scripts were provided with the DEXSeq package; 




created the reduced models for each gene and dexseq_count.py was used to 
tabulate the number of reads mapping to each exonic region in HTSeq format. 
ENSEMBL Rnor6.0 GTF file was used to prepare the annotation. Default analysis 
was performed as suggested in the manual. 
DEXSeq used generalized linear model (GLM) employed in DESeq (Anders et 
al., 2012) to test for differential exon usage and compared it to the null model. 
Exon usage was calculated as the ratio of the number of transcripts from the gene 
containing the exon to the total number of transcripts of the gene. DEXSeq 
modelled count data using negative binomial distribution. Functions from the 
DESeq package were adapted to DEXSeq model to estimate dispersion or 
variability of the data. To normalize for relative sequencing depth across 
samples, size factors were generated using the DESeq2 package. Dispersion 
estimates were calculated using the DESEq2 package. Cox-Reid likelihood 
method (McCarthy, Chen, et al., 2012) was used to calculate per-exon dispersion, 
followed by dispersion-mean calculation and empirical Bayes shrinkage of per-
exon estimate to the fitted values. Differential exon usage was calculated using 
the number of reads mapping to the exon relative to the number of reads 
mapping to the other exons of the gene. The deviances of GLM and null model 
were compared using the chi-square distribution to generate p-values. The p-
values were adjusted using the Benjamini-Hochberg method (Benjamini & 
Hochberg, 1995). An HTML file with the results summarized, expression plots 
and tables was generated for easy visualization of all significant genes 
(Appendix I).  
6.2.2 JunctionSeq 
JunctionSeq v1.5.4, an R package (Hartley & Mullikin, 2016) was used to identify 
significant splicing events with VPA exposure. Default analysis was performed 




QC, analysis and visualization of the results. The Java dependent R package 
QoRTs was first used to prepare the count data from the aligned bam files for 
differential AS analysis with junctionSeq. QoRTs package can identify errors, 
biases and artefacts generated in paired-end RNA-Seq data. QoRTs contained 
two files; the java jar file was used for the data processing and quality check of 
the name-ranked bam files, and companion R package was used to generate the 
tables, figures and plots. QoRTs generated size factors which were used to 
normalize all samples. ENSEMBL Rnor6.0 GTF file was used to generate a 
flattened gff file and novel junctions were added to this flattened gff. Differential 
splicing analysis was done with junctionSeq using the hybrid analysis of 
detecting both differential exon and splicing junction usage simultaneously. An 
HTML file containing the expression summary, plots and tables was generated 
for easy visualization of all significant genes (Appendix I).  
JunctionSeq is similar to DEXSeq in detecting differential exon usage except it 
counts each read pair only once towards exonic regions and splice junctions. It 
first partitions genes into non-overlapping exonic regions and assigns read pairs 
to these to calculate relative expression of each exon and identify splice junctions 
associated with each. It then uses DESeq2 package with specialized GLMs to test 
the differential usage of each exon and splice junction. JunctionSeq uses gene-
level counts instead of the sum of all exonic regions employed by DEXSeq to 
estimate gene-wide expression.  
6.2.3 rMATS 
rMATS v3.2.5 (Shen et al., 2014) was used to find significant splicing events with 
VPA exposure. Default analysis was performed as suggested in the manual and 
described in section 2.1.7.3. AS events were identified from the aligned bam files 
and the annotation provided in the GTF file. rMATS analysed five types of AS 




site (A5SS), alternative 3’ splice site (A3SS) and retained intron (RI). The output 
contained two files for each AS event type; the first file contained splicing output 
with only reads spanning splicing junctions, and the second file contained 
splicing information with the reads spanning splicing junctions and reads on 
target.  
6.2.4 IsoformSwitchAnalyzeR 
IsoformSwitchAnalyzeR v1.3.1, an R package (Vitting-Seerup & Sandelin, 2017) 
was used to analyse isoform switching events from the quantified isoforms 
obtained with the STAR-Cufflinks2 (v2.2.1) output (Trapnell et al., 2012; Trapnell 
et al., 2010). Isoform switching is referred to as the differential usage of 
transcripts or isoforms between conditions. IsoformSwitchAnalyzeR is a new 
package which combined identification of significant splicing events or isoform 
switching with predicted consequences, unlike other available software.  
Default analysis was performed as suggested in the isoformSwitchAnalyzeR 
manual and described in section 2.1.7.4. This package measured isoform usage 
by calculating the isoform fraction (IF) values which are the ratio of the number 
of reads uniquely assigned to a particular isoform and the number of reads 
assigned to the gene. The difference in isoform fraction (dIF) was calculated as 
IF2 (VPA)-IF1 (control). A positive dIF value showed isoform usage was 
increased relative to control, after exposure of cells to VPA.  
The first step of the analysis was identification of isoform switches. Before 
annotation, ORF information was added using the coding sequence information 
from the annotation GTF file. Once the ORFs were known, corresponding amino 
acid and nucleotide sequence were extracted into fasta files. These fasta files 
were uploaded on webservers for the respective databases to obtain the 




(http://lilab.research.bcm.edu/cpat/) (Wang et al., 2013), Pfam protein domains 
(http://pfam.xfam.org/search#tabview=tab1) (Finn et al., 2014) and signalP for 
signal peptides (http://www.cbs.dtu.dk/services/SignalP/) (Petersen et al., 2011); 
these databases were used to add annotation to the isoforms.  
Open reading frame (ORF) analysis and annotated coding sequences (CDS) 
information was used to predict the sensitivity of transcripts to nonsense 
mediated decay (NMD). The identified isoform switches and annotation were 
combined to predict the functional consequences for the isoforms. The R package 
generated plots and summary statistics for easy visualization of results.  
6.3 Results 
A total of 100,234,924 reads were aligned from three VPA-treated samples and 
three untreated samples using the STAR-aligner, and the resulting six bam files 
were analysed for AS events with DEXSeq, junctionSeq and rMATS. The results 
from each package are described below.  
6.3.1 DEXSeq 
To detect the differential exon usage, the logarithm of fold change versus average 
normalized count per exon was plotted (MA plot), and the exons which were 
considered significant marked in red colour; here, the exons with padj < 0.1 were 
selected (Figure 6.3). Exons and genes showing significant differential splicing at 







Figure 6.3 Mean expression versus log2 fold change plot. This figure shows 
the significant exons (at padj<0.1), which were coloured in red. 
  
Table 6.1 Significant exonic regions and genes affected vary according to 
padj.  
Adjusted P-value (padj) Significant Exonic 
Regions 
Genes affected 
0.1 49 31 
0.05 41 26 




Forty-one significant AS events (padj < 0.05) are listed in Table 6.2 which shows 
the gene affected and the significant exons, padj and log2 fold change. 
 
Table 6.2 Differential exon usage between VPA-treated and untreated 
RN46A cells as identified with DEXSeq for padj <0.05. 
Gene name Exons padj log2FC_ 
VPA/CC 
 Gene name Exons padj log2FC_ 
VPA/CC 
TPM1 E015 1.1E-16 -0.98  PPFIBP1 E013 1.0E-03 1.34 
TPM1 E014 5.9E-12 0.93  TMEM59 E001 1.3E-03 -0.29 
ALDOA E011 5.5E-11 -1.03  RTN4 E005 1.4E-03 1.08 
TPM1 E017 4.1E-10 -0.86  MDM2 E014 2.1E-03 -1.22 
SLFN4 E004 7.2E-07 0.53  SLFN4 E002 2.4E-03 0.71 
EPB41 E008 1.2E-06 2.03  DLGAP4 E002 4.9E-03 2.96 
CACNA1G E002 1.6E-06 -1.01  ABCB1A E045 5.1E-03 -0.40 
SPTAN1 E042 1.8E-06 1.50  TPM2 E018 5.1E-03 -0.74 
FLNB1 E018 9.4E-06 1.63  PLCD4 E007 6.2E-03 -2.94 
EPB41 E007 1.1E-05 2.18  AABR07052502.1 E002 8.5E-03 -0.21 
SLFN4 E003 1.1E-04 0.75  AABR07052502.1 E001 8.7E-03 0.39 
SLFN4 E001 1.2E-04 0.83  MYZAP E009 1.1E-02 1.04 
NAP1L1 E014 8.4E-04 -0.24  ASH2L E019 1.8E-02 -0.67 
ASPH E025 8.4E-04 1.16  LOC100174910 E001 1.9E-02 -0.40 
BIN1 E015 8.4E-04 0.89  PCCA E029 3.0E-02 -1.14 
MAP4K4 E026 1.0E-03 -0.38      






To detect differential exon usage, the logarithm of fold change versus average 
normalized count per exon was plotted (MA plot), and the exons which were 
considered significant marked in red colour; here, the exons with padj < 0.1 were 
selected (Figure 6.4). Twenty-two events were higher in control, whereas 31 
events were higher in VPA exposure.  
 
 
Figure 6.4 Mean expression versus log2 fold change plot. Significant hits 





Fifty-five events were identified for differential exon usage between VPA-treated 
and untreated RN46A cells at padj <0.05. Fourteen of these were novel events, 
with respect to the annotation used. The output shows the significant exon or 






Table 6.3 Differential exon usage between VPA-treated and untreated RN46A cells as identified with JunctionSeq for padj 
<0.05. 
Gene Name Exon or Splice 
Junction 




TPM1 E015 1.0E-16 -1.52  AABR07052502.1 E001 6.6E-04 1.10 
KCNH3 N030 2.8E-12 -0.20  SLFN4 E002 7.6E-04 0.76 
TPM1 E014 1.1E-10 0.39  MDM2 E014 1.3E-03 -0.44 
TPM1 E017 2.6E-10 -1.40  PPFIBP1 J049 1.8E-03 -0.81 
TPM1 J036 5.3E-10 -1.62  ABCB1A E032 1.8E-03 -0.43 
ALDOA E011 8.0E-10 -0.43  NAP1L1 E014 2.1E-03 -0.34 
ALDOA J021 1.6E-09 -0.44  BIN1 E015 2.5E-03 1.07 
TPM1 J033 3.9E-08 0.39  S100A6 N006 2.9E-03 0.20 
SLFN4 E004 2.0E-07 0.58  CAPG N019 2.9E-03 0.28 
CACNA1G E002 1.0E-06 0.15  RTN4 E005 3.2E-03 1.21 
TPM1 J034 1.0E-06 -1.58  TPM1 E018 3.5E-03 -1.28 





KIF23 N056 8.0E-06 -1.47  PPFIBP1 E013 3.6E-03 1.21 
EPB41 J035 8.0E-06 2.70  ARHGDIA N014 4.1E-03 -1.96 
PPFIBP1 J050 9.9E-06 1.52  BIN1 J037 4.4E-03 1.46 
EPB41 E007 2.0E-05 2.39  NAP1L1 J029 4.7E-03 -0.38 
PLOD2 J041 2.0E-05 2.87  ANP32A N016 4.7E-03 -2.56 
FLNB E018 3.3E-05 1.87  AABR07015079.1 N002 4.7E-03 1.12 
SLFN4 E001 4.6E-05 0.88  COPG1 N063 6.9E-03 1.84 
SLFN4 E003 4.6E-05 0.79  MDM2 J026 7.4E-03 -0.45 
SLFN4 J012 4.6E-05 0.85  ABCB1A E030 7.7E-03 -0.62 
SLFN4 J013 6.3E-05 0.85  DLGAP4 E002 7.7E-03 3.29 
PPFIBP1 J048 1.3E-04 1.43  NDUFC1 N007 7.7E-03 0.25 
ALDOA N022 1.3E-04 1.38  TMEM59 E001 8.7E-03 -0.27 
EPB41 J032 2.8E-04 2.56  AABR07052502.1 N010 9.8E-03 0.31 
EPB41 J036 4.4E-04 2.27  ABCB1A E033 3.3E-02 -0.40 
FLNB J064 6.5E-04 1.86  ABCB1A J121 4.6E-02 -0.40 





About 18000 exon skipping events were identified with rMATS. Out of these, 
1609 skipped exon events were significant when using reads in junction counts 
and 1624 events were significant when using both splicing junction reads and 
target exon reads (Table 6.4). The inclusion level informed about the alternatively 
spliced region. Higher inclusion levels in skipped exons meant the middle (target 
or cassette) exon is used more. For mutually exclusive exons, 814 significant 
events were identified with junction counts only, and 839 significant were 
identified events with both junction counts and reads on target exon. The same 
number of significant alternative 5’ splice site (A5SS), alternative 3’ splice site 
(A3SS) and retained intron (RI) events were identified with both approaches.  
 
















2532 814 (400:414) 2541 839 (415:424) 
Alternative 
5’ start site 
(A5SS) 
145 32 (18:14) 145 35 (18:17) 
Alternative 
3’ start site 
(A3SS) 
241 56 (26:30) 241 56 (25:31) 
Retained 
intron 
175 54 (26:28) 176 59 (29:30) 
1For significant events, number in parentheses (n1:n2) refer to the number of 






A total of 79377 isoforms from 37263 genes was analysed. The list was filtered 
for poorly expressed isoforms and 41758 transcripts were removed, leaving only 
37619 isoforms for further analysis. Differential isoform usage was calculated 
with the IsoformSwitchAnalyzeR function which used 16476 isoforms for switch 
analysis. 197 putative ORFs were identified and analysed. Domain information 
from the Pfam protein database was added to 177 transcripts. A signal peptide 
from SignalP database was added to five transcripts. The coding potential from 
the CPAT database was added to 197 transcripts. The identified isoform 
information and their annotation were used to predict functional consequence of 
these isoform switches such as coding switching, potential or functional domain 
loss. Fifty-two isoforms in 45 genes were identified at a dIF cutoff of 0.1 (Figure 






Figure 6.5 Volcano plot for isoform switching. This plot shows significant 
isoform switches in red. A higher dIF cut-off results in fewer isoform switches. 








Figure 6.6 Comparison of isoform switching with gene expression changes.  
dIF values are plotted vs log2 fold change which shows whether isoform usage 
was associated with change in expression at gene level or not. Few genes with 
isoform switching also showed changes in expression at the gene level. 
 
Figure 6.6 shows gene expression changes and isoform switching were not 
mutually exclusive; some of the genes were differentially expressed and 
contained isoform switches. Forty-five genes were identified with significant AS 
events. Out of these, 15 genes contained predicted AS consequences. These were 
TPM1, DBT1, TOR1AIP1, TRIB1, AP5M1, PTPN4, CERS4, TAF9B, EDRF1, 
RC3H2, MYD88, DIEXF, FKTN, DNAJC27 and TEPSIN.  
One example of isoform switching was TPM1 (Figure 6.7). There was no 
significant change in expression of TPM1 with VPA exposure as shown in Figure 
6.8 however, the expression of one of the isoforms (TCONS_00071725) was 
downregulated by VPA (Figure 6.9) and differential usage was observed for two 
of the isoforms (TCONS_00071722 and TCONS_00071725) showing isoform 







Figure 6.7 Isoform usage in TPM1.  Isoforms TCONS_00071722 (boxed in red) and TCONS_00071725 (boxed in blue) showed 






Figure 6.8 Gene expression of TPM1 in VPA exposure and control showed 
that TPM1 expression level was not affected by VPA. This image is derived 
from Cufflinks2.2.1 RNA-Seq analysis done in Chapter 3. The error-bars 
indicate 95% confidence intervals 
 
 
Figure 6.9 Expression of isoforms of TPM1  showing only TCONS_00071725 






Figure 6.10. Differential isoform usage of TPM1 isoforms. Isoforms 
TCONS_00071722 and TCONS_00071725 were differentially used between 
VPA expressed cells and controls. The error-bars indicate 95% confidence 
intervals. 
  
6.3.5 Summary of differential AS events detected 
TPM1 was the only gene consistently identified with all four software packages. 
DEXSeq and junctionSeq identified 14 common genes, and five of them were 
additionally identified with rMATS as well (Table 6.5). Eleven out of 37 genes 
were differentially expressed and alternatively spliced as well. The DEG lists are 
included from RNA-Seq analysis in Chapter 3, to examine if there is any overlap 




Table 6.5 Summary of genes with significant AS events as identified with 
four software packages1 
Gene Name DEXSeq JunctionSeq rMATS IsoformSwitchA
nalyzeR 
DEG lists 
AABR07015079.1      
AABR07052502.1      
ABACB1A      
ADGRB2     1,2,3 
ALDOA      
ANP32A      
ARHGDIA      
ASH2L      
ASPH     1,3 
BIN1      
CACNA1G      
CAPG      
COPG1      
DLGAP4      
EPB41      
EPB42      
FLNB     3 
FLNB1      
KCNH3     2 
KIF23      
LOC100174910      
MAP4K4      
MDM2     1, 2, 3 
MYZAP      
NAP1L1      
NDUFC1      
PCCA     1, 2, 4 
PLCD4     1, 2, 3 
PLOD2     1, 3, 4 
PPFIBP1      
RTN4     1, 3 




SLFN4      
SPTAN1      
TMEM59      
TPM1     1,3 
TPM2     1, 3, 4 
1 DEG lists column wherein 1 refers to kallisto, 2 is DESEq2, 3 is salmon and 4 is 
cuffdiff2. Green shading shows genes common in DEXSeq and junctionSeq; blue 




6.3.6 Attempted validation of differential isoform usage in TPM1 
Differential isoform usage was observed in TPM1 with cufflinks and 
isoformSwitchAnalyzeR with no change in expression at the gene level with 
VPA exposure, and changes were observed at the exon level with DEXSeq, 
junctionSeq and rMATS. All the analysis was done using bioinformatic tools so 
these findings should be validated using other experimental method. We 
attempted to measure the change in levels of two of these isoforms, 
TCONS_00071722 and TCONS_00071725 using real-time PCR (RT-qPCR). Total 
RNA used in the RNA-Seq and NanoString experiments were converted to 
cDNA and qPCR reaction were set up in LightCycler® 480 384-well plates 
(Roche Applied Science, Mannheim, Germany). GAPDH and ACTB were used 
as housekeeping genes. Two sets of primers were designed using the Geneious 
vR9.1 software (Biomatters, Auckland, New Zealand). One of the isoforms had 
a different start site so primers were designed with two different forward 
primers and the same reverse primer for both the isoforms. Melt-curve analysis 
of the primers in qPCR run showed two peaks suggesting primer dimers. Sanger 
sequencing of PCR products failed to identify single PCR product, thus 
suggesting multiple PCR products. In summary, we could not validate the 
differential isoform usage of TPM1 with qPCR. This could be due to at least two 
reasons: (1) the primers were not well designed resulting in primer dimers; (2) 
low expression of these isoforms under VPA exposure, and presence of multiple 
isoforms for both the start sites, may have confounded amplification of the 
targeted isoforms. Therefore, the results observed via RNA-Seq analysis for 
differential TPM1 isoform expression must be regarded as provisional, and other 





HDAC inhibitors influence alternative splicing. The HDAC inhibitor NaB has 
been shown to affect splicing of 683 genes in HeLa cells using splicing-sensitive 
exon arrays (Hnilicová et al., 2011). Similarly, both TSA and VPA affected 
splicing of the fibronectin gene similar to NaB and HDAC1 was essential for this 
effect but not HDAC2 (Hnilicová et al., 2011). VPA affected splicing of 198 genes 
in K562 cells (Zhang et al., 2012). These studies suggest VPA is a weaker HDAC 
inhibitor than NaB (Bora-Tatar et al., 2009; Chen, Ghazawi, et al., 2006; Li, Qian, 
et al., 2012; Mali et al., 2010) and may target fewer HDAC isoforms which could 
explain the difference in number of spliced genes in this study. To examine 
whether VPA could influence alternative splicing, we analysed RNA-Seq data 
generated in RN46A cell cultures exposed to VPA (Chapter 3) with four different 
analytical pipelines.  
The number of reads generated in RNA-Seq can affect the proportion of AS 
events identified. With 100-150 M reads, a bias is seen towards abundant 
transcripts and to detect 80% of differences, 400M reads are required (Liu et al., 
2013; Seqc Maqc Iii Consortium, 2014). We generated only 16M reads per sample, 
therefore, this may have limited the range of AS events detected.  
6.4.1 Comparison of the differential splicing tools 
Fourteen genes with significant splicing events were identified by DEXSeq and 
junctionSeq. Both DEXSeq and junctionSeq used the same GLM statistical model 
from DESEq2 to calculate differential exon usage so their results were similar. 
DEXSeq did not calculate isoform proportion or use splicing junctions in its 
model. JunctionSeq was similar to DEXSeq in detecting differential exon usage 
except it used gene-level counts instead of sum of all exonic regions employed 
by DEXSeq to estimate gene-wide expression. Using splice junction coverage 




When identifying a novel AS event, splice junction showed the change in 
coverage, which might not be reflected clearly across the exons.  
rMATS used both reads on targets and splicing junction. rMATS results differed 
significantly from these two tools as it used a different metric of AS detection, 
percentage spliced in (psi) (Katz et al., 2010). It used a hierarchical model to 
estimate exon-inclusion levels followed by a likelihood ratio test to calculate the 
p-value. More significant AS events were identified with rMATS with low p-
values. Five out of fourteen genes, TPM1, BIN1, MDM2, RTN4 and PPFIBP1 were 
identified by the three algorithms DEXSeq, junctionSeq and rMATS.  
rMATS and isoformSwitchAnalyzeR both identified other types of AS events 
unlike DEXSeq and junctionSeq. rMATS identified a high proportion of skipped 
exon events, most of which were associated with low transcript numbers. Poorly 
expressed transcripts were filtered out in isoformSwitchAnalyzeR reducing the 
number of AS genes.  
6.4.2 Genes with best bioinformatic evidence for VPA-induced 
alternative splicing 
The most significant genes were similar across the three exon-centric tools even 
with differences in analysis methods (Table 6.5). Two of these significant genes 
are discussed below.  
6.4.2.1 TPM1 
TPM1 encodes for the tropomyosin 1 protein, which regulates the Ca++ 
dependent regulation of smooth muscle contraction. Alternative splicing in 
TPM1 was identified with all four AS methods (Table 6.5). Notably, differential 
expression at gene level was observed with kallisto and salmon (Table 6.5) only 




Exons 14, 15 and 17 were alternatively spliced as identified with DEXSeq, 
junctionSeq and rMATS. Isoform switching was identified with 
isoformSwitchAnalyzeR (Figure 6.10). One of the TPM1 isoforms had differential 
transcript expression and usage change after VPA exposure, whereas another 
isoform had a significant usage change without change in transcript expression.  
TPM1 is an actin binding protein involved in stabilization of cytoskeleton actin. 
A few studies suggest that this gene may play an important role in SCZ and BD. 
TPM1 was one of the cytoskeletal proteins differentially regulated in the anterior 
cingulate cortex in SCZ (Martins-de-Souza et al., 2010). This gene was 
differentially expressed in BD patients compared to controls (Föcking et al., 
2016). Lithium decreased TPM1 expression at both mRNA (Fatemi et al., 2009) 
and protein levels (Nielsen et al., 2008) in rats.  
Even though we could not validate the differential isoform expression using 
qPCR due to technical issues and time pressures, this gene has an interesting 
function and should be explored further. Use of better primers or a higher 
sensitivity assay such as nanoString (Chapter 4 and 5), may be a more effective 
way to detect the differential isoform usage. Furthermore, functional assays 
might reveal how the different isoforms of TPM1 and TPM2 interact with the 
actin cytoskeleton to regulate the shape or function of neurons. VPA induced 
isoform switching could potentially regulate the actin cytoskeleton binding, 
which may be of consequence in the therapeutic effects of this drug.  
6.4.2.2 BIN1 
BIN1 encodes for the bridging integrator 1 (bin1) or amphiphysin2 (AMP2) 
protein expressed in multiple cell types. Exon 15 was differentially upregulated 
with VPA exposure as identified with DEXSeq, junctionSeq and rMATS (Table 
6.5). Splicing of exon 15 leads to a truncated protein with missing domains and 




apoptosis, cell cycle progression, cytoskeleton regulation and DNA repair 
(Prokic et al., 2014). The encoded protein is an MYC-interacting protein with 
tumour suppressor features. SNPs in BIN1 have been linked to increased risk of 
Alzheimer’s disease (Almeida et al., 2018; Hu et al., 2011; Li et al., 2015; Ramos 
Dos Santos et al., 2016; Wang, Wan, et al., 2016).  
Alternative splicing produces many isoforms of this gene; brain-specific exons 
include 7, 13, 14, 15 and 16, and exon 11 is muscle-specific, and improper splicing 
of exons 7 and 11 leads to centronuclear myopathy (Cox et al., 2013). The brain–
specific isoforms of BIN1 contain additional clathrin and AP2 binding domains 
(Ramjaun & McPherson, 1998). Its expression in the brain is linked to clathrin-
mediated endocytosis of synaptic vesicles and potentially interacts with 
synaptojanin, dynamin, endophilin and clathrin (Holler et al., 2014). Alternative 
splicing resulted in an inactive form of BIN1 which lacks the membrane-
tubulating and phosphatidyinositol-5 binding activities (Fugier et al., 2011). BIN1 
may play a role in actin bundling and stabilization in BD pathophysiology, and 
its apparent splicing modulation by VPA is worthy of further exploration.  
6.4.3 Genes both differentially expressed and spliced by VPA 
Eleven genes were both alternatively spliced and differentially expressed in 
response to VPA exposure (Table 6.5). Two genes, MDM2 and RTN4 were 
identified AS by DEXSeq, junctionSeq and rMATS, and upregulated by VPA.  
The MDM2 proto-oncogene encodes for nuclear-localized E3 ligase, which 
mediates ubiquitination of p53. More than 40 splice variants have been identified 
in tumour and normal tissues which play important role in both tumour growth 
and inhibition (Okoro et al., 2012). Although the role of MDM2 has been 
extensively studied in the context of cancer, not much is known about its role in 




postsynaptic proteins and affects glutamatergic synaptic transmission (Colledge 
et al., 2003; Lussier et al., 2011). The MDM2-p53 pathway is linked to 
neuroprotection in neurodegenerative diseases such as Alzheimer’s, spinal 
muscular atrophy and ischaemia (Proctor & Gray, 2010; Van Alstyne et al., 2018; 
Vecino et al., 2018). MDM2 levels were shown to be increased in fragile X mice 
and inhibition of MDM2 rescued the neurogenic and cognitive defects (Li et al., 
2016). Taken together, these studies suggest MDM2 might have a novel and 
interesting function in the brain and should be further examined in the context 
of the therapeutic actions of VPA. 
RTN4 encodes for Nogo-A, a neurite outgrowth inhibitor, which facilitates 
neurite branching, and is involved in secretion and trafficking in neuroendocrine 
cells (Watari & Yutsudo, 2003). RTN4 along with its receptor RTN4R is a known 
SCZ risk gene (Jitoku et al., 2011; Kimura et al., 2017) and has been shown to affect 
cognitive function linked to neuronal CA3 circuitry (Ginsberg et al., 2018). 
LINGO1, partner protein of RTN4R, was found to be upregulated by VPA 
(Chapter 3), a result which was validated with nCounter® assay (Chapter 4 and 
5). RTN4 gene produces three splice variants Nogo-A, B and C; Nogo A and C 
were elevated in SCZ whereas Nogo B was increased in BD and MDD 
postmortem tissues (Novak & Tallerico, 2006). Taken together, these studies 
suggest this gene is an excellent candidate for further examination with regard 
to the therapeutic effects of VPA.  
Alternative splicing of ADGRB2/BAI2 was detected with rMATS alone. Our 
RNA-Seq analysis revealed upregulation of this gene by VPA (Chapter 3) and 
this was validated with the nCounter® assay in two independent experiments 
(Chapter 4 and 5). The BAI2 family of adhesion-GPCRs regulate synapse 
development and plasticity (Duman, Tu, et al., 2016). Knockout mice for this gene 
showed antidepressant-like behaviour in stress tests and increased hippocampal 




alternative splicing of this gene may regulate synaptic plasticity, which is 
essential in the BD pathophysiology (Akil et al., 2017; Bachmann et al., 2005; 
Carlson et al., 2006). 
TPM2 was alternatively spliced and downregulated by VPA (Table 6.5) and 
similar to TPM1 encodes the protein involved in smooth muscle contraction of 
the actin cytoskeleton. Taken together, TPM1/2 and other cytoskeleton-
interacting genes may be important in regulating the shape and function of 
neurons, neurite outgrowth, and maintenance of synaptic plasticity, and could 
have consequences in BD pathophysiology.  
6.5 Summary of the chapter 
In this chapter I showed that VPA appeared to differentially regulate alternative 
splicing of a range of genes, in the RN46A cell culture model. Some of these genes 
were differentially expressed in response to VPA. However, preliminary 
attempts at validating these findings on isoforms of one gene, TPM1, using 
qPCR, were not successful. Therefore, the bioinformatics observations in this 
Chapter must be regarded as provisional until they are effectively validated. 
Differential splicing is another layer of regulation that enables the genome to 
code for more proteins, bringing in more complexity to the organism. These 
initial findings on the influence of VPA on regulation of alternative splicing in a 
serotonergic cell model suggest this is a potentially informative area for further 





Chapter 7  
Analysis of VPA effects on gene expression 
in rat brains 
 
In chapter 5 of this thesis, I showed several genes were regulated by VPA, via either 
HDACi mediated and non-HDACi mediated mechanisms. The RNA-Seq and 
nCounter® gene expression experiments in this thesis were done in differentiated 
RN46A cells. The gene expression changes were validated in the RN46A cell line in 
three independent experiments. However, an important question that arises is the 
biological relevance of genes identified through cell culture experiments and whether 
the same regulatory effects can be seen in an in vivo experimental system. I carried out 
an exploratory study to examine a subset of the observed gene expression changes in 
an in vivo model at the protein expression level. This model was developed previously 
in our laboratory, and involved exposure of rats to VPA. Formalin fixed paraffin 
embedded (FFPE) brain samples were available from this previous study, for the work 
described here.  
7.1 Immunohistochemical detection of protein expression in rat brain 
The gene expression changes in response to VPA were seen at the mRNA level in both 
RNA-Seq and nCounter® experiments. However, any change seen at the mRNA level 
might not be reflected at the protein level. To examine the in vivo effect of VPA on 
protein expression for a subset of genes, immunohistochemistry (IHC) was carried out 
in 5µm coronal rat brain sections. The main aim was to pilot methods for examining 




7.1.1 The rationale for choosing the antibodies 
The following criteria were used for selecting the genes to be examined in these rat 
brain IHC experiments:  
1. Differentially expressed in response to VPA, in both RNA-Seq and nCounter® 
gene expression experiments. 
2. Relatively high mRNA count as evidenced by nCounter® data. 
3. Preferably regulated by lithium and other HDAC inhibitors.  
4. Brain expression as evidenced by the ABA and GTEx databases.  
5. Availability of an antibody suitable for IHC, and likely to react with the rat 
protein.  
To examine the protein expression changes in rat brain, the list of nCounter® 
validated genes was limited to genes with brain expression as shown in section 
4.3.1. The RN46A cell line is derived from the medullary raphe so expression of 
these genes in the brain was examined using the ABA mouse ISH database and 
human GTEx database as described in section 4.3.1.1 and 4.3.1.2 respectively. This 
analysis showed 18 of 24 genes were expressed in the brain and 11 of these were 
expressed in the medullary raphe. The shortlisted genes were further filtered based 
on mRNA expression and genes with high to medium expression were selected. 
From this list, four genes were selected for final examination of protein expression 
with IHC. Three out of the four genes, MAOB, PAK3 and VGF were expressed in 
the medullary raphe. MMP13 was an exception; it was widely expressed in the 
brain as demonstrated by the ABA mouse ISH database and in the dorsal raphe, 
but not in the medullary raphe. This gene was included as it had the lowest p-
value both in my RNA-Seq and previous pilot RNA-Seq data (Balasubramanian et 
al., 2019). All these four genes had high expression in adult mouse brain as 




results, so it was reasonable to infer that protein expression may be at a detectable 
level.  
7.1.1.1 MAOB 
The MAOB gene encodes for the enzyme which catalyses the oxidative deamination 
of monoamines. This enzyme is located intracellularly in the outer mitochondrial 
membrane (Mitoma & Ito, 1992; Squires, 1997). In neuronal cells, it is primarily 
expressed in the serotonergic regions of the dorsal and medullary raphe as evidenced 
from the ABA mouse ISH data (Chapter 5).  VPA and HDAC1 inhibitor CI994 
upregulate MAOB expression as shown in Chapter 5. Dysfunctions in MAOB gene can 
impair mitochondrial function through oxidative stress and affect emotional 
regulation and cognitive function (Petschner et al., 2018). MAOB is implicated in 
multiple psychiatric disorders, including BD (Harmanci et al., 2016), ASD (Chakraborti 
et al., 2016), ADHD (Li et al., 2008) and neurodegenerative disorders like Parkinson’s 
(Dezsi & Vecsei, 2017) and Alzheimer’s (Schedin-Weiss et al., 2017). Together, these 
studies suggest that MAOB protein was a strong candidate to examine expression in 
VPA-treated rat brains. 
7.1.1.2 MMP13 
The MMP13 gene encodes for the matrix metalloproteinase enzyme which cleaves the 
extracellular matrix and regulates cell-cell communication. The protein is located in 
the cytoplasm. MMP13 is widely expressed in the brain and is expressed in the dorsal 
raphe, but not in the medullary raphe as evidenced from ABA ISH data (Chapter 5). 
Matrix metalloproteinases are widely expressed in the brain and regulate several 
processes such as inflammation, microglial activation and dopaminergic apoptosis 
(Singh et al., 2015). Not much is known about the role of MMP13 in mood regulation. 
This gene may be involved in tissue remodelling in the brain and regulate neuronal 
and synaptic plasticity. Given that this gene was observed three times in RNA-Seq 




prior RNA-Seq analysis (Balasubramanian et al., 2019), it was a good candidate to 
examine protein expression in VPA-treated rat brains.  
7.1.1.3 PAK3 
The PAK3 gene encodes for a kinase involved in signalling pathways that regulate cell 
cycle, cell migration and cytoskeleton. This protein is located in the cytoplasm. This 
gene is widely expressed in the brain, and in the medullary and dorsal raphe as 
evidenced from ABA ISH data (Chapter 5). Animal studies show PAK3 knockout 
results in abnormalities in long-term synaptic plasticity and reduced expression of 
CREB, which regulates synaptic plasticity and cognition (Meng, 2005). Pak inhibitors 
are shown to restore synaptic deterioration in vitro (Hayashi-Takagi et al., 2014). PAK3 
kinase regulates synapse formation and plasticity, which is implicated in BD (Du et 
al., 2004; Eastwood & Harrison, 2010; Pantazopoulos & Berretta, 2016; Zarate et al., 
2006). Therefore, this gene was a good candidate to examine protein expression in 
VPA-treated rat brains.  
7.1.1.4 VGF 
The VGF gene encodes for a neural precursor peptide which regulates synaptic 
plasticity. This is a secreted protein located in the cytoplasm. VGF is primarily 
expressed in the brain, and is highly expressed in the medullary and dorsal raphe as 
demonstrated by ABA ISH data (Chapter 5). HDAC inhibitors VPA and TSA 
upregulate VGF expression as shown in Chapter 5. This gene has been linked to the 
therapeutic action of both mood stabilizers and antidepressants. Levels of VGF were 
reduced in BD post-mortem brains and lithium restored VGF to normal levels in 
animal models (Thakker-Varia et al., 2010). Animal model studies show VGF regulates 
antidepressant-like behaviour (Jiang, Lin, et al., 2017). Therefore, this gene was a good 




7.1.2 The rationale for choosing a region of interest 
The RN46A cell line is derived from the medullary raphe (White et al., 1994) so I was 
initially interested in examining protein expression in the serotonergic medullary and 
dorsal raphe regions in the rat brain samples. However, the samples from these 
regions were already sectioned in the original experiments conducted 10 years ago. In 
the original experiments, rat brains were sectioned into frontal and rostral halves and 
paraffin-embedded. The rostral half was further sectioned into thin 5µm slides and 
these contained the medullary and dorsal raphe regions. At the time of conducting 
IHC experiments for this thesis, the sections were almost 10 years old and appeared 
to have lost antigenicity over such a long time. We only had FFPE brain sample from 
the frontal half available to us. This required us to examine the effect of VPA on other 
regions in the brain with the four antibodies selected. Fresh 5µm sections were cut 
from the front half of the embedded brains. 
7.2 Methods 
7.2.1 Treatment of rats 
The rats used in this experiment were obtained from a previous study in our 
laboratory (Doudney, Harley, Allington and Kennedy, unpublished). Briefly, 6-8 
week old male Sprague-Dawley rats were administered VPA (240mg/kg/day) or a 
vehicle comprising distilled water and 50% v/v 99.9% ethanol for 12 days with Alzet 
2ML2 osmotic minipumps (Alzet, Cupertino, CA). These minipumps were surgically 
implanted subcutaneously and released VPA at a constant rate of ~5.0 μl/hr. Six rats 
were treated with VPA, and three rats were in the control group. All the animal work 
was approved by the Institutional Animal Ethics Committee and carried out in 
accordance with the Animal Welfare Office of University of Otago. The whole brains 
were harvested after 12 days, dissected into equal halves and immediately fixed in 10%, 




in paraffin blocks. Coronal sections at 5µm were mounted on charged slides and 
dehydrated through a series of increasing ethanol concentrations and ultimately xylene. 
These slides were stored in dry and dark conditions to be used later in IHC analysis. For 
the experiments in this Chapter, fresh coronal sections at 5µm were prepared for IHC 
staining.  
7.2.2 Immunohistochemistry 
Coronal sections mounted on glass slides were rehydrated through two xylene washes 
and a series of increasing ethanol concentrations of 100%, 90%, 70% and 50% for 5 min 
each. The slides were placed in a water bath for 10 min while preparing for antigen 
retrieval. Heat-induced antigen retrieval was carried out in a pressure cooker. The 
slides were incubated in boiling 10 mM sodium citrate solution, pH 6.0, containing 0.05% 
Tween 20 for 3 min at full pressure. The sections were then cooled at room temperature 
(RT) for 30 min. 
For blocking and immunostaining, the anti-Rabbit HRP-DAB cell & tissue staining kit 
(RDSCTS005) was used (R&D systems, Minneapolis, USA). The recommended 
protocol was modified to improve the immunostaining. Briefly, cooled sections were 
incubated with 1 drop of peroxidase blocking reagent for 3 min to block endogenous 
peroxidase. The slides were rinsed and washed in TBST (containing 0.025% w/v 
Triton™ X-100) buffer for 5 min. For blocking endogenous proteins and reducing the 
background staining, the slides were incubated with 1 drop of serum blocking reagent 
G for 60 min at RT. Excess serum was drained and wiped off the slides. The slides 
were next incubated with 1 drop of avidin blocking reagent for 15 min at RT and 
rinsed. This was followed by incubation with biotin blocking reagent for 15 min at RT 
and rinsing with buffer. The slides were incubated with 100µl of primary antibody at 
40C overnight in a humid chamber. The following primary antibodies were procured 




used for IHC (Table 7.1). For PAK3, an antibody targeting the non-phosphorylated 
form was selected. 
 
Table 7.1 List of the primary antibodies used in IHC experiments. 
Primary 
Antibody 
Type Species Catalogue 
no 
Supplier 
MAOB Polyclonal Rabbit HPA002328 Sigma-Aldrich 
MMP13 Polyclonal Rabbit ab39012 Abcam 
PAK3 Monoclonal Rabbit ab40808 Abcam 
VGF Polyclonal Rabbit ab69989 Abcam 
 
After overnight incubation, slides were washed in TBST three times for 5 min each 
and incubated with 1 drop of biotinylated anti-rabbit secondary antibody for 60 min 
at RT. The slides were washed in TBST three times for 5 min each. This was followed 
by incubation with 1 drop of HSS-HRP for 30 min at RT. The slides were washed in 
TBST three times for 2 min each. The slides were stained with 50µl of DAB chromogen 
solution for 3 min and washed with running tap water for 5 min. This was followed 
immediately by counterstaining with Mayer’s hematoxylin and washing with running 
tap water for 5 min. The sections were dehydrated through 90% and 100% alcohol 
series followed by xylene and mounted with xylene-based mounting media. The 
slides were visualized on a Zeiss AxioCam microscope (Gottingen, Germany) using 
the Axioimager.Z1 software. The images were first viewed under 5x objective 
followed by 20x magnification for clear evaluation of cell types, protein localization 





Four antibodies were chosen for IHC staining. I first used sections that were prepared 
several years ago prior to my analysis and these resulted in poor IHC staining. Three 
of the antibodies MAOB, MMP13 and VGF were polyclonal which resulted in the 
diffuse background staining, whereas PAK3 monoclonal antibody showed little 
background staining. Therefore, to improve the staining quality, I prepared fresh 
sections from the paraffin-embedded brains.  
A negative control IHC with primary antibody omitted was carried out on one of these 
newly prepare sections, which demonstrated no non-specific binding with the anti-





Figure 7.1 Photomicrograph from coronal rat brain sections showing negative 
control at the hippocampus. The immunostaining was performed with the primary 
antibody omitted at 20X magnification and showed no staining with DAB. Purple 
dots indicate counter-stained nuclei. This negative control showed no non-specific 




Figure 7.2 shows the cytoplasmic expression of MMP13 in cingulate cortex from one 
of the VPA-treated samples (panel A) and panel C but not in the other VPA-treated 
(panel B) and untreated rat brain samples (panel D). At higher resolution of 40X, the 







Figure 7.2 Photomicrograph from coronal rat brain sections showing MMP13-
positive cells at the cingulate cortex. Coronal sections from rats treated with 
250mg/kg body weight VPA for 12 days (A and B) and untreated rats (C and D) at 
20x objective lens magnification. No difference in the number of MMP13-positive 
cells was observed between the treated and untreated samples. Arrows indicate 
MMP13-immunoreactive cells stained brown (DAB staining). Purple dots indicate 











Figure 7.3 Photomicrograph from coronal rat brain sections showing MMP13-
positive cells at the cingulate cortex. Coronal sections from rats treated with 
250mg/kg body weight VPA for 12 days at 40x objective lens magnification. Black 
arrows indicate MMP13-immunoreactive cells stained brown (DAB staining). Red 







Figure 7.4 shows VGF is expressed in the cytoplasm in the cingulate cortex of rat brain 
in both VPA-treated and untreated samples. There was inconsistent staining among 
VPA-treated as well as untreated brains. However, for the sections that stained, higher 
VGF immunostaining was observed in VPA-treated brains compared to untreated 
samples. However, this is clearly not quantitative, and would need to be further 






Figure 7.4 Photomicrograph from coronal rat brain sections showing VGF-positive 
cells at the cingulate cortex. Coronal sections from rats treated with 250mg/kg body 
weight VPA for 12 days (panels A, 20X and B, 40X) and untreated rats (panels C, 20X 
and D, 40X) at 20x and 40x objective lens magnification. No difference in the number 
of VGF-positive cells was observed between the treated and untreated samples. 
Arrows indicate VGF-immunoreactive cells stained brown (DAB staining). Purple 









MAOB is expressed in the astrocytes and serotonergic neurons (Levitt et al., 1982; 
Westlund et al., 1988). Figure 7.5 shows the expression of MAOB in astrocytes from 
cerebral cortex in both VPA-treated and untreated rat brains. There was inconsistent 
staining among VPA-treated as well as untreated brains. However, for the sections 
that stained, higher MAOB immunostaining was observed in VPA-treated brains 
compared to untreated samples. Although interesting, this very preliminary 








Figure 7.5 Photomicrograph from coronal rat brain sections showing MAOB-
positive cells at the cerebral cortex. Coronal sections from rats treated with 
250mg/kg body weight VPA for 12 days (panels A and B) and untreated rats (panels 
C and D) at 20x objective lens magnification. No difference in the number of MAOB-
positive cells was observed between the treated and untreated samples. Arrows 
indicate MAOB-immunoreactive cells stained brown (DAB staining). Purple dots 







Figure 7.6 shows PAK3 expressed in the cytoplasm of cells in the rat hippocampus of 
both VPA-treated and untreated samples. Similar to other antibodies, inconsistent 
immunostaining was observed among both the treated and untreated samples. 
However, for the sections that stained, more cells appeared to be positive for PAK3 in 







Figure 7.6 Photomicrograph from coronal rat brain sections showing PAK3-
positive cells at the hippocampus. Coronal sections from rats treated with 
250mg/kg body weight VPA for 12 days (A and B) and untreated rats (C and D) at 
40x objective lens magnification. No difference in the number of PAK3-positive cells 
was observed between the treated and untreated samples. Arrows indicate PAK3-
immunoreactive cells stained brown (DAB staining). Purple dots indicate counter-








It becomes crucial that gene expression differences observed in cell lines should 
be tested in higher complex models. Also, expression at mRNA level should be 
validated at protein level. Most of the work done in this thesis has been in a cell 
culture model. In this chapter, an attempt was made to carry out a preliminary 
examination of the effects of VPA on expression of selected proteins in rat brains 
using samples generated from a previous experiment in our laboratory. IHC 
experiments were attempted with four different antibodies.  
Based on the cell line RN46A which is derived from the medullary raphe, we 
were interested in examining the effect of VPA treatment in the medullary and 
dorsal raphe which contain the serotonergic neurons. However, these regions 
were not available to us as the sections with the medullary and dorsal raphe had 
been already used therefore, I focused on the material left. The brain in the 
original experiment was cut in two halves and the frontal half of the rat brain 
was available to us. This frontal half containing the frontal cortex was sectioned 
and immunostained. 
Four genes were chosen based on their mRNA expression levels in RN46A cells 
from RNA-Seq and nCounter® experiments and expression in the brain using 
the ABA ISH data and human GTEx database. These four genes MAOB, MMP13, 
PAK3 and VGF were shown to be abundantly expressed in the mouse brain. IHC 
was attempted for each of these genes and immunostaining revealed the 
astrocytic expression of MAOB and cytoplasmic expression of MMP13, PAK3 
and VGF. The expression of these genes in rat brain samples matched prior 
literature and ABA mouse ISH data. IHC with the polyclonal antibodies MAOB, 
MMP13 and VGF resulted in the diffuse background staining. The monoclonal 




unable to validate the effect of VPA on the protein expression of these genes due 
to inconsistent IHC staining within and between samples. 
The biological samples used in this chapter were more than 10 years old. No data 
were available for their processing and embedding in the paraffin wax (these 
records were lost in the Christchurch earthquake). The sections were not evenly 
cut through the FFPE samples. Due to the uneven surface of sections, antibody 
staining was not consistent throughout the sample. Some of the sections from 
both VPA-treated and control samples for VGF and MMP13 did not show the 
cytoplasmic stain. This made it difficult to interpret the positive staining 
observed in sections from treated and untreated rats.  
The IHC results were inconclusive due to the inconsistent immunostaining 
observed with some of the VPA-treated and untreated samples. Few of the rat 
brain sections were properly immunostained. In this chapter, I have shown some 
of the best IHC images for the antibodies used. All the images show the high 
background observed with the chosen polyclonal antibodies. This inconsistent 
staining between samples, whether VPA-treated or untreated, was observed 
with all four antibodies.  
The main issues with the work described in this chapter was lack of good quality 
samples and sectioning of the FFPE samples. I had limited choice with the rat 
brain samples available. RNA expression data from RN46A cell line was 
corroborated from the RNA ISH data from the mouse Allen brain atlas. This was 
used as evidence for likely expression of these proteins in the rat brain. This was 
an exploratory analysis to see if IHC would be appropriate to examine protein 
expression. Due to poor tissue samples and lack of target tissue of interest, we 
were not able to validate the effect of VPA treatment on the protein expression 




fresh tissue obtained from another series of rats exposed to VPA, and with a 
much more extensive series of IHC analyses. 
7.5 Summary of the chapter 
A preliminary examination using IHC was attempted to extend the cell culture 
effects of VPA to rat model. We showed immunostaining of MAOB, MMP13, 
PAK3 and VGF in rat brain samples. However, due to the limitation of the 
biological material and lack of tissue of interest, we were unable to establish any 
effect of VPA in rat brain sections.  Thus, this chapter has been a testing of the 




Chapter 8  
General discussion 
 
8.1 Thesis Summary 
The mood stabilizer VPA is widely used in the treatment of BD and other 
diseases, but we still do not understand the underlying mechanisms of its 
therapeutic action (Chiu et al., 2013). Several genes and signalling pathways have 
been shown to be affected by VPA. In this thesis, the gene expression effects of 
VPA in a serotonergic cell line were studied to try to better understand the 
mechanism of action of VPA.  
8.1.1 Gene expression effects of VPA 
The principal goal of this thesis was to examine the genome-wide expression 
effects of VPA. Even though VPA has been used as a mood stabilizer for more 
than 50 years in BD treatment, previous attempts to find differential gene 
expression effects of the drug have focused mostly on a handful of candidate 
genes (Chen, Huang, et al., 1999; Chen et al., 1994; Chen et al., 1996; Chen et al., 
1997; Chen, Yuan, et al., 1999; Chen, Peng, et al., 2006; Daniel et al., 2005). 
Subsequently, microarrays were used to study the gene expression effects in 
neuroblastoma or glioma cell lines (Adams & Schofield, 2001; Bosetti et al., 2005; 
Chetcuti et al., 2006; Fukuchi et al., 2009; LaBonte et al., 2009; Lee, Pirooznia, et al., 
2015; Zhang et al., 2012). Gene expression studies with microarrays have limited 
scope for identifying novel genes; in contrast, high-throughput RNA-Seq 
allowed us to identify differential expression changes of many genes with high 
sensitivity. This study is the first RNA-Seq study in a serotonergic context to 




Using RNA-Seq, we showed VPA resulted in extensive changes in gene 
expression (Chapter 3). Pathway analysis of 712 upregulated and 273 
downregulated genes revealed several key neuronal genes and pathways such 
as Wnt pathway, that were relevant to BD and SCZ. VPA affected several 
biological processes such as neurogenesis and synaptic plasticity, which are 
important in BD and SCZ pathophysiology (de Sousa et al., 2014; Duman, 
Aghajanian, et al., 2016; Gundersen et al., 2013; Hill et al., 2015; Kraus et al., 2017; 
Pantazopoulos & Berretta, 2016).  
Furthermore, this thesis has validated several DEGs observed in the previous 
RNA-Seq study from our laboratory (Balasubramanian et al., 2019). My 
corroboration of results generated with similar VPA concentration and exposure 
time, but in undifferentiated RN46A cells, and performed by another researcher 
confirms that the RNA-Seq findings are robust. We have also shown that most 
of the VPA-regulated genes identified in the RN46A model system, are 
expressed in mouse and human brain (Chapter 4). 
The nCounter® gene expression assay is a novel and PCR-free method that uses 
optical barcodes to directly measure mRNA counts. Twenty-three of RNA-Seq 
DEGs were chosen for validation with nCounter® assay. Validation in 
independent experiments showed 17 out of 23 genes changed expression in the 
same direction and with similar magnitude when compared to RNA-Seq 
(Chapter 4 and 5). That 70% of the selected RNA-Seq DEGs validated with 
nCounter® assay gives confidence that the larger RNA-Seq dataset contains 
many genuine VPA regulated DEG, which could be further mined for interesting 
pathways or genes. 
The RN46A cell line has been used in our laboratory to study the gene expression 
effect of several antidepressants and mood stabilizers (Balasubramanian et al., 




2009). We generated the full expression profile of RN46A cells with RNA-Seq 
and compared the expression profile with in-situ hybridization data from the 
medullary and dorsal raphe of the ABA mouse atlas which emphasized the 
serotonergic nature of the cell line (Chapter 3).  
8.1.2 VPA has a complex gene regulatory pattern 
We have shown VPA to have a complex pattern of effects on gene regulation. 
This mood stabilizer is a known HDAC inhibitor (Gurvich et al., 2004; Phiel et al., 
2001) and using other HDAC inhibitors and the non-HDACi analogue VPD, it 
was demonstrated that VPA could regulate gene expression through both 
HDACi-dependent and independent mechanisms (Chapter 5). One interesting 
observation was that for genes regulated through HDAC inhibition, the direction 
of change could be different between VPA and TSA. For example, VPA and 
CI994 upregulated SHANK3 and ZCCHC12 whereas TSA downregulated it.  
8.1.3 VPA affects alternative splicing 
HDAC inhibitors modulate alternative splicing (Hnilicová et al., 2011; Zhang et 
al., 2012). Differential splicing analysis of RNA-Seq data revealed that VPA 
exposure of RN46A cells led to alternative splicing effects, and differential 
splicing was observed both at exon and isoform level (Chapter 6). For most of 
the alternatively spliced genes, differential isoform usage was observed along 
with changes in gene expression. Thus, VPA, through alternative splicing could 
affect the expression of several genes as well as promote usage of different 
isoforms influencing protein function. Further work needs to be done to validate 
these bioinformatic observations, and explore the functional implications of 




8.1.4 Lithium and VPA co-regulate genes 
Several gene targets of lithium and VPA have been identified, yet we do not 
understand the expression and regulation of genes related to their therapeutic 
action (Chiu et al., 2013). The structurally dissimilar mood stabilizers lithium and 
VPA affect the same signalling pathways therefore, common genetic targets 
might be relevant to their therapeutic effects (Balasubramanian et al., 2019; Gupta 
et al., 2012; Gurvich & Klein, 2002; Lee, Pirooznia, et al., 2015; Valvassori, Dal-
Pont, et al., 2017). We identified four genes co-regulated by lithium and VPA 
CDKN1C, LSP1, SERPINB2 and WNT6 (Chapter 4).  
CDKN1C is a maternally imprinted gene regulated by HDAC inhibitors (Van de 
Pette et al., 2017) and linked with neurogenesis in the developing brain 
(Furutachi et al., 2013). LSP1 is expressed in monocytes, neutrophils, 
macrophages as well as neuropils and may be linked to neuroinflammation in 
the brain. Both mania and depression are associated with increased pro-
inflammatory cytokines secreted by macrophages, T-lymphocytes and 
endothelial cells, and decreased anti-inflammatory markers (Barbosa, Machado-
Vieira, et al., 2014; Brietzke et al., 2009; Kunz et al., 2011; Modabbernia et al., 2013). 
SERPINB2 is involved in cell proliferation, differentiation and growth and 
regulates synaptic plasticity in hippocampal neurons (Zhang et al., 2009). 
Reduced synaptic plasticity is observed in BD (Carlson et al., 2006; Rocha et al., 
2017) and antidepressants have been shown to enhance neuroplasticity and 
resilience (Castrén & Hen, 2013; Malberg et al., 2000; Santarelli et al., 2003). Wnt 
proteins regulate several processes such as brain development, cell growth, 
differentiation, migration and fate determination among others, implicated in 
BD pathophysiology. Both lithium and VPA affect expression of Wnt signalling 
pathway genes (Boku et al., 2014; Wexler et al., 2008). Further study is needed to 




Our initial RNA-Seq analysis with 0.5mM lithium yielded no significant gene 
expression changes and later experiments with higher doses of lithium were 
limited to the nCounter® panel of 24 genes, selected due to expression change 
after exposure of cells to VPA. From this analysis, four of the 24 genes appeared 
to be co-regulated by lithium. This suggests that RNA-Seq with higher doses of 
lithium could potentially yield many more genes that are co-regulated by VPA, 
and this would be an interesting and worthwhile future experiment to carry out. 
8.1.5 Matrix metalloproteinases 
The matrix metalloproteinases and their inhibitors were some of the 
differentially expressed genes in response to VPA as shown in this thesis and 
prior RNA-Seq study (Balasubramanian et al., 2019). MMP13 was upregulated 
by the HDAC inhibitors TSA and CI994 as well (Chapter 5). The level of MMP9 
has been shown to be elevated in serum from BD patients (Rybakowski, 2009; 
Rybakowski et al., 2013; Singh et al., 2015). Even though the role of other MMPs 
in mood disorders has not been studied in detail, MMPs play an important role 
in the brain development, extracellular matrix remodelling, blood-brain barrier 
development, neuroprotection and multiple other physiological processes 
(Singh et al., 2015). Extracellular matrix remodelling can play a significant role in 
BD through modulating neuronal and synaptic plasticity in disease and its 
treatment.  
However, the upregulation of MMPs by VPA could be due to the stress-response 
nature of these genes. Cells experience stress in the dish so the expression of 
MMPs might be due to the experimental stress and could potentially have no 
connection with the mood-stabilizing effects of VPA. The defence of this 
possibility is that the MMP genes were detected due to an expression difference 
between VPA treated cells and equivalent untreated cells cultured in parallel. 




and animal studies to demonstrate these genes are involved in mood-stabilizing 
mechanism of VPA. 
8.2 Future work 
Although we have identified and validated gene expression changes in response 
to VPA, further studies are needed to understand the role of individual genes in 
mood regulation, mechanism of gene regulation by VPA of their promoters, and 
in complex model systems. There is a need to examine the changes at both post-
transcriptional and post-translational level.  
8.2.1 Other RNA families/species 
Apart from mRNA, other RNA species play an important role in gene regulation. 
Some of the RNA species such as miRNA and non-coding long RNA are 
increasingly being studied for their role in gene regulation in mood disorders 
(Alural et al., 2017; Bavamian et al., 2015; Chen et al., 2009; Choi et al., 2015; 
Hansen & Obrietan, 2013; Hunsberger et al., 2013; Meganathan et al., 2015). 
Several studies have identified populations of miRNAs that were targeted by 
mood stabilizers lithium and VPA (Chen et al., 2009; Oikawa et al., 2015; Zhang 
et al., 2013; Zhou et al., 2009). It would be interesting to examine the effect of VPA 
on these non-coding RNA populations and how miRNAs might regulate the 
expression of the DEGs identified in my RNA-Seq study. 
8.2.2 Chromatin changes may regulate gene expression 
VPA as an HDAC inhibitor can alter the chromatin status of many genes 
(Fukuchi et al., 2009; Gavin et al., 2009; Green et al., 2017; Kao et al., 2013; Lee, 
Pirooznia, et al., 2015; Milutinovic et al., 2007; Sharma et al., 2006). It would be 
interesting to examine the effects of VPA on promoters of affected genes such as 




marks such as H3K9, H3K14 and H3K4me3 at the promoter level could be 
examined to better understand how VPA regulates these genes. Genome-wide 
analysis of methylation marks with ChIP-Seq would reveal insights into the 
epigenetic targets of VPA. It would be desirable to identify genes important to 
its therapeutic effects and corroborate the histone acetylation and methylation 
data with gene expression data. This would identify coordinated patterns of 
histone modifications associated with such changes in gene expression. 
8.2.3 Other model systems to examine the effects of VPA 
Several lines of evidence show that, in addition to the serotonergic system, the 
dopaminergic system is dysregulated in mood disorders. VPA affects the 
dopaminergic system (Chen, Peng, et al., 2006; Del' Guidice & Beaulieu, 2015; 
Green et al., 2017; Hashimoto et al., 2012) and dopaminergic cell lines might be 
useful models in studying gene expression changes. Brain organoids are also a 
potentially useful model to study the complex and interdependent role of the 
serotonergic, dopaminergic and glutamatergic neurotransmitters as well as 
electrophysiological abnormalities in BD. These brain organoids can be used to 
study the finer details of synapse formation, vesicle trafficking, synaptic 
remodelling among others (Quadrato et al., 2016).  
Mood disorders are syndromic and show heterogeneous symptoms which may 
be examined more specifically with animal models and human post-mortem 
samples. Post-mortem tissues are an invaluable source to study disease-specific 
pathology (McCullumsmith et al., 2014). Gene expression studies using post-
mortem tissues from VPA-treated BD and SCZ patients may reflect the changes 
associated with VPA treatment and disease pathophysiology. For example, the 
neuropathology consortium from the Stanley Medical Research Institute 
(Kensington, MD, USA) contains a total of 60 brains from 15 patients each of BD, 




from BD and SCZ group have been treated with VPA (personal communication). 
These tissues and samples could potentially allow more detailed examination of 
some of the genes observed in this thesis, in a human context, and such a study 
would represent a useful next step in the development of this work. 
8.2.4 Screening for potential mood stabilizers 
A useful potential application of this thesis would be to establish a gene 
expression signature to screen other drugs and compounds as potential mood 
stabilizers. Other HDAC inhibitors with similar gene expression signatures to 
VPA could be potential mood stabilizers. Currently used HDACi in research, 
such as the non-selective HDACi TSA is toxic or otherwise not suitable as drugs. 
Identifying compounds that have a similar action to VPA, but perhaps work 
better or have a better side-effect profile, would be desirable. Several HDACi 
such as vorinostat, romidepsin, belinostat, and panobinostat are already being 
used as drugs and they could be repurposed as mood stabilisers. The RN46A cell 
culture model could potentially be used to screen other HDAC inhibitors as 
potential mood stabilising drugs. 
8.3 Final conclusion 
This thesis examined the gene expression effects of the widely used mood 
stabilizer VPA using two different platforms- RNA-Seq and nCounter® assay. 
We showed RN46A cell line is a good model to study the mechanism of action 
of mood stabilizers. The thesis sought genes relevant to the therapeutic action of 
VPA. This has potential for further research into biological pathways and cellular 
mechanisms associated with the effects of VPA, which might be relevant to both 
BD and SCZ. We also showed VPA has complex gene regulatory mechanism and 
could regulate gene expression through both HDACi dependent and 




could promote differential isoform usage without change in gene expression. 
Both lithium and VPA co-regulate certain genes which suggests shared 
mechanisms of gene regulation in serotonergic neurons. This thesis offers 
insights into gene regulation by VPA and lithium, and provides an improved 
understanding of the genes and pathways that may underlie the mechanism of 
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Appendix A: List of software used  
All software used in this thesis is listed below along with the version used, date downloaded and resources required. 
 
Table 1 Software used in this thesis.  
Name Version Date of 
download 
Source Language  Computing 
resource used 
STAR aligner 2.5.1b 3 Feb 2016 GitHub repository C++ Linux 
Kallisto  0.42.4 31 Oct 2015 GitHub repository C++ Linux 
Salmon 0.6.1 13 Jan 2016 GitHub repository C++ Linux 
Sleuth 0.28.0 31 Oct 2015 GitHub repository R Rstudio, Win7 
(16GB RAM) 






Name Version Date of 
download 
Source Language  Computing 
resource used 
Cufflinks2 2.2.1 7 Aug 2015 GitHub repository C++ Linux 
DEXseq 1.20.2 11 Dec 2017 Bioconductor R Rstudio, Win7 
(16GB RAM) 
JunctionSeq 1.5.4 12 Apr 2017 Bioconductor R, Java Rstudio, Win7 
(16GB RAM) 
rMATS 3.2.5 28 Mar 2017 Website Python Linux 
IsoformSwitchAnalyzeR 1.3.1 26 Jun 2018 Bioconductor R Rstudio, Win7 
(16GB RAM) 
nSolver™ 3.0 22 Jun 2016 NanoString website Java Win7 (16GB RAM) 
NanoStringDiff 1.10 30 Jan 2018 
 





Appendix B: RNA QC report for RNA-Seq 
experiment 
Quality control data for RNA samples. Table 1 shows RNA QC report for 
samples from experiment 1 and table 2 shows RNA QC report for experiments 
2-4. 
Table 1. Sample description for Trizol-extracted RNA for experiment 1 as 
shown in Figure 3.3 
Well RINe 28/18S(Area) Conc.[ng/µl] Sample 
description 
OD260/280 OD260/230 
A1 8.7 1.2 102 Ladder   
B1 9.4 2.2 106 Li_01122014_1 2.06 0.76 
C1 9.7 2.6 98.7 VPA_01122014_1 2.05 1.23 
D1 9.6 2.5 131 CC_01122014_1 2.01 0.84 
E1 9.6 2.1 55.0 Li_01122014_2 1.97 0.5 
F1 9.7 2.0 59.6 VPA_01122014_2 2.02 1.08 
G1 9.4 2.3 69.4 CC_01122014_2 2.03 0.63 
H1 9.4 2.4 89.3 Li_01122014_1 2.06 0.76 
 
 
Table 2. Sample description for Trizol-extracted RNA for experiment 2-4 as 
shown in Figure 3.41. 
Well RINe 28/18S(Area) Conc.[ng/µl] Sample 
description 
OD260/280 OD260/230 
A0 - - 137 Ladder   
A1 9.8 2.5 180 Li_06122014_1 2.18 1.09 




Well RINe 28/18S(Area) Conc.[ng/µl] Sample 
description 
OD260/280 OD260/230 
C1 9.3 3.0 190 CC_06122014_1 1.97 1.57 
D1 9.8 3.1 349 Li_06122014_2 2.16 1.68 
E1 9.5 3.2 483 VPA_06122014_2 2.17 1.76 
F1 8.9 2.9 1050 CC_06122014_2 2.17 1.46 
G1 8.9 2.8 762 Li_05122014_1 2.16 1.51 
H1 8.3 1.7 1560 VPA_05122014_1 2.21 1.37 
A2 9.0 2.6 894 CC_05122014_1 2.03 1.21 
B2 9.1 2.7 577 Li_05122014_2 2.15 1.41 
C2 9.1 2.7 388 VPA_05122014_2 2.07 1.67 
D2 8.7 2.6 326 CC_05122014_2 2.15 1.24 
E2 9.2 2.7 242 Li_03122014_1 2.16 1.22 
F2 9.4 3.0 460 VPA_03122014_1 2.16 1.84 
G2 9.2 2.5 275 CC_03122014_1 2.02 1.64 
H2 9.1 2.4 400 Li_03122014_2 2.12 1.44 
1Cells highlighted in blue represent the samples used in RNA-Seq experiment. 
Table 2. Sample description for Trizol-extracted RNA for experiment 2 as 
shown in Figure 3.5. 
Well RINe 28/18S(Area) Conc.[ng/µl] Sample 
description 
OD260/280 OD260/230 
A1 9.4 2.7 312 VPA_03122014_2 2.15 1.55 





Appendix C: RNA QC and cDNA library QC at Novogene 
The Agilent Bioanalyzer RNA quality control carried out at Novogene (Beijing, China). Figure 1 shows the RNA QC report for 
initial samples shipped. Four samples were unqualified so another set of samples for the failed ones were sent. Each cell culture 
experiment was carried out in duplicate so all the total RNA samples was sent to Novogene.   
Figure 2 shows the RNA QC report for second set of samples shipped. Only two of the samples, VPA_01122014_1 (A2) and 
CC_01122014_1 (A3) passed QC check and rest failed. However, we decided to continue with library preparation for the failed 
samples as per the advice from Novogene. Therefore, both duplicates for lithium, VPA and control were merged together from 
experiment 1 (series A) and for CC_05122014 (C3). In the end, library preparation was successful for all the samples. Figure 3 
shows the cDNA library quality control generated at Novogene (Beijing, China).  


























Table 1. RNA-Seq samples and cDNA library codes used in this thesis.  
Sample name Novogene Code Treatment Batch Date Duplicates merged 
Li_01112014_1 A1 Lithium A 1-Dec-14 Yes 
VPA_0112014_1 A2 VPA A 1-Dec-14 Yes 
CC_0112014_1 A3 Control A 1-Dec-14 Yes 
Li_03112014_1 B1 Lithium B 3-Dec-14 No 
VPA_0312014_1 B2 VPA B 3-Dec-14 No 
CC_0312014_1 B3 Control B 3-Dec-14 No 
Li_05112014_2 C1 Lithium C 5-Dec-14 No 
VPA_0512014_2 C2 VPA C 5-Dec-14 No 
CC_0512014_1 C3 Control C 5-Dec-14 Yes 
Li_06112014_2 D1 Lithium D 6-Dec-14 No 
VPA_0612014_2 D2 VPA D 6-Dec-14 No 






Appendix D: RNA-Seq QC report of all 12 samples 
RNA-Seq QC report generated at Novogene for all 12 samples with both raw and cleaned reads. 
Table 1 RNA-Seq data quality summary generated by Novogene. 
Sample Treatment Raw reads Clean reads Clean bases Error (%) Q20 (%) Q30 (%) GC (%) 
A1_1 Lithium 17,049,065 15,060,617 1.88G 0.03 96.38 92.28 59.90 
A1_2 Lithium 17,049,065 15,060,617 1.88G 0.04 94.08 88.69 59.91 
A2_1 VPA 19,618,024 17,096,645 2.14G 0.03 96.92 93.82 50.21 
A2_2 VPA 19,618,024 17,096,645 2.14G 0.04 94.70 90.22 50.18 
A3_1 Control 17,87,0112 16,882,335 2.11G 0.03 97.10 94.18 49.67 
A3_2 Control 17,87,0112 16,882,335 2.11G 0.03 95.40 91.43 49.66 
B1_1 Lithium 17,355,602 16,892,244 2.11G 0.03 96.77 93.46 49.86 
B1_2 Lithium 17,355,602 16,892,244 2.11G 0.03 95.30 91.23 49.88 
B2_1 VPA 18,731,368 17,872,590 2.23G 0.03 96.30 92.62 48.90 
B2_2 VPA 18,731,368 17,872,590 2.23G 0.04 94.47 89.79 48.88 
B3_1 Control 16,576,139 15,856,005 1.98G 0.03 95.94 91.91 49.29 
B3_2 Control 16,576,139 15,856,005 1.98G 0.04 94.45 89.69 49.27 
C1_1 Lithium 17,343,662 16,547,378 2.07G 0.03 96.01 92.03 49.32 
C1_2 Lithium 17,343,662 16,547,378 2.07G 0.04 94.59 89.69 49.30 
C2_1 VPA 17,191,084 16,457,809 2.06G 0.03 96.03 92.00 50.73 
C2_2 VPA 17,191,084 16,457,809 2.06G 0.04 94.47 89.65 50.73 
C3_1 Control 16,949,182 15,90,420 1.99G 0.03 96.56 92.95 51.47 
C3_2 Control 16,949,182 15,90,420 1.99G 0.04 93.93 88.78 51.45 





D1_2 Lithium 19,419,296 18,589,272 2.32G 0.04 94.55 89.84 50.22 
D2_1 VPA 18,259,110 17,513,575 2.19G 0.03 96.02 92.02 50.30 
D2_2 VPA 18,259,110 17,513,575 2.19G 0.04 94.50 89.77 50.28 
D3_1 Control 17,251,749 16,625,525 2.08G 0.03 96.76 93.42 51.05 




Appendix E: Code used in thesis 
All the code and bash scripts used in this thesis are listed below.  
1. Mapping with STAR aligner 
# Four valproate-treated and four untreated samples from 
RN46A cell line. 
# valproate-treated: A2, B2, C2, D2 
# Control: A3, B3, C3, D3 
# Mapping with STAR 2-pass 
# Rat Rnor6 assembly last updated 12/8/16 





#Path of the directory for STAR-aligner 
STAR=./STAR-2.5.1b/source/STAR 
# Output directory 
mainDir=./STAR 
mkdir $mainDir 




# Genome fasta file 
genomeFasta=./Rattus_norvegicus.Rnor_6.0.dna.toplevel.fa 












# Step 1:Prepare rat genome index 
$STAR --runThreadN 4 --runMode genomeGenerate --genomeDir 
$genomeDir --genomeFastaFiles $genomeFasta --sjdbGTFfile 








# Defining common parameters for all STAR runs 
 
CommonPars="--runThreadN 4 --limitBAMsortRAM 15000000000--
genomeLoad LoadAndKeep --outSAMstrandField intronMotif --
outSAMtype BAM SortedByCoordinate --alignEndsType 
EndToEnd" 
 
cd $mainDir  
 
#Step 2: STAR mapping 1-pass 
 
for i in A1 A2 A3 B1 B2 B3 C1 C2 C3 D1 D2 D3 
do 
 set -x 
 runDir=$mainDir/"$i"_1Pass 
 mkdir $runDir 
 
 cd $runDir 




 cd .. 
done 
 
$STAR --genomeDir $genomeDir --genomeLoad Remove 
 
# Step 3 :Concatenating splice jucntions 
cat $(find -name \SJ.out.tab) >concatenated_SJ.out.tab 
 
# Step 4:generate genome with junctions from the 1st pass 
genomeDir2pass=$mainDir/genome2pass 
mkdir $genomeDir2pass 
$STAR --genomeDir $genomeDir2pass --runMode genomeGenerate 
--genomeFastaFiles $genomeFasta --sjdbFileChrStartEnd 
$mainDir/concatenated_SJ.out.tab --sjdbOverhang 124 --
sjdbGTFfile $gtfFile --runThreadN 4 
 
# Step 4: Running STAR 2-pass 
for i in A1 A2 A3 B1 B2 B3 C1 C2 C3 D1 D2 D3 
do 
 set -x 
 runDir=$mainDir/"$i"_1Pass 
 mkdir $runDir 
 
 cd $runDir 










$STAR --genomeDir $genomeDir --genomeLoad Remove 
 
 






















2. Differential gene expression analysis with 
Cufflinks2 suite  
#!/bin/bash 










# Directory with STAR aligned bam files 
mainDir=./STAR  
# Genome fasta file 
genomeFasta=./Rattus_norvegicus.Rnor_6.0.dna.toplevel.fa 







# Step 1 Run Cufflinks on aligned bam files 
for i in A2 A3 B1 B2 B3 C1 C2 C3 D1 D2 D3 
do 





$cufflinks --verbose --num-threads 4 --GTF $gtfFile -







# Step 2: Cuffmerge 
# Writing assembly_GTF_list.txt file 
 











# Running Cuffmerge 
# Rnor_6.0 annotation, release 80, contains two lines with 
# "Selenocysteine" in the 3rd column. 
# Cufflinks/Cuffdiff/cuffmerge don't seem to recognize # 
this, and thus they crash. 
 




# Run on command line 
./cufflinks-2.2.1.Linux_x86_64/cuffmerge --num-threads 4 -










for i in A2 A3 B1 B2 B3 C1 C2 C3 D1 D2 D3 
do 













# Step 4: Running Cuffdiff 
 




$cuffdiff -v -L VPA,Control -p 4 \ 










3. Differential gene expressiion analysis with 
DESeq2 
#Install DESeq2 
if (!requireNamespace("BiocManager", quietly = TRUE)) 






#directory <- "/path/to/counts/directory/" 





# Merge individual sample files (i.e. ctrl1.counts, 
ctrl2.counts, etc.) 
sampleFiles <- grep("count", 
list.files(directory),value=T) 
 
# view sampleFiles 
sampleFiles 
 
sampleCondition<-c("Control", "Control", Control", 




















# DESeq2 analysis 
dds<-DESeq(ddsHTSeq) 
res<-results(dds) 




# Save data results and normalized reads to csv! 
resdata <- merge(as.data.frame(res), 
as.data.frame(counts(dds,normalized=T)), 
by='row.names',sort=F) 
















# produce DataFrame of results of statistical tests 
# record experimental design 
mcols(res, use.names = T) 
write.csv(as.data.frame(mcols(res, use.name = T)),file = 
"DESeq2-test-conditions.csv") 
 
# replacing outlier value with estimated value as 
predicted by distrubution using 
ddsClean <- replaceOutliersWithTrimmedMean(dds) 
ddsClean <- DESeq(ddsClean) 
tab <- table(initial = results(dds)$padj < 0.1, 




resClean <- results(ddsClean) 




# MA plot of RNAseq data for entire dataset 
# genes with padj < 0.1 are colored Red 




# transform raw counts into normalized values 
# DESeq2 has two options:  1) rlog transformed and 2) 
variance stabilization 
rld <- rlogTransformation(dds, blind=T) 
vsd <- varianceStabilizingTransformation(dds, blind=T) 
 
# save normalized values 
write.table(as.data.frame(assay(rld),file='DESeq2-rlog-







p <- plotPCA(rld, intgroup=c("condition")) 
p <- p + geom_text(aes_string(x = "PC1", y = "PC2", label 










p <- plotPCA(rld, intgroup=c("condition")) 
p <- p + geom_text(aes_string(x = "PC1", y = "PC2", label 





pcaData <- plotPCA(vsd, intgroup=c("condition", "type"), 
returnData=TRUE) 
percentVar <- round(100 * attr(pcaData, "percentVar")) 
ggplot(pcaData, aes(PC1, PC2, color=condition, 
shape=type)) + 
  geom_point(size=3) + 
  xlab(paste0("PC1: ",percentVar[1],"% variance")) + 
  ylab(paste0("PC2: ",percentVar[2],"% variance")) +  
  coord_fixed() 
 
4. Transcriptome mapping with Kallisto 
#!/bin/bash 
# Running kallisto 
$kallisto=./bin/kallisto 




#Build kallisto index 
 
$kallisto index -i Rnor6.idx 
./Rattus_norvegicus.Rnor_6.0.cdna.all.fa 
 
# Using a for loop to run kallisto for each sample,  
for i in A2 A3 B1 B2 B3 C1 C2 C3 D1 D2 D3  
do 
 runDir=$mainDir/"$i"/kallisto 
 mkdir -p $runDir  
 cd $runDir 
 kallisto quant -i $mainDir/Rnor6.idx -o $runDir -b 
100 -t 4 ./NHHW150002/data_give/clean_data/"$i"_1.clean.fq 
./NHHW150002/data_give/clean_data/"$i"_2.clean.fq 
 cd .. 
done 
 
5. Differential expression analysis with Sleuth 










# Differential expression analysis of kallisto-aligned  
# data with sleuth 
base_dir<-"./kallisto_results" 
sample_id <- dir(file.path(base_dir,"results")) 
sample_id 
kal_dirs <- sapply(sample_id, function(id) 
file.path(base_dir, "results", id, "kallisto")) 
kal_dirs 
s2c <- read.table(file.path(base_dir,"hiseq_info.txt"), 
header = TRUE, stringsAsFactors=FALSE) 
s2c <- dplyr::select(s2c, sample = run_accession, 
condition) 
s2c <- dplyr::mutate(s2c, path = kal_dirs) 
s2c 
 
#Adding gene names from biomart 
tx2gene <- function(){ 
  mart <- biomaRt::useMart(biomart = "ensembl", dataset = 
"rnorvegicus_gene_ensembl") 
  t2g <- biomaRt::getBM(attributes = 
c("ensembl_transcript_id", "ensembl_gene_id", 
                                       
"external_gene_name"), mart = mart) 
  t2g <- dplyr::rename(t2g, target_id = 
ensembl_transcript_id, 
                       ens_gene = ensembl_gene_id, 
ext_gene = external_gene_name) 
  return(t2g) 
} 
 
t2g <- tx2gene() 
so <- sleuth_prep(s2c, ~ condition, target_mapping = t2g) 
so <- sleuth_fit(so) 
so <- sleuth_wt(so, which_beta = 'conditionValproate') 
models(so) 
plot_volcano(so, 'conditionValproate') 
so <- sleuth_wt(so, which_beta = 'conditionLithium') 
plot_volcano(so, 'conditionLithium') #No points 
significant for Lithium 
 
#likelihood ratio test 
so <- sleuth_fit(so, formula = ~1, fit_name = "reduced") 
so <- sleuth_lrt(so, "reduced", "full") 




lrt_results <- sleuth_results(so, test = 'reduced:full', 
test_type = 'lrt') 
wt_results <- sleuth_results(so, test = 
'conditionValproate') 
 












#Build a index 





for i in B1 B2 B3 C1 C2 C3 D1 D2 D3 
do 
 runDir=$mainDir/"$i" 
 mkdir $runDir 
 cd $runDir 
 $salmon quant -p 4 --numBootstraps 100 --biasCorrect 
-i ./transcripts_index -l IU --geneMap $gtf -1 
./NHHW150002/data_give/clean_data/"$i"_1.clean.fq -2 
./NHHW150002/data_give/clean_data/"$i"_2.clean.fq -o ./ 




7. Differential expression analysis with Sleuth for 
Salmon-Wasabi 
 
#Install required packages 
#devtools, biomart, sleuth, wasabi 
source("http://bioconductor.org/biocLite.R") 










#Set working sirectory to quants 
setwd() 
sf_dirs <- dir() 
sf_dirs 
 
# convert the sailfish dirs to kallisto h5 format 
prepare_fish_for_sleuth(sf_dirs) 
 
#Creating s2c as data frame for the samples 
sample = sf_dirs 
run_accession <-c('CC_2', 'CC_3', 'CC_4', 'Li_2', 'Li_3', 
'Li_4', 'VPA_2', 'VPA_3', 'VPA_4') 
condition = c('control', 'control', 'control', 'Lihium', 
'Lihium', 'Lihium', 'Valproate', 'Valproate', 'Valproate') 
path = sf_dirs 
s2c <- data.frame(sample, run_accession, condition, path)  
s2c$path <- as.character(s2c$path) 
s2c 
 
# model the experimental question 
model <- "~ condition" 
tx2gene <- function(){ 
  mart <- biomaRt::useMart(biomart = "ensembl", dataset = 
"rnorvegicus_gene_ensembl") 
  t2g <- biomaRt::getBM(attributes = 
c("ensembl_transcript_id", "ensembl_gene_id", 
                                       
"external_gene_name"), mart = mart) 
  t2g <- dplyr::rename(t2g, target_id = 
ensembl_transcript_id, 
                       ens_gene = ensembl_gene_id, 
ext_gene = external_gene_name) 
  return(t2g) 
} 
 
t2g <- tx2gene() 
so <- sleuth_prep(s2c, ~ condition, target_mapping = t2g) 
so <- sleuth_fit(so) 
so <- sleuth_wt(so, which_beta = 'conditionValproate') 










































           sheetName = "VPA_Run2",  
           col.names = TRUE, row.names = TRUE, append = 
TRUE) 
 

































           sheetName = "VPA_Run1",  





#### Running Li and control from Run2 #### 
path<-("./NanoStringDiff/NS_Run2_LiCC.csv") 


























           sheetName = "Li_Run2",  
           col.names = TRUE, row.names = TRUE, append = 
TRUE) 
 
#### Running Li and control from NS Run1 2016 #### 
path<-("./NanoStringDiff/NS_Run1_LiCC.csv") 
 
designs=data.frame(group=c("Li", "CC", "Li", "CC", "Li",






















           sheetName = "Li_Run1",  
           col.names = TRUE, row.names = TRUE, append = 
TRUE) 




























           sheetName = "LTG_Run1.1",  









#### Running NanoStringDiff analysis for VPD and TSA from 
NS Run1 2016 #### 
path<-("./NanoStringDiff/NS_Run1_VPD.csv") 






















sheetName = "VPD_Run1", 

























sheetName = "TSA_Run1", 
col.names = TRUE, row.names = TRUE, append = TRUE) 
 
#### Running NanoStringDiff analysis for CI994, RGFP966, 
PCI34051 and TubaA from NS Run2 2017 #### 
##### VPD Run2 ###### 
path<-("./NanoStringDiff/NS_Run2_vpd.csv") 




















sheetName = "VPD_Run2", 
col.names = TRUE, row.names = TRUE, append = F) 

























sheetName = "CI994", 
col.names = TRUE, row.names = TRUE, append = TRUE) 






















sheetName = "RGFP966", 
col.names = TRUE, row.names = TRUE, append = F) 

























sheetName = "PCI34051", 
col.names = TRUE, row.names = TRUE, append = F) 
########## TubaA #################### 
path<-("./NanoStringDiff/NS_Run2_TubaA.csv") 




















sheetName = "TubaA", 
col.names = TRUE, row.names = TRUE, append = F) 
 
 
9. Alternative Splicng analysis with rMATS  
#!/bin/bash 





# Genome reference gtf file 
gtfFile=./Rattus_norvegicus.Rnor_6.0.88.gtf 
 
# Running rMATS on bam files 
outDir=./rMats 
mkdir $outDir 






igned.sortedByCoord.out.bam -gtf $gtfFile -o $outDir -t 





10. Alternative splicing analysis with 
IsoformSwitchAnalyzeR 
 










# Importing data from Cufflinks 22Apr2018 run 
# Z directory HCS copied in C drive 
setwd("C:/IsoformSwitchAnalyzeR/cuffdiff_3July18") 
SwitchList <- importCufflinksFiles( 
  pathToGTF= "merged.gtf", 
  pathToGeneDEanalysis = "gene_exp.diff", 
  pathToIsoformDEanalysis = "isoform_exp.diff", 
  pathToGeneFPKMtracking = "genes.fpkm_tracking", 
  pathToIsoformFPKMtracking = "isoforms.fpkm_tracking", 
  pathToIsoformReadGroupTracking = 
"isoforms.read_group_tracking", 
  pathToSplicingAnalysis = "splicing.diff", 
  pathToReadGroups = "read_groups.info", 




  fixCufflinksAnnotationProblem=TRUE, 
  quiet=FALSE 
) 
SwitchList 
# Filtering the switchAnalyzeRlist  
SwitchListFiltered <- preFilter(SwitchList, 
geneExpressionCutoff = 1, isoformExpressionCutoff = 0, 
removeSingleIsoformGenes = TRUE) 
SwitchListFilteredStrict <- preFilter(SwitchList, 
geneExpressionCutoff = 10, isoformExpressionCutoff = 3, 
removeSingleIsoformGenes = TRUE) 
 
# DIU with DRIMSeq 
SwitchListAnalyzedFiltered <- isoformSwitchTestDRIMSeq( 
  switchAnalyzeRlist = SwitchListFiltered, 
  testIntegration='isoform_only', 





  switchAnalyzeRlist = SwitchListFilteredStrict, 
  testIntegration='isoform_only', 















SwitchListAnalyzedORF <- analyzeORF(SwitchListAnalyzed, 
genomeObject = Rnorvegicus, showProgress=FALSE) 
head(SwitchListAnalyzedORF$orfAnalysis, 3) 
 
# Extract nucleotide and protein sequence 
SwitchListAnalyzed <- extractSequence( 
  SwitchListAnalyzedORF,  
  genomeObject = Rnorvegicus, 










SwitchListAnalyzed <- analyzePFAM( 
  switchAnalyzeRlist   = SwitchListAnalyzed, 
  pathToPFAMresultFile = "pfam.txt", 




SwitchListAnalyzed <- analyzeSignalP( 
  switchAnalyzeRlist       = SwitchListAnalyzed, 
  pathToSignalPresultFile = "signalP.txt" 
) 
 
### Add CPAT analysis 
SwitchListAnalyzed <- analyzeCPAT( 
  switchAnalyzeRlist   = SwitchListAnalyzed, 
  pathToCPATresultFile = "cpat.txt", 
  codingCutoff         = 0.725, # the coding potential 
cutoff we suggested for human 
  removeNoncodinORFs   = TRUE   # because ORF was 
predicted de novo 
) 
 
### Predicting Alternative Splicing 
SwitchListAnalyzed <- 
analyzeAlternativeSplicing(SwitchListAnalyzed, quiet=TRUE) 
### overview of number of intron retentions (IR) 
table(SwitchListAnalyzed$isoformFeatures$IR) 
 
#Global splicing analysis 
extractSplicingSummary( SwitchListAnalyzed ) 
extractSplicingEnrichment( SwitchListAnalyzed ) 
extractSplicingEnrichmentComparison( SwitchListAnalyzed  ) 
extractSplicingGenomeWide( SwitchListAnalyzed  ) 
 





SwitchListAnalyzed <- analyzeSwitchConsequences( 
  SwitchListAnalyzed, 
  consequencesToAnalyze = consequencesOfInterest,  
  dIFcutoff = 0.1, # 0.4 very high cutoff for fast 
runtimes  didn't produce output so switched to 0.1 
  showProgress=FALSE) 
# Visualization 
extractSwitchSummary( 
  SwitchListAnalyzed, 






extractSwitchSummary(SwitchListAnalyzed, dIFcutoff = 0.4, 
filterForConsequences = FALSE) 
extractSwitchSummary(SwitchListAnalyzed, dIFcutoff = 0.4, 
filterForConsequences = TRUE) 
extractTopSwitches( 
  SwitchListAnalyzed,  
  filterForConsequences = TRUE,  
  n = 2,  
  sortByQvals = TRUE 
) 
 
switchPlot(SwitchListAnalyzed, gene = 'Tpm1') 
switchPlotTopSwitches( 
  switchAnalyzeRlist = SwitchListAnalyzed,  
  n = 10, 
  filterForConsequences = FALSE,  
  splitFunctionalConsequences = TRUE 
) 








11. Alternative Splicing analysis with DEXSeq 





# Count the number of reads that overlap with each of the 










for i in A1 A2 A3 B1 B2 B3 C1 C2 C3 D1 D2 D3 
do 






library/DEXSeq/python_scripts/dexseq_count.py -r pos -p 













# Show working directory 
setwd("./RNASeq_results/dexseq") 
getwd() 
countFiles = list.files(path = ".", pattern=".count", 
full.names=TRUE) 
countFiles 




  row.names=c("B2_dexseq.count", "B3_dexseq.count", 
"C2_dexseq.count", "C3_dexseq.count", "D2_dexseq.count", 
"D3_dexseq.count"),  





suppressPackageStartupMessages( library( "DEXSeq" ) ) 
dxd = DEXSeqDataSetFromHTSeq( 
  countFiles, 
  sampleData=sampleTable, 
  design= ~ sample + exon + condition:exon, 
  flattenedfile=flattenedFile ) 
 
colData(dxd) 
head( geneIDs(dxd) ) 
head( exonIDs(dxd) ) 
 
#access the first 5 rows from the count data 
head( counts(dxd), 5 ) 
split( seq_len(ncol(dxd)), colData(dxd)$exon ) 
head( featureCounts(dxd), 5 ) 
head( rowRanges(dxd), 3 ) 





### Generating and saving plots 
dxd = estimateSizeFactors( dxd ) 
dxd = estimateDispersions( dxd ) 
plotDispEsts( dxd ) 
dxd = testForDEU( dxd ) 
dxd = estimateExonFoldChanges( dxd, 
fitExpToVar="condition") 
dxr1 = DEXSeqResults( dxd ) 
dxr1 
 





table ( dxr1$padj < 0.1 ) 
table ( tapply( dxr1$padj < 0.1, dxr1$groupID, any ) ) 
plotMA( dxr1, cex=0.8 ) 





plotDEXSeq( dxr1, "ENSRNOG00000018184", legend=TRUE, 
cex.axis=1.2, cex=1.3, lwd=2 ) 
plotDEXSeq( dxr1, "ENSRNOG00000018184", 
displayTranscripts=TRUE, legend=TRUE, 
            cex.axis=1.2, cex=1.3, lwd=2 ) 
plotDEXSeq( dxr1, "ENSRNOG00000018184", expression=FALSE, 
norCounts=TRUE, 
            legend=TRUE, cex.axis=1.2, cex=1.3, lwd=2 ) 
plotDEXSeq( dxr1, "ENSRNOG00000018184", expression=FALSE, 
splicing=TRUE, 
            legend=TRUE, cex.axis=1.2, cex=1.3, lwd=2 ) 





12. Alternative Splicing analysis with JunctionSeq 
#QoRTs 
#!/bin/bash 
# QoRT for quanlity control check of raw fastq files 














# QoRT for generating counts 
 
# Vpa2 
java -Xmx16G -jar ./java_programs/QoRTs.jar QC \ 






























































































# set working directory 
setwd("Z:/PriyankaS/AS/JunctionSeq_QoRT") 
library(JunctionSeq) 




                      header=TRUE, 
                      stringsAsFactors=FALSE); 
print(decoder) 





#Run the analysis: 
jscs <- runJunctionSeqAnalyses( 
  sample.files = countFiles, 
   sample.names = decoder$sample.ID, 
   condition = decoder$group.ID, 
   flat.gff.file = "forJunctionSeq.gff.gz", 
   nCores = 1, 
   verbose=TRUE, 
   debug.mode = TRUE 
 ) 
 
 extracting test results 
 writeCompleteResults(jscs, 
                      outfile.prefix="./test", 
                      save.jscs = TRUE) 
  
 buildAllPlots(jscs=jscs, 
               outfile.prefix = "./plots/", 
               use.plotting.device = "png", 
               FDR.threshold = 0.01, 
               variance.plot = T, 
               ma.plot = T, 
               rawCounts.plot = T, 
               verbose = T) 
Merge novel junctions 
Decoder file changed to include size factors 




                      header=TRUE, 
                      stringsAsFactors=FALSE); 
print(decoder) 








#Run the analysis: 
 jscs.Novel <- runJunctionSeqAnalyses( 
  sample.files = countFiles.Novel, 
  sample.names = decoder$sample.ID, 
  condition = decoder$group.ID, 
   flat.gff.file = "withNovel.forJunctionSeq.gff.gz", 
   nCores = 1, 
   verbose=TRUE, 
  debug.mode = TRUE 
 ) 
 # extracting test results 
 writeCompleteResults(jscs.Novel, 
                      outfile.prefix="./withNovel_", 
                      save.jscs = TRUE) 
 buildAllPlots(jscs=jscs.Novel, 
           outfile.prefix = "./plots_Novel/", 
           use.plotting.device = "png", 
           FDR.threshold = 0.01, 
            variance.plot = T, 
            ma.plot = T, 
            rawCounts.plot = T, 






       function(g){  
         
fData(jscs)$geneWisePadj[as.character(fData(jscs)$geneID) 
== g][1] 
       },  








Appendix F: List of DEGs identified with all four methods 
Complete list of DEGs in response to VPA at log2 fold change > 1.5 and padj <0.05 for each of the four software used. Table 1 lists the DEGs for kallisto analysis, 
table 2 lists the DEGs for DESEq2 analysis, table 3 lists the DEGs for salmon analysis and table 4 lists the DEGs for Cuffdiff2 analysis. 
Table 1. DEGs in response to VPA as identified with kallisto, ranked by padj values. 
No. Gene Name padj LFC No. Gene Name padj LFC No. Gene Name padj LFC No. Gene Name padj LFC 
1 Adgrb2 1.3E-29 2.48 19 LOC100909521 5.9E-10 3.08 37 LOC100911874 3.7E-07 2.37 55 Raver2 7.7E-05 1.65 
2 Aqp1 1.3E-29 -1.67 20 Lzts1 8.1E-10 3.62 38 Prelp 3.7E-07 -3.28 56 NA 8.3E-05 2.22 
3 Mmp13 7.9E-26 1.83 21 Ppm1j 1.0E-09 1.81 39 Rab6b 6.8E-07 1.87 57 Crmp1 9.1E-05 2.06 
4 Zcchc12 2.3E-20 1.95 22 NA 1.0E-09 1.75 40 Ogdhl 1.0E-06 1.59 58 Mfap3l 1.0E-04 2.06 
5 Ngfr 6.5E-16 1.75 23 Col3a1 2.5E-09 -2.02 41 Ppp1r1b 2.9E-06 2.46 59 Gpr85 1.2E-04 1.72 
6 Il20rb 6.5E-16 -2.56 24 Olfm2 4.9E-09 1.58 42 Camsap3 2.9E-06 1.62 60 Gzmbl3 1.2E-04 -1.68 
7 Lsp1 9.0E-15 -2.27 25 Tbkbp1 5.2E-09 1.95 43 Sorcs2 3.5E-06 1.70 61 Epha10 1.2E-04 -2.19 
8 Camta1 2.3E-14 1.79 26 Gfra4 5.2E-09 -1.66 44 Slc30a3 5.5E-06 1.80 62 Rundc3b 1.3E-04 2.12 
9 Wnt6 2.3E-14 1.98 27 Arhgap20 1.8E-08 1.80 45 Scara5 6.6E-06 -1.60 63 Adam33 1.7E-04 -1.88 
10 Adam23 6.5E-14 2.28 28 NA 3.4E-08 2.14 46 Dpyd 1.3E-05 2.00 6 Cachd1 2.8E-04 1.69 
11 Tmem130 6.5E-14 2.04 29 Snap91 4.9E-08 2.23 47 Maob 1.5E-05 1.76 65 Bean1 2.8E-04 2.08 
12 Atp1b2 2.0E-12 1.73 30 Slc6a15 5.0E-08 1.58 48 Ocln 2.5E-05 2.21 66 Map3k9 2.8E-04 1.67 
13 Erbb3 1.8E-11 1.61 31 Slc17a7 6.9E-08 2.03 49 Car12 2.7E-05 1.53 67 Slurp1 4.4E-04 -2.77 
14 Perp 3.2E-11 1.70 32 Serpinb2 8.7E-08 1.59 50 Kcnip4 4.3E-05 -2.20 68 Slc1a1 5.0E-04 1.67 
15 RGD1563349 7.2E-11 2.15 33 NA 1.3E-07 1.70 51 Wnt11 4.7E-05 1.71 69 Elmod1 8.8E-04 1.68 
16 Clgn 1.5E-10 1.82 34 Cyp24a1 1.6E-07 1.96 52 Crlf1 5.6E-05 2.78 70 Hax1 1.2E-03 -3.04 
17 NA 2.5E-10 1.83 35 Lingo1 1.9E-07 2.19 53 Akr1c3 6.0E-05 -1.57 71 Mcpt8l2 1.3E-03 -1.93 
18 Mpp3 4.5E-10 1.74 36 Ptprz1 3.2E-07 1.58 54 Ablim3 6.6E-05 1.91 72 Lcp1 1.4E-03 2.33 





No. Gene Name padj LFC No. Gene Name padj LFC No. Gene Name padj LFC 
73 Olfm3 1.5E-03 -2.07 100 Tubb4a 6.4E-03 2.01 127 Fgf11 2.0E-02 1.76 
74 Hapln2 1.6E-03 2.04 101 Sncb 6.6E-03 1.98 128 Dcn 2.1E-02 -3.55 
75 Slpi 1.6E-03 1.90 102 F2rl2 6.7E-03 1.80 129 Scn8a 2.2E-02 1.73 
76 Tnik 1.6E-03 1.60 103 Abi3 6.9E-03 -1.65 130 Pak3 2.3E-02 2.07 
77 Kcnn4 1.6E-03 -1.82 104 Ugt8 7.0E-03 1.78 131 Mmp9 2.3E-02 1.59 
78 Nfe2l3 1.7E-03 1.75 105 Csgalnact1 7.1E-03 1.69 132 NA 2.3E-02 -5.22 
79 Hpcal4 1.8E-03 2.05 106 NA 7.2E-03 2.15 133 Pkib 2.5E-02 2.76 
80 Tnn 1.9E-03 -1.87 107 Crabp1 7.5E-03 2.15 134 Galnt18 2.6E-02 1.81 
81 Aldh3a1 2.0E-03 -2.44 108 Dchs1 8.9E-03 1.72 135 Pnmal2 2.9E-02 1.75 
82 Stk32c 2.1E-03 2.18 109 Ccl7 9.2E-03 -1.80 136 Htr5b 3.1E-02 1.77 
83 Akap5 2.2E-03 1.60 110 NA 9.6E-03 1.68 137 Pabpc1l2a 3.2E-02 1.54 
84 Fam46c 2.2E-03 1.89 111 Cntn1 9.7E-03 1.60 138 Lppr4 3.5E-02 1.77 
85 Syn2 2.5E-03 1.53 112 Map3k7cl 1.0E-02 -2.20 139 Ptn 3.5E-02 -2.06 
86 Notch3 2.5E-03 1.68 113 Adora1 1.0E-02 1.57 140 NA 4.0E-02 -1.85 
87 Mpp7 2.6E-03 1.84 114 Fa2h 1.1E-02 1.67 141 NA 4.5E-02 1.56 
88 Slc8a2 2.8E-03 2.21 115 Rprml 1.2E-02 1.72 142 NA 4.7E-02 1.61 
89 Syt1 2.8E-03 2.21 116 RGD1310819 1.3E-02 2.71 143 NA 4.7E-02 -1.80 
90 Smim22 2.9E-03 -2.00 117 Cldn23 1.3E-02 2.10 144 Syt8 5.0E-02 -2.23 
91 Hck 3.8E-03 1.88 118 Itgbl1 1.3E-02 -2.06  
   
92 Grid2ip 3.9E-03 1.94 119 Adora2a 1.5E-02 1.56  
   
93 Cnn1 4.0E-03 1.56 120 Camk2n2 1.7E-02 1.94  
   
94 Dusp2 4.5E-03 1.73 121 Slc22a25 1.7E-02 2.50  
   
95 Mcoln3 4.5E-03 1.53 122 Mcpt8 1.7E-02 -2.88  
   
96 Qrich2 5.4E-03 -2.60 123 Lpl 1.8E-02 1.69  
   
97 Sdf2l1 5.8E-03 1.60 124 Slc4a7 1.8E-02 3.62  
   
98 Klk6 5.9E-03 1.78 125 Plod2 1.9E-02 1.89  
   
99 Klhl32 6.3E-03 3.17 126 Wdr17 2.0E-02 1.79  





Table 2. DEGs in response to VPA as identified with DESeq2, ranked by padj values. 
No. Gene Name padj LFC No. Gene Name padj LFC No. Gene Name padj LFC No. Gene Name padj LFC 
1 Igf2 8.4E-32 4.15 26 Mapt 1.1E-11 2.15 51 Slpi 5.5E-10 2.10 76 Rnf128 2.2E-08 2.24 
2 Adgrb2 4.4E-28 3.03 27 Ppm1j 1.1E-11 2.17 52 Ppp1r1b 5.5E-10 2.42 77 Rab40b 2.7E-08 1.58 
3 Aqp1 7.4E-28 -2.26 28 Cacna1b 1.5E-11 2.28 53 Bean1 7.2E-10 2.30 78 Ifitm3 4.4E-08 -1.72 
4 Mmp13 1.2E-25 2.39 29 Nr2f1 1.5E-11 -1.59 54 Cyp24a1 1.1E-09 2.19 79 Cpm 4.6E-08 1.83 
5 Vgf 1.1E-24 3.34 30 RGD1310110 1.5E-11 1.78 55 Plcg2 1.3E-09 1.69 80 Snap25 5.1E-08 2.20 
6 Zcchc12 1.2E-22 2.52 31 Aplp1 1.6E-11 1.75 56 Fez1 1.6E-09 1.83 81 RGD1310819 5.9E-08 2.10 
7 Il20rb 3.3E-20 -2.95 32 Adamts1 1.7E-11 -1.81 57 Ntrk1 1.8E-09 2.30 82 Maob 7.0E-08 1.97 
8 Ngfr 1.8E-19 2.38 33 Slc6a15 2.1E-11 2.26 58 LOC100912195 2.7E-09 1.75 83 Nefm 1.0E-07 2.01 
9 Tspan13 1.9E-18 2.33 34 Syt1 2.4E-11 2.11 59 Efna3 3.1E-09 1.98 84 Tubb4a 1.0E-07 2.16 
10 Col3a1 4.2E-17 -2.53 35 Mpp3 3.3E-11 2.09 60 Kif1a 3.4E-09 2.16 85 Ssc5d 1.0E-07 -1.60 
11 Lsp1 4.6E-17 -2.61 36 L1cam 3.9E-11 2.33 61 Rundc3b 3.5E-09 2.24 86 Olfm2 1.1E-07 1.60 
12 Agap2 1.3E-16 3.31 37 Lzts1 4.4E-11 2.74 62 Pkib 3.7E-09 2.35 87 Slc6a17 1.1E-07 1.78 
13 Snap91 2.2E-16 2.63 38 Nrgn 4.4E-11 2.64 63 Stk39 4.4E-09 1.68 88 Clic5 1.2E-07 2.22 
14 Wnt6 8.0E-16 2.38 39 Crlf1 4.8E-11 2.52 64 Cdkn1c 5.6E-09 1.91 89 Adam33 1.2E-07 -1.96 
15 Nxph4 8.4E-16 2.98 40 Clec2g 6.4E-11 -2.06 65 Olfm3 7.4E-09 -2.41 90 Itgb2 1.3E-07 1.95 
16 Tmem130 1.5E-14 2.47 41 Nrxn2 6.4E-11 2.53 66 Txnrd3 7.7E-09 1.59 91 B3gnt5 1.5E-07 1.63 
17 Adam23 1.9E-14 2.55 42 Slc17a7 8.7E-11 2.27 67 Scara5 9.5E-09 -1.88 92 Ocln 1.5E-07 2.17 
18 Clgn 8.3E-14 2.20 43 Tbkbp1 9.8E-11 2.21 68 Hpcal4 1.1E-08 2.12 93 1500009L16Rik 1.6E-07 2.25 
19 Erbb3 3.4E-13 1.99 44 Serpinb2 1.0E-10 1.92 69 Kcnh3 1.1E-08 2.39 94 Fn1 1.6E-07 -1.56 
20 RGD1563349 7.4E-13 2.73 45 Rab6b 2.6E-10 2.13 70 Mboat2 1.2E-08 1.73 95 Tubb3 1.6E-07 1.54 
21 Chrna5 1.3E-12 2.86 46 Arhgap20 2.7E-10 2.16 71 Tfcp2l1 1.8E-08 1.83 96 Col8a1 1.7E-07 -1.60 
22 Atp1b2 1.3E-12 2.11 47 Lingo1 3.7E-10 2.38 72 Dpyd 1.9E-08 2.10 97 Gfra4 1.9E-07 -1.82 
23 Tmeff1 1.7E-12 2.87 48 S100a4 4.5E-10 -1.89 73 Car12 2.0E-08 1.89 98 Icam5 1.9E-07 1.56 
24 Fam25a 2.1E-12 -2.71 49 Psmb10 5.5E-10 -1.82 74 Kif5c 2.0E-08 1.60 99 Ptprz1 1.9E-07 1.81 





No. Gene Name padj LFC No. Gene Name padj LFC No. Gene Name padj LFC 
101 Ogdhl 2.2E-07 1.76 128 Tnfrsf11b 4.2E-06 -1.55 155 Ablim3 1.4E-05 1.79 
102 Nptx1 2.2E-07 2.02 129 Cp 4.5E-06 -1.56 156 Sh2d5 1.4E-05 1.70 
103 Sel1l3 2.4E-07 2.26 130 Nrg1 4.8E-06 1.54 157 Pstpip2 1.4E-05 1.82 
104 Esrp1 2.5E-07 2.14 131 Rn50_8_0646.1 4.9E-06 1.55 158 Unc13a 1.7E-05 1.55 
105 Insig1 3.1E-07 1.73 132 Akr1c3 5.0E-06 -1.74 159 Chrm4 1.7E-05 1.95 
106 Crym 4.1E-07 1.73 133 Csgalnact1 5.2E-06 1.90 160 Mpp7 2.2E-05 1.81 
107 Mcoln3 4.9E-07 1.78 134 Prelp 5.2E-06 -2.06 161 C1qtnf5 2.8E-05 -1.53 
108 Syn2 6.0E-07 2.04 135 Mfap3l 5.7E-06 1.89 162 Gli1 3.1E-05 1.83 
109 Camk2n1 6.6E-07 1.52 136 Kcnc3 5.8E-06 1.92 163 Pde9a 3.4E-05 1.91 
110 Nfasc 6.8E-07 1.96 137 Camsap3 6.2E-06 1.74 164 Abcg2 4.1E-05 1.61 
111 Sorcs2 7.3E-07 1.85 138 Abca5 6.5E-06 1.56 165 Raver2 4.4E-05 1.66 
112 Golm1 7.9E-07 1.67 139 Shank3 6.7E-06 1.79 166 Map3k9 4.4E-05 1.65 
113 RGD1564664 7.9E-07 1.59 140 Lcp1 6.9E-06 1.99 167 AABR07037520.1 4.5E-05 1.52 
114 Kcnip4 8.5E-07 -1.93 141 AABR07041411.1 6.9E-06 1.58 168 Trim36 4.6E-05 1.53 
115 Crmp1 9.2E-07 2.01 142 Clmn 6.9E-06 1.54 169 Sncb 4.9E-05 1.83 
116 Padi2 1.1E-06 1.69 143 Plxdc1 7.2E-06 1.68 170 Gng7 5.0E-05 1.71 
117 Rbm11 1.2E-06 1.69 144 Abhd3 7.3E-06 1.66 171 RGD1311575 5.0E-05 1.73 
118 Rgs9 1.2E-06 1.51 145 Wnt11 7.5E-06 1.74 172 Lcn3 5.1E-05 -1.54 
119 Sox10 1.3E-06 2.15 146 Stk32c 7.6E-06 1.96 173 Ppp4r4 5.9E-05 1.83 
120 Nrcam 1.3E-06 1.61 147 Ccnd2 9.1E-06 2.01 174 Abca1 6.2E-05 -1.54 
121 Slc1a1 1.4E-06 1.75 148 Grid2ip 9.4E-06 1.91 175 Wisp2 6.2E-05 -1.84 
122 Osr1 1.5E-06 -1.54 149 Bdh1 9.4E-06 1.53 176 Fam46c 6.4E-05 1.77 
123 Inpp5d 1.5E-06 -1.65 150 Lum 1.1E-05 -1.99 177 Reln 6.7E-05 1.66 
124 Ero1b 1.6E-06 1.54 151 Fgf11 1.1E-05 1.65 178 Nsg2 6.9E-05 1.58 
125 Hapln2 2.2E-06 1.98 152 Elmod1 1.3E-05 1.78 179 Dmd 7.0E-05 1.55 
126 Cilp2 3.8E-06 1.66 153 Gpr85 1.3E-05 1.81 180 F2rl2 7.5E-05 1.66 





No. Gene Name padj LFC No. Gene Name padj LFC 
182 Acer2 8.2E-05 1.63 208 Rn60_20_0031.1 6.0E-04 1.62 
183 Cldn23 8.6E-05 1.72 209 Ptpru 6.8E-04 1.62 
184 Meox2 9.2E-05 -1.81 210 AC130391.3 7.0E-04 -1.50 
185 Moxd1 9.7E-05 1.81 211 Wdr17 7.0E-04 1.56 
186 Tnik 9.7E-05 1.66 212 Kcnn4 7.4E-04 -1.59 
187 Lynx1 1.0E-04 1.68 213 Tmem151b 8.3E-04 1.59 
188 Rims1 1.0E-04 1.78 214 Crabp1 8.4E-04 1.56 
189 Rtn4rl2 1.3E-04 1.79 215 Hck 8.5E-04 1.56 
190 Dtna 1.3E-04 1.68 216 Elavl3 9.3E-04 1.59 
191 Stap2 1.5E-04 -1.61 217 Ugt8 1.0E-03 1.53 
192 Klk6 1.6E-04 1.69 218 Mmp9 1.1E-03 1.51 
193 Camta1 1.8E-04 1.59 219 Tex15 1.1E-03 1.57 
194 Klk13 1.8E-04 1.71 220 Shank1 1.2E-03 1.54 
195 Pak3 1.8E-04 1.66 221 Erc2 1.2E-03 1.56 
196 Ankrd34b 1.9E-04 1.74 222 Mcpt8l2 1.3E-03 -1.54 
197 RGD1309108 2.1E-04 1.56 223 Epha10 1.6E-03 -1.54 
198 Gdpd2 2.9E-04 -1.54 224 Hsd11b1 1.8E-03 1.51 
199 Ppp1r1a 3.0E-04 1.71 No. Gene Name padj LFC 
200 Lrp2 3.4E-04 1.63 208 Rn60_20_0031.1 6.0E-04 1.62 
201 St6gal1 3.7E-04 1.66 209 Ptpru 6.8E-04 1.62 
202 Rtn1 4.0E-04 1.60 210 AC130391.3 7.0E-04 -1.50 
203 Sfrp4 4.1E-04 -1.55 211 Wdr17 7.0E-04 1.56 
204 Cachd1 4.4E-04 1.54 212 Kcnn4 7.4E-04 -1.59 
205 Cnn1 4.6E-04 1.55 213 Tmem151b 8.3E-04 1.59 
206 Ifit1 5.8E-04 -1.55 214 Crabp1 8.4E-04 1.56 





Table 3. DEGs in response to VPA as identified with salmon, ranked by padj values. 
No. Gene Name padj LFC No. Gene Name padj LFC No. Gene Name padj LFC No. Gene Name padj LFC 
1 Aqp1 7.2E-29 -1.67 26 Ntrk1 8E-09 2.23 51 Car12 7E-05 1.56 76 Nfe2l3 2E-03 1.78 
2 Mmp13 2.2E-25 1.83 27 Lzts1 2E-08 3.62 52 L1cam 7E-05 1.71 77 Mpp7 2E-03 1.94 
3 Zcchc12 7.0E-20 1.96 28 Nxph4 2E-08 3.02 53 Crlf1 7E-05 2.78 78 Gng7 2E-03 1.53 
4 Adgrb2 1.1E-17 2.35 29 Serpinb2 5E-08 1.60 54 Akr1c3 8E-05 -1.57 79 Cachd1 2E-03 1.62 
5 Ngfr 2.4E-17 1.87 30 Syt1 6E-08 1.72 55 RGD1310819 9E-05 1.94 80 Elmod1 2E-03 1.69 
6 Il20rb 2.2E-16 -2.57 31 Stap2 2E-07 -1.64 56 Raver2 1E-04 1.66 81 Notch3 2E-03 1.70 
7 Lsp1 5.7E-14 -2.28 32 Dpysl5 4E-07 1.66 57 Bean1 1E-04 2.12 82 Hpcal4 2E-03 2.06 
8 Erbb3 1.3E-13 1.59 33 Mapt 6E-07 1.79 58 Wnt11 1E-04 1.71 83 Ifit1 3E-03 -1.54 
9 Wnt6 1.3E-13 1.98 34 Cyp24a1 6E-07 1.96 59 Adam33 2E-04 -1.90 84 Akap5 3E-03 1.61 
10 Tmem130 1.5E-13 2.05 35 Slc30a3 7E-07 1.82 60 Gnai1 2E-04 1.98 85 Plod2 3E-03 1.89 
11 Atp1b2 1.0E-12 1.76 36 Kcnip4 1E-06 -1.82 61 Fgf11 2E-04 1.56 86 Kcnn4 3E-03 -1.89 
12 Adam23 1.3E-12 2.28 37 Lingo1 1E-06 2.20 62 Gpr85 2E-04 1.77 87 Dpyd 3E-03 1.91 
13 Perp 6.4E-11 1.70 38 Nefm 3E-06 1.86 63 Mfap3l 3E-04 2.06 88 Hax1 4E-03 -3.20 
14 Snap91 1.0E-10 2.29 39 Ptprz1 3E-06 1.59 64 1500009L16Rik 4E-04 2.80 89 Crabp1 4E-03 2.15 
15 Clgn 4.7E-10 1.81 40 Kif1a 3E-06 1.95 65 Crmp1 4E-04 2.07 90 Smim22 4E-03 -2.01 
16 Vgf 6.4E-10 3.08 41 Ogdhl 4E-06 1.57 66 RGD1311575 1E-03 1.75 91 Cdkn1c 4E-03 2.16 
17 Fam25a 8.8E-10 -2.68 42 Sorcs2 5E-06 1.71 67 Arhgap20 1E-03 1.90 92 Cnn1 5E-03 1.56 
18 Col3a1 2.8E-09 -2.02 43 Nptx1 5E-06 1.88 68 Spats2l 1E-03 3.16 93 Tnn 5E-03 -1.88 
19 Ppm1j 3.2E-09 1.80 44 Rab6b 8E-06 1.96 69 Mcpt8l2 1E-03 -2.18 94 Cubn 5E-03 3.90 
20 Pstpip2 3.5E-09 1.68 45 Ppp1r1b 9E-06 2.46 70 Tubb4a 1E-03 2.19 95 Cacna1b 6E-03 3.09 
21 Gfra4 4.0E-09 -1.66 46 Gzmbl3 1E-05 -1.62 71 Epha10 2E-03 -2.01 96 Lcp1 6E-03 2.33 
22 Bex4 4.4E-09 1.77 47 Slc40a1 1E-05 2.33 72 Slc8a2 2E-03 2.72 97 Fam46c 6E-03 1.90 
23 RGD1563349 4.4E-09 2.73 48 Slpi 3E-05 1.91 73 Cp 2E-03 -1.64 98 Dtna 6E-03 1.60 
24 Tbkbp1 4.4E-09 1.95 49 Maob 5E-05 1.66 74 Olfm3 2E-03 -2.07 99 Sdf2l1 6E-03 1.61 





No. Gene Name padj LFC No. Gene Name padj LFC No. Gene Name padj LFC 
101 Mcoln3 6.3E-03 1.52 127 Adora2a 2E-02 1.56 153 Nrxn2 4E-02 2.32 
102 F2rl2 6.4E-03 1.82 128 Abi3 2E-02 -1.65 154 Mpp3 4E-02 1.58 
103 Rn60_20_0031.1 6.5E-03 2.37 129 Htr5b 2E-02 1.69 155 Pnmal2 4E-02 1.75 
104 Csgalnact1 7.1E-03 1.88 130 MGC109340 2E-02 1.74 156 Rab37 4E-02 2.00 
105 Dusp2 7.3E-03 1.74 131 Camk2n2 2E-02 1.98 157 Rtn1 4E-02 1.76 
106 Rundc3b 7.6E-03 2.05 132 Ccl7 2E-02 -1.80 158 Iqsec2 5E-02 -3.56 
107 Map3k7cl 7.8E-03 -2.20 133 Fa2h 2E-02 1.67         
108 LOC685157 8.6E-03 -2.62 134 Esrp1 2E-02 3.22         
109 LOC102553099 8.6E-03 3.77 135 Kcnh2 2E-02 3.19         
110 Aldh3a1 8.9E-03 -2.44 136 Dcn 2E-02 -3.56         
111 Stk32c 9.1E-03 2.18 137 Lynx1 2E-02 1.74         
112 Clasrp 9.4E-03 -3.35 138 Zfp819 2E-02 2.55         
113 Syne4 9.5E-03 -3.29 139 RGD1309108 3E-02 1.50         
114 Sncb 1.0E-02 2.02 140 Ifi44 3E-02 -1.54         
115 Ugt8 1.1E-02 1.81 141 Rprml 3E-02 1.72         
116 Klk6 1.1E-02 1.77 142 Sox6 3E-02 2.76         
117 Scn8a 1.1E-02 2.82 143 Cfap99 3E-02 1.63         
118 Flvcr2 1.2E-02 2.60 144 Wdr17 3E-02 1.77         
119 Hck 1.3E-02 1.89 145 Adora1 3E-02 1.76         
120 Pak3 1.3E-02 2.70 146 Hsd11b1 4E-02 1.87         
121 Ciita 1.4E-02 -3.95 147 Lpl 4E-02 1.70         
122 Cldn23 1.5E-02 2.10 148 Itgbl1 4E-02 -2.06         
123 Dchs1 1.5E-02 1.72 149 Slc17a7 4E-02 3.20         
124 Slurp1 1.5E-02 -2.37 150 Sfrp4 4E-02 -1.76         
125 Lrp2 1.6E-02 1.71 151 LOC103694876 4E-02 4.57         






Table 4. DEGs in response to VPA as identified with cuffdiff2, ranked by padj values. 
No. Gene Name padj LFC No. Gene Name padj LFC No. Gene 
Name 
padj LFC No. Gene 
Name 
padj LFC 
1 Nxph4 1.6E-03 4.23 26 Slc17a7 1.6E-03 2.87 51 Perp 1.6E-03 2.56 76 Tfcp2l1 1.6E-03 2.14 
2 RGD1563349 1.6E-03 4.06 27 Camk2n2 1.6E-03 2.87 52 Elmod1 1.6E-03 2.55 77 Fgf11 1.6E-03 2.14 
3 Nrgn 1.6E-03 4.04 28 Clgn 1.6E-03 2.86 53 Trnp1 1.6E-03 2.52 78 Car12 1.6E-03 2.13 
4 Crlf1 1.6E-03 3.59 29 Gpr85 1.6E-03 2.83 54 Dpyd 1.6E-03 2.52 79 Fez1 1.6E-03 2.13 
5 Snap25 1.6E-03 3.58 30 Zcchc12 1.6E-03 2.80 55 Sdf2l1 1.6E-03 2.52 80 Scn7a 1.6E-03 2.13 
6 Ppp1r1b 1.6E-03 3.52 31 Hpcal4 1.6E-03 2.77 56 Ppm1j 1.6E-03 2.51 81 Akap5 1.6E-03 2.11 
7 Kif1a 1.6E-03 3.37 32 Nefm 1.6E-03 2.75 57 Syt1 1.6E-03 2.44 82 Slc6a17 1.6E-03 2.11 
8 Ocln 1.6E-03 3.33 33 Tbkbp1 1.6E-03 2.73 58 Rab37 1.6E-03 2.43 83 Plxdc1 1.6E-03 2.09 
9 Pkib 1.6E-03 3.33 34 Arhgap20 1.6E-03 2.73 59 Ablim3 1.6E-03 2.41 84 Ogdhl 1.6E-03 2.08 
10 Gnai1 1.6E-03 3.22 35 Mfap3l 1.6E-03 2.72 60 Sorcs2 1.6E-03 2.35 85 Abhd3 1.6E-03 2.08 
11 Snap91 1.6E-03 3.21 36 Cpm 1.6E-03 2.69 61 Slc1a1 1.6E-03 2.34 86 Rbm11 1.6E-03 2.06 
12 Lingo1 1.6E-03 3.17 37 Cacna1b 1.6E-03 2.68 62 Camsap3 1.6E-03 2.33 87 Padi2 1.6E-03 2.05 
13 Rnf128 1.6E-03 3.16 38 Nptx1 1.6E-03 2.68 63 Cdkn1c 1.6E-03 2.31 88 Nsg2 1.6E-03 2.05 
14 Tubb4a 1.6E-03 3.13 39 Ngfr 1.6E-03 2.67 64 Raver2 1.6E-03 2.31 89 Notch3 1.6E-03 2.04 
15 Syn2 1.6E-03 3.11 40 Rab6b 1.6E-03 2.67 65 Wnt11 1.6E-03 2.29 90 Insig1 1.6E-03 2.02 
16 Hapln2 1.6E-03 3.09 41 Slpi 1.6E-03 2.63 66 Shank3 1.6E-03 2.26 91 RGD1310110 1.6E-03 2.02 
17 Cyp24a1 1.6E-03 3.07 42 Rtn1 1.6E-03 2.62 67 Cnn1 1.6E-03 2.26 92 Cilp2 1.6E-03 2.01 
18 Pstpip2 1.6E-03 3.04 43 Mpp3 1.6E-03 2.62 68 Dtna 1.6E-03 2.25 93 Mcoln3 1.6E-03 1.99 
19 Klk13 1.6E-03 3.03 44 Mpp7 1.6E-03 2.62 69 Bex4 1.6E-03 2.24 94 Crym 1.6E-03 1.98 
20 Tmem130 1.6E-03 2.98 45 Mapt 1.6E-03 2.60 70 Erbb3 1.6E-03 2.18 95 Mboat2 1.6E-03 1.97 
21 RGD1310819 1.6E-03 2.95 46 Mmp13 1.6E-03 2.60 71 Ly6l 1.6E-03 2.18 96 Abca5 1.6E-03 1.97 
22 Bean1 1.6E-03 2.92 47 Cldn23 1.6E-03 2.59 72 Serpinb2 1.6E-03 2.18 97 Abcg2 1.6E-03 1.96 
23 Slc6a15 1.6E-03 2.91 48 Tspan13 1.6E-03 2.58 73 Ptprz1 1.6E-03 2.17 98 Pak3 1.6E-03 1.95 
24 Slc8a2 1.6E-03 2.90 49 Adam23 1.6E-03 2.58 74 LOC100912
195 
1.6E-03 2.15 99 Plcg2 1.6E-03 1.95 





No. Gene Name padj LFC No. Gene Name padj LFC No. Gene 
Name 
padj LFC No. Gene 
Name 
padj LFC 
101 Aplp1 1.6E-03 1.92 127 AABR07041411.1 1.6E-03 1.74 153 Fzd4 1.6E-03 1.57 179 Olfml2b 1.6E-03 -1.73 
102 Bdh1 1.6E-03 1.92 128 Pcyt1b 1.6E-03 1.73 154 Idi1 1.6E-03 1.56 180 Nr2f1 1.6E-03 -1.74 
103 Spire2 1.6E-03 1.89 129 Rab40b 1.6E-03 1.71 155 Scamp5 1.6E-03 1.56 181 Sytl1 1.6E-03 -1.75 
104 Clmn 1.6E-03 1.89 130 Pkia 1.6E-03 1.71 156 Dbndd1 1.6E-03 1.55 182 Atg9b 1.6E-03 -1.76 
105 Col22a1 1.6E-03 1.89 131 Rgs9 1.6E-03 1.70 157 AABR070062
58.2 
1.6E-03 1.55 183 Ccdc9b 1.6E-03 -1.77 
106 Jph4 1.6E-03 1.88 132 Carmil3 1.6E-03 1.70 158 Hmx3 1.6E-03 1.54 184 Lcn3 1.6E-03 -1.79 
107 AABR07010468.
1 
1.6E-03 1.87 133 Atrnl1 1.6E-03 1.69 159 Plagl1 1.6E-03 1.52 185 Pinlyp 1.6E-03 -1.82 
108 Rnf182 1.6E-03 1.87 134 Mpp2 1.6E-03 1.68 160 Mgat4a 1.6E-03 1.52 186 Osr1 1.6E-03 -1.82 
109 Stk39 1.6E-03 1.87 135 Rassf4 1.6E-03 1.68 161 Camkv 1.6E-03 1.51 187 Cntnap5c 1.6E-03 -1.85 
110 Kif5c 1.6E-03 1.87 136 Ggh 1.6E-03 1.68 162 Ier5l 1.6E-03 -1.50 188 Col8a1 1.6E-03 -1.87 
111 B3gnt5 1.6E-03 1.86 137 Efr3b 1.6E-03 1.67 163 Mme 1.6E-03 -1.51 189 Tnfrsf11b 1.6E-03 -1.87 
112 Ncald 1.6E-03 1.84 138 Acss3 1.6E-03 1.67 164 Calhm2 1.6E-03 -1.52 190 Arrdc4 1.6E-03 -1.87 
113 Mpzl2 1.6E-03 1.83 139 Stox2 1.6E-03 1.66 165 Tm4sf4 1.6E-03 -1.54 191 Cp 1.6E-03 -1.94 
114 5330417C22Rik 1.6E-03 1.83 140 Eml5 1.6E-03 1.64 166 Jade2 1.6E-03 -1.54 192 Inpp5d 1.6E-03 -1.96 
115 Nrg1 1.6E-03 1.82 141 Rhox5 1.6E-03 1.63 167 Ube2l6 1.6E-03 -1.54 193 Gdpd2 1.6E-03 -2.00 
116 Fbxl16 1.6E-03 1.81 142 Sipa1l2 1.6E-03 1.63 168 Tnc 1.6E-03 -1.57 194 Angptl4 1.6E-03 -2.01 
117 Ero1b 1.6E-03 1.81 143 Serinc2 1.6E-03 1.63 169 Foxq1 1.6E-03 -1.58 195 Ifitm3 1.6E-03 -2.04 
118 Gas7 1.6E-03 1.78 144 Slc45a3 1.6E-03 1.62 170 Rcbtb2 1.6E-03 -1.58 196 Gnb3 1.6E-03 -2.06 
119 Nipal1 1.6E-03 1.77 145 Lonrf3 1.6E-03 1.61 171 Grin2d 1.6E-03 -1.59 197 Adamts1 1.6E-03 -2.08 
120 Lef1 1.6E-03 1.77 146 Cd68 1.6E-03 1.61 172 Tspo 1.6E-03 -1.61 198 Abca1 1.6E-03 -2.14 
121 Dusp15 1.6E-03 1.76 147 Papss2 1.6E-03 1.60 173 Txnip 1.6E-03 -1.61 199 Scara5 1.6E-03 -2.20 
122 Dmd 1.6E-03 1.76 148 Lrfn1 1.6E-03 1.60 174 Mxra8 1.6E-03 -1.61 200 LOC100910200 
 
1.6E-03 -2.20 
123 Txnrd3 1.6E-03 1.76 149 Car2 1.6E-03 1.59 175 Akr1c19 1.6E-03 -1.63 201 S100a4 1.6E-03 -2.25 
124 Hmgcs1 1.6E-03 1.75 150 Fgfr3 1.6E-03 1.59 176 Krt8 1.6E-03 -1.69 202 Psmb10 1.6E-03 -2.28 
125 Icam5 1.6E-03 1.75 151 Bspry 1.6E-03 1.58 177 Tm4sf1 1.6E-03 -1.69 203 Akr1c3 1.6E-03 -2.28 





No. Gene Name padj LFC No. Gene Name padj LFC No. 
Gene 
Name padj LFC No. 
Gene 
Name padj LFC 
205 Aqp1 1.6E-03 -2.46 230 S100a16 4.1E-03 -1.82 255 Hspa5 8.1E-03 1.76 280 Lhx6 2.2E-02 2.07 
206 Clec2g 1.6E-03 -2.46 231 Fn1 4.1E-03 -1.83 256 Trim36 8.1E-03 1.63 281 Dpep2 2.4E-02 -2.01 
207 Pkp3 1.6E-03 -2.46 232 Clic5 5.3E-03 3.45 257 Pik3r5 8.1E-03 1.59 282 Tmod2 2.5E-02 1.92 
208 Sfrp4 1.6E-03 -2.66 233 AABR07044359.1 5.3E-03 2.90 258 Bfsp2 8.1E-03 -1.71 283 Cd28 2.6E-02 1.75 
209 Gzmbl3 1.6E-03 -2.73 234 Fam46c 5.3E-03 2.68 259 Wnt6 9.0E-03 3.03 284 Sep03 2.6E-02 2.55 
210 Epha10 1.6E-03 -2.91 235 Actn3 5.3E-03 2.22 260 Dusp2 9.0E-03 2.43 285 Col11a2 2.8E-02 1.86 
211 Kcnip4 1.6E-03 -2.95 236 Camk2n1 5.3E-03 1.84 261 Adora1 1.1E-02 2.03 286 Hsd11b1 3.0E-02 2.48 
212 AABR07070161.1 1.6E-03 -3.22 237 Dnai2 5.3E-03 1.73 262 Chst1 1.1E-02 1.89 287 Rprml 3.1E-02 2.08 
213 Col3a1 1.6E-03 -3.30 238 Syt3 5.3E-03 1.55 263 Fam171a1 1.2E-02 1.77 288 Ctrb1 3.1E-02 -1.51 
214 Il20rb 1.6E-03 -3.33 239 Tmc7 6.3E-03 3.69 264 Chrna5 1.2E-02 4.80 289 Lsp1 3.1E-02 -3.07 
215 Wisp2 1.6E-03 -3.43 240 AABR07039334.1 6.3E-03 2.33 265 Arhgap27 1.2E-02 -1.55 290 Ppp1r16b 3.3E-02 1.76 
216 Olfm3 1.6E-03 -3.95 241 Tmem74 6.3E-03 2.03 266 Socs2 1.3E-02 1.59 291 Mreg 3.4E-02 1.82 
217 Fam25a 1.6E-03 -4.41 242 Mmp12 6.3E-03 1.66 267 Hck 1.4E-02 2.51 292 Timd2 3.8E-02 1.67 
218 Csgalnact1 2.9E-03 2.87 243 AABR07019341.2 6.3E-03 1.51 268 Fgf9 1.6E-02 3.05 293 Rhbdl3 3.9E-02 2.18 
219 Cntn1 2.9E-03 2.54 244 Cmtm5,Il25 6.3E-03 -1.54 269 Ccr1 1.6E-02 1.87 294 Rbp2 3.9E-02 -1.64 
220 Stmn4 2.9E-03 2.19 245 LOC100910996 7.3E-03 3.77 270 Ptpn5 1.6E-02 1.51 295 Nfe2l3 4.0E-02 2.96 
221 Triqk 2.9E-03 2.00 246 Crabp1 7.3E-03 2.53 271 Gfi1 1.7E-02 1.71 296 Nrcam 4.0E-02 1.75 
222 Stc1 2.9E-03 1.66 247 Mmp9 7.3E-03 1.94 272 Angpt4 1.7E-02 -1.58 297 
AABR07026032.
1 4.1E-02 1.66 
223 Tmem86a 2.9E-03 1.63 248 AABR07037520.1 7.3E-03 1.94 273 Pnma8b 1.8E-02 2.25 298 LOC100912373 4.3E-02 2.14 
224 Ephb2 2.9E-03 1.50 249 Slain1 7.3E-03 1.81 274 Ispd 1.8E-02 -1.67 299 Efhc2 4.7E-02 2.57 
225 Klk6 4.1E-03 2.74 250 Nkd1 7.3E-03 1.58 275 Mcpt8l2 1.8E-02 -3.03 300 Abi3 4.8E-02 -2.15 
226 Iglon5 4.1E-03 2.63 251 Gip 7.3E-03 -1.81 276 Stk32c 1.9E-02 3.54 301 Fgfbp1 5.0E-02 -2.13 
227 Lrrc4b 4.1E-03 1.94 252 Igf2 8.1E-03 7.47 277 Lrrc3 1.9E-02 2.37 302 Pnck 5.0E-02 1.85 
228 Nectin1 4.1E-03 1.62 253 Insig1 8.1E-03 2.43 278 Fa2h 2.0E-02 2.21     





Appendix G: NanoString normalized counts 
Normalized counts for NanoString nCounter® experiments. Table 1 shows the normalized counts for Run1, whereas Table 2 
shows the normalized counts for Run2.  
Table 8.1 Normalized mRNA counts for NanoStrung Run1 for all samples.  
Description Li_1_24032016 VPA_2_24032016 Val_1_24032016 LTG_1_24032016 TSA_1_24032016 CC_1_24032016 
Gene RLF 
 
NZGL01938_C4434 NZGL01938_C4434 NZGL01938_C4434 NZGL01938_C4434 NZGL01938_C4434 NZGL01938_C4434 
Lane ID 
 
1 2 3 4 5 6 
FOV Count 555 555 555 555 555 555 
FOV Counted 515 536 539 542 537 549 
Scanner ID 
 
1310C0122 1310C0122 1310C0122 1310C0122 1310C0122 1310C0122 
Stage Position 2 2 2 2 2 2 
Binding Density 0.09 0.09 0.09 0.09 0.09 0.09 
Positive POS_A 18104.66 22751.95 25013.27 26130.29 24701.27 30302 
Positive POS_B 4388.66 5581.95 6189.27 6534.29 5911.27 7297 
Positive POS_C 1177.66 1514.95 1655.27 1670.29 1604.27 2009 
Positive POS_D 305.66 380.95 405.27 422.29 395.27 494 
Positive POS_E 56.66 82.95 94.27 100.29 73.27 113 
Positive POS_F 36.66 47.95 75.27 68.29 67.27 66 
Negative NEG_A 6.66 4.95 2.27 4.29 7.27 23 
Negative NEG_B 1 1 3.27 2.29 1 2 
Negative NEG_C 1 1 1 1.29 2.27 1 
Negative NEG_D 1 1 1.27 1 1 1 
Negative NEG_E 12.66 12.95 20.27 18.29 15.27 10 





Description Li_1_24032016 VPA_2_24032016 Val_1_24032016 LTG_1_24032016 TSA_1_24032016 CC_1_24032016 
Negative NEG_G 1 1 1 1 1 1 
Negative NEG_H 1 1 1 1 1 1 
Endogenous ADAM23 2.01 7.07 1 1 3.53 1.99 
Endogenous ADGRB2 2.01 15.08 14.3 3.95 10.16 15.88 
Endogenous CACNA1B 11.68 29.31 33.63 16.65 10.16 23.82 
Endogenous CDKN1C 62.43 128.05 69.66 56.23 51.58 43.01 
Endogenous CNTN1 8.05 5.3 1 1 4.36 1 
Endogenous ERBB3 116.8 154.74 140.85 130.17 117.02 134.97 
Endogenous GNAI1 1.21 1 1 1 1 1 
Endogenous IGF2 1.21 1 1 1 1 2.65 
Endogenous LINGO1 1.21 14.19 2.87 4.7 1 4.63 
Endogenous LSP1 190.51 83.57 156.67 193.65 125.31 165.41 
Endogenous LZTS1 1.21 1 1 1 1 2.65 
Endogenous MAOB 12.88 23.98 13.42 11.42 16.79 15.22 
Endogenous MMP13 1297.34 3693.33 731.45 1608.18 4624.33 1925.98 
Endogenous MPP3 34.63 69.34 27.48 35.32 26.73 34.41 
Endogenous NGFR 1.21 15.08 7.27 6.94 4.36 14.56 
Endogenous NOTCH3 1.21 1.74 6.39 1 6.85 5.96 
Endogenous PAK3 95.05 137.84 85.48 104.03 75.6 89.32 
Endogenous SERPIN2B 6.84 16.86 6.39 6.94 13.48 17.87 
Endogenous SHANK3 17.72 24.87 21.33 14.4 10.99 21.17 
Endogenous SNAP91 163.93 214.34 164.58 169 68.15 155.48 
Endogenous SPR 14.09 25.75 19.57 13.66 9.33 12.57 
Endogenous VGF 23.76 78.24 29.24 20.38 64.01 31.1 
Endogenous WNT6 1.21 2.63 2.87 1 1 2.65 
Endogenous ZCCHC12 15.3 83.57 17.81 33.08 7.68 31.76 





Description Li_1_24032016 VPA_2_24032016 Val_1_24032016 LTG_1_24032016 TSA_1_24032016 CC_1_24032016 
Housekeeping MAPK6 2578.16 2312.76 2459.31 2378.18 2770.38 2401.68 
 
Description Li_1_25032016 VPA-1_25032016 VAL_1_25032016 LTG_1_25032016 TSA_1_25032016 CC_1_25032016 
Gene RLF 
 
NZGL01938_C4434 NZGL01938_C4434 NZGL01938_C4434 NZGL01938_C4434 NZGL01938_C4434 NZGL01938_C4434 
Lane ID 
 
7 8 9 10 11 12 
FOV Count 555 555 555 555 555 555 
FOV Counted 549 541 548 532 544 549 
Scanner ID 
 
1310C0122 1310C0122 1310C0122 1310C0122 1310C0122 1310C0122 
Stage Position 2 2 2 2 2 2 
Binding Density 0.09 0.09 0.09 0.09 0.09 0.09 
Positive POS_A 27384.92 26314.7 22635.04 26205.75 25535.08 25053.02 
Positive POS_B 6447.92 6290.7 5591.04 6344.75 6116.08 5861.02 
Positive POS_C 1772.92 1656.7 1392.04 1777.75 1701.08 1598.02 
Positive POS_D 403.92 430.7 404.04 407.75 426.08 388.02 
Positive POS_E 83.92 99.7 77.04 93.75 99.08 88.02 
Positive POS_F 55.92 70.7 62.04 53.75 49.08 62.02 
Negative NEG_A 10.92 7.7 12.04 8.75 5.08 16.02 
Negative NEG_B 1 1 1 3.75 1.08 1.02 
Negative NEG_C 1 1 1 1 1 1 
Negative NEG_D 1.92 1 1 1 1 2.02 
Negative NEG_E 18.92 14.7 11.04 17.75 13.08 13.02 
Negative NEG_F 6.92 10.7 3.04 14.75 15.08 3.02 
Negative NEG_G 1 1 1 1 1 1 
Negative NEG_H 1 1 1 1 1 1 
Endogenous ADAM23 1 7.74 6.51 2.81 1 1 
Endogenous ADGRB2 4.09 9.33 10.81 1.31 5.09 3.92 





Description Li_1_24032016 VPA_2_24032016 Val_1_24032016 LTG_1_24032016 TSA_1_24032016 CC_1_24032016 
Endogenous CDKN1C 78.04 129.78 79.74 41.84 45.28 45.37 
Endogenous CNTN1 7.42 5.34 6.51 1.31 2.58 2.36 
Endogenous ERBB3 97.99 198.38 117.44 109.38 122.32 88.38 
Endogenous GNAI1 1 1 1.08 1 1 1 
Endogenous IGF2 1 1.35 1.08 1 1 1 
Endogenous LINGO1 2.43 17.31 3.27 2.81 1 3.92 
Endogenous LSP1 182.74 73.94 106.67 164.92 129.02 161.89 
Endogenous LZTS1 1 1 1.12 1 1 1 
Endogenous MAOB 14.89 22.89 23.74 7.32 14.3 9.4 
Endogenous MMP13 1281.21 3988.83 835.81 1616.41 3346.96 1901.15 
Endogenous MPP3 39.82 77.13 28.05 22.33 27.7 24.26 
Endogenous NGFR 2.43 16.51 10.81 4.31 3.41 2.36 
Endogenous NOTCH3 1 10.13 2.2 1 1 1 
Endogenous PAK3 88.01 152.11 64.66 67.36 76.26 71.18 
Endogenous SERPIN2B 5.75 26.88 1.12 14.82 15.14 9.4 
Endogenous SHANK3 9.08 25.28 20.51 11.82 9.27 13.31 
Endogenous SNAP91 130.39 244.64 169.14 144.66 118.13 128.27 
Endogenous SPR 14.89 21.3 17.28 12.57 13.46 18 
Endogenous VGF 19.05 89.89 17.28 21.58 40.26 25.82 
Endogenous WNT6 1 7.74 14.04 1 1 1 
Endogenous ZCCHC12 17.39 97.07 33.43 29.83 19.32 25.82 
Housekeeping G6PD 2854.13 3040.42 3025.41 2986.09 2735.69 2931.1 
Housekeeping MAPK6 2524.25 2369.59 2381.35 2412.7 2633.54 2457.97 
 
Description Li_2_26032016 VPA_2_26032016 VAL_1_26032016 LTG_1_26032016 TSA_1_26032016 CC_2_26032016 
Gene RLF 
 
NZGL01938_C4434 NZGL01938_C4434 NZGL01938_C4434 NZGL01938_C4434 NZGL01938_C4434 NZGL01938_C4434 
Lane ID 
 





Description Li_1_24032016 VPA_2_24032016 Val_1_24032016 LTG_1_24032016 TSA_1_24032016 CC_1_24032016 
FOV Count 555 555 555 555 555 555 
FOV Counted 552 552 553 540 545 554 
Scanner ID 
 
1310C0122 1310C0122 1310C0122 1310C0122 1310C0122 1310C0122 
Stage Position 3 3 3 3 3 3 
Binding Density 0.11 0.11 0.12 0.13 0.13 0.13 
Positive POS_A 17963.54 20621.59 18141.63 20360.64 25610.69 22812.71 
Positive POS_B 4702.54 5331.59 4606.64 5290.64 6251.69 5621.71 
Positive POS_C 1194.54 1357.59 1239.64 1396.64 1698.69 1518.71 
Positive POS_D 298.54 338.59 323.64 322.64 418.69 413.71 
Positive POS_E 70.54 88.59 66.64 70.64 96.69 81.71 
Positive POS_F 34.54 48.59 49.64 42.64 66.69 47.71 
Negative NEG_A 4.54 2.59 2.64 6.64 10.69 6.71 
Negative NEG_B 1 1 1 1 1 1 
Negative NEG_C 1 2.59 1 1 1.69 1 
Negative NEG_D 1 1 1 1 1 1 
Negative NEG_E 9.54 10.59 15.64 11.64 12.69 13.71 
Negative NEG_F 7.54 8.59 8.64 5.64 7.69 1.71 
Negative NEG_G 1 1 1 1 1 1 
Negative NEG_H 1 1 1 1 1 1 
Endogenous ADAM23 9.58 4.86 5.78 1.36 6.39 1 
Endogenous ADGRB2 11.3 11.62 10.54 3.6 17.62 10.74 
Endogenous CACNA1B 16.49 26.5 21.67 14.52 19.87 10.74 
Endogenous CDKN1C 90.83 141.46 91.58 48.63 74.9 56.84 
Endogenous CNTN1 1.73 2.15 1.59 13.16 4.15 3.72 
Endogenous ERBB3 73.54 127.94 85.22 112.77 101.86 105.95 
Endogenous GNAI1 1.73 1.35 1.59 1.36 1.12 1 





Description Li_1_24032016 VPA_2_24032016 Val_1_24032016 LTG_1_24032016 TSA_1_24032016 CC_1_24032016 
Endogenous LINGO1 4.39 12.97 7.37 2.24 6.39 3.72 
Endogenous LSP1 230.86 104.94 188.5 187.82 95.12 166.08 
Endogenous LZTS1 1.73 1.35 1.59 1.36 1.12 2.72 
Endogenous MAOB 25.13 21.09 20.08 14.52 24.36 16.75 
Endogenous MMP13 2151.56 5065.9 1241.96 3154.34 4907.58 2515.3 
Endogenous MPP3 26.86 60.31 35.97 32.26 36.72 28.78 
Endogenous NGFR 6.12 10.27 5.78 9.06 3.02 10.74 
Endogenous NOTCH3 6.12 6.21 12.13 13.16 16.5 5.73 
Endogenous PAK3 104.66 190.15 96.35 101.85 94 88.91 
Endogenous SERPIN2B 7.85 27.85 1.59 9.06 19.87 15.75 
Endogenous SHANK3 16.49 14.33 20.08 15.88 4.15 19.76 
Endogenous SNAP91 128.86 225.32 188.5 178.27 132.18 146.04 
Endogenous SPR 18.22 42.73 35.97 22.71 40.09 29.78 
Endogenous VGF 33.78 114.41 20.08 17.25 46.83 13.74 
Endogenous WNT6 1.73 4.86 8.95 4.97 4.15 2.72 
Endogenous ZCCHC12 18.22 76.54 26.43 19.98 17.62 26.77 
Housekeeping G6PD 2869.02 3029.04 3021.55 2970.12 2598.5 2989.35 
Housekeeping MAPK6 2511.15 2378.49 2384.39 2425.67 2772.58 2410.07 
 
Description Li_2_27032016 VPA_2_27032016 VAL_1_27032016 LTG_2_27032016 TSA_1_27032016 CC_2_27032016 
Gene RLF 
 
NZGL01938_C4434 NZGL01938_C4434 NZGL01938_C4434 NZGL01938_C4434 NZGL01938_C4434 NZGL01938_C4434 
Lane ID 
 
7 8 9 10 11 12 
FOV Count 555 555 555 555 555 555 
FOV Counted 549 552 548 534 525 547 
Scanner ID 
 
1310C0122 1310C0122 1310C0122 1310C0122 1310C0122 1310C0122 
Stage Position 3 3 3 3 3 3 





Description Li_1_24032016 VPA_2_24032016 Val_1_24032016 LTG_1_24032016 TSA_1_24032016 CC_1_24032016 
Positive POS_A 23619.93 22139.54 19763.92 24405.23 21839.51 17835.13 
Positive POS_B 5840.92 5487.54 4997.92 5965.23 5342.51 4305.13 
Positive POS_C 1530.93 1489.54 1295.92 1597.23 1404.51 1169.13 
Positive POS_D 387.93 346.54 305.92 414.23 386.51 286.13 
Positive POS_E 95.93 70.54 69.92 81.23 68.51 63.13 
Positive POS_F 39.93 46.54 47.92 50.23 49.51 44.13 
Negative NEG_A 11.93 2.54 9.92 15.23 14.51 4.13 
Negative NEG_B 1 1 3.92 1 1 1.13 
Negative NEG_C 1 5.54 1 1.23 1 1.13 
Negative NEG_D 1 1.54 1 1 1 2.13 
Negative NEG_E 7.93 10.54 18.92 14.23 19.51 3.13 
Negative NEG_F 6.93 1 5.92 1 7.51 2.13 
Negative NEG_G 1 1 1 1 1 1 
Negative NEG_H 1 1 1 1 1 1 
Endogenous ADAM23 1.08 8.88 1.5 3.87 5.03 1.26 
Endogenous ADGRB2 7.51 14.08 8.86 11.19 16.16 5.18 
Endogenous CACNA1B 12.93 26.57 20.85 23.08 8.37 2.67 
Endogenous CDKN1C 72.58 143.08 85.27 45.03 60.71 41.58 
Endogenous CNTN1 3.17 1.04 8.86 6.61 1.11 2.67 
Endogenous ERBB3 113.79 149.33 98.76 102.66 103.04 143.24 
Endogenous GNAI1 1.08 1.04 1.5 1 1.11 1.26 
Endogenous IGF2 1.08 1.04 2.87 1 12.82 1.26 
Endogenous LINGO1 5.34 10.96 7.37 1 3.91 1.26 
Endogenous LSP1 213.55 88.99 143.7 162.12 139.79 175.87 
Endogenous LZTS1 1.08 1.04 1.5 1 3.91 1.26 
Endogenous MAOB 18.35 28.65 17.85 13.93 26.19 18.99 





Description Li_1_24032016 VPA_2_24032016 Val_1_24032016 LTG_1_24032016 TSA_1_24032016 CC_1_24032016 
Endogenous MPP3 33.54 106.67 35.83 27.65 46.24 24.01 
Endogenous NGFR 1.08 14.08 2.87 2.95 15.05 3.93 
Endogenous NOTCH3 1.08 6.8 5.87 1 21.73 1.26 
Endogenous PAK3 107.28 226.31 98.76 131.02 106.38 124.41 
Endogenous SERPIN2B 6.43 17.2 5.87 7.53 26.19 6.44 
Endogenous SHANK3 5.34 25.53 22.35 19.42 10.6 1.26 
Endogenous SNAP91 145.23 237.75 172.17 145.65 111.95 143.24 
Endogenous SPR 18.35 20.32 16.36 23.08 31.76 11.46 
Endogenous VGF 47.63 164.93 41.82 30.4 56.26 20.24 
Endogenous WNT6 2.09 7.84 7.37 2.04 3.91 1.26 
Endogenous ZCCHC12 43.3 87.95 47.82 38.63 7.25 50.36 
Housekeeping G6PD 2727.3 2846.91 2919.87 2827.73 2564.41 2802.73 
Housekeeping MAPK6 2641.63 2530.65 2467.42 2547.82 2809.43 2570.54 
 
 
Table 2 Normalized counts for NanoString nCounter® Run2 for Li, VPA, VPD, CI994, RGFP-966, PCI-34-51, tubastatin A and 
untreated cells (CC). 




























1 2 3 4 5 6 7 8 
FOV Count 555 555 555 555 555 555 555 555 
FOV Counted 507 542 526 541 543 545 532 523 
Scanner ID 
 





Stage Position 3 3 3 3 3 3 3 3 
Binding Density 0.09 0.11 0.12 0.11 0.11 0.1 0.1 0.12 
Messages 
         
Positive POS_A 23940.97 25563.7 28212.06 26525.31 28411.16 23945.28 25861.62 25860.19 
Positive POS_B 6268.97 6719.7 7601.06 6952.31 7388.16 6200.28 6857.62 6509.19 
Positive POS_C 1665.97 1589.7 1977.06 1726.31 1897.16 1595.28 1689.62 1708.19 
Positive POS_D 421.97 462.7 501.06 408.31 495.16 398.28 425.62 461.19 
Positive POS_E 61.97 70.7 85.06 71.31 94.16 86.28 100.62 95.19 
Positive POS_F 46.97 74.7 66.06 51.31 57.16 52.28 58.62 50.19 
Negative NEG_A 1 1 1 1 2.16 1 1 1 
Negative NEG_B 1 1 1 1 1 1 1 1 
Negative NEG_C 1 1 1 1 1 1 1 1 
Negative NEG_D 1 1 1 1 1 1 1 1 
Negative NEG_E 8.97 1 1 1.31 3.16 5.28 7.62 6.19 
Negative NEG_F 1 3.7 5.06 2.31 1 1 1 1.19 
Negative NEG_G 1 1 1 1 1 1 1 1 
Negative NEG_H 1 1 1 1 1 1 1 1 
Endogenous ADAM23 11.14 117.7 56.5 16.84 57.44 36.24 39.71 27.9 
Endogenous ADGRB2 28.54 234.45 38.03 68.82 84.68 53.67 39.71 41.18 
Endogenous CACNA1B 1.24 6.45 1.03 1.37 1 7.93 5.78 1.11 
Endogenous CDKN1C 100.6 146.55 156.03 133.11 81.86 151.67 113.75 120.91 
Endogenous CNTN1 208.68 511.9 479.26 399.84 567.42 417.38 373.91 394.43 
Endogenous ERBB3 1.24 14.69 2.12 1.37 1 1.09 1.03 1.11 
Endogenous GNAI1 1.24 10.57 1.03 1.37 1 1.09 1.03 1.11 
Endogenous IGF2 1.24 1.37 1.03 1.37 1 1.09 1.03 1.11 
Endogenous LINGO1 1.24 1.37 1.03 1.37 1 1.4 1.03 1.11 
Endogenous LSP1 503.13 290.76 255.56 765.05 605.93 700.51 746.15 672.38 





Endogenous MAOB 95.63 342.96 52.39 82.49 127.88 76.53 78.78 69.98 
Endogenous MMP13 4328.48 5699.59 3067.1 3856.4 4265.93 3822.58 4064.48 3763.01 
Endogenous MPP3 1.24 9.2 1.03 7.26 8.6 3.57 1.03 1.11 
Endogenous NGFR 44.69 304.5 73.94 41.46 101.58 54.75 52.05 55.58 
Endogenous NOTCH3 11.14 88.86 18.53 37.36 39.6 40.6 33.54 16.82 
Endogenous PAK3 11.14 58.64 30.85 26.41 47.11 25.35 27.37 24.57 
Endogenous SERPIN2B 2816.48 2919.64 1775.23 1416.15 2068.24 1677.31 1559.54 1592.59 
Endogenous SHANK3 1.24 1.37 1.03 1.37 1 1.09 1.03 1.11 
Endogenous SNAP91 3.69 68.26 26.74 20.94 28.33 24.26 21.2 25.68 
Endogenous SPR 2.45 38.04 5.19 19.57 14.24 21 7.83 2.43 
Endogenous VGF 21.08 62.76 46.24 19.57 62.14 46.04 19.14 17.93 
Endogenous WNT6 1.24 136.93 42.13 29.15 33.96 42.78 32.51 11.29 
Endogenous ZCCHC12 17.35 204.23 29.82 26.41 58.38 40.6 39.71 31.22 
Housekeeping G6PD 1749.26 1760.41 1957.88 1743.07 1547.93 1744.83 1671.62 1760.91 
Housekeeping MAPK6 2508.36 2492.48 2241.09 2517.27 2834.61 2514.73 2624.86 2491.77 
 




























9 10 11 12 1 2 3 4 
FOV Count 555 555 555 555 555 555 555 555 
FOV Counted 527 512 515 532 523 549 553 551 
Scanner ID 
 
1310C0122 1310C0122 1310C0122 1310C0122 1310C0122 1310C0122 1310C0122 1310C0122 
Stage Position 3 3 3 3 4 4 4 4 
Binding Density 0.13 0.12 0.11 0.1 0.13 0.13 0.12 0.12 
Messages 
         
Positive POS_A 31466.22 26730.66 26051.41 19010.05 36062.2 37036.64 34791.24 34625.3 





Positive POS_C 2079.22 1674.66 1615.41 1227.05 2360.19 2505.64 2349.24 2347.3 
Positive POS_D 520.22 453.66 441.41 313.05 541.19 630.64 598.24 554.3 
Positive POS_E 106.22 59.66 77.41 45.05 105.19 120.64 109.24 114.3 
Positive POS_F 63.22 53.66 54.41 43.05 67.19 59.64 67.24 81.3 
Negative NEG_A 1 1 1 1 5.19 1 8.24 3.3 
Negative NEG_B 1 1 1 1 1 1 1 1 
Negative NEG_C 1 1 1 1 1 1 1 1 
Negative NEG_D 1 1 1 1 1 1 1 1 
Negative NEG_E 2.22 1.66 5.41 5.05 7.19 7.64 3.24 5.3 
Negative NEG_F 6.22 2.66 1 1 1 1 1 1 
Negative NEG_G 1 1 1 1 1 1 1 1 
Negative NEG_H 1 1 1 1 1 1 1 1 
Endogenous ADAM23 20.09 185.03 120.54 53.25 33.13 23.08 39.03 26.67 
Endogenous ADGRB2 42.81 258.31 107.84 59.69 66.93 26.85 37.3 57.08 
Endogenous CACNA1B 1 47.36 52.8 1.61 1 1 1 9.43 
Endogenous CDKN1C 95.83 156.17 209.45 119.3 74.54 98.43 124.43 178.75 
Endogenous CNTN1 275.72 675.76 315.3 375.47 470.07 352.34 317.68 345.04 
Endogenous ERBB3 1 11.84 1.41 1.61 1 1 1 1.01 
Endogenous GNAI1 1 35.15 1.41 1.61 1 1 1 1.01 
Endogenous IGF2 1 9.62 27.39 1.61 1 1 1 1.01 
Endogenous LINGO1 1 26.27 61.26 1.61 1 1 1 1.01 
Endogenous LSP1 474.54 309.38 243.32 686.41 606.14 689.13 707.61 748.58 
Endogenous LZTS1 1 18.5 25.98 1.61 1 1 1 1.01 
Endogenous MAOB 135.59 394.87 72.55 56.47 171.73 69.04 93.38 64.18 
Endogenous MMP13 4078 5011.25 1831.03 3057.96 3780.56 3106.2 2986.84 3082.63 
Endogenous MPP3 8.73 44.03 89.49 1.69 1 1 1 9.43 
Endogenous NGFR 72.16 398.2 145.94 72.58 115.95 63.02 71.81 64.18 





Endogenous PAK3 34.29 88.44 57.03 27.47 47.49 41.92 45.07 31.74 
Endogenous SERPIN2B 2505.39 2749.69 891.11 1256.74 1998.12 1368.75 1412.43 1245.4 
Endogenous SHANK3 1 4.07 4.81 1.61 1 1 1 1.01 
Endogenous SNAP91 29.56 109.54 102.19 48.41 12.84 29.11 16.6 47.96 
Endogenous SPR 25.77 56.25 120.54 21.02 25.52 33.63 29.54 57.08 
Endogenous VGF 38.08 127.3 97.96 22.63 60.17 23.84 34.71 40.86 
Endogenous WNT6 12.51 156.17 79.61 29.08 61.86 24.59 29.54 37.82 
Endogenous ZCCHC12 32.4 232.78 40.09 14.58 75.38 44.93 33.85 28.69 
Housekeeping G6PD 1845.48 1847.06 2196.56 1889.91 1708.23 1908.97 1907.61 1930.81 
Housekeeping MAPK6 2377.57 2375.54 1997.57 2321.69 2568.6 2298.5 2300.14 2272.5 
          




























5 6 7 8 9 10 11 12 
FOV Count 555 555 555 555 555 555 555 555 
FOV Counted 552 552 544 549 547 548 551 550 
Scanner ID 
 
1310C0122 1310C0122 1310C0122 1310C0122 1310C0122 1310C0122 1310C0122 1310C0122 
Stage Position 4 4 4 4 4 4 4 4 
Binding Density 0.12 0.11 0.12 0.12 0.12 0.13 0.12 0.13 
Messages 
         
Positive POS_A 38628.91 27714.09 35274.37 38664.48 32761.02 29579.93 38326.63 42194.79 
Positive POS_B 10134.92 7320.09 9191.37 10272.48 8747.02 7901.93 10085.63 11070.79 
Positive POS_C 2678.92 1850.09 2343.37 2553.48 2223.02 2023.93 2616.63 2862.79 
Positive POS_D 642.92 449.09 585.37 626.48 562.02 515.93 602.63 679.79 
Positive POS_E 106.92 95.09 101.37 106.48 121.02 85.93 112.63 146.79 
Positive POS_F 84.92 51.09 83.37 77.48 68.02 60.93 79.63 81.79 





Negative NEG_B 1 1 1 1 1 1 1 1 
Negative NEG_C 1 1 1 1 1 1 1 1 
Negative NEG_D 1 1 1 1 1 1 1 1 
Negative NEG_E 6.92 1.09 1 3.48 5.02 1 8.63 4.79 
Negative NEG_F 1 1 1 1 1 2.93 2.63 1.79 
Negative NEG_G 1 1 1 1 1 1 1 1 
Negative NEG_H 1 1 1 1 1 1 1 1 
Endogenous ADAM23 9.07 142.05 47.65 42.4 31.92 25.53 29.39 32.87 
Endogenous ADGRB2 25.68 230.76 70.76 37.94 61.82 46.72 42.59 42.09 
Endogenous CACNA1B 1 35.58 19.29 1 1 1 2.17 1 
Endogenous CDKN1C 55.58 98.79 121.19 87.05 28.93 71.43 88.79 94.32 
Endogenous CNTN1 223.36 608.93 258.79 264.76 366.83 287.66 272.76 270.21 
Endogenous ERBB3 1 20.06 1.05 1 1 1 1 1 
Endogenous GNAI1 1 8.97 1.05 1 1 1 1 1 
Endogenous IGF2 1 6.75 5.64 1 1 1 1 1 
Endogenous LINGO1 1 4.53 15.09 1 1 1 1 1 
Endogenous LSP1 463.4 258.49 189.46 645.19 556.22 608.93 623.38 603.57 
Endogenous LZTS1 1 15.62 1.05 1 1 1 1 1 
Endogenous MAOB 88.8 391.57 69.71 62.05 116.65 92.61 78.07 67.43 
Endogenous MMP13 3081.43 5132.48 1724.15 3023.32 4682.83 2673.31 2740.27 2641.36 
Endogenous MPP3 1 16.73 21.39 1 1 1 15.37 3.68 
Endogenous NGFR 69.7 441.47 76.02 79.91 117.64 77.61 71.47 70.51 
Endogenous NOTCH3 14.05 117.65 48.71 14.72 28.93 36.13 23.62 27.49 
Endogenous PAK3 35.65 99.9 45.55 33.47 39.89 40.54 30.22 27.49 
Endogenous SERPIN2B 2147.85 2477.57 1250.41 1375.69 1219.07 1299.12 1358.43 1336.35 
Endogenous SHANK3 1 1.11 1.05 1 1 1 1 1 
Endogenous SNAP91 35.65 89.92 70.76 32.58 29.93 29.06 22.79 28.26 





Endogenous VGF 45.61 179.75 115.93 91.52 85.75 71.43 77.24 62.06 
Endogenous WNT6 1 154.24 44.5 21.86 44.88 37.89 41.77 28.26 
Endogenous ZCCHC12 16.54 157.57 21.39 43.29 45.88 35.24 21.14 22.88 
Housekeeping G6PD 1841.36 1826.6 2152.73 1861.49 1578.9 1827.79 1882.29 1798.75 
Housekeeping MAPK6 2382.9 2402.16 2038.23 2357.12 2779.01 2400.59 2331.08 2439.35 
 
 
